



US010435695B2

(12) **United States Patent**
Puckette et al.

(10) **Patent No.:** US 10,435,695 B2
(b4) **Date of Patent:** Oct. 8, 2019

(54) **FUSION PROTEIN COMPRISING GAUSSIA LUCIFERASE, TRANSLATION INTERRUPTER SEQUENCE, AND INTERFERON AMINO ACID SEQUENCES**

(71) Applicant: **The United States of America, as represented by the Secretary of Homeland Security**, Washington, DC (US)

(72) Inventors: **Michael Puckette**, Waterford, CT (US); **Max V. Rasmussen**, Guilford, CT (US)

(73) Assignee: **The Government of the United States of America, as represented by the Secretary of Homeland Security**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/583,459**

(22) Filed: **May 1, 2017**

(65) **Prior Publication Data**

US 2018/0066267 A1 Mar. 8, 2018

Related U.S. Application Data

(63) Continuation-in-part of application No. 15/259,409, filed on Sep. 8, 2016.

(51) **Int. Cl.**

C12N 15/63 (2006.01)
A61K 39/21 (2006.01)
C07K 14/005 (2006.01)
CI2Q 1/66 (2006.01)
A61K 38/21 (2006.01)
C07K 14/705 (2006.01)
C07K 14/56 (2006.01)
C12N 9/02 (2006.01)
C07K 14/00 (2006.01)
C12N 15/00 (2006.01)
A61K 38/00 (2006.01)

(52) **U.S. Cl.**

CPC **C12N 15/63** (2013.01); **A61K 38/21** (2013.01); **C07K 14/56** (2013.01); **C07K 14/705** (2013.01); **CI2N 9/0069** (2013.01);
CI2Q 1/66 (2013.01); **A61K 38/00** (2013.01);
C07K 14/00 (2013.01); **C07K 2319/00** (2013.01); **C12N 15/00** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,232,107 B1 * 5/2001 Bryan A61K 49/0013
435/183
8,236,548 B2 8/2012 Chen

2011/0143362 A1 *	6/2011	Oyler	C12N 15/1034
			435/6.18
2011/0236416 A1	9/2011	Audonnet et al.	
2012/0122182 A1	5/2012	Tannous et al.	
2012/0258133 A1	10/2012	Charleston	
2012/0315295 A1	12/2012	Rieder et al.	
2013/0243809 A1	9/2013	Liao et al.	
2014/0186959 A1	7/2014	Slater et al.	
2018/0066235 A1	3/2018	Puckette et al.	
2018/0066267 A1 *	3/2018	Puckette	C07K 14/56

OTHER PUBLICATIONS

Wu et al. (Biochimica et Biophysica Acta. 2015; 1854: 1392-1399).*

Alignment of SEQ ID 24 with Genseq access No. ABB81097 Jun. 2007 Zuckermann in WO200260921.*

Cheng et al. (Gene. 2006; 382: 28-38).*

Alignment of SEQ ID 4 with Genseq db access AYL17606 Dec. 2010 Sungbae et al in WO2010119721.*

Luker et al. (Nature Medicine. Jan. 2012; 18 (1): 172-177).*

G. R. Stark, I. M. Kerr, B. R. Williams, R. H. Silverman, R. D. Schreiber, How cells respond to interferons. Annual review of biochemistry 67, 227-264 (1998).

K. Schroder, P. J. Hertzog, T. Ravasi, D. A. Hume, Interferon-gamma: an overview of signals, mechanisms and functions. Journal of leukocyte biology 75, 163-189 (2004).

H. M. Lazear, T. J. Nice, M. S. Diamond, Interferon-lambda: Immune Functions at Barrier Surfaces and Beyond. Immunity 43, 15-28 (2015).

J. Chinsangaram, M. Koster, M. J. Grubman, Inhibition of L-deleted foot-and-mouth disease virus replication by alpha/beta interferon involves double-stranded RNA-dependent protein kinase. Journal of virology 75, 5498-5503 (2001).

J. Chinsangaram, M. P. Moraes, M. Koster, M. J. Grubman, Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. Journal of virology 77, 1621-1625 (2003).

H. Yin et al., Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Scientific reports 5, 16975 (2015).

M. Nakamura et al., Expression and visualization of a human interferon-beta-enhanced green fluorescent protein chimeric molecule in cultured cells. Biological & pharmaceutical bulletin 27, 411-414 (2004).

M. Maruyama et al., Simultaneous detection of DsRed2-tagged and EGFP-tagged human beta-interferons in the same single cells. Journal of cellular biochemistry 93, 497-502 (2004).

M. M. Mizokami, P. Hu, L. A. Khawli, J. Li, A. L. Epstein, Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybridoma and hybridomics 22, 197-207 (2003).

M. Verhaegen, T. K. Christopoulos, Recombinant *Gaussia luciferase*. Overexpression, purification, and analytical application of a bioluminescent reporter for DNA hybridization. Analytical chemistry 74, 4378-4385 (2002).

(Continued)

Primary Examiner — Shanon A. Foley

(74) Attorney, Agent, or Firm — Lavanya Ratnam; Kelly G. Hyndman; Joseph Hsiao

(57)

ABSTRACT

Polynucleotides encoding fusion proteins comprising interferons and luciferases which have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields.

33 Claims, 10 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited**OTHER PUBLICATIONS**


- B. A. Tannous, D. E. Kim, J. L. Fernandez, R. Weissleder, X. O. Breakefield, Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. *Molecular therapy : the journal of the American Society of Gene Therapy* 11, 435-443 (2005).
- S. B. Kim, H. Suzuki, M. Sato, H. Tao, Superluminescent variants of marine luciferases for bioassays. *Analytical chemistry* 83, 8732-8740 (2011).
- Diaz-San Segundo F, et al. Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. *Virology*. May 10, 2011;413(2):283-92.
- Perez-Martin E, et al. Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. *J Virol*. Apr. 2012;86(8):4477-87.
- Birtley JR, Curry S. Crystallization of foot-and-mouth disease virus 3C protease: surface mutagenesis and a novel crystal-optimization strategy. *Acta Crystallographica Section D Biological Crystallography*. 2005;61:646-650.
- Birtley JR, Knox SR, Jaulent AM, Brick, P, Leatherbarrow RJ, et al. Crystal structure of foot-and-mouth disease virus 3C protease. 2005;280:11520-527.
- Sweeney, TR, Roqué-Rosell N, Birtley JR, Leatherbarrow RJ, Curry S. Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the □-ribbon in proteolysis. *J Virol*. Jan. 2007;81(1):115-24. Epub Oct. 25, 2006.
- Vakharia VN, Devaney MA, Moore DM, Dunn JJ, Grubman MJ. Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts. *Journal of virology*. 1987;61:3199-207.
- Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. *Virology*. 1999;263:496-506.
- Mayr GA, O'Donnell V, Chinsangaram J, Mason PW, Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. *Vaccine*. 2001;19:2152-62.
- Moraes MP, Mayr GA, Mason PW, Grubman MJ. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. *Vaccine*. 2002;20:1631-9.
- Gullberg M, Muszynski B, Organtini LJ, Ashley RE, Hafenstein SL, Belsham GJ, et al. Assembly and characterization of foot-and-mouth disease virus empty capsid particles expressed within mammalian cells. *The Journal of general virology*. 2013;94:1769-79.
- Porta C, Xu X, Loureiro S, Paramasivam S, Ren J, Ai-Khalil T, et al. Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity. *Journal of virological methods*. 2013;187:406-12.
- Porta C, Kotecha A, Burman A, Jackson T, Ren J, Loureiro S, et al. Rational engineering of recombinant Picornavirus capsids to produce safe, protective vaccine antigen. *PLOS Pathogens*. 2013;9:e1003255.
- Dus Santos MJ, Carrillo C, Ardila F, Rios RD, Franzone P, Piccone ME, et al. Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen. *Vaccine*. 2005;23:1838-43.
- Grubman MJ, Zellner M, Bablani G, Mason PW, Piccone ME. Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus. *Virology*. 1995;213:581-9.
- Falk MM, Grigera PR, Bergmann IE, Zibert A, Multhaup G, Beck E. Foot-and-mouth disease virus protease 3C induces specific proteolytic cleavage of host cell histone H3. *Journal of virology*. 1990;64:748-56.
- Belsham GJ, McInerney GM, Ross-Smith N. Foot-and-mouth disease virus 3C protease induces cleavage of translation initiation factors eIF4A and eIF4G within infected cells. *Journal of virology*. 2000;74:272-80.
- Li W, Ross-Smith N, Proud CG, Belsham GJ. Cleavage of translation initiation factor 4AI(eIF4AI) but not eIF4AII by foot-and-mouth disease virus 3C protease: identification of the eIF4AI cleavage site. *FEBS letters*. 2001;507:1-5.
- Lawrence P, Schafer EA, Rieder E. The nuclear protein Sam68 is cleaved by the FMDV 3C protease redistributing Sam68 to the cytoplasm during FMDV infection of host cells. *Virology*. 2012;425:40-52.
- Wang D, Fang L, Li K, Zhong H, Fan J, Ouyang C, et al. Foot-and-mouth disease virus 3C protease cleaves NEMO to impair innate immune signaling. *Journal of virology*. 2012;86:9311-22.
- Zhou Z, Mogensen MM, Powell PP, Curry S, Wileman T. Foot-and-mouth disease virus 3C protease induces fragmentation of the Golgi compartment and blocks intra-Golgi transport. *Journal of virology*. 2013;87:11721-9.
- Zunszain PA, Knox SR, Sweeney TR, Yang J, Roque-Rosell N, Belsham GJ, et al. Insights into cleavage specificity from the crystal structure of foot-and-mouth disease virus 3C protease complexed with a peptide substrate. *Journal of molecular biology*. 2010;395:375-89.
- Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. *Mol Ther*. 2005;11:435-43.
- Verhaegen M, Christopoulos TK. Recombinant Gaussia luciferase. Overexpression, purification, and analytical application of a bioluminescent reporter for DNA hybridization. *Anal Chem*. 2002;74:4378-85.
- Chung E, Yamashita H, Au P, Tannous BA, Fukumura D, Jain RK. Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. *PLoS One*. 2009;4:e8316.
- Tannous BA. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. *Nat Protoc*. 2009;4:582-91.
- Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO, et al. A secreted luciferase for ex vivo monitoring of in vivo processes. *Nat Methods*. 2008;5:171-3.
- Inoue Y, Sheng F, Kiryu S, Watanabe M, Ratanakanit H, Izawa K, et al. Gaussia luciferase for bioluminescence tumor monitoring in comparison with firefly luciferase. *Mol Imaging*. 2011;10:377-85.
- El-Amouri SS, Cao P, Miao C, Pan D. Secreted luciferase for in vivo evaluation of systemic protein delivery in mice. *Mol Biotechnol*. 2012;53:63-73.
- Griesenbach U, Vicente CC, Roberts MJ, Meng C, Soussi S, Xenariou S, et al. Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer. *Biomaterials*. 2011;32:2614-24.
- Kim SB, Suzuki H, Sato M, Tao H. Superluminescent variants of marine luciferases for bioassays. *Anal Chem*. 2011;83:8732-40.
- De Felipe P. Polycistronic viral vectors. *Current gene therapy*. 2002;2:355-78.
- Ryan MD, Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. *The EMBO journal*. 1994;13:928-33.
- Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, et al. Analysis of the aphthovirus 2A/2B polyprotein cleavage mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. *The Journal of general virology*. 2001;82:1013-25.
- Minskaia E, Ryan MD. Protein coexpression using FMDV 2A: effect of "linker" residues. *BioMed research international*. 2013;2013:291730.
- Donnelly ML, Gani D, Flint M, Monaghan S, Ryan MD. The cleavage activities of aphthovirus and cardiovirus 2A proteins. *J Gen Virol*. 1997;78 (Pt 1):13-21.
- Luke GA, de Felipe P, Lukashev A, Kallioinen SE, Bruno EA, Ryan MD. Occurrence, function and evolutionary origins of '2A-like' sequences in virus genomes. *J Gen Virol*. 2008;89:1036-42.

(56)


References Cited**OTHER PUBLICATIONS**

- Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. *PLoS One.* 2011;6:e18556.
- Torres V, Barra L, Garces F, Ordenes K, Leal-Ortiz S, Garner CC, et al. A bicistronic lentiviral vector based on the 1D/2A sequence of foot-and-mouth disease virus expresses proteins stoichiometrically. *Journal of biotechnology.* 2010;146:138-42.
- Ahier A, Jarriault S. Simultaneous expression of multiple proteins under a single promoter in *Caenorhabditis elegans* via a versatile 2A-based toolkit. *Genetics.* 2014;196:605-13.
- Daniels RW, Rossano AJ, Macleod GT, Ganetzky B. Expression of multiple transgenes from a single construct using viral 2A peptides in *Drosophila*. *PLoS One.* 2014;9:e100637.
- Unkles SE, Valiante V, Maffern DJ, Brakhage AA. Synthetic biology tools for bioprospecting of natural products in eukaryotes. *Chemistry & biology.* 2014;21:502-8.
- Heinonen AM, Rahman M, Dogbevia G, Jakobi H, Wolf S, Sprengel R, et al. Neuroprotection by rAAV-mediated gene transfer of bone morphogenic protein 7. *BMC neuroscience.* 2014;15:38.
- Jung L, Tropel P, Moal Y, Teletin M, Jeandidier E, Gayon R, et al. ONSL and OSKM cocktails act synergistically in reprogramming human somatic cells into induced pluripotent stem cells. *Molecular human reproduction.* 2014;20:538-49.
- Beekwilder J, van Rossum HM, Koopman F, Sonntag F, Buchhaupt M, Schrader J, et al. Polycistronic expression of a beta-carotene biosynthetic pathway in *Saccharomyces cerevisiae* coupled to betanone production. *Journal of biotechnology.* 2014.
- De Felipe P, Martin V, Cortes ML, Ryan M, Izquierdo M. Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. *Gene Ther.* 1999;6:198-208.
- Geu-Flores F, Olsen CE, Halkier BA. Towards engineering glucosinolates into non-cruciferous plants. *Planta.* 2009;229:261-70.
- Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. *Proceedings of the National Academy of Sciences of the United States of America.* 2009;106:157-62.
- Shao L, Feng W, Sun Y, Bai H, Liu J, Currie C, et al. Generation of iPS cells using defined factors linked via the self-cleaving 2A sequences in a single open reading frame. *Cell research.* 2009;19:296-306.
- Mir FA, Kaufmann SH, Eddine AN. A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire. *Clinical and vaccine immunology : CVI.* 2009;16:1467-75.
- Rothwell DG, Crossley R, Bridgeman JS, Sheard V, Zhang Y, Sharp TV, et al. Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent. *Human gene therapy.* 2010;21:1631-7.
- Breese SS, Jr., Graves JH. Electron microscopic observation of crystalline arrays of foot-and-mouth disease virus. *Journal of bacteriology.* 1966;92:1835-7.
- Breese SS. Reactions of intracellular crystals of foot-and-mouth disease virus with ferritin-tagged antibody. *J Gen Virol.* 1969;4:343-6.
- Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors, *Nature Biotechnology.* 2010;28:1287-89.
- Yang et al., "Crystal structure of the 3C protease from Southern African Territories type 2 foot-and-mouth disease virus", (*Peer J*. DOI 10.7717/peerj.1964) dated Apr. 26, 2016.
- Veerapen et al., "Novel expression of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana", (*Virus Research*, 2018; 244: 213-217).
- Zunszain et al., "Insights into Cleavage Specificity from the Crystal Structure of Foot-and-Mouth Disease Virus 3C Protease Complexed with a Peptide Substrate", *Journal of Molecular Biology*, 395 pp. 375-389, 2010.
- Sweeney et al., "Structural and Mutagenic Analysis of Foot-and-Mouth Disease Virus 3C Protease Reveals the Role of the β-Ribbon in Proteolysis", *Journal of Virology*, vol. 81, No. 1, pp. 115-124, Jan. 2007.
- International Search Report and the Written Opinion of the International Searching Authority for PCT/US2017/048828 dated Jan. 29, 2018.


* cited by examiner

FIG. 1

Layout of the three interferon α containing constructs created and evaluated. “sp” = secretion peptide sequence of interferon α .

FIG. 2A

Luciferase readings of constructs separated by the Δ1D2A translational interrupter and corresponding controls.

FIG. 2B

Western blots of media harvested off of cells transfected with constructs separated by the Δ1D2A translational interrupter and corresponding controls.

FIG. 3

Porcine IFN α	<u>M</u> APTS AFI TA VV LSC NAI C S L G C D I P Q T H S I A H T R A L R I I A Q M R R I S P F S C L D H R R D F G S P H E A F G G N Q V Q K A Q A M A L V H E M I L Q Q T F Q L F S T E G S A A A W N E S L L H Q F C T G L D Q Q L R D L E A C V M Q E A G L E G T P L L E E D S I A V R K Y F H R L T L Y L Q E K S Y S P C A W E I V R A E V M R S F S S S R N L Q D R L R K K E
Porcine IFN β	<u>M</u> AN K C I L Q I A I L L M C F S T T A L S M S Y D V L R Y Q Q R S S N L A C Q K I L L G Q L P G T P Q Y C L E D R M N F E V P E E I M Q P P Q F Q K E D A V L I I H E M I L Q Q J F G I L R R N F S S T G W N E T V I K T I L V E L D G Q M D D L E T I L E E I M E E E N F P R G D M T I L H L K K Y Y L S I Q Y L K S K E Y R S C A W T V V Q V E I L R N F S F L N R L T D Y L R N
Bovine IFN γ	<u>M</u> K Y T S Y F L A L L C G L L G F S G S Y G Q G Q F F R E I E N L K E Y F N A S S P D V A K G G P L F S E I L K N W K D E S D K K I I Q S Q I V S F Y F K L F E N L K D N Q V I Q R S M D I I K Q D M F Q K F L N G S S E K L E D F K K L I Q I P V D D L Q J Q R K A I N E L I K V M N D L S P K S N L R K R K R S Q N L F R G R R A S T
Bovine IFN λ	<u>M</u> A P G C T L V L V M L T T V A L S R T G A V P V P S A P R A L P P A R G C H V A Q Q K S L S P Q E L Q A F K T A R D A F E D S F L P K D W D C S T H L F P R T R D L K H L Q V V W E R P V A L E A E L A I L T V L E A M A N S S L G H S L E Q P L L T L Q N I H S K L Q A C V P A Q P T A S S R P R G R L H H W L H R L Q E A R K E S Q D C L E A S V M F N I L R L L T R D L K C V A S G D Q C V


Amino acid sequences for Porcine Interferon α , Porcine Interferon β , Bovine Interferon γ , and Bovine Interferon λ . Underlined letters represent the secretion domains of each interferon sequence.

FIG. 4


SGLucON α	<i>MGVKVLFALICIAVAEAKPTENNEDFNIVAVASNFTTLDADRGKLPGKKLPLEVLKEMEAN</i> ARKAGCTRGCCLCILSHIKCTPKMKKKWLPGRCHTYEGDKESAQGGIGEAIVDIPEIPGFKDLEP <i>MEOFIAQVDLCVDCTTGCLKGLANVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGDGP</i> GCDLPQTHSLAHTRALRLLAQMRRISSPFSCLDHRRDFGSPEAFGGNQVQKAQAMALVHE <i>MLQQTFQLFSTEGSAAAWNESLLHQFCCTGLDQQLRDLEACVMQEAGLEGTPILLEEDSILAV</i> <i>RKYFHRRLTLYLQEKSYSPCAWEIVRAEVMRSFSSRNQLQDRLRKKE</i>
SGLucON β	<i>MGVKVLFALICIAVAEAKPTENNEDFNIVAVASNFTTLDADRGKLPGKKLPLEVLKEMEAN</i> ARKAGCTRGCCLCILSHIKCTPKMKKKWLPGRCHTYEGDKESAQGGIGEAIVDIPEIPGFKDLEP <i>MEOFIAQVDLCVDCTTGCLKGLANVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGDGP</i> <i>MSYDVLRYQQRSSNLACQKLLGQLPGTPQYCLEDRMNFEVPEEIMQPPQFQKEDAVLIIHE</i> <i>MLQQIFGILRRRNFSSTGWNETVIKTILVELDGQMDDLETILEEIIMEEENFPRGDMTLHLKKY</i> <i>YLSILQYLKSKEYRSCAWTVVQVEILRNFSFLNRLTDYLRN</i>
SGLucON γ	<i>MGVKVLFALICIAVAEAKPTENNEDFNIVAVASNFTTLDADRGKLPGKKLPLEVLKEMEAN</i> ARKAGCTRGCCLCILSHIKCTPKMKKKWLPGRCHTYEGDKESAQGGIGEAIVDIPEIPGFKDLEP <i>MEOFIAQVDLCVDCTTGCLKGLANVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGDGP</i> <i>QGQFFREIENKEYFNASSPDVAKGGPLFSEILKNWKDESDKKIIQSQIVSFYFKLFENLKDNQ</i> <i>VIQRSMDIICKQDMFQKFLNGSSEKLEDFKKLIQIPVDDLQIQRKAINELIKVMNDLSPKSNLRK</i> <i>RKRSQNLFRGRRAST</i>
SGLucON λ	<i>MGVKVLFALICIAVAEAKPTENNEDFNIVAVASNFTTLDADRGKLPGKKLPLEVLKEMEAN</i> ARKAGCTRGCCLCILSHIKCTPKMKKKWLPGRCHTYEGDKESAQGGIGEAIVDIPEIPGFKDLEP <i>MEOFIAQVDLCVDCTTGCLKGLANVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGDGP</i> <i>RTGAVPVPSAPRALPPARGCHVAQFKSLSPQELOAFKTARDAFEDSFLPKDWDCSTHLFPRT</i> <i>RDLKHLQVWERPVALEAELALTIVLEAMANSSLGHSLEQPLLTLQNIHSKLQACVPAQPTAS</i> <i>SRPRGRLHHWLHRLQEARKESQDCLEASVMFNILLRLLTRDLKCVASGDQCV</i>

Amino acid sequences for SGLucON α , SGLucON β , SGLucON γ , and SGLucON λ .


Italicized white letters with black background represent the *Gaussia* Luciferase amino acids.

FIG. 5A

Western blots of media harvested from transfected cells using anti-GLuc, Anti-IFN α, Anti-IFN β, and Anti-IFN λ antibodies.

FIG. 5B

Relative Luciferase Units per half second for IFN and SGLucon α , β , γ , and λ media samples.

FIG. 6

Plaque assay of IFN α, SGLuc-Δ1D2A-IFN α, IFN α-Δ1D2A-SGLuc (Δ1M), and SGLucON α activity against VSV-NJ.

FIG. 7

Sample	Concentration of IFN α \pm standard deviation (ng/ml)
IFN α	1239 \pm 86
SGLuc- Δ 1D2A-IFN α	921 \pm 55
IFN α - Δ 1D2A-SGLuc Δ 1M	528 \pm 72
Δ 1D2A-SGLuc Δ 1M (IFN α negative control)	<18 (limit of detection at 1:500 dilution)
SGLuc- Δ 1D2A (IFN α negative control)	<18 (limit of detection at 1:500 dilution)

Concentration of IFN α in harvested media from cells transfected with pTarget IFN α , pTarget SGLuc- Δ 1D2A-IFN α , pTarget IFN α - Δ 1D2A-SGLuc Δ 1M, pTarget Δ 1D2A-SGLuc Δ 1M, and pTarget SGLuc- Δ 1D2A. There were 3 replicates per each of 4 dilutions for each sample.

FIG 8.

Sample	Concentration of IFN α in each sample (ng/ml)					
	5	2.5	1.25	0.625	0.312	0.1525
IFN α	0	0	0	4.5	19	58
SGLuc- Δ 1D2A-IFN α	0	0	2	17.5	53.5	116.5
IFN α - Δ 1D2A-SGLuc Δ 1M	0	0	1	11.5	37	91.5
SGLucON α	0	0	0	1.5	9.5	25.5
SGLuc- Δ 1D2A (IFN α negative control)	245	230	220.5	ND	ND	ND

Effects of IFN α on growth of Vesicular Stomatitis Virus-NJ (VSV-NJ). IFN α levels produced in growth media harvested from HEK293-T cells transfected with pTarget IFN α , pTarget SGLuc- Δ 1D2A-IFN α , pTarget IFN α - Δ 1D2A-SGLuc Δ 1M, mpTarget SGLucON α , or pTarget SGLuc- Δ 1D2A (negative control) were measured and adjusted to concentrations listed before samples were exposed to MDBK cells. VSV-NJ was added to the MDBK cells and Plaque Forming Units (PFU) were counted after the growth period; average of 2 replicates are reported. ND, not determined.

1

FUSION PROTEIN COMPRISING *GAUSSIA LUCIFERASE*, TRANSLATION INTERRUPTER SEQUENCE, AND INTERFERON AMINO ACID SEQUENCES

CROSS-REFERENCE TO RELATED APPLICATIONS

This continuation in part (CIP) application claims priority to U.S. application Ser. No. 15/259,409, filed Sep. 8, 2016, which is incorporated by reference in its entirety.

REFERENCE TO A SEQUENCE LISTING

In accordance with 37 CFR § 1.52(e)(5), the present specification makes reference to a Sequence Listing submitted electronically as a .txt file named “500012us_ST25.txt” on May 1, 2017. The .txt file was generated on Feb. 21, 2017, and is 308 kb in size. The entire contents of the Sequence Listing are herein incorporated by reference.

BACKGROUND OF THE INVENTION

Field of the Invention

The present disclosure generally relates to fusion poly-nucleotides encoding fusion proteins comprising interferons and luciferases which have biotherapeutic, diagnostic, and quality control uses in both the medical and veterinary fields.

Description of the Related Art

Interferons (IFN) are a class of cytokines that interfere with viral replication. Interferons are divided into three classes, type I, type II, and type III. Type I interferons utilize the IFNAR1-IFNAR2 receptor complex and include IFN α and IFN β . Type II interferons consist of IFN γ and utilize the IFNAR1-IFNAR2 receptor complex. Type III interferons consist of IFN λ , also called interleukin-28A, interleukin-28B, and interleukin-29, the most recently discovered interferon type. Type III interferons utilize the IFNLR1-IL10R β receptor complex.

Type I interferons are used to treat a number of medical conditions in humans. Commercially available IFN alpha is used for the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma while IFN beta has been used as a treatment for relapsing-remitting and secondary-progressive forms of multiple sclerosis. In a veterinary setting IFN alpha can be used to treat Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, and Canine papilloma virus in companion animals while in livestock both IFN α and IFN β have been found to inhibit Foot-and-Mouth Disease Virus (FMDV). Type III interferon, IFN λ , is also capable of inhibiting FMDV in cattle.

Interferons are naturally secreted, often by specialized cell types, and are comprised of a secretion peptide sequence along with an activity domain. The secretion domain is not essential for protective activity. Protective activity of interferons, and in particular IFN α , is often evaluated using Vesicular Stomatitis Virus (VSV). VSV is a member of the Rhabdoviridae family and is capable of infecting insects, cattle, horses, pigs, and under the right circumstances humans.

Hybrid peptides comprised of interferons and various molecules have been constructed and evaluated for a number of reasons. Previous work has made hybrid molecules com-

2

prised of IFN α and portions of placental growth factor-2 to enhance the anti-tumor properties of IFN α . Chimeras of interferons with different reporter molecules such as DsRed2 and GFP as well as with antibodies for immunotherapy have also been previously reported in literature.

Quantification of interferon concentrations is typically dependent upon either an activity assay or antibody based methods such as an ELISA. Measurements obtained by interferon activity assays are related to interferon concentration but not definitively related. For example, addition of placental growth factor-2 can enhance interferon activity resulting in detection of a higher interferon activity. However, this higher interferon activity is not directly related to the absolute concentration of interferon. This raises the potential that undesired and/or unknown contaminations during production can artificially influence determination of a final product concentration.

Antibody-based detection assays, such as ELISA, can be inaccurate because antibodies used to detect interferon can bind to more than one type of interferon or can exhibit different affinities for interferon under different conditions. Antibody binding affinities are dependent upon recognition of structural elements such as linear and conformational epitopes in the target substrate such as interferon. Amino acid sequence differences or conformation differences between or among interferon molecules in a sample can cause antibodies to exhibit different binding affinities. This leads to inaccuracies in determining the absolute concentration of an interferon, or a particular interferon, in a sample. As a result the usage of ELISA to determine the absolute concentrations of molecules with different amino acid sequences is not always a reliable option. Antibody-based detection assays also carry a high cost associated with the need to produce a consistent antibody amongst different production batches. The usage of antibodies also contributes to a limited shelf life.

In view of these problems, the inventors developed novel chimeric proteins that fuse a luciferase reporter with an interferon or enzyme of interest. The resulting chimeric proteins allow for easy and accurate determination of absolute concentrations for interferons and other biologically active molecules.

BRIEF SUMMARY OF THE INVENTION

The inventors disclose herein chimeric proteins fusing a *Gaussia Luciferase* (GLuc) or Super-luminescent *Gaussia Luciferase* (SGLuc) reporter to different kinds of interferons.

GLuc is a 185 amino acid naturally secreted luciferase isolated from *Gaussia princeps*. Mutations to GLuc which enhance luciferase output may include, but are not limited to, the 8990 mutant also identified as SGLuc.

GLuc and SGLuc constructs with 2A or 2A-like protein sequences such as, for example, a Δ1D2A translational interrupter, retained both luciferase activity and secretion, which make them viable biomarkers for expression in a single open reading frame.

Several types of such chimeric fusion proteins are exemplified. In one or more embodiments, three different chimeric molecules were created using IFN α sequence, as exemplified in FIG. 1. As a first example, SGLuc-Δ1D2A-IFN α is a SGLuc-Δ1D2A fused to a complete IFN α sequence on the C-terminus. This translated construct expresses two separate proteins—SGLuc-Δ1D2A and IFN α . As a second example, IFN α -Δ1D2A-SGLuc Δ1M, is a complete IFN α sequence with a Δ1D2A-SGLuc Δ1M fused on the C-ter-

minus. This translated construct expresses two separate proteins IFN α -A1D2A and SGLuc Δ 1M. As a third example, SGLucON α is a SGLuc sequence with just the activity domain of IFN α fused to the C-terminus. This translated construct expresses a single protein SGLucON α which is comprised of both SGLuc and just the activity domain of IFN α .

SGLucON α was used as a template to create three additional chimeric molecules based off of porcine IFN β , bovine IFN γ , and bovine IFN λ . For the creation of these constructs each IFN sequence was examined and the secretion domains identified, FIG. 3. Chimeric molecules were constructed by making chimeras only of SGLuc with the resulting non-secretion related amino acid sequences, FIG. 4. The resulting chimeras are identified as SGLucON β , SGLucON γ , and SGLucON λ .

Utilization of chimeric molecules of GLuc or SGLuc with interferons or a protein of interest provides a simple and fast method to substantially quantify an absolute concentration of a particular kind of interferon or protein of interest. When utilizing a construct containing the Δ 1D2A translational interrupter the resulting product is two proteins and concentration is determined of the luciferase as a correlate to concentration of interferon or a protein of interest. When utilizing fused protein like SGLucON α , the concentration can be measured directly using the resulting luciferase activities of the chimeric protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the layout of the three interferon α containing construct open reading frames.

FIG. 2A describes luciferase readings of constructs separated by the Δ 1D2A translational interrupter and corresponding controls.

FIG. 2B depicts Western blots of media harvested off of cells transfected with constructs separated by the Δ 1D2A translational interrupter and corresponding controls.

FIG. 3 describes amino acid sequences for Porcine Interferon α (SEQ ID NO: 24), Porcine Interferon β (SEQ ID NO: 66), Bovine Interferon γ (SEQ ID NO: 75), and Bovine Interferon λ , (SEQ ID NO: 84). Underlined residues represent the secretion domains of each interferon sequence.

FIG. 4 describes amino acid sequences for SGLucON α (SEQ ID NO: 48), SGLucON β (SEQ ID NO: 70), SGLucON γ (SEQ ID NO: 111), and SGLucON λ (SEQ ID NO: 113). Underlined residues represent the *Gaussia* Luciferase amino acids.

FIG. 5A depicts Western blots of media harvested from transfected cells using anti-GLuc, Anti-IFN α , Anti-IFN β , and Anti-IFN λ , antibodies.

FIG. 5B describes relative Luciferase Units per half second for IFN and SGLucON α , β , γ , and λ , media samples.

FIG. 6 depicts a plaque assay of IFN α , SGLuc- Δ 1D2A-IFN α , IFN α - Δ 1D2A-SGLuc (Δ 1M), and SGLucON α activity against Vesicular Stomatitis Virus-NJ.

FIG. 7 depicts concentration of IFN α in harvested media from cells transfected with pTarget IFN α , pTarget SGLuc- Δ 1D2A-IFN α , pTarget IFN α - Δ 1D2A-SGLuc Δ 1M, pTarget Δ 1D2A-SGLuc Δ 1M, and pTarget SGLuc- Δ 1D2A. There were 3 replicates per each of 4 dilutions for each sample.

FIG. 8 depicts effects of IFN α on growth of VSV-NJ. IFN α levels produced in growth media harvested from HEK293-T cells transfected with pTarget IFN α , pTarget SGLuc- Δ 1D2A-IFN α , pTarget IFN α - Δ 1D2A-SGLuc Δ 1M, mpTarget SGLucON α , or pTarget SGLuc- Δ 1D2A (negative control) were measured and adjusted to concentrations listed

before samples were exposed to MDBK cells. VSV-NJ was added to the MDBK cells and Plaque Forming Units (PFU) were counted after the growth period; average of 2 replicates are reported. ND, not determined.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

The term “fusion protein” or “chimeric protein” refers to a polypeptide containing polypeptides or segments of polypeptides from different sources, such as a segment of a luciferase from *Gaussia princeps* and a biologically active segment of an interferon. A fusion protein may be produced by joining two or more polynucleotides that originally coded for the separate proteins or protein segments into a single fusion polynucleotide. Besides the polynucleotide sequences encoding for the separate proteins, a fusion polynucleotide may comprise other polynucleotide sequences such as those encoding translation interrupter sequences or those encoding amino acid sequences which otherwise traffic or process an expressed protein. In some embodiments, the term “fusion protein” will refer to an intact fusion protein, such as a fusion between a luciferase and interferon sequence. In other embodiments, this term may refer to separate polypeptides derived from translation of a fusion polynucleotide, for example, can encompass separate polypeptides produced from a fusion construct containing a translation interrupter sequence.

Translation of the fusion polynucleotide results in a single or multiple polypeptides with functional properties derived from each of the original proteins. A single fusion protein may be expressed from a fusion polynucleotide. Such a single fusion protein may be processed into one, two or more polypeptides depending on the design of the fusion polynucleotide and the host cell expressing it. A fusion polynucleotide can express more than one polypeptide depending on its design, for example, depending on the presence of translation interrupters, stop codons, or other regulatory elements.

A polypeptide encoded by a fusion polynucleotide need not exactly correspond to all the residues of the original protein, for example, it may contain fewer or more amino acid residues than a full-length source protein, but contain an active site or functional domain of the source protein, for example, it may be a fragment of interferon that retains at least one interferon activity. A fusion polynucleotide may also be engineered to encode modified forms of a source protein, such as those having at least 70, 80, 90, 95 or 99% sequence identity or similarly with a source protein or with a functional segment thereof.

The term “fragment thereof,” as applied to a polypeptide component of a fusion polypeptide described herein, refers to a polypeptide comprising any portion of the amino acid sequence of the polypeptide, wherein the fragment substantially retains at least one function of the full-length polypeptide from which it was derived. For example, a fragment of a luciferase may emit light or be processed and/or secreted in a manner similar to the full-length luciferase; a fragment of a translation interruption or interrupter sequence can retain the ability to interrupt translation, and a fragment of a biologically active molecule, such as interferon, can retain at least one physiological, pharmacodynamics, pharmacokinetic or immunological activity of the full-length molecule and/or an ability to be processed, trafficked or

secreted in a way similar to the native biologically active molecule from which it was derived.

The term “derivative thereof” or “modified sequence” as applied to the polypeptide components disclosed herein, refers to a polypeptide consisting of an amino acid sequence that is at least 70, 80, 90, 95, or 99% identical or similar to the amino acid sequence of a biologically active molecule such as a luciferase, translation interruption or interrupter sequence, or interferon, wherein the polypeptide derivative substantially retains the ability to induce the secretion of a target polypeptide to which it is fused. In some embodiments, the derivative comprises an amino acid sequence that is at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of a native or previously engineered sequence. The derivative may comprise additions, deletions, substitutions, post-translational modifications, chemical modifications, or a combination thereof to the amino acid sequence of a native or previously engineered molecule. A derivative may include a mutant polypeptide with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11-15, 16-20, 21-25, or 26-30 additions, substitutions, post-translational modifications, chemical modifications, or deletions. Additions or substitutions also include the use of non-naturally occurring amino acids or modified amino acids.

BLASTN may be used to identify a polynucleotide sequence having at least 70%, 75%, 80%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, 98%, 99% sequence identity to a reference polynucleotide. A representative BLASTN setting optimized to find highly similar sequences uses an Expect Threshold of 10 and a Wordsize of 28, max matches in query range of 0, match/mismatch scores of 1/-2, and linear gap cost. Low complexity regions may be filtered or masked. Default settings of a Standard Nucleotide BLAST are described by and incorporated by reference to blast.ncbi.nlm.nih.gov/_Blast.cgi?PROGRAM=blastn&BLAST_PROGRAMS=megaBlast&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=blasthome (last accessed Feb. 4, 2016).

BLASTP can be used to identify an amino acid sequence having at least 70%, 75%, 80%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, 98%, 99% sequence identity, or similarity to a reference amino acid using a similarity matrix such as BLOSUM45, BLOSUM62 or BLOSUM80 where BLOSUM45 can be used for closely related sequences, BLOSUM62 for midrange sequences, and BLOSUM80 for more distantly related sequences. Unless otherwise indicated a similarity score will be based on use of BLOSUM62. When BLASTP is used, the percent similarity is based on the BLASTP positives score and the percent sequence identity is based on the BLASTP identities score. BLASTP “Identities” shows the number and fraction of total residues in the high scoring sequence pairs which are identical; and BLASTP “Positives” shows the number and fraction of residues for which the alignment scores have positive values and which are similar to each other. Amino acid sequences having these degrees of identity or similarity or any intermediate degree of identity or similarity to the amino acid sequences disclosed herein are contemplated and encompassed by this disclosure. A representative BLASTP setting that uses an Expect Threshold of 10, a Word Size of 3, BLOSUM 62 as a matrix, and Gap Penalty of 11 (Existence) and 1 (Extension) and a conditional compositional score matrix adjustment. Other default settings for BLASTP are described by and incorporated by reference to the disclosure available at: blast.ncbi.nlm.nih.gov/_Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_

LOC=blasthome (last accessed Jun. 29, 2016). Derivatives, analogs or modified versions of any of the polynucleotide or amino acid sequences specifically described herein or in the sequence listing having the above-mentioned ranges of sequence identity or similarly are specifically contemplated.

A “biologically active” or “active” interferon or other polypeptide of interest will exhibit at least one activity of the native molecule, such as an ability to modulate the immune system, treat an autoimmune disease, induce humoral or cellular immunity, interfere with virus replication, treat a tumor or microbial infection, contain diagnostically or immunologically useful epitopes, or any other function of the native molecule. These functions will depend on the nature of the native polypeptide of interest.

A “biotherapeutic” or a composition containing a fusion protein or cleavage product(s) of such a fusion protein, as described herein, including living cells which express or contain such a fusion protein or fusion protein fragments, may be formulated by any of the methods known in the art.

It can be typically prepared as an injectable (e.g. subcutaneous, intradermal and intramuscular injection, jet injections) or as a formulation for oral administration, intranasal administration (e.g. aerosol inhalation or instillation), topical administration to the eye, electroporation, gene gun, transfection, liposome-mediated delivery or combinations thereof, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid prior to injection or other administration may also be prepared.

The preparation may also be emulsified or encapsulated in liposomes. Suitable excipients include but are not limited to water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In a further embodiment, example diluents include, but are not limited to, water, physiological saline solution, human serum albumin, oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulfite, chelating agents, such as ethylene diamine-tetra-acetic acid, buffers such as acetates, citrates or phosphates and agents for adjusting osmolarity, such as sodium chloride or dextrose. In a further embodiment, example carriers include, but are not limited to, liquid carriers (e.g., water, saline, culture medium, saline, aqueous dextrose, aqueous glycols) and solid carriers (e.g., carbohydrates such as starch, glucose, lactose, sucrose, dextrans; anti-oxidants such as ascorbic acid and glutathione, hydrolyzed proteins).

In a further embodiment, pharmaceutically acceptable salts, include but are not limited to, the acid addition salts (formed with free amino groups of the peptide) which are formed with inorganic acids (e.g., hydrochloric acid or phosphoric acids) and organic acids (e.g., acetic, oxalic, tartaric, or maleic acid). Salts formed with the free carboxyl groups may also be derived from inorganic bases (e.g., sodium, potassium, ammonium, calcium, or ferric hydroxides), and organic bases (e.g., isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, and procaine).

In a further embodiment, the biotherapeutic or other compositions according to the invention may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or other agents, which enhance the effectiveness of the vaccine. Examples of agents which may be effective include, but are not limited to: aluminum hydroxide; N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP); N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP); N-acetyl muramyl-L-alanyl-D-isoglutaminyl 1-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethyl amine (CGP

19835A, referred to as MTP-PE); and RIBI, which contains three components extracted from bacteria: monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.

In one or more embodiments, the biotherapeutics and compositions described herein may be administered prophylactically (e.g., to prevent or ameliorate the effects of a future infection), therapeutically (e.g., to treat or to empower the immune system of an infected subject) or both, in a manner compatible with the dosage formulation, and in such an amount and manner as will be prophylactically and/or therapeutically effective.

In an alternative embodiment, polynucleotides encoding a fusion protein according to the invention may be administered as a DNA composition which can be administered at dosages such as in the range of 0.05-3 µg/µl. Other factors that can form the basis of what dosage range to implement include but are not limited the size of the subject, the particular pathogen or disease being treated and the particular type of interferon or other biologically active molecule encoded.

A polynucleotide-based composition may be given in a single dose; two dose schedule, for example two to eight weeks apart; or a multiple dose schedule. A multiple dose schedule is one in which a primary course of administration may include 1 to 10 or more separate doses, followed by other doses administered at subsequent time intervals as required to maintain and/or reinforce the desired response on a subject's immune system.

Gaussia luciferase” or “GLuc” describes luciferases produced by members of the genus *Gaussia*, amino acid sequence variants of native *Gaussia* luciferases, such as those having at least 70, 80, 90, 95, 99% sequence identity or homology to a native or previously engineered *Gaussia* luciferase or that contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid deletions, substitutions or insertions to a native *Gaussia* luciferase amino acid sequence, and truncated native or variant *Gaussia* luciferases that retain luciferase activity. *Gaussia* luciferase or GLuc from *G. princeps* is commercially available (SEQ ID NO: 2). GLuc is a 185 amino acid naturally secreted luciferase isolated from *Gaussia princeps* and has a higher luminescence intensity than firefly or *Renilla* luciferases. It has been used to monitor tumor growth in vivo.

“Super-luminescent *Gaussia* luciferase” or “SGLuc” describes amino acid sequence variants of *Gaussia* luciferase containing an amino acid substitution at residues 89 and 90 of GLuc (SEQ ID NO:4) and which exhibit a higher stability than unmodified *G. princeps* luciferase in certain cell lysis buffers. This term encompasses other luciferase variants that are at least 70, 80, 90, 95, or 99% identical or similar to the GLuc or SGLuc of SEQ ID NO: 2 or 4, respectively, which exhibit substantially the same properties. The addition of 30 amino acid sequence comprising the FMDV 2A translational interrupter sequence, Δ1D2A, to the C-terminus of GLuc or the 8990 GLuc mutant (SGLuc) did not prevent either secretion or luminescence.

The luciferases described herein may be expressed in a form, or processed and expressed in a form that is capable of secretion from a host cell expressing a fusion polypeptide expressing them.

The term “interferon” includes native or previously-engineered mammalian Type I (IFN- α , IFN- β , IFN- ϵ , - κ , - δ , and - ζ , IFN- ω and IFN- ν), and non-mammalian interferons, such as those from birds, reptiles, amphibians, fish and other vertebrates. It also includes Type II interferon (IFN- γ) and

Type III interferon (IFN- λ). Representative interferon polynucleotide or amino acids sequences are described by SEQ ID NOS: 23/24, 49/50, 53/54, 57/58, 61/62, 65/66, 71/72, 75/76, 79/80, 83/84, 87/88, or 91/92.

This term includes IFN α , β , and γ interferons, amino acid sequence variants of native interferons, such as those having at least 70, 80, 90, 95, 99% sequence identity or homology to a native or previously engineered interferon or that contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more deletions, substitutions or insertions to a native or previously engineered interferon amino acid sequence, and truncated native or variant interferons that retain at least one functional activity of the native or previously-engineered interferon.

An interferon may be obtained or derived from a human or other mammal, avian, or vertebrate, including but not limited to monkeys and other primates, mice, rats, rabbits, horses, domestic dogs and other *Canidae*, domestic cats and other *Felidae*, pigs and other *Suidae*, cows and other *Bovinae*, cattle, sheep, goats, water buffalos, yaks, reindeer, deer, elk, llamas, alpacas, bison, moose, camels, chamois, giraffes, hogs, warthogs, kudus, antelopes, gazelles, and wildebeests.

The term “interferon secretion sequence” includes, but is not limited to, native amino acid sequences that facilitate secretion of interferons, such as those described by the amino acid sequences of SEQ ID NOS: 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 and 46. Other interferon secretion sequences include those that are at least 70, 80, 90, 95, 99% identical or similar to a native interferon secretion sequence which facilitate secretion of interferon or other biologically active proteins. Modified interferon secretion sequences also include those with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid deletions, substitutions or insertions to a native sequence. Representative polynucleotides encoding these secretion sequences are described by SEQ ID NOS: 25, 27, 29, 31, 33, 35, 37, 39, 41, 43 and 45 as well as by degenerate versions of these sequences and by modified polynucleotide sequences that encode an interferon secretion sequence that is at least 70, 80, 90, 95, 99% identical or similar to a native interferon secretion sequence as described herein.

The term “biologically active” or “active” molecule includes members of the interferon family described herein, as well as other cytokines such as members of the IL-2 family (including IL-4, IL-7, IL-9, IL-15, IL-21, EPO, TPO and other molecules having a four alpha helix bundle), IL-10 family (including IL-19, IL-20, IL-22, IL-24 and IL-26), IL-1 family (including IL-1 and IL-18), IL-17 family (including IL17A-IL17F) and cysteine-knot family (TNF- β 1, TNF- β 2, TNF- β 3). It includes lymphokines, interleukins and chemokines as well as peptide hormones such as amyline, anti-mullerian hormone, adiponectin, adrenocorticotrophic hormone, angiotensinogen, angiotensin, antidiuretic hormone, atrial-natriuretic peptide, brain natriuretic peptide, calcitonin, cholecystokinin, corticotropin-releasing hormone, cortistatin, enkephalin, endothelin, erythropoietin, follicle-stimulating hormone, galanin, gastric inhibitory polypeptide, gastrin, ghrelin, glucagon, glucagon-like peptide-1, gonadotropin-releasing hormone, growth hormone-releasing hormone, hepcidin, human chorionic gonadotropin, human placental lactogen, growth hormone, inhibin, insulin, insulin like growth factor, leptin, lipotropin, luteinizing hormone, melanocyte stimulating hormone, motilin, orexin, oxytocin, pancreatic polypeptide, parathyroid hormone, pituitary adenylate cyclase-activating peptide, prolactin, prolactin releasing hormone, relaxin, renin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone, thyrotropin-releasing hormone, vasoactive intes-

tinal peptide, guanylin, and uroguanylin. Modified versions of these native molecules are included, such as those that are at least 70, 80, 90, 95, 99% identical or similar to a native biologically active molecule and which retain at least one activity thereof as well as those having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid deletions, substitutions or insertions to a native sequence.

A “translation interrupter” includes 2A, Δ1D2A, or other 2A-like translational interrupters. The 2A translation interrupter is well known in the art pertaining to Foot-and-mouth Disease Virus (FMDV). Other such translational interrupters from other viruses are known. Variants of such interrupters with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 insertions, deletions or substitutions of an amino acid residues that retain the ability to interrupt translation also may be used to process fusion proteins described herein. Non-limiting examples of translation interrupter sequences or polynucleotides encoding them are described by SEQ ID NOS: 5-14.

A “pharmaceutically acceptable carrier”, “adjuvant”, or “excipient” is known in the art, including, but not limited to, physiological saline, mineral oil, vegetable oils, aqueous carboxymethyl cellulose or polyvinylpyrrolidone. The skilled practitioner will recognize that such carriers should be compatible with the fusion proteins or nucleic acid constructs. Phosphate buffered saline (PBS) is one example of an acceptable carrier. The concentration and amount of the proteins or nucleic acid constructs in the final composition may vary depending upon the desired use and type of response needed, and the host animal. The fusion proteins or nucleic acid constructs should be provided in an amount effective to induce the preferred response as determined by routine testing. Appropriate adjuvants as known in the art may also be included in the formulation. Without being limited thereto, suitable adjuvants include but are not limited to mineral oil, vegetable oils, alum, Freund’s incomplete adjuvant, and microparticles or nanoparticles or beads of biocompatible matrix materials such as agar or polyacrylate. Other known immunogenic agents used in conventional vaccines for a subject may also be included in the formulation as well as other therapeutic agents, such as antibacterial or antiviral drugs.

Additional non-limiting aspects and embodiments of the disclosure are described in the following enumerated paragraphs. Some embodiments are directed to compositions containing polynucleotides, these include, without limitation, the following:

1. A polynucleotide that encodes at least one fusion protein comprising at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which, preferably, when expressed can be secreted, and at least one interferon, cytokine, enzyme, or other polypeptide of interest. Examples of polynucleotides encoding GLuc and SGLuc include those comprising the sequences of SEQ ID NO: 1 and SEQ ID NO: 3. Representative luciferase sequences are described by SEQ ID NO: 2 and SEQ ID NO: 4, respectively. The polynucleotides encoding the luciferase may be directly adjoined to those encoding the interferon or other polypeptide of interest or may be separated from the sequences encoding the interferon or other polypeptide of interest, for example, by an intervening translation interruption or interrupter sequence. A polynucleotide sequence encoding a luciferase may replace a polynucleotide sequence encoding the N-terminal portion of an interferon or other polypeptide of interest, for example, it may replace a native secretion sequence or sequence not essential for the biological activity (or immunogenicity) of an interferon or other polypeptide of interest.

The above-mentioned polynucleotide sequence may encode fusion proteins having their various components in any order. For example, it may encode a fusion protein comprising in order from the N-terminal: a luciferase amino acid sequence (such as GLuc or SGLuc), a translation interrupter amino acid sequence (such as 2A or Δ1D2A) and a biologically active molecule amino acid sequence (such as IFN α). In this embodiment the fusion polynucleotide, upon translation, can produce two separate proteins: the first comprising the luciferase-translation interrupter and the second comprising the biologically active amino acid sequence, e.g., (SGLuc-Δ1D2A and IFN α).

This embodiment may encode a fusion protein comprising in order from the N-terminal: a biologically active molecule amino acid sequence (such as IFN α), a translation interrupter amino acid sequence (such as 2A or Δ1D2A), and a luciferase amino acid sequence (such as GLuc or SGLuc). In this embodiment, upon translation, the fusion polynucleotide can produce two separate proteins: the first comprising the luciferase and the second comprising the translation interrupter sequence and the biologically active amino acid sequence which may be expressed without an N-terminal Met residue (e.g., IFNα-Δ1D2A and SGLuc Δ1M).

This embodiment it may encode a GLuCON or SGLuCON sequence comprising in order from the N-terminal a luciferase amino acid sequence (such as GLuc or SGLuc) fused to an active domain of a biologically active protein, such as IFN α with its native secretion domain replaced with GLuc or SGLuc secretion sequence. No translation interrupter sequence is required for this fusion protein construct which can be transported out of a host cell intact.

2. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises at least one promoter or other transcription regulatory element, at least one prokaryotic or eukaryotic translation initiation sequence or other translation regulatory element, at least one translational interrupter sequence, or at least one reporter gene operatively linked to, or embedded within the polynucleotide sequence encoding the at least one fusion protein.

3. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises at least one of a 2A, Δ1D2A, or other translational interrupter sequence.

4. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises at least one an Aphthovirus 2A, Δ1D2A, or other Aphthovirus translational interrupter sequence. Representative examples of polynucleotides encoding translation interrupter sequences include those comprising SEQ ID NOS: 5, 7, 9, 11, 13, 15, 17, 19, and 21. Representative encoded amino acid sequences are respectively described by SEQ ID NOS: 6, 8, 10, 12, 14, 16, 18, 20 and 22.

5. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises at least one of a foot and mouth disease virus (FMDV) 2A, FMDV Δ1D2A, or other FMDV translational interrupter sequence.

6. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises a Δ1D2A sequence engineered at the C-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase.

7. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises a Δ1D2A sequence engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase.

8. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises a translational

11

interrupter sequence engineered at the C-terminus of at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase.

9. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises a translational interrupter sequence engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase.

10. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises an FMDV 2A sequence engineered at the C-terminus of at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase.

11. The polynucleotide of embodiment 1, wherein the at least one fusion protein further comprises an FMDV 2A sequence engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase.

12. The polynucleotide of embodiment 1, wherein the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted does not have an N-terminal methionine residue.

13. The polynucleotide of embodiment 1 that encodes at least one fusion protein comprising at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase, and at least one interferon, cytokine, enzyme, or other polypeptide of interest. Representative, but not limited, polynucleotides may comprise one or more polynucleotide subsequences (e.g., encoding a luciferase, a secretion polypeptide, interferon or other biologically active molecule, translation terminator, translation interrupter sequence, etc.) described in the sequence listing or may comprise a fusion polynucleotide such as those described by SEQ ID NOS: 97-103 and 108-109. Modified polynucleotides, which retain the functional properties of those described herein are included, such as polynucleotides that are at least 70, 80, 90, 95, or 99% identical or similar to those of SEQ ID NOS: 97-109 and which encode functional luciferases, translational terminators, or interferons or fusions or secretable fusions thereof. The polynucleotides described herein may be incorporated into a vector, including transposons, or into a host chromosome.

Other embodiments of the invention are directed to vectors these include, without limitation, the following:

14. A vector comprising the polynucleotide of embodiment 1 which encodes at least one fusion protein comprising at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase, preferably, in a form which can be secreted, and at least one interferon, cytokine, enzyme, or other polypeptide of interest.

15. The vector of embodiment 14, wherein the polynucleotide encoding the at least one fusion protein further comprises at least one promoter or other transcription regulatory element, at least one prokaryotic or eukaryotic translation initiation sequence or other translation regulatory element, at least one translational interrupter sequence, or at least one reporter gene operatively linked to, or embedded within, the polynucleotide sequence encoding the at least one fusion protein.

16. The vector of embodiment 14, wherein the at least one fusion protein further comprises at least one of a 2A, Δ1D2A, or other translational interrupter sequence.

17. The vector of embodiment 14, wherein the at least one fusion protein further comprises at least one an Aphthovirus 2A, Δ1D2A, or other Aphthovirus translational interrupter sequence.

12

18. The vector of embodiment 14, wherein the at least one fusion protein further comprises at least one of a foot and mouth disease virus (FMDV) 2A, FMDV Δ1D2A, or other FMDV translational interrupter sequence.

19. The vector of embodiment 14, wherein the at least one fusion protein further comprises a Δ1D2A sequence engineered at the C-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

20. The vector of embodiment 14, wherein the at least one fusion protein further comprises a Δ1D2A sequence engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

21. The vector of embodiment 14, wherein the at least one fusion protein further comprises a translational interrupter sequence engineered at the C-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

22. The vector of embodiment 14, wherein the at least one fusion protein further comprises a translational interrupter sequence engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

23. The vector of embodiment 14, wherein the at least one fusion protein further comprises an FMDV 2A sequence engineered at the C-terminus of at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

24. The vector of embodiment 14, wherein the at least one fusion protein further comprises an FMDV 2A sequence engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

25. The vector of embodiment 14, wherein the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted does not have an N-terminal methionine residue.

26. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in a eukaryotic cell.

27. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in a yeast cell.

28. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in a fungus cell.

29. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in an insect cell.

30. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in a vertebrate cell.

31. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in a mammalian cell.

32. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in a prokaryotic cell.

33. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in a gram-positive prokaryote.

34. The vector of embodiment 14 that expresses the at least one engineered polypeptide of interest in a gram-negative prokaryote.

35. The vector of embodiment 14 that is a minicircle vector, a replication deficient adenovirus vector, a vaccinia virus vector, or other viral vector that expresses the at least

13

one fusion protein comprising at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest.

36. The vector of embodiment 14, further comprising a polynucleotide described by any of embodiments 1-13. A vector includes episomes, plasmids, phage sequences, viral sequences, transposons, and other polynucleotide constructs that can transform a host cell or be expressed by a host cell.

Other embodiments of the invention are directed to host cells, these include, without limitation, the following:

37. A host cell comprising a vector of embodiment 14, wherein the host cell expresses the at least one fusion protein comprising at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest.

38. The host cell of embodiment 37, wherein the vector comprises at least one promoter or other transcription regulatory element, at least one prokaryotic or eukaryotic translation initiation sequence or other translation regulatory element, at least one translational interrupter sequence, or at least one reporter gene operatively linked to, or embedded within, the polynucleotide sequence encoding the at least one fusion protein.

39. The host cell of embodiment 37, wherein the at least one fusion protein further comprises at least one of a 2A, Δ1D2A, or other translational interrupter sequence.

40. The host cell of embodiment 37, wherein the at least one fusion protein further comprises at least one of an Aphthovirus 2A, Δ1D2A, or other Aphthovirus translational interrupter sequence.

41. The host cell of embodiment 37 wherein the at least one fusion protein further comprises at least one of a foot and mouth disease virus (FMDV) 2A, FMDV Δ1D2A, or other FMDV translational interrupter sequence.

42. The host cell of embodiment 37, wherein the at least one fusion protein further comprises a Δ1D2A sequence engineered at the C-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

43. The host cell of embodiment 37, wherein the at least one fusion protein further comprises a Δ1D2A sequence engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

44. The host cell of embodiment 37, wherein the at least one fusion protein further comprises a translational interrupter sequence engineered at the C-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

45. The host cell of embodiment 37, wherein the at least one fusion protein further comprises a translational interrupter sequence engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

46. The host cell of embodiment 37, wherein the at least one fusion protein further comprises an FMDV 2A sequence engineered at the C-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

47. The host cell of embodiment 37, wherein the at least one fusion protein further comprises an FMDV 2A sequence

14

engineered at the N-terminus of the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted.

48. The host cell of embodiment 37, wherein the at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted does not have an N-terminal methionine residue.

49. The host cell of embodiment 37 that is a eukaryotic cell.

50. The host cell of embodiment 37 that is a yeast cell.

51. The host cell of embodiment 37 that is a fungus cell.

52. The host cell of embodiment 37 that is an insect cell.

53. The host cell of embodiment 37 that is a vertebrate cell.

54. The host cell of embodiment 37 that is mammalian cell.

55. The host cell of embodiment 37 that is a prokaryotic cell.

56. The host cell of embodiment 37 that is a gram-positive prokaryote.

57. The host cell of embodiment 37 that is a gram-negative prokaryote.

58. The host cell of embodiment 37, wherein the vector is a minicircle vector, a replication deficient adenovirus vector, a vaccinia virus vector, or other viral vector that expresses the at least one fusion protein comprising at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest.

59. The host cell of embodiment 37, wherein the vector further comprises a polynucleotide selected from the group of polynucleotide sequences or vectors described by embodiments 1-36.

Other embodiments of the invention are directed to polypeptides or fusion proteins these include, without limitation, the following:

60. A fusion protein comprising at least one of *Gaussia* Luciferase (GLuc), super-luminescent *Gaussia* luciferase (SGLuc) or other luciferase, preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest. The fusion protein may be expressed intact with the luciferase and polypeptide of interest fused together, or may be expressed, for example, via translation interruption, where the fusion protein is separated into at least two polypeptide components.

61. The fusion protein of embodiment 60, which is encoded by a polynucleotide or vector further comprising at least one promoter or other transcription regulatory element, at least one prokaryotic or eukaryotic translation initiation sequence or other translation regulatory element, at least one translational interrupter sequence, or at least one reporter gene operatively linked to, or embedded within, the polynucleotide sequence encoding the fusion protein.

62. The fusion protein of embodiment 60, further comprising at least one of a 2A, Δ1D2A, or other translational interrupter sequence.

63. The fusion protein of embodiment 60, further comprising at least one of an Aphthovirus 2A, Δ1D2A, or other Aphthovirus translational interrupter sequence.

64. The fusion protein of embodiment 60, further comprising at least one of a foot and mouth disease virus (FMDV) 2A, FMDV Δ1D2A, or other FMDV translational interrupter sequence.

65. The fusion protein of embodiment 60, further comprising a Δ1D2A sequence engineered at the C-terminus of

15

the at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase which can be secreted.

66. The fusion protein of embodiment 60, further comprising a Δ 1D2A sequence engineered at the N-terminus of the at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase which can be secreted.

67. The fusion protein of embodiment 60, further comprising a translator interrupter sequence engineered at the N-terminus of the at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase which can be secreted.

68. The fusion protein of embodiment 60, further comprising a translator interrupter sequence engineered at the C-terminus of the at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase which can be secreted.

69. The fusion protein of embodiment 60, further comprising an FMDV 2A sequence engineered at the N-terminus of the at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase which can be secreted.

70. The fusion protein of embodiment 60, further comprising an FMDV 2A sequence engineered at the C-terminus of the at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase which can be secreted.

71. The fusion protein of embodiment 60, wherein the at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase which can be secreted does not have an N-terminal methionine residue.

72. The fusion protein of embodiment 60 that encoded by any of the polynucleotide or vector embodiments 1-36 or which expressed by the host cells of any of embodiments 37-59.

Other embodiments of the invention are directed to vaccines, these include, without limitation, the following:

73. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 60 and a suitable carrier, excipient or adjuvant.

74. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 61 and a suitable carrier, excipient or adjuvant.

75. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 62 and a suitable carrier, excipient or adjuvant.

76. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 63 and a suitable carrier, excipient or adjuvant.

77. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 64 and a suitable carrier, excipient or adjuvant.

78. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 65 and a suitable carrier, excipient or adjuvant.

79. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 66 and a suitable carrier, excipient or adjuvant.

80. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 67 and a suitable carrier, excipient or adjuvant.

81. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 68 and a suitable carrier, excipient or adjuvant.

16

82. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 69 and a suitable carrier, excipient or adjuvant.

83. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 70 and a suitable carrier, excipient or adjuvant.

84. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 71 and a suitable carrier, excipient or adjuvant.

85. An antigen, immunogen, or vaccine comprising the fusion protein of embodiment 72 and a suitable carrier, excipient or adjuvant.

The antigen, immunogen or vaccine described above may comprise an intact fusion protein or may be in the form of one or more immunologically active fragments of such a fusion protein. Suitable carriers, excipients or adjuvants are known in the art and are described elsewhere herein.

Other embodiments of the invention include a method of making fusion protein and include, without limitation, the following:

86. A method for making, expressing and/or processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase, preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 37 in a suitable medium and recovering the fusion protein.

87. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase, preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 38 in a suitable medium and recovering the fusion protein.

88. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 39 in a suitable medium and recovering the fusion protein.

89. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 40 in a suitable medium and recovering the fusion protein.

90. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 41 in a suitable medium and recovering the fusion protein.

91. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell

according to embodiment 42 in a suitable medium and recovering the fusion protein.

92. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 43 in a suitable medium and recovering the fusion protein.

93. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 44 in a suitable medium and recovering the fusion protein.

94. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 45 in a suitable medium and recovering the fusion protein.

95. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 46 in a suitable medium and recovering the fusion protein.

96. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 47 in a suitable medium and recovering the fusion protein.

97. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to any of embodiments 48-57 in a suitable medium and recovering the fusion protein.

98. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 58 in a suitable medium and recovering the fusion protein.

99. A method for expressing and processing a fusion protein comprising at least one of *Gaussia Luciferase* (GLuc), super-luminescent *Gaussia luciferase* (SGLuc) or other luciferase preferably in a form which can be secreted, and at least one interferon, cytokine, enzyme or other polypeptide of interest, comprising culturing the host cell according to embodiment 59 in a suitable medium and recovering the fusion protein.

In preferred embodiments of the method described above, the luciferase will be one that can be expressed and exported from the cell. Prior to export or secretion from the cell, it may be processed, for example, by action of a translation interruption sequence, to separate it from other sequences encoded by a fusion polynucleotide. Alternatively, if may be exported or secreted as part of a fusion polypeptide.

Other embodiments of the invention include a method for quantifying an amount of interferon, cytokine, enzyme or other polypeptide of interest and include, without limitation, the following:

100. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

providing the vector according to embodiment 14;
transforming the vector into a host cell;
culturing the cells in a medium;
harvesting the medium; and

15 quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

101. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

providing the vector according to embodiment 15;
transforming the vector into a host cell;
culturing the cells in a medium;
harvesting the medium; and

30 quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

102. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

providing the vector according to embodiment 16;
transforming the vector into a host cell;
culturing the cells in a medium;
harvesting the medium; and

35 quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

103. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

providing the vector according to embodiment 17;
transforming the vector into a host cell;
culturing the cells in a medium;
harvesting the medium; and

40 quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

104. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

providing the vector according to embodiment 18;
transforming the vector into a host cell;
culturing the cells in a medium;
harvesting the medium; and

45 quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

19

105. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 19;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and
- quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

106. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 20;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and
- quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

107. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 21;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and
- quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

108. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 22;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and
- quantifying the intensity of luminescent output.

109. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 23;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and

quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

110. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 24;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and

quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

111. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 25;

20

transforming the vector into a host cell;

culturing the cells in a medium;

harvesting the medium; and

quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

112. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 35;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and

15 quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

113. A method for quantifying an amount of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 36;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and

25 quantifying the intensity of luminescent output in the harvested medium, thus quantifying the amount of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

In the methods described above the intensity of the luminescent output in the harvested medium is usually measured. This luminescent output may be correlated to the amount of luciferase or fusion protein containing luciferase in the medium and used to quantify expression or activity of a biological molecule. However, in some embodiments, the luminescent intensity of cells separated from the harvested medium may be measured, or measurements may be taken for a combination of both cells and medium or for each separately. In other embodiments, the harvested medium or cells may be further processed, diluted, or purified prior to detection of luminescence. This method may be practiced in conjunction with conventional methods for determining the presence, activity or quantity of a biologically active molecule, such as antibody-based methods, as described herein.

30 40 45 Luminescence may be detected or quantified by equipment or methods known in the art, for example, spectrophotometrically.

Other embodiments of the invention include a method for quantifying a concentration of interferon, cytokine, enzyme or other polypeptide of interest and include, without limitation, the following:

114. A method for quantifying a concentration of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- 55 providing the vector according to embodiment 14;
- transforming the vector into a host cell;
- culturing the cells in a medium;
- harvesting the medium; and

quantifying the intensity of luminescent output in the harvested medium, thus quantifying the concentration of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

115. A method for quantifying a concentration of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

- providing the vector according to embodiment 15,
- transforming the vector into a host cell;

21

culturing the cells in a medium;
harvesting the medium; and
quantifying the intensity of luminescent output in the harvested medium, thus quantifying the concentration of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

116. A method for quantifying a concentration of an interferon, cytokine, enzyme produced in an expression system comprising:

providing the vector according to embodiment 16;
transforming the vector into a host cell;
culturing the cells in a medium;
harvesting the medium; and

quantifying the intensity of luminescent output in the harvested medium, thus quantifying the concentration of the interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system.

117. A method for quantifying a concentration of an interferon, cytokine, enzyme or other polypeptide of interest produced in an expression system comprising:

providing the vector according to any one embodiments 17-36,
transforming the vector into a host cell;
culturing the cells in a medium;
harvesting the medium; and
quantifying the intensity of luminescent output.

In the methods described above the intensity of the luminescent output in the harvested medium is usually measured. This luminescent output may be correlated to the concentration of luciferase or fusion protein containing luciferase in the medium and used to quantify expression or activity of a biological molecule. However, in some embodiments, the luminescent intensity of cells separated from the harvested medium may be measured, or measurements may be taken for a combination of both cells and medium or for each separately. In other embodiments, the harvested medium or cells may be further processed, diluted, or purified prior to detection of luminescence. This method may be practiced in conjunction with conventional methods for determining the presence, activity or quantity of a biologically active molecule, such as antibody-based methods, as described herein. Luminescence may be detected or quantified by equipment or methods known in the art, for example, spectrophotometrically.

Other embodiments of the invention include a method for facilitating secretion of a fusion protein and include, without limitation, the following:

118. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 14;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

119. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 15;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

120. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 16;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

121. A method for facilitating secretion of a fusion protein from a host cell comprising:

22

providing the vector according to embodiment 17;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

122. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 18;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

123. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 19;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

124. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 20;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

125. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 21;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

126. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 22;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

127. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 23;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

128. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 24;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

129. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to any one of embodiments 25-34;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

130. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 35;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

131. A method for facilitating secretion of a fusion protein from a host cell comprising:

providing the vector according to embodiment 36;
transforming the vector into a host cell;
culturing the cells in a medium; and
recovering the secretable fusion protein from the medium.

Recovery of a fusion protein includes concentration, purification, and/or isolation from other polypeptide com-

ponents or nonpolypeptide components of a medium, cells or cell lysate. Examples of recovery methods include chromatographic isolation or separation of a fusion protein, affinity purification using antibodies or ligands that bind to epitopes of tags in a target fusion protein, PAGE, isoelectric focusing, or dialysis and concentration. A recovered fusion protein may be purified to homogeneity or to represent 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99% by mass of the protein content (or the solid, nonaqueous content) in a recovered fusion protein composition.

Other embodiments of the invention include a method for measuring an amount of a biotherapeutic peptide in a subject and include, without limitation, the following:

132. A method for measuring an amount of a biotherapeutic peptide (or biotherapeutic polypeptide) in a subject in need thereof comprising:

providing the vector according to embodiment 14;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

133. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 15;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

134. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 16;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

135. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 17;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

136. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 18;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

137. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 19;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

138. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 20;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

139. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 21;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

140. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 22;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

141. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 23;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

142. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 24;
transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

143. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to any of embodiments 25-34;

transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

144. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 35;

transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

145. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

providing the vector according to embodiment 36;

transforming the vector into the subject;

recovering from the subject a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a biotherapeutic peptide and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby determining an amount of a biotherapeutic peptide in the subject.

Recovery of a fusion protein comprising a biotherapeutic peptide or polypeptide includes concentration, dilution, purification, and/or isolation from other polypeptide components or nonpolypeptide components of a medium, cells or cell lysate. Examples of recovery methods include chromatographic isolation or separation of a fusion protein, affinity purification using antibodies or ligands that bind to epitopes of tags in a target fusion protein, PAGE, isoelectric focusing, or dialysis and concentration. In some embodiments luminescence may be determined directly from a biological sample or a diluted biological sample. A recovered biotherapeutic peptide or polypeptide may be purified to homogeneity or to represent 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99% by mass of the protein content (or the solid, nonaqueous content) in a recovered fusion protein composition.

Other embodiments of the invention include a method for certifying expression of a polypeptide vaccine in a subject and include, without limitation, the following:

146. A method for certifying vaccine expression in vivo comprising:

providing the vector according to embodiment 14;

transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

147. A method for certifying vaccine expression in vivo comprising:

providing the vector according to embodiment 15;

transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, 10 containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the 15 vaccine peptide or polypeptide in the host organism.

148. A method for certifying vaccine expression in vivo comprising:

providing the vector according to embodiment 16;

transforming the vector into a host organism;

20 recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

25 detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

149. A method for certifying vaccine expression in vivo comprising:

30 providing the vector according to embodiment 17;

transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, 35 containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

40 150. A method for certifying vaccine expression in vivo comprising:

providing the vector according to embodiment 18;

transforming the vector into a host organism;

45 recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent 50 output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

151. A method for certifying vaccine expression in vivo comprising:

55 providing the vector according to embodiment 19;

transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, 60 containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

152. A method for certifying vaccine expression in vivo 65 comprising:

providing the vector according to embodiment 20;

transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

153. A method for certifying vaccine expression in vivo comprising:

- providing the vector according to embodiment 21;
- transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

154. A method for certifying vaccine expression in vivo comprising:

- providing the vector according to embodiment 22;
- transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

155. A method for certifying vaccine expression in vivo comprising:

- providing the vector according to embodiment 23;
- transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

156. A method for certifying vaccine expression in vivo comprising:

- providing the vector according to embodiment 24;
- transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

157. A method for certifying vaccine expression in vivo comprising:

- providing the vector according to embodiment 25-34;
- transforming the vector into a host organism;
- recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

158. A method for certifying vaccine expression in vivo comprising:

- providing the vector according to embodiment 35;
- transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

159. A method for certifying vaccine expression in vivo comprising:

- providing the vector according to embodiment 36;
- transforming the vector into a host organism;

recovering from the host organism a sample of biological material, such as blood, serum, plasma, CSF, or urine, containing a fusion protein comprising a vaccine peptide (or polypeptide) and a luciferase, or a luciferase expressed by the vector; and

25 detecting or quantifying the intensity of luminescent output in the sample thereby certifying expression of the vaccine peptide or polypeptide in the host organism.

Recovery of a fusion protein comprising a vaccine peptide or polypeptide includes concentration, dilution, purification, 30 and/or isolation from other polypeptide components or non-polypeptide components of a medium, cells or cell lysate. Examples of recovery methods include chromatographic isolation or separation of a fusion protein, affinity purification using antibodies or ligands that bind to epitopes of tags in a target fusion protein, PAGE, isoelectric focusing, or dialysis and concentration. In some embodiments luminescence may be determined directly from a biological sample or a diluted biological sample. In the methods above, vaccine expression may be formally certified such as by a formal medical or scientific statement, attestation, logs or other records or less formally detected, determined, or recorded, for example in a laboratory notebook or work-book, photo, audio/visual recording, or other record.

Other embodiments of the invention include a pharmaceutical composition containing a fusion protein and include, without limitation, the following:

160. A pharmaceutical composition comprising the fusion protein of embodiment 60 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

50 161. A pharmaceutical composition comprising the fusion protein of embodiment 61 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

162. A pharmaceutical composition comprising the fusion protein of embodiment 62 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

55 163. A pharmaceutical composition comprising the fusion protein of embodiment 63 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

164. A pharmaceutical composition comprising the fusion protein of embodiment 64 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

60 165. A pharmaceutical composition comprising the fusion protein of embodiment 65 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

166. A pharmaceutical composition comprising the fusion protein of embodiment 66 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

167. A pharmaceutical composition comprising the fusion protein of embodiment 67 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

168. A pharmaceutical composition comprising the fusion protein of embodiment 68 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

169. A pharmaceutical composition comprising the fusion protein of embodiment 69 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

170. A pharmaceutical composition comprising the fusion protein of embodiment 70 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

171. A pharmaceutical composition comprising the fusion protein of embodiment 71 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

172. A pharmaceutical composition comprising the fusion protein of embodiment 72 and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

Other embodiments of the invention include a biotherapeutic comprising a fusion protein and include, without limitation, the following:

173. A biotherapeutic comprising the fusion protein of embodiment 60 and a suitable carrier, excipient or adjuvant.

174. A biotherapeutic comprising the fusion protein of embodiment 61 and a suitable carrier, excipient or adjuvant.

175. A biotherapeutic comprising the fusion protein of embodiment 62 and a suitable carrier, excipient or adjuvant.

176. A biotherapeutic comprising the fusion protein of embodiment 63 and a suitable carrier, excipient or adjuvant.

177. A biotherapeutic comprising the fusion protein of embodiment 64 and a suitable carrier, excipient or adjuvant.

178. A biotherapeutic comprising the fusion protein of embodiment 65 and a suitable carrier, excipient or adjuvant.

179. A biotherapeutic comprising the fusion protein of embodiment 66 and a suitable carrier, excipient or adjuvant.

180. A biotherapeutic comprising the fusion protein of embodiment 67 and a suitable carrier, excipient or adjuvant.

181. A biotherapeutic comprising the fusion protein of embodiment 68 and a suitable carrier, excipient or adjuvant.

182. A biotherapeutic comprising the fusion protein of embodiment 69 and a suitable carrier, excipient or adjuvant.

183. A biotherapeutic comprising the fusion protein of embodiment 70 and a suitable carrier, excipient or adjuvant.

184. A biotherapeutic comprising the fusion protein of embodiment 71 and a suitable carrier, excipient or adjuvant.

185. A biotherapeutic comprising the fusion protein of embodiment 72 and a suitable carrier, excipient or adjuvant.

In the biotherapeutics described above, the fusion protein preferably comprises a biologically active polypeptide, such as an interferon (e.g., interferon-alpha or interferon-beta or modified versions thereof) or an immunogenic polypeptide. These biotherapeutics may constitute a fusion protein according to the invention or a polynucleotide encoding such a fusion protein. The fusion protein may be intact or processed, for example, into separate fusion protein fragments by action of a translation interruption sequence. The fusion protein may be in a purified form isolated from other cellular components of a host cell expressing it, or may be contained within a host cell or transformed cell, such as a cell obtained from a subject being treated for a particular disease, disorder or condition. A biotherapeutic may comprise a living cell, such as a leukocyte, bone marrow, muscle, endothelial, or stem cell, that expresses interferon or other polypeptide of interest that produced by transformation of a subject's or patient's cells with a vector as described herein. It may be homologous to the subject or patient or obtained from a suitable donor.

Other embodiments of the invention include a method of treating a subject and include, without limitation, the following:

186. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 160 to a subject in need thereof.

187. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 161 to a subject in need thereof.

188. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 162 to a subject in need thereof.

189. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 163 to a subject in need thereof.

190. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 164 to a subject in need thereof.

191. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 165 to a subject in need thereof.

192. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 166 to a subject in need thereof.

193. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 167 to a subject in need thereof.

194. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 168 to a subject in need thereof.

195. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 169 to a subject in need thereof.

196. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 170 to a subject in need thereof.

197. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 171 to a subject in need thereof.

198. A method for treating Foot-and-Mouth Disease comprising administering the composition according to embodiment 172 to a subject in need thereof.

199. A method for treating malignant melanoma comprising administering the composition according to embodiment 160 to a subject in need thereof.

200. A method for treating malignant melanoma comprising administering the composition according to embodiment 161 to a subject in need thereof.

201. A method for treating malignant melanoma comprising administering the composition according to embodiment 162 to a subject in need thereof.

202. A method for treating malignant melanoma comprising administering the composition according to embodiment 163 to a subject in need thereof.

203. A method for treating malignant melanoma comprising administering the composition according to embodiment 164 to a subject in need thereof.

204. A method for treating malignant melanoma comprising administering the composition according to embodiment 165 to a subject in need thereof.

205. A method for treating malignant melanoma comprising administering the composition according to embodiment 166 to a subject in need thereof.

206. A method for treating malignant melanoma comprising administering the composition according to embodiment 167 to a subject in need thereof.

31

207. A method for treating malignant melanoma comprising administering the composition according to embodiment 168 to a subject in need thereof.

208. A method for treating malignant melanoma comprising administering the composition according to embodiment 169 to a subject in need thereof.

209. A method for treating malignant melanoma comprising administering the composition according to embodiment 170 to a subject in need thereof.

210. A method for treating malignant melanoma comprising administering the composition according to embodiment 171 to a subject in need thereof.

211. A method for treating malignant melanoma comprising administering the composition according to embodiment 172 to a subject in need thereof.

212. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 160 to a subject in need thereof.

213. A method for treating hepatitis B, hepatitis C or other viral infection comprising administering the composition according to embodiment 161 to a subject in need thereof.

214. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 162 to a subject in need thereof.

215. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 163 to a subject in need thereof.

216. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 164 to a subject in need thereof.

217. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 165 to a subject in need thereof.

218. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 166 to a subject in need thereof.

219. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 167 to a subject in need thereof.

220. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 168 to a subject in need thereof.

221. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 169 to a subject in need thereof.

222. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 170 to a subject in need thereof.

223. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 171 to a subject in need thereof.

224. A method for treating hepatitis B, hepatitis C, or other viral infection comprising administering the composition according to embodiment 172 to a subject in need thereof.

32

In the methods described above, the fusion protein preferably comprises a biologically active polypeptide that induces a protective effect against the particular pathological condition or pathogens mentioned, such as an interferon (e.g., interferon-alpha or interferon-beta or modified versions thereof) that enhances immune responses to FMDV, melanoma or other tumors or cancers, or hepatitis B or C infection, or such as an immunogen that induces cellular or humoral immunity against tumors or viral pathogens. This method may be performed by administering a fusion protein according to the invention or a polynucleotide encoding such a fusion protein, for example, by transformation of a cell with a vector encoding a fusion protein, and administration of the transformed cells to a subject or patient in need treatment for a particular disease, disorder or condition.

Other embodiments of the invention include a method of treating a subject and include, without limitation, the following:

20 225. A method for cytokine therapy comprising administering the composition according to embodiment 160 to a subject in need thereof.

226. A method for cytokine therapy comprising administering the composition according to embodiment 161 to a subject in need thereof.

227. A method for cytokine therapy comprising administering the composition according to embodiment 162 to a subject in need thereof.

228. A method for cytokine therapy comprising administering the composition according to embodiment 163 to a subject in need thereof.

229. A method for cytokine therapy comprising administering the composition according to embodiment 164 to a subject in need thereof.

30 230. A method for cytokine therapy comprising administering the composition according to embodiment 165 to a subject in need thereof.

231. A method for cytokine therapy comprising administering the composition according to embodiment 166 to a subject in need thereof.

232. A method for cytokine therapy comprising administering the composition according to embodiment 167 to a subject in need thereof.

45 233. A method for cytokine therapy comprising administering the composition according to embodiment 168 to a subject in need thereof.

234. A method for cytokine therapy comprising administering the composition according to embodiment 169 to a subject in need thereof.

235. A method for cytokine therapy comprising administering the composition according to embodiment 170 to a subject in need thereof.

50 236. A method for cytokine therapy comprising administering the composition according to embodiment 171 to a subject in need thereof.

237. A method for cytokine therapy comprising administering the composition according to embodiment 172 to a subject in need thereof.

In the method described above, the fusion protein preferably comprises a biologically active cytokine that modulates or enhances a subject's immune system. This method may be performed by administering a fusion protein according to the invention or a polynucleotide encoding such a fusion protein. It may be practiced with cells transformed to express a fusion protein or fusion protein fragments having cytokine activity, for example, by transformation of a cell

with a vector encoding a fusion protein, and administration of the transformed cells to a subject or patient in need of cytokine activity.

Other embodiments of the invention include a method of treating a subject and include, without limitation, the following:

238. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 160 to the animal in need thereof.

239. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 161 to the animal in need thereof.

240. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 162 to the animal in need thereof.

241. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 163 to the animal in need thereof.

242. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 164 to the animal in need thereof.

243. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 165 to the animal in need thereof.

244. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 166 to the animal in need thereof.

245. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 167 to the animal in need thereof.

246. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 168 to the animal in need thereof.

247. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 169 to the animal in need thereof.

248. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 170 to the animal in need thereof.

249. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 171 to the animal in need thereof.

250. A method for treating Feline Herpesvirus 1, Feline infectious peritonitis, Feline Immunodeficiency Virus, Feline Leukemia Virus, Canine papilloma virus or other viral infection in domestic or wild animals comprising administering the composition according to embodiment 172 to the animal in need thereof.

In the methods described above, the fusion protein preferably comprises a biologically active cytokine that modulates or enhances a subject's immune system response to the above-mentioned viruses or that comprises protective antigens or epitopes of said viruses. This method may be performed by administering a fusion protein according to the invention or a polynucleotide encoding such a fusion protein.

The methods described above for treating feline diseases or disorders may be practiced with *Felis catus* α , β and/or γ interferon(s) such as those encoded by Accession numbers: NM_001031830.1 or GI:73611927 (α interferon); NM_001009297.1 or GI:57163828 (β interferon); or NM_001009873.1 or GI:57619124 (γ interferon); or analogs, derivatives or modified forms thereof as described herein. These accession numbers are incorporated by reference.

The methods described above for treating canine diseases or disorders may be practiced with *Canis lupus familiaris* α , β and/or γ interferon(s) such as those encoded by Accession numbers: M28624.1 or GI:163973 (α), GenBank: E11229.1 (β) and EF095772.1 or GI: 118505119 (γ); or analogs, derivatives or modified forms thereof as described herein. These accession numbers are incorporated by reference.

Example 1

Δ 1D2A Constructs Retain Luciferase and Interferon Secretion

Two constructs comprising interferon and luciferase sequences were made utilizing the translation interrupter Δ 1D2A to separate SGLuc and IFN α , see FIG. 1.

These constructs expressed two polypeptides which differed as to which polypeptide retained the Δ 1D2A sequence, see FIG. 1. The addition of the Δ 1D2A sequence to either the N-terminus or C-terminus of SGLuc was found to not inhibit either secretion or luminescence of the SGLuc and as shown by FIG. 2A top two bars (media luminescence) and FIG. 2B (Western blot of harvested media). To confirm that the addition of an IFN α sequence to either the N-terminus, in the case of IFN α - Δ 1D2A-SGLuc Δ 1M, or to the C-terminus, in the case of SGLuc- Δ 1D2A-IFN α , did not alter critical luminescence properties, media from HEK293-T cells transfected with constructs pTarget IFN α - Δ 1D2A-SGLuc Δ 1M and pTarget SGLuc- Δ 1D2A-IFN α was evaluated for luciferase activity, see FIG. 2A. HEK293-T cells transfected with constructs pTarget SGLuc- Δ 1D2A and pTarget Δ 1D2A-SGLuc Δ 1M were used as controls, see FIG. 2A.

35

Confirmation of the presence of GLuc in the media and of separation of the fusion protein by Δ1D2A was performed by western blotting using a polyclonal anti-GLuc antibody, see FIG. 2B, which shows efficient separation of GLuc from fusion polypeptides. Only a small amount of unseparated fused peptide was present in the media, FIG. 2B.

To confirm that the addition of an IFN α sequence to either the N-terminus, in the case of IFN α -Δ1D2A-SGLuc Δ1M, or to the C-terminus, in the case of SGLuc-Δ1D2A-IFN α , did not alter critical secretion properties the presence of IFN α and IFN α -Δ1D2A in cell culture media was determined using a commercially available ELISA assay. A standard curve of IFN α concentration was determined using nine different concentrations of an IFN α standard. Four different dilutions of media from cells transfected with pTarget IFN α , pTarget IFN α -Δ1D2A-SGLuc Δ1M, pTarget SGLuc-Δ1D2A-IFN α , pTarget SGLuc-Δ1D2A, and pTarget Δ1D2A-SGLuc Δ1M were assayed using the same ELISA assay, see FIG. 7. The ELISA results of media show in FIG. 7 demonstrate that IFN α is present in the media of cells transfected with plasmids pTarget IFN α , pTarget IFN α -Δ1D2A-SGLuc Δ1M, and pTarget SGLuc-Δ1D2A-IFN α but not in cells transfected with the control plasmids pTarget SGLuc-Δ1D2A, and pTarget Δ1D2A-SGLuc Δ1M. This confirms that the addition of the Δ1D2A peptide to either the N- or C-terminus of IFN α does not prevent secretion.

This example demonstrates that the Δ1D2A sequence can be successfully used to separate SGLuc and IFN α components of a fusion polypeptide and that both the SGLuc and IFN α components retain the ability to be secreted.

These results provide a new way to design a luciferase assay that can be used to quantify the amount of IFN produced in an expression system without the drawbacks of an antibody-based system. Such an assay provides a fast and reliable way to substantially determine the absolute concentration of a molecule in an expression system. The amount of GLuc or SGLuc moieties secreted into culture medium measured by luminescence, after these are released from a longer precursor fusion polypeptide by translational interruption, provides a proportionate way to substantially determine the absolute amount of interferon expressed. The amount of interferon expressed by the expression system will directly correlate with the amount of luminescence appearing in the culture medium. No interferon-binding antibodies are necessary.

This new method provides a more reliable way to standardize samples and avoid the unpredictability and problems associated with antibody-based systems like ELISA. As described above, many of these problems are attributable to the variation of antibody binding affinities for different interferon mutants, different kinds of interferons, or interferons in different kinds of samples.

While constructs using the Δ1D2A sequence can be conveniently used to monitor interferon expression, they do not directly quantify interferon concentrations. That is because they detect extracellular luminescence produced by the luciferase, not a direct and dependent property of interferon. Indirect methods using Δ1D2A may be biased by differential expression, degradation or trafficking of soluble GLuc moieties into the extracellular medium. For example, differential rates of GLuc or SGLuc moiety degradation for a mutant compared to a non-mutant IFN might bias results. To address these problems the inventors tested interferon-luciferase constructs that did not contain the Δ1D2A translation interruption sequence, see FIG. 4. The luminescent

36

moieties in such constructs are directly attached to interferon and thus luminescence detected extracellularly indicates the amount of interferon present.

Example 2

Comparison of Secretion of Interferon to GLucON Constructs

Native interferons contain an N-terminal secretion domain to facilitate their secretion into the extracellular medium. Examples of the secretion domains for interferons are described by SEQ ID NOS: 25-46. This secretion sequence is not necessary to elicit a desired immune stimulatory response. To this end the inventors constructed fusion peptides that contain the SGLuc luciferase and the non-secretion domain of four different interferons, α , β , γ , and λ , collectively identified as SGLucONs and depicted by FIG. 4.

The secretion of two types of porcine interferons, α and β , and two types of bovine interferons, γ and λ , were compared to SGLucON constructs containing the same interferon types. The SGLucON constructs take advantage of the naturally secretable properties of SGLuc to facilitate the secretion of the fusion peptide.

All four interferons and all four SGLucON constructs were demonstrated to be secreted into the extracellular medium as shown in FIGS. 5A and 5B. This confirms that the creation of these fusion peptides does not prevent the secretion of the peptide from the cell. Since all SGLucONs (α , β , γ , λ) showed retention of secretion, FIG. 5A, we tested media samples harvested from transfected HEK293-T cells for luciferase activity, FIG. 5B. Media harvested from cells expressing Interferon (α , β , γ , λ) samples was also tested for luciferase activity to ensure that any luciferase activity observed was the result of the presence of the SGLuc component. All four SGLucON samples (α , β , γ , λ) and only the SGLucON samples showed luciferase activity, FIG. 5B. This confirms that the addition of the interferon sequence to SGLuc does not prevent luminescence.

The SGLucON λ sample showed a more than two-fold higher luciferase readings than the other three other SGLucON samples, FIG. 5B, but did not appear to have a proportionally greater concentration when examined by western blotting with the anti-GLuc antibody, FIG. 5A. This result suggests that in the case of SGLucON λ the addition of the IFN λ sequence may either enhance luminescence or hinder luminescence less than the other IFN sequences, α , β , γ , when comparing amongst the SGLucON constructs.

Control constructs of IFN α , β , and γ were also shown to be secreted by usage of antibodies specific to each one. There was no reliable available antibody to bovine IFN γ limiting the ability to confirm its presence. Western blots using anti-GLuc, anti-IFN α , anti-IFN β , and anti-IFN λ show that the SGLucON chimeras retain both luciferase and interferon components fused together and are not post-translationally processed, FIG. 5A. In the case of Interferon β there was a notable difference in post-translational modifications between IFN β and SGLucON β , FIG. 5A. IFN β shows substantial post-translational modifications, possibly through glycosylation or differential processing, resulting in multiple bands being present in the anti-IFN β western blot FIG. 5A. SGLucON β is predominantly in a single band as shown by FIG. 5A, suggesting that SGLucON β is not subject to the same degree of post-translational modifications as IFN β .

These results demonstrate that direct fusion of SGLuc to an interferon can be successfully secreted by a cell and then

detected by luminescence. These constructs do not rely on separation of SGLuc from the interferon and thus are not subject to the same risks associated with the utilization of a Δ1D2A translation interruption sequence to produce two separate molecules.

Quantifying luciferase activity with SGLucON samples is a direct quantification of the concentration in the sample rather than an indirect quantification as is the case when utilizing the Δ1D2A sequence. This removes variables that may alter concentrations of either SGLuc or IFN after translation such as differential secretion rates and the potential for preferential protein degradation.

Example 3

Δ1D2A IFN Constructs Retain Biological Activity

An IFN α ELISA assay was performed to quantify the concentrations of IFN α in the cell culture media of HEK293-T cells transfected with plasmids pTarget IFN α, pTarget SGLuc-Δ1D2A-IFNα, pTarget IFNα-Δ1D2A-SGLuc Δ1M, and pTarget SGLuc-Δ1D2A. These concentrations were used to set up a dilution series to test for retention of antiviral activity against VSV and to compare this activity to an established commercially available porcine IFNα, FIG. 6 and FIG. 8.

The results show that IFN α produced from constructs pTarget SGLuc-Δ1D2A-IFNα and pTarget IFNα-Δ1D2A-SGLuc Δ1M retains anti-viral activity, FIG. 6 and FIG. 8. This was particularly novel as the IFN α produced from these constructs contains additional amino acids compared to a native IFN α sequence. The IFN α produced from the pTarget SGLuc-Δ1D2A-IFNα construct contains an addition N-terminal proline while the IFN α produced from the pTarget IFNα-Δ1D2A-SGLuc Δ1M construct contains an additional 40 amino acids, containing the Δ1D2A sequence, on the C-terminus, FIG. 1. For the pTarget IFNα-Δ1D2A-SGLuc Δ1M construct the 40 additional amino acids represent a 20% increase in length for the resulting molecule. The substantial increase in the size of the molecule makes the result that it retained anti-viral activity all the more unexpected.

IFN α produced from the pTarget IFN α serves as a control to compare effectiveness to an unmodified protein produced in a similar manner. The IFN α samples only showed plaques at 0.625 ng/mL suggesting that a protective concentration was 1.25 ng/mL or less. Both the IFN α produced from the pTarget SGLuc-Δ1D2A-IFNα construct and that from the pTarget IFNα-Δ1D2A-SGLuc Δ1M construct provided complete protection at 2.5 ng/mL with plaques present at 1.25 ng/mL, FIG. 6. Even at the lowest doses tested, 0.1265 ng/mL, the plaques present in samples were noticeably smaller than those present in the SGLuc-Δ1D2A negative control.

Example 4

GLucON a Construct Retains Biological Activity

An IFN α ELISA assay was performed to quantify the concentrations of both IFN α and SGLucON α in harvested media. Equivalent concentrations of each were determined and used in a plaque assay for interferon anti-viral activity against Vesicular Stomatitis Virus (VSV). The results are shown by FIG. 6 and FIG. 8.

The results show that SGLucON α retained anti-viral activity against VSV. A concentration of less than or equal

to 1.25 ng/mL but greater than 0.625 ng/mL of SGLucON α was sufficient to completely inhibit VSV and concentrations as low as 0.1265 ng/mL were shown to partially inhibit VSV when compared to the negative control SGLuc-Δ1D2A.

5 IFN α produced by the same means was also able to provide complete protection at a concentration of less than or equal to 1.25 ng/mL but greater than 0.3125 ng/mL. This suggests that SGLucON α has at least equivalent anti-viral activity than IFN α, FIG. 6 and FIG. 8. Interestingly 10 SGLucON α gives consistently lower PFUs than IFN α alone at equivalent concentrations FIG. 8. While complete protection from VSV was obtained at the same concentration for both IFN α and SGLucON α consistently lower PFU numbers at susceptible dilutions suggest that SGLucON α offers better protection than IFN α, FIG. 8.

Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the 15 singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As 20 used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.

Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein 25 for ease of description to describe one element or feature’s relationship to another element(s) or feature(s) as illustrated 30 in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” 35 other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative 40 descriptors used herein interpreted accordingly. Similarly, 45 the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.

Although the terms “first” and “second” may be used 50 herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature;element from another feature;element. Thus, a first feature;element discussed below could be termed a second feature;element, and similarly, a second feature;element discussed below could be termed a first feature;element without departing from the 55 teachings of the present invention.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” mean various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term 60 “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.

39

As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word "substantially", "about" or "approximately," even if the term does not expressly appear. The terms "substantially", "substantially no", "substantially free", "about" or "approximately" may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/-0.1% of the stated value (or range of values), +/-1% of the stated value (or range of values), +/-2% of the stated value (or range of values), +/-5% of the stated value (or range of values), +/-10% of the stated value (or range of values), etc. Any numerical range recited herein is intended to include all sub-ranges subsumed therein.

When a feature or element is herein referred to as being "on" another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being "directly on" another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being "connected", "attached" or "coupled" to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being "directly connected", "directly attached" or "directly coupled" to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed "adjacent" another feature may have portions that overlap or underlie the adjacent feature.

Although various illustrative embodiments are described above, any of a number of changes may be made to various

40

embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.

The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term "invention" merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.

All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference, especially referenced disclosure appearing in the same sentence, paragraph, page or section of the specification in which the incorporation by reference appears.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 113

```

<210> SEQ ID NO 1
<211> LENGTH: 558
<212> TYPE: DNA
<213> ORGANISM: Gaussia princeps
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(558)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(558)
<223> OTHER INFORMATION: GLuc polynucleotide

```

<400> SEQUENCE: 1

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag	48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	

gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc	96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	

agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc	144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	

US 10,435,695 B2

41

42

-continued

ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala 50 55 60	192
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile 65 70 75 80	240
aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr 85 90 95	288
tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag gcg atc Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100 105 110	336
gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115 120 125	384
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130 135 140	432
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp 145 150 155 160	480
ctg ccg caa cgc tgt ggc acc ttt gcc agc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175	528
gac aag atc aag ggg gcc ggt ggt gac taa Asp Lys Ile Lys Gly Ala Gly Gly Asp 180 185	558

<210> SEQ_ID NO 2
<211> LENGTH: 185
<212> TYPE: PRT
<213> ORGANISM: *Gaussia princeps*

<400> SEQUENCE: 2

Met Gly Val Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu 1 5 10 15
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala 20 25 30
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro 35 40 45
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala 50 55 60
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile 65 70 75 80
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr 85 90 95
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100 105 110
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115 120 125
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130 135 140
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp 145 150 155 160
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175
Asp Lys Ile Lys Gly Ala Gly Gly Asp 180 185

-continued

<210> SEQ_ID NO 3
<211> LENGTH: 558
<212> TYPE: DNA
<213> ORGANISM: *Gaussia princeps*
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1) ..(558)
<223> OTHER INFORMATION: SGLuc polynucleotide

<400> SEQUENCE: 3

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag	48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc	96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	
agc aac ttt gcg acc acg gat ctc gat gct gac cga ggg aag ttg ccc	144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	
ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc	192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc	240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	
aag tgc acg ccc aag atg aag aag tgg ctc cca gga cgc tgc cac acc	288
Lys Cys Thr Pro Lys Met Lys Trp Leu Pro Gly Arg Cys His Thr	
85 90 95	
tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag gcg atc	336
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Glu Ala Ile	
100 105 110	
gtc gat att cct gag att cct ggg ttc aag gac ttg gag cca atg gag	384
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115 120 125	
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc	432
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130 135 140	
ctc aaa ggg ctt gcc aac gtc cag tgt tct gac ctg ctc aag aag tgg	480
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145 150 155 160	
ctg ccg caa cgc tgt ggc acc ttt gcc agc aag atc cag ggc cag gtg	528
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val	
165 170 175	
gac aag atc aag ggg gcc ggt ggt gac taa	558
Asp Lys Ile Lys Gly Ala Gly Gly Asp	
180 185	

<210> SEQ_ID NO 4
<211> LENGTH: 185
<212> TYPE: PRT
<213> ORGANISM: *Gaussia princeps*

<400> SEQUENCE: 4

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	

-continued

50 55 60

Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
65 70 75 80

Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr
85 90 95

Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile
100 105 110

Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu
115 120 125

Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys
130 135 140

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
145 150 155 160

Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
165 170 175

Asp Lys Ile Lys Gly Ala Gly Gly Asp
180 185

```

<210> SEQ_ID NO 5
<211> LENGTH: 90
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Translation interrupter motif
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(90)
<223> OTHER INFORMATION: Translation interrupter motif (TIM) DNA
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (6)..(7)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9)..(9)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (12)..(13)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (15)..(15)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (18)..(18)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (27)..(27)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature

```

-continued

```

<222> LOCATION: (36)..(36)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (39)..(39)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (51)..(51)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (54)..(54)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (60)..(60)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (63)..(63)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (66)..(66)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (72)..(72)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (78)..(78)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (84)..(84)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (87)..(87)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (90)..(90)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 5

```

nrn mrn nhn vmn nyn ryn rvn syn ghn arr car vyn ykn ary tty gay	48
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Xaa Xaa Phe Asp	
1 5 10 15	

ytn ytn aar ytn gcn ggn gay gtn gar tcn aay ccn ggn ccn	90
Leu Leu Lys Leu Ala Gly Asp Val Glu Xaa Asn Pro Gly Pro	
20 25 30	

```

<210> SEQ ID NO 6
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: The 'Xaa' at location 1 stands for Arg, Ser,
Lys, Asn, Gly, Glu, Asp, Gln, His, Trp, Cys, or Tyr.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: The 'Xaa' at location 2 stands for Arg, Ser,
Lys, Asn, Gln, or His.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: The 'Xaa' at location 3 stands for Lys, Asn,
Thr, Ile, Met, Glu, Asp, Ala, Val, Gln, His, Pro, Leu, Tyr, Ser,
or Phe.
<220> FEATURE:

```

-continued

```

<221> NAME/KEY: misc_feature
<222> LOCATION: (4)..(4)
<223> OTHER INFORMATION: The 'Xaa' at location 4 stands for Lys, Asn,
    Thr, Glu, Asp, Ala, Gln, His, or Pro.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (5)..(5)
<223> OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ile,
    Met, Ala, Val, Pro, Leu, Ser, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (6)..(6)
<223> OTHER INFORMATION: The 'Xaa' at location 6 stands for Ala, Val,
    Thr, Ile, or Met.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (7)..(7)
<223> OTHER INFORMATION: The 'Xaa' at location 7 stands for Glu, Asp,
    Gly, Ala, Lys, Asn, Arg, Ser, or Thr.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (8)..(8)
<223> OTHER INFORMATION: The 'Xaa' at location 8 stands for Ala, Val,
    Pro, or Leu.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9)..(9)
<223> OTHER INFORMATION: The 'Xaa' at location 9 stands for Glu, Asp,
    Ala, or Val.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10)..(10)
<223> OTHER INFORMATION: The 'Xaa' at location 10 stands for Arg, or
    Lys.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (12)..(12)
<223> OTHER INFORMATION: The 'Xaa' at location 12 stands for Thr, Ile,
    Met, Ala, Val, Pro, or Leu.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (13)..(13)
<223> OTHER INFORMATION: The 'Xaa' at location 13 stands for Arg, Leu,
    Trp, Cys, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (14)..(14)
<223> OTHER INFORMATION: The 'Xaa' at location 14 stands for Ser, or
    Asn.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (26)..(26)
<223> OTHER INFORMATION: The 'Xaa' at location 26 stands for Ser.
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 6

Xaa Gln Xaa Xaa Xaa Phe Asp
1          5           10          15

Leu Leu Lys Leu Ala Gly Asp Val Glu Xaa Asn Pro Gly Pro
20          25           30


```

```

<210> SEQ ID NO 7
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Translation interrupter motif 2
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(57)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:

```

-continued

```

<221> NAME/KEY: misc_feature
<222> LOCATION: (6)..(6)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (12)..(12)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (15)..(15)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (18)..(18)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (27)..(27)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (30)..(30)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (33)..(33)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (39)..(39)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (45)..(45)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (51)..(51)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (54)..(54)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (57)..(57)
<223> OTHER INFORMATION: n is a, c, g, or t

```

<400> SEQUENCE: 7

ryh bhn ary wwn kmn ctn ctn mwn cdn gcn ggn gay rtn gar wsn aay	48
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Gly Asp Xaa Glu Ser Asn	
1	5
	10
	15

ccn ggn ccn	57
Pro Gly Pro	

```

<210> SEQ_ID NO 8
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: The 'Xaa' at location 1 stands for Ala, Val,
    Thr, Ile, or Met.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: The 'Xaa' at location 2 stands for Arg, Ser,

```

-continued

```

Thr, Ile, Met, Pro, Leu, Trp, Cys, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: The 'Xaa' at location 3 stands for Ser, or Asn.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (4)..(4)
<223> OTHER INFORMATION: The 'Xaa' at location 4 stands for Lys, Asn,
Ile, Met, Tyr, Leu, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (5)..(5)
<223> OTHER INFORMATION: The 'Xaa' at location 5 stands for Glu, Asp,
Ala, Tyr, or Ser.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (6)..(6)
<223> OTHER INFORMATION: The 'Xaa' at location 6 stands for Leu.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (7)..(7)
<223> OTHER INFORMATION: The 'Xaa' at location 7 stands for Leu.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (8)..(8)
<223> OTHER INFORMATION: The 'Xaa' at location 8 stands for Lys, Asn,
Ile, Met, Gln, His, or Leu.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9)..(9)
<223> OTHER INFORMATION: The 'Xaa' at location 9 stands for Gln, His,
Arg, or Leu.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (13)..(13)
<223> OTHER INFORMATION: The 'Xaa' at location 13 stands for Val, Ile,
or Met.
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 8

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala Gly Asp Xaa Glu Ser Asn
1           5           10          15

Pro Gly Pro

```

```

<210> SEQ ID NO 9
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Translation interruptor motif 3
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(30)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (6)..(6)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (12)..(12)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (18)..(18)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:

```

-continued

```

<221> NAME/KEY: misc_feature
<222> LOCATION: (27)..(27)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (30)..(30)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 9
gcn ggn gay rtn gar wsn aay ccn ggn ccn
Ala Gly Asp Xaa Glu Ser Asn Pro Gly Pro
1           5           10

30

<210> SEQ_ID NO 10
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (4)..(4)
<223> OTHER INFORMATION: The 'Xaa' at location 4 stands for Val, Ile, or
Met.
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 10
Ala Gly Asp Xaa Glu Ser Asn Pro Gly Pro
1           5           10

10

<210> SEQ_ID NO 11
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Translation interruptor 4
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(42)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (6)..(12)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (15)..(15)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (18)..(18)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (22)..(24)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (28)..(30)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (36)..(36)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (39)..(39)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (42)..(42)
<223> OTHER INFORMATION: n is a, c, g, or t

```

-continued

<400> SEQUENCE: 11

```

ctn ctn nnn nnn gcn ggn gay nnn gar nnn aay ccn ggn ccn
Xaa Xaa Xaa Ala Gly Asp Xaa Glu Xaa Asn Pro Gly Pro
1           5           10

```

42

```

<210> SEQ ID NO 12
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: The 'Xaa' at location 1 stands for Leu.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: The 'Xaa' at location 2 stands for Leu.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: The 'Xaa' at location 3 stands for Lys, Asn,
    Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
    Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (4)..(4)
<223> OTHER INFORMATION: The 'Xaa' at location 4 stands for Lys, Asn,
    Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
    Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (8)..(8)
<223> OTHER INFORMATION: The 'Xaa' at location 8 stands for Lys, Asn,
    Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
    Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10)..(10)
<223> OTHER INFORMATION: The 'Xaa' at location 10 stands for Lys, Asn,
    Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
    Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct

```

<400> SEQUENCE: 12

```

Xaa Xaa Xaa Xaa Ala Gly Asp Xaa Glu Xaa Asn Pro Gly Pro
1           5           10

```

```

<210> SEQ ID NO 13
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Translation interruptor sequence 5
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(24)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (4)..(6)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10)..(12)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (18)..(18)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature

```

US 10,435,695 B2

59**60**

-continued

<222> LOCATION: (24)..(24)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 13

```
gay nnn gar nnn aay ccn ggn ccn
Asp Xaa Glu Xaa Asn Pro Gly Pro
1 5
```

24

<210> SEQ ID NO 14

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(2)

<223> OTHER INFORMATION: The 'Xaa' at location 2 stands for Lys, Asn, Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro, Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (4)..(4)

<223> OTHER INFORMATION: The 'Xaa' at location 4 stands for Lys, Asn, Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro, Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Construct

<400> SEQUENCE: 14

```
Asp Xaa Glu Xaa Asn Pro Gly Pro
1 5
```

<210> SEQ ID NO 15

<211> LENGTH: 90

<212> TYPE: DNA

<213> ORGANISM: Foot-and-mouth disease virus

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(90)

<223> OTHER INFORMATION: Delta-2A

<400> SEQUENCE: 15

```
cac aag caa aag atc att gca cca gca aag cag ctt ctg aat ttt gac
His Lys Gln Lys Ile Ile Ala Pro Ala Lys Gln Leu Leu Asn Phe Asp
1 5 10 15
```

48

```
ctg ctc aag ttg gcc gga gac gtt gag tcc aac cct gga ccc
Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly Pro
20 25 30
```

90

<210> SEQ ID NO 16

<211> LENGTH: 30

<212> TYPE: PRT

<213> ORGANISM: Foot-and-mouth disease virus

<400> SEQUENCE: 16

```
His Lys Gln Lys Ile Ile Ala Pro Ala Lys Gln Leu Leu Asn Phe Asp
1 5 10 15
```

```
Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly Pro
20 25 30
```

<210> SEQ ID NO 17

<211> LENGTH: 60

<212> TYPE: DNA

<213> ORGANISM: Foot-and-mouth disease virus

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(60)

<223> OTHER INFORMATION: FMDV 2A polynucleotide

<400> SEQUENCE: 17

US 10,435,695 B2

61**62**

-continued

```
cag ctt ctg aat ttt gac ctg ctc aag ttg gcc gga gac gtt gag tcc      48
Gln Leu Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser
1           5           10          15
```

```
aac cct ggg ccc      60
Asn Pro Gly Pro
20
```

```
<210> SEQ ID NO 18
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Foot-and-mouth disease virus
```

```
<400> SEQUENCE: 18
Gln Leu Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser
1           5           10          15
```

```
Asn Pro Gly Pro
20
```

```
<210> SEQ ID NO 19
<211> LENGTH: 63
<212> TYPE: DNA
<213> ORGANISM: Bovine rhinitis virus A
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(63)
<223> OTHER INFORMATION: Bovine rhinitis A 2A
```

```
<400> SEQUENCE: 19
```

```
tct ggt ata agc aac aag gac ctg cta ttg cag gcc ggt gat gtt gag      48
Ser Gly Ile Ser Asn Lys Asp Leu Leu Leu Gln Ala Gly Asp Val Glu
1           5           10          15
```

```
aca aac cct ggt ccc      63
Thr Asn Pro Gly Pro
20
```

```
<210> SEQ ID NO 20
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Bovine rhinitis virus A
```

```
<400> SEQUENCE: 20
Ser Gly Ile Ser Asn Lys Asp Leu Leu Leu Gln Ala Gly Asp Val Glu
1           5           10          15
```

```
Thr Asn Pro Gly Pro
20
```

```
<210> SEQ ID NO 21
<211> LENGTH: 51
<212> TYPE: DNA
<213> ORGANISM: Equine rhinitis B
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(51)
<223> OTHER INFORMATION: Equine rhinitis B 2A
```

```
<400> SEQUENCE: 21
```

```
aac ttt gac ctg ctc aaa ctg gca ggc gat gtg gaa tca aac cca ggc      48
Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly
1           5           10          15
```

```
ccc      51
Pro
```

```
<210> SEQ ID NO 22
<211> LENGTH: 17
```

US 10,435,695 B2

63**64**

-continued

<212> TYPE: PRT
<213> ORGANISM: Equine rhinitis B

<400> SEQUENCE: 22

Asn	Phe	Asp	Leu	Leu	Lys	Leu	Ala	Gly	Asp	Val	Glu	Ser	Asn	Pro	Gly
1			5			10			15						

Pro

<210> SEQ ID NO 23
<211> LENGTH: 570
<212> TYPE: DNA
<213> ORGANISM: Sus scrofa
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(570)
<223> OTHER INFORMATION: Porcine Interferon Alpha

<400> SEQUENCE: 23

atg	gcc	cca	acc	tca	gcc	ttc	ctc	acg	gcc	ctg	gtg	cta	ctc	agc	tgc	48
Met	Ala	Pro	Thr	Ser	Ala	Phe	Leu	Thr	Ala	Leu	Val	Leu	Leu	Ser	Cys	
1			5			10			15							
aat	gcc	atc	tgc	tct	ctg	ggc	tgt	gac	ctg	cct	cag	acc	cac	agc	ctg	96
Asn	Ala	Ile	Cys	Ser	Leu	Gly	Cys	Asp	Leu	Pro	Gln	Thr	His	Ser	Leu	
20			25			30										
gct	cac	acc	aga	gcc	ctg	agg	ctc	ctg	gca	caa	atg	agg	aga	atc	tct	144
Ala	His	Thr	Arg	Ala	Leu	Arg	Leu	Leu	Ala	Gln	Met	Arg	Arg	Ile	Ser	
35			40			45										
ccc	ttc	tcc	tgc	ctg	gac	cac	aga	agg	gac	ttt	ggt	tcc	cct	cat	gag	192
Pro	Phe	Ser	Cys	Leu	Asp	His	Arg	Arg	Asp	Phe	Gly	Ser	Pro	His	Glu	
50			55			60										
gct	ttt	ggg	ggc	aac	cag	gtc	cag	aag	gct	caa	gcc	atg	gct	ctg	gtg	240
Ala	Phe	Gly	Gly	Asn	Gln	Val	Gln	Lys	Ala	Gln	Ala	Met	Ala	Leu	Val	
65			70			75			80							
cat	gag	atg	ctc	cag	cag	acc	ttc	cag	ctc	tcc	atc	aca	gag	ggc	tcg	288
His	Glu	Met	Leu	Gln	Gln	Thr	Phe	Gln	Leu	Phe	Ser	Thr	Glu	Gly	Ser	
85			90			95										
gct	gct	gcc	tgg	aat	gag	agc	ctc	ctg	cac	cag	tcc	act	gga	ctg	336	
Ala	Ala	Ala	Trp	Asn	Glu	Ser	Leu	Leu	His	Gln	Phe	Cys	Thr	Gly	Leu	
100				105			110									
gat	cag	cag	ctc	agg	gac	ctg	gaa	gcc	tgt	gtc	atg	cag	gag	gcg	ggg	384
Asp	Gln	Gln	Leu	Arg	Asp	Leu	Glu	Ala	Cys	Val	Met	Gln	Glu	Ala	Gly	
115			120			125										
ctg	gaa	ggg	acc	ccc	ctg	ctg	gag	gag	gac	tcc	atc	ctg	gct	gtg	agg	432
Leu	Glu	Gly	Thr	Pro	Leu	Leu	Glu	Glu	Asp	Ser	Ile	Leu	Ala	Val	Arg	
130			135			140										
aaa	tac	ttc	cac	aga	ctc	acc	ctc	tat	ctg	caa	gag	aag	agc	tac	agc	480
Lys	Tyr	Phe	His	Arg	Leu	Thr	Leu	Tyr	Leu	Gln	Glu	Lys	Ser	Tyr	Ser	
145			150			155			160							
ccc	tgt	gcc	tgg	gag	atc	gtc	agg	gca	gaa	gtc	atg	aga	tcc	ttc	tct	528
Pro	Cys	Ala	Trp	Glu	Ile	Val	Arg	Ala	Glu	Val	Met	Arg	Ser	Phe	Ser	
165			170			175										
tcc	tcc	aga	aac	ctg	caa	gac	aga	ctc	agg	aag	aag	gag	tga		570	
Ser	Ser	Arg	Asn	Leu	Gln	Asp	Arg	Leu	Arg	Lys	Lys	Glu				
180				185												

<210> SEQ ID NO 24
<211> LENGTH: 189
<212> TYPE: PRT
<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 24

Met Ala Pro Thr Ser Ala Phe Leu Thr Ala Leu Val Leu Ser Cys

US 10,435,695 B2

65**66**

-continued

1	5	10	15
Asn	Ala	Ile	Cys
Ser	Leu	Gly	Cys
Asp	Leu	Pro	Gln
Thr	His	Ser	Leu
20	25	30	
Ala	His	Thr	Arg
Ala	Leu	Arg	Leu
Leu	Ala	Gln	Met
Arg	Arg	Arg	Arg
35	40	45	
Pro	Phe	Ser	Cys
Cys	Leu	Asp	His
Asp	Arg	Arg	Asp
50	55	60	
Pro	Phe	Gly	Gly
Ala	Phe	Gly	Asn
Gln	Val	Gln	Lys
Ala	Gln	Ala	Met
65	70	75	80
Ala	Phe	Gly	Gly
Glu	Met	Leu	Asn
Gln	Gln	Gln	Thr
Thr	Phe	Gln	Leu
Gln	Leu	Phe	Ser
85	90	95	
His	Glu	Met	Leu
Met	Gln	Gln	Thr
Leu	Gln	Thr	Phe
100	105	110	
Asp	Gln	Gln	Leu
Leu	Arg	Asp	Glu
Glu	Ala	Cys	Val
115	120	125	
Leu	Glu	Gly	Thr
Gly	Thr	Pro	Leu
Leu	Glu	Asp	Ser
130	135	140	
Lys	Tyr	Phe	His
Arg	Leu	Thr	Leu
145	150	155	160
Tyr	Gln	Glu	Lys
Ser	Tyr	Ser	Tyr
Pro	Cys	Ala	Trp
Glu	Ile	Val	Arg
165	170	175	
Ala	Glu	Val	Met
Glu	Val	Arg	Ser
Ser	Phe	Ser	Ser
Ser	Ser	Arg	Asn
Arg	Leu	Gln	Asp
Leu	Arg	Arg	Leu
180	185		
Lys	Lys	Glu	

<210> SEQ ID NO 25
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: Sus scrofa
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(66)
<223> OTHER INFORMATION: Porcine Interferon Alpha Secretion Peptide

<400> SEQUENCE: 25

atg	gcc	cca	acc	tca	gcc	ttc	ctc	acg	gcc	ctg	gtg	cta	ctc	agc	tgc
Met	Ala	Pro	Thr	Ser	Ala	Phe	Leu	Thr	Ala	Leu	Val	Leu	Leu	Ser	Cys
1	5	10							15						48

aat	gcc	atc	tgc	tct	ctg
Asn	Ala	Ile	Cys	Ser	Leu
20					

<210> SEQ ID NO 26
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 26

Met	Ala	Pro	Thr	Ser	Ala	Phe	Leu	Thr	Ala	Leu	Val	Leu	Leu	Ser	Cys
1	5	10							15						

Asn	Ala	Ile	Cys	Ser	Leu
20					

<210> SEQ ID NO 27
<211> LENGTH: 69
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(69)
<223> OTHER INFORMATION: Human Interferon Alpha Secretion peptide

US 10,435,695 B2

67

-continued

<400> SEQUENCE: 27

atg gcc tcg ccc ttt gct tta ctg atg gtc ctg gtg gtg ctc agc tgc	48
Met Ala Ser Pro Phe Ala Leu Leu Met Val Leu Val Val Leu Ser Cys	
1 5 10 15	

aag tca agc tgc tct ccg ggc	69
Lys Ser Ser Cys Ser Pro Gly	
20	

<210> SEQ ID NO 28

<211> LENGTH: 23	
<212> TYPE: PRT	
<213> ORGANISM: Homo sapiens	

<400> SEQUENCE: 28

Met Ala Ser Pro Phe Ala Leu Leu Met Val Leu Val Val Leu Ser Cys	
1 5 10 15	

Lys Ser Ser Cys Ser Pro Gly	
20	

<210> SEQ ID NO 29

<211> LENGTH: 63	
<212> TYPE: DNA	
<213> ORGANISM: Bos taurus	
<220> FEATURE:	
<221> NAME/KEY: CDS	
<222> LOCATION: (1)..(63)	
<223> OTHER INFORMATION: Bovine Interferon Beta Secretion Peptide	

<400> SEQUENCE: 29

atg acc tac cgg tgc ctc ctc cag atg gtt ctc ctg ctg tgt ttc tcc	48
Met Thr Tyr Arg Cys Leu Leu Gln Met Val Leu Leu Cys Phe Ser	
1 5 10 15	

acc aca gct ctt tcc	63
Thr Thr Ala Leu Ser	
20	

<210> SEQ ID NO 30

<211> LENGTH: 21	
<212> TYPE: PRT	
<213> ORGANISM: Bos taurus	

<400> SEQUENCE: 30

Met Thr Tyr Arg Cys Leu Leu Gln Met Val Leu Leu Cys Phe Ser	
1 5 10 15	

Thr Thr Ala Leu Ser	
20	

<210> SEQ ID NO 31

<211> LENGTH: 63	
<212> TYPE: DNA	
<213> ORGANISM: Sus scrofa	
<220> FEATURE:	
<221> NAME/KEY: CDS	
<222> LOCATION: (1)..(63)	
<223> OTHER INFORMATION: Porcine Interferon Beta Secretion Peptide	

<400> SEQUENCE: 31

atg gct aac aag tgc atc ctc caa atc gct ctc ctg atg tgt ttc tcc	48
Met Ala Asn Lys Cys Ile Leu Gln Ile Ala Leu Leu Met Cys Phe Ser	
1 5 10 15	

acc aca gct ctt tcc	63
Thr Thr Ala Leu Ser	
20	

68

US 10,435,695 B2

69

70

-continued

```

<210> SEQ ID NO 32
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 32

Met Ala Asn Lys Cys Ile Leu Gln Ile Ala Leu Leu Met Cys Phe Ser
1           5           10          15

Thr Thr Ala Leu Ser
20

```

```
<210> SEQ ID NO 33
<211> LENGTH: 63
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(63)
<223> OTHER INFORMATION: Human Interferon Beta Secretion peptide

<400> SEQUENCE: 33

atg acc aac aag tgt ctc ctc caa att gct ctc ctg ttg tgc ttc tcc
Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe Ser
1           5           10          15

acg aca gct ctt tcc
Thr Thr Ala Leu Ser
20
```

```

<210> SEQ ID NO 34
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 34

Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe Ser
1           5               10                      15

Thr Thr Ala Leu Ser
20

```

```
<210> SEQ ID NO 35
<211> LENGTH: 69
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(69)
<223> OTHER INFORMATION: Bovine Interferon Gamma Secretion peptide

<400> SEQUENCE: 35

atg aaa tat aca agc tat ttc tta gct tta ctg ctc tgt ggg ctt ttg
Met Lys Tyr Thr Ser Tyr Phe Leu Ala Leu Leu Cys Gly Leu Leu
1           5           10          15

ggt ttt tct ggt tct tat ggc
Gly Phe Ser Gly Ser Tyr Gly
20
```

```
<210> SEQ ID NO 36
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Bos taurus

<400> SEQUENCE: 36

Met Lys Tyr Thr Ser Tyr Phe Leu Ala Leu Leu Leu Cys Gly Leu Leu
1           5           10          15

Gly Phe Ser Gly Ser Tyr Gly
```

-continued

20

<210> SEQ ID NO 37
<211> LENGTH: 69
<212> TYPE: DNA
<213> ORGANISM: Sus scrofa
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(69)
<223> OTHER INFORMATION: Porcine Interferon Gamma Secretion peptide

<400> SEQUENCE: 37

atg agt tat aca act tat ttc tta gct ttt cag ctt tgc gtg act ttg Met Ser Tyr Thr Phe Leu Ala Phe Gln Leu Cys Val Thr Leu 1 5 10 15	48
tgt ttt tct ggc tct tac tgc Cys Phe Ser Gly Ser Tyr Cys 20	69

<210> SEQ ID NO 38
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 38

Met Ser Tyr Thr Phe Leu Ala Phe Gln Leu Cys Val Thr Leu 1 5 10 15
Cys Phe Ser Gly Ser Tyr Cys 20

<210> SEQ ID NO 39
<211> LENGTH: 69
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(69)
<223> OTHER INFORMATION: Human Interferon Gamma Secretion peptide

<400> SEQUENCE: 39

atg aaa tat aca agt tat atc ttg gct ttt cag ctc tgc atc gtt ttg Met Lys Tyr Thr Ser Tyr Ile Leu Ala Phe Gln Leu Cys Ile Val Leu 1 5 10 15	48
ggc tct ctt ggc tgt tac tgc Gly Ser Leu Gly Cys Tyr Cys 20	69

<210> SEQ ID NO 40
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 40

Met Lys Tyr Thr Ser Tyr Ile Leu Ala Phe Gln Leu Cys Ile Val Leu 1 5 10 15
Gly Ser Leu Gly Cys Tyr Cys 20

<210> SEQ ID NO 41
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(57)
<223> OTHER INFORMATION: Bovine Interferon Lambda Secretion peptide

-continued

<400> SEQUENCE: 41

atg gcc ccg ggc tgc acg ctg gtg ctg gtg ctg atg	48
Met Ala Pro Gly Cys Thr Leu Val Leu Val Met Leu	
1 5 10 15	
gcg ctg agc	57
Ala Leu Ser	

<210> SEQ ID NO 42

<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: Bos taurus

<400> SEQUENCE: 42

Met Ala Pro Gly Cys Thr Leu Val Leu Val Met Leu	
1 5 10 15	

Ala Leu Ser

<210> SEQ ID NO 43

<211> LENGTH: 48
<212> TYPE: DNA
<213> ORGANISM: Sus scrofa
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(48)
<223> OTHER INFORMATION: Porcine Interferon Lambda Secretion peptide

<400> SEQUENCE: 43

atg gct aca gct tgg atc gtg gtg ctg gcg act gtg atg	48
Met Ala Thr Ala Trp Ile Val Val Leu Ala Thr Val Met	
1 5 10 15	

<210> SEQ ID NO 44

<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 44

Met Ala Thr Ala Trp Ile Val Val Leu Ala Thr Val Met	
1 5 10 15	

<210> SEQ ID NO 45

<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(45)
<223> OTHER INFORMATION: Human Interferon Lambda Secretion peptide

<400> SEQUENCE: 45

atg gct gca gct tgg acc gtg gtg ctg gtg act ttg gtg cta	45
Met Ala Ala Ala Trp Thr Val Val Leu Val Thr Leu Val	
1 5 10 15	

<210> SEQ ID NO 46

<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 46

Met Ala Ala Ala Ala Trp Thr Val Val Leu Val Thr Leu	
1 5 10 15	

<210> SEQ ID NO 47

-continued

<211> LENGTH: 1065
<212> TYPE: DNA
<213> ORGANISM: Sus scrofa
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1065)
<223> OTHER INFORMATION: Porcine SGLuCON Alpha

<400> SEQUENCE: 47

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag	48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc	96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	
agc aac ttt gcg acc acg gat ctc gat gct gac cga ggg aag ttg ccc	144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	
ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc	192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc	240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	
aag tgc acg ccc aag atg aag aag tgg ctc cca gga cgc tgc cac acc	288
Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr	
85 90 95	
tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag gcg atc	336
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Ile Gly Glu Ala Ile	
100 105 110	
gtc gat att cct gag att cct ggg ttc aag gac ttg gag cca atg gag	384
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115 120 125	
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc	432
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130 135 140	
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg	480
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145 150 155 160	
ctg ccg caa cgc tgt ggc acc ttt gcc agc aag atc cag ggc cag gtg	528
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val	
165 170 175	
gac aag atc aag ggg gcc ggt ggt gac ggg ccc ggg tgt gac ctg cct	576
Asp Lys Ile Lys Gly Ala Gly Asp Gly Pro Gly Cys Asp Leu Pro	
180 185 190	
cag acc cac agc ctg gct cac acc aga gcc ctg agg ctc ctg gca caa	624
Gln Thr His Ser Leu Ala His Thr Arg Ala Leu Arg Leu Leu Ala Gln	
195 200 205	
atg agg aga atc tct ccc ttc tcc tgc ctg gac cac aga agg gac ttt	672
Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Asp His Arg Arg Asp Phe	
210 215 220	
ggt tcc cct cat gag gct ttt ggg ggc aac cag gtc cag aag gct caa	720
Gly Ser Pro His Glu Ala Phe Gly Gly Asn Gln Val Gln Lys Ala Gln	
225 230 235 240	
gcc atg gct ctg gtg cat gag atg ctc cag cag acc ttc cag ctc ttc	768
Ala Met Ala Leu Val His Glu Met Leu Gln Gln Thr Phe Gln Leu Phe	
245 250 255	
agc aca gag ggc tcg gct gct gcc tgg aat gag agc ctc ctg cac cag	816
Ser Thr Glu Gly Ser Ala Ala Ala Trp Asn Glu Ser Leu Leu His Gln	
260 265 270	
ttc tgc act gga ctg gat cag cag ctc agg gac ctg gaa gcc tgt gtc	864

US 10,435,695 B2

77

78

-continued

Phe Cys Thr Gly Leu Asp Gln Gln	Leu Arg Asp Leu Glu Ala Cys Val		
275	280	285	
atg cag gag gcg ggg ctg gaa ggg acc ccc ctg ctg gag gag gac tcc		912	
Met Gln Glu Ala Gly Leu Glu Gly Thr Pro Leu Leu Glu Glu Asp Ser			
290	295	300	
atc ctg gct gtg agg aaa tac ttc cac aga ctc acc ctc tat ctg caa		960	
Ile Leu Ala Val Arg Lys Tyr Phe His Arg Leu Thr Leu Tyr Leu Gln			
305	310	315	320
gag aag agc tac agc ccc tgt gcc tgg gag atc gtc agg gca gaa gtc		1008	
Glu Lys Ser Tyr Ser Pro Cys Ala Trp Glu Ile Val Arg Ala Glu Val			
325	330	335	
atg aga tcc ttc tct tcc aga aac ctg caa gac aga ctc agg aag		1056	
Met Arg Ser Phe Ser Ser Arg Asn Leu Gln Asp Arg Leu Arg Lys			
340	345	350	
aag gag tga		1065	
Lys Glu			

<210> SEQ ID NO 48

<211> LENGTH: 354

<212> TYPE: PRT

<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 48

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu			
1	5	10	15

Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala		
20	25	30

Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro		
35	40	45

Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala		
50	55	60

Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile			
65	70	75	80

Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr		
85	90	95

Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile		
100	105	110

Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu		
115	120	125

Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys		
130	135	140

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp			
145	150	155	160

Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val		
165	170	175

Asp Lys Ile Lys Gly Ala Gly Gly Asp Gly Pro Gly Cys Asp Leu Pro		
180	185	190

Gln Thr His Ser Leu Ala His Thr Arg Ala Leu Arg Leu Leu Ala Gln		
195	200	205

Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Asp His Arg Arg Asp Phe		
210	215	220

Gly Ser Pro His Glu Ala Phe Gly Gly Asn Gln Val Gln Lys Ala Gln			
225	230	235	240

Ala Met Ala Leu Val His Glu Met Leu Gln Gln Thr Phe Gln Leu Phe		
245	250	255

Ser Thr Glu Gly Ser Ala Ala Ala Trp Asn Glu Ser Leu Leu His Gln

US 10,435,695 B2

79

80

-continued

260

265

270

Phe Cys Thr Gly Leu Asp Gln Gln Leu Arg Asp Leu Glu Ala Cys Val
 275 280 285

Met Gln Glu Ala Gly Leu Glu Gly Thr Pro Leu Leu Glu Glu Asp Ser
 290 295 300

Ile Leu Ala Val Arg Lys Tyr Phe His Arg Leu Thr Leu Tyr Leu Gln
 305 310 315 320

Glu Lys Ser Tyr Ser Pro Cys Ala Trp Glu Ile Val Arg Ala Glu Val
 325 330 335

Met Arg Ser Phe Ser Ser Arg Asn Leu Gln Asp Arg Leu Arg Lys
 340 345 350

Lys Glu

<210> SEQ ID NO 49

<211> LENGTH: 570

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(570)

<223> OTHER INFORMATION: Human Interferon Alpha

<400> SEQUENCE: 49

atg gcc tcg ccc ttt gct tta ctg atg gtc ctg gtg gtc	48
Met Ala Ser Pro Phe Ala Leu Leu Met Val Leu Val Val	
1 5 10 15	

aag tca agc tgc tct ccg ggc tgt gat ctc cct gag acc cac	96
lys Ser Ser Cys Ser Pro Gly Cys Asp Leu Pro Glu Thr His Ser Leu	
20 25 30	

gat aac agg acc ttg atg ctc ctg gca caa atg agc aga atc tct	144
Asp Asn Arg Arg Thr Leu Met Leu Leu Ala Gln Met Ser Arg Ile Ser	
35 40 45	

cct tcc tcc tgt ctg atg gac aga cat gac ttt gga ttt ccc cag gag	192
Pro Ser Ser Cys Leu Met Asp Arg His Asp Phe Gly Phe Pro Gln Glu	
50 55 60	

gag ttt gat ggc aac cag ttc cag aag gct cca gcc atc tct gtc ctc	240
Glu Phe Asp Gly Asn Gln Phe Gln Lys Ala Pro Ala Ile Ser Val Leu	
65 70 75 80	

caa gag ctg atc cag cag atc ttc aac ctc ttt acc aca aaa gat tca	288
Gln Glu Leu Ile Gln Gln Ile Phe Asn Leu Phe Thr Thr Lys Asp Ser	
85 90 95	

tct gct gct tgg gat gag gac ctc cta gac aaa ttc tgc acc gaa ctc	336
Ser Ala Ala Trp Asp Glu Asp Leu Leu Asp Lys Phe Cys Thr Glu Leu	
100 105 110	

tac cag cag ctg aat gac ttg gaa gcc tgt gtg atg cag gag gag agg	384
Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Met Gln Glu Glu Arg	
115 120 125	

gtg gga gaa act ccc ctg atg aat gcg gac tcc atc ttg gct gtg aag	432
Val Gly Glu Thr Pro Leu Met Asn Ala Asp Ser Ile Leu Ala Val Lys	
130 135 140	

aaa tac ttc cga aga atc act ctc tat ctg acg gag aag aaa tac agc	480
Lys Tyr Phe Arg Arg Ile Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser	
145 150 155 160	

cct tgt gcc tgg gag gtc aga gca gaa atc gtg aga tcc ctc tct	528
Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile Val Arg Ser Leu Ser	
165 170 175	

tta tca aca aac ttg caa gaa aga tta agg agg aag gaa taa	570
Leu Ser Thr Asn Leu Gln Glu Arg Leu Arg Arg Lys Glu	
180 185	

-continued

<210> SEQ ID NO 50
<211> LENGTH: 189
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 50

```

Met Ala Ser Pro Phe Ala Leu Leu Met Val Leu Val Val Leu Ser Cys
1           5          10          15

Lys Ser Ser Cys Ser Pro Gly Cys Asp Leu Pro Glu Thr His Ser Leu
20          25          30

Asp Asn Arg Arg Thr Leu Met Leu Leu Ala Gln Met Ser Arg Ile Ser
35          40          45

Pro Ser Ser Cys Leu Met Asp Arg His Asp Phe Gly Phe Pro Gln Glu
50          55          60

Glu Phe Asp Gly Asn Gln Phe Gln Lys Ala Pro Ala Ile Ser Val Leu
65          70          75          80

Gln Glu Leu Ile Gln Gln Ile Phe Asn Leu Phe Thr Thr Lys Asp Ser
85          90          95

Ser Ala Ala Trp Asp Glu Asp Leu Leu Asp Lys Phe Cys Thr Glu Leu
100         105         110

Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Met Gln Glu Glu Arg
115         120         125

Val Gly Glu Thr Pro Leu Met Asn Ala Asp Ser Ile Leu Ala Val Lys
130         135         140

Lys Tyr Phe Arg Arg Ile Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser
145         150         155         160

Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile Val Arg Ser Leu Ser
165         170         175

Leu Ser Thr Asn Leu Gln Glu Arg Leu Arg Arg Lys Glu
180         185

```

<210> SEQ ID NO 51
<211> LENGTH: 1056
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1056)
<223> OTHER INFORMATION: Human GlucON Alpha

<400> SEQUENCE: 51

```

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag      48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu
1           5          10          15

gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc      96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala
20          25          30

agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc    144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
35          40          45

ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc    192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
50          55          60

cggttggaaaactggccaccaggggttgtctgtatcgttgcgtccacatc            240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
65          70          75          80

aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc    288
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr
85          90          95

```

-continued

tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag ggc atc Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100 105 110	336
gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115 120 125	384
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130 135 140	432
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp 145 150 155 160	480
ctg ccg caa cgc tgt gcg acc ttt gcc agc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175	528
gac aag atc aag ggg gcc ggt ggt gac tgt gat ctc cct gag acc cac Asp Lys Ile Lys Gly Ala Gly Asp Cys Asp Leu Pro Glu Thr His 180 185 190	576
agc ctg gat aac agg agg acc ttg atg ctc ctg gca caa atg agc aga Ser Leu Asp Asn Arg Arg Thr Leu Met Leu Ala Gln Met Ser Arg 195 200 205	624
atc tct cct tcc tcc tgt ctg atg gac aga cat gac ttt gga ttt ccc Ile Ser Pro Ser Ser Cys Leu Met Asp Arg His Asp Phe Gly Phe Pro 210 215 220	672
cag gag gag ttt gat ggc aac cag ttc cag aag gct cca gcc atc tct Gln Glu Phe Asp Gly Asn Gln Phe Gln Lys Ala Pro Ala Ile Ser 225 230 235 240	720
gtc ctc caa gag ctg atc cag cag atc ttc aac ctc ttt acc aca aaa Val Leu Gln Glu Leu Ile Gln Ile Phe Asn Leu Phe Thr Thr Lys 245 250 255	768
gat tca tct gct tgg gat gag gac ctc cta gac aaa ttc tgc acc Asp Ser Ser Ala Ala Trp Asp Glu Asp Leu Leu Asp Lys Phe Cys Thr 260 265 270	816
gaa ctc tac cag cag ctg aat gac ttg gaa gcc tgt gtg atg cag gag Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Met Gln Glu 275 280 285	864
gag agg gtg gga gaa act ccc ctg atg aat gcg gac tcc atc ttg gct Glu Arg Val Gly Glu Thr Pro Leu Met Asn Ala Asp Ser Ile Leu Ala 290 295 300	912
gtg aag aaa tac ttc cga aga atc act ctc tat ctg acg gag aag aaa Val Lys Lys Tyr Phe Arg Arg Ile Thr Leu Tyr Leu Thr Glu Lys Lys 305 310 315 320	960
tac agc cct tgt gcc tgg gag gtt gtc aga gca gaa atc gtg aga tcc Tyr Ser Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile Val Arg Ser 325 330 335	1008
ctc tct tta tca aca aac ttg caa gaa aga tta agg agg aag gaa taa Leu Ser Leu Ser Thr Asn Leu Gln Glu Arg Leu Arg Arg Lys Glu 340 345 350	1056

<210> SEQ ID NO 52

<211> LENGTH: 351

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 52

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	

Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	

US 10,435,695 B2

85

86

-continued

Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
35 40 45

Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
50 55 60

Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
65 70 75 80

Lys Cys Thr Pro Lys Met Lys Phe Ile Pro Gly Arg Cys His Thr
85 90 95

Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile
100 105 110

Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu
115 120 125

Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys
130 135 140

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
145 150 155 160

Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
165 170 175

Asp Lys Ile Lys Gly Ala Gly Gly Asp Cys Asp Leu Pro Glu Thr His
180 185 190

Ser Leu Asp Asn Arg Arg Thr Leu Met Leu Leu Ala Gln Met Ser Arg
195 200 205

Ile Ser Pro Ser Ser Cys Leu Met Asp Arg His Asp Phe Gly Phe Pro
210 215 220

Gln Glu Glu Phe Asp Gly Asn Gln Phe Gln Lys Ala Pro Ala Ile Ser
225 230 235 240

Val Leu Gln Glu Leu Ile Gln Gln Ile Phe Asn Leu Phe Thr Thr Lys
245 250 255

Asp Ser Ser Ala Ala Trp Asp Glu Asp Leu Leu Asp Lys Phe Cys Thr
260 265 270

Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Met Gln Glu
275 280 285

Glu Arg Val Gly Glu Thr Pro Leu Met Asn Ala Asp Ser Ile Leu Ala
290 295 300

Val Lys Lys Tyr Phe Arg Arg Ile Thr Leu Tyr Leu Thr Glu Lys Lys
305 310 315 320

Tyr Ser Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile Val Arg Ser
325 330 335

Leu Ser Leu Ser Thr Asn Leu Gln Glu Arg Leu Arg Arg Lys Glu
340 345 350

<210> SEQ ID NO 53

<211> LENGTH: 570

<212> TYPE: DNA

<213> ORGANISM: Bos taurus

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(570)

<223> OTHER INFORMATION: Bovine Interferon Alpha

<400> SEQUENCE: 53

atg gcc cca gcc tgg tcc ttc ctg cta tcc ctg ttg ctg ctc agc tgc
Met Ala Pro Ala Trp Ser Phe Leu Leu Ser Leu Leu Leu Ser Cys
1 5 10 15

48

aac gcc atc tgc tct ctg ggt tgc cac ctg cct cac acc cac agc ctg
Asn Ala Ile Cys Ser Leu Gly Cys His Leu Pro His Thr His Ser Leu
20 25 30

96

-continued

gcc aac agg agg gtc ctg atg ctc ctg caa caa ctg aga agg gtc tcc Ala Asn Arg Arg Val Leu Met Leu Leu Gln Gln Leu Arg Arg Val Ser 35 40 45	144
cct tcc tcc tgc ctg cag gag aat gac ttc gaa ttc ctc cag gag Pro Ser Ser Cys Leu Gln Asp Arg Asn Asp Phe Glu Phe Leu Gln Glu 50 55 60	192
gct ctg ggt ggc agc cag ttg cag aag gct caa gcc atc tct gtg ctc Ala Leu Gly Gly Ser Gln Leu Gln Lys Ala Gln Ala Ile Ser Val Leu 65 70 75 80	240
cac gag gtg acc cag cac acc ttc cag ctc ttc agc aca gag ggc tcg His Glu Val Thr Gln His Thr Phe Gln Leu Phe Ser Thr Glu Gly Ser 85 90 95	288
ccc gcc acg tgg gac aag agc ctc ctg gac aag cta cgc gct gcg ctg Pro Ala Thr Trp Asp Lys Ser Leu Leu Asp Lys Leu Arg Ala Ala Leu 100 105 110	336
gat cag cag ctc act gac ctg caa gcc tgt ctg acg cag gag gag ggg Asp Gln Gln Leu Thr Asp Leu Gln Ala Cys Leu Thr Gln Glu Glu Gly 115 120 125	384
ctg cga ggg gct ccc ctg ctc aag gag gac tcc agc ctg gct gtg agg Leu Arg Gly Ala Pro Leu Leu Lys Glu Asp Ser Ser Leu Ala Val Arg 130 135 140	432
aaa tac ttc cac aga ctc act ctc tat ctg caa gag aag aga cac agc Lys Tyr Phe His Arg Leu Thr Leu Tyr Leu Gln Glu Lys Arg His Ser 145 150 155 160	480
cct tgt gcc tgg gag gtt gtc aga gca gaa gtc atg aga gcc ttc tct Pro Cys Ala Trp Glu Val Val Arg Ala Glu Val Met Arg Ala Phe Ser 165 170 175	528
tcc tca aca aac ttg cag gag agt ttc agg aga aag gac tga Ser Ser Thr Asn Leu Gln Glu Ser Phe Arg Arg Lys Asp 180 185	570

<210> SEQ ID NO 54

<211> LENGTH: 189

<212> TYPE: PRT

<213> ORGANISM: Bos taurus

<400> SEQUENCE: 54

Met Ala Pro Ala Trp Ser Phe Leu Leu Ser Leu Leu Leu Ser Cys
1 5 10 15

Asn Ala Ile Cys Ser Leu Gly Cys His Leu Pro His Thr His Ser Leu
20 25 30

Ala Asn Arg Arg Val Leu Met Leu Leu Gln Gln Leu Arg Arg Val Ser
35 40 45

Pro Ser Ser Cys Leu Gln Asp Arg Asn Asp Phe Glu Phe Leu Gln Glu
50 55 60

Ala Leu Gly Gly Ser Gln Leu Gln Lys Ala Gln Ala Ile Ser Val Leu
65 70 75 80

His Glu Val Thr Gln His Thr Phe Gln Leu Phe Ser Thr Glu Gly Ser
85 90 95

Pro Ala Thr Trp Asp Lys Ser Leu Leu Asp Lys Leu Arg Ala Ala Leu
100 105 110

Asp Gln Gln Leu Thr Asp Leu Gln Ala Cys Leu Thr Gln Glu Glu Gly
115 120 125

Leu Arg Gly Ala Pro Leu Leu Lys Glu Asp Ser Ser Leu Ala Val Arg
130 135 140

Lys Tyr Phe His Arg Leu Thr Leu Tyr Leu Gln Glu Lys Arg His Ser
145 150 155 160

US 10,435,695 B2

89

90

-continued

Pro Cys Ala Trp Glu Val Val Arg Ala Glu Val Met Arg Ala Phe Ser
165 170 175

Ser Ser Thr Asn Leu Gln Glu Ser Phe Arg Arg Lys Asp
180 185

<210> SEQ ID NO 55

<211> LENGTH: 1056

<212> TYPE: DNA

<213> ORGANISM: Bos taurus

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1) ..(1056)

<223> OTHER INFORMATION: Bovine GlucON Alpha

<400> SEQUENCE: 55

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag	48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	

gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc	96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	

agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc	144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	

ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc	192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	

cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc	240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	

aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc	288
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr	
85 90 95	

tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag gcg atc	336
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile	
100 105 110	

gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag	384
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115 120 125	

cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc	432
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130 135 140	

ctc aaa ggg ctt gcc aac gtc gac tgc ttt gac aag atc cag ggc cag gtg	480
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145 150 155 160	

ctg ccg caa cgc tgt gcg acc ttt gcc agc aag atc cag ggc cag gtg	528
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val	
165 170 175	

gac aag atc aag ggg gcc ggt ggt gac tgc cac ctg cct cac acc cac	576
Asp Lys Ile Lys Gly Ala Gly Gly Asp Cys His Leu Pro His Thr His	
180 185 190	

agc ctg gcc aac agg agg gtc ctg atg ctc ctg caa caa ctg aga agg	624
Ser Leu Ala Asn Arg Arg Val Met Leu Leu Gln Gln Leu Arg Arg	
195 200 205	

gtc tcc cct tcc tgc ctg cag gac aga aat gac ttc gaa ttc ctc	672
Val Ser Pro Ser Ser Cys Leu Gln Asp Arg Asn Asp Phe Glu Phe Leu	
210 215 220	

cag gag gct ctg ggt ggc agc cag ttg cag aag gct caa gcc atc tct	720
Gln Glu Ala Leu Gly Gly Ser Gln Leu Gln Lys Ala Gln Ala Ile Ser	
225 230 235 240	

gtg ctc cac gag gtg acc cag cac acc ttc cag ctc ttc agc aca gag	768
---	-----

US 10,435,695 B2

91**92**

-continued

Val	Leu	His	Glu	Val	Thr	Gln	His	Thr	Phe	Gln	Leu	Phe	Ser	Thr	Glu	
				245				250				255				
ggc	tgc	ccc	gcc	acg	tgg	gac	aag	agc	ctc	ctg	gac	aag	cta	cgc	gct	816
Gly	Ser	Pro	Ala	Thr	Trp	Asp	Lys	Ser	Leu	Leu	Asp	Lys	Leu	Arg	Ala	
				260				265				270				
gcg	ctg	gat	cag	cag	ctc	act	gac	ctg	caa	gcc	tgt	ctg	acg	cag	gag	864
Ala	Leu	Asp	Gln	Gln	Leu	Thr	Asp	Leu	Gln	Ala	Cys	Leu	Thr	Gln	Glu	
				275				280			285					
gag	ggg	ctg	cga	ggg	gct	ccc	ctg	ctc	aag	gag	gac	tcc	acg	ctg	gct	912
Glu	Gly	Leu	Arg	Gly	Ala	Pro	Leu	Leu	Lys	Glu	Asp	Ser	Ser	Leu	Ala	
				290				295			300					
gtg	agg	aaa	tac	ttc	cac	aga	ctc	act	ctc	tat	ctg	caa	gag	aag	aga	960
Val	Arg	Lys	Tyr	Phe	His	Arg	Leu	Thr	Leu	Tyr	Leu	Gln	Glu	Lys	Arg	
				305				310			315			320		
cac	agc	cct	tgt	gcc	tgg	gag	gtt	gtc	aga	gca	gaa	gtc	atg	aga	gcc	1008
His	Ser	Pro	Cys	Ala	Trp	Glu	Val	Val	Arg	Ala	Glu	Val	Met	Arg	Ala	
				325				330			335					
tcc	tct	tcc	tca	aca	aac	ttg	cag	gag	agt	ttc	agg	aga	aag	gac	tga	1056
Phe	Ser	Ser	Thr	Asn	Leu	Gln	Ser	Phe	Arg	Arg	Lys	Asp				
				340				345			350					

<210> SEQ ID NO: 56

<211> LENGTH: 351

<212> TYPE: PRT

<213> ORGANISM: Bos taurus

<400> SEQUENCE: 56

Met	Gly	Val	Lys	Val	Leu	Phe	Ala	Leu	Ile	Cys	Ile	Ala	Val	Ala	Glu	
1				5				10				15				
Ala	Lys	Pro	Thr	Glu	Asn	Asn	Glu	Asp	Phe	Asn	Ile	Val	Ala	Val	Ala	
				20				25			30					
Ser	Asn	Phe	Ala	Thr	Thr	Asp	Leu	Asp	Ala	Asp	Arg	Gly	Lys	Leu	Pro	
				35				40			45					
Gly	Lys	Lys	Leu	Pro	Leu	Glu	Val	Leu	Lys	Glu	Met	Glu	Ala	Asn	Ala	
				50				55			60					
Arg	Lys	Ala	Gly	Cys	Thr	Arg	Gly	Cys	Leu	Ile	Cys	Leu	Ser	His	Ile	
				65				70			75			80		
Lys	Cys	Thr	Pro	Lys	Met	Lys	Lys	Phe	Ile	Pro	Gly	Arg	Cys	His	Thr	
				85				90			95					
Tyr	Glu	Gly	Asp	Lys	Glu	Ser	Ala	Gln	Gly	Gly	Ile	Gly	Glu	Ala	Ile	
				100				105			110					
Val	Asp	Ile	Pro	Glu	Ile	Pro	Gly	Phe	Lys	Asp	Leu	Glu	Pro	Met	Glu	
				115				120			125					
Gln	Phe	Ile	Ala	Gln	Val	Asp	Leu	Cys	Val	Asp	Cys	Thr	Thr	Gly	Cys	
				130				135			140					
Leu	Lys	Gly	Leu	Ala	Asn	Val	Gln	Cys	Ser	Asp	Leu	Leu	Lys	Lys	Trp	
				145				150			155			160		
Leu	Pro	Gln	Arg	Cys	Ala	Thr	Phe	Ala	Ser	Lys	Ile	Gln	Gly	Gln	Val	
				165				170			175					
Asp	Lys	Ile	Lys	Gly	Ala	Gly	Gly	Asp	Cys	His	Leu	Pro	His	Thr	His	
				180				185			190					
Ser	Leu	Ala	Asn	Arg	Arg	Val	Leu	Met	Leu	Leu	Gln	Gln	Leu	Arg	Arg	
				195				200			205					
Val	Ser	Pro	Ser	Ser	Cys	Leu	Gln	Asp	Arg	Asn	Asp	Phe	Glu	Phe	Leu	
				210				215			220					
Gln	Glu	Ala	Leu	Gly	Gly	Ser	Gln	Leu	Gln	Lys	Ala	Gln	Ala	Ile	Ser	
				225				230			235			240		

-continued

Val Leu His Glu Val Thr Gln His Thr Phe Gln Leu Phe Ser Thr Glu
245 250 255

Gly Ser Pro Ala Thr Trp Asp Lys Ser Leu Leu Asp Lys Leu Arg Ala
260 265 270

Ala Leu Asp Gln Gln Leu Thr Asp Leu Gln Ala Cys Leu Thr Gln Glu
275 280 285

Glu Gly Leu Arg Gly Ala Pro Leu Leu Lys Glu Asp Ser Ser Leu Ala
290 295 300

Val Arg Lys Tyr Phe His Arg Leu Thr Leu Tyr Leu Gln Glu Lys Arg
305 310 315 320

His Ser Pro Cys Ala Trp Glu Val Val Arg Ala Glu Val Met Arg Ala
325 330 335

Phe Ser Ser Ser Thr Asn Leu Gln Glu Ser Phe Arg Arg Lys Asp
340 345 350

<210> SEQ ID NO 57

<211> LENGTH: 564

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1) ..(564)

<223> OTHER INFORMATION: Human Interferon Beta

<400> SEQUENCE: 57

atg acc aac aag tgt ctc ctc caa att gct ctc ctg ttg tgc ttc tcc	48
Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Cys Phe Ser	
1 5 10 15	

acg aca gct ctt tcc atg agc tac aac ttg ctt gga ttc cta caa aga	96
Thr Thr Ala Leu Ser Met Ser Tyr Asn Leu Leu Gly Phe Leu Gln Arg	
20 25 30	

agc agc aat tgt cag tgt cag aag ctc ctg tgg caa ttg aat ggg agg	144
Ser Ser Asn Cys Gln Cys Gln Lys Leu Leu Trp Gln Leu Asn Gly Arg	
35 40 45	

ctt gaa tac tgc ctc aag gac agg aac ttt gac atc cct gag gag	192
Leu Glu Tyr Cys Leu Lys Asp Arg Arg Asn Phe Asp Ile Pro Glu Glu	
50 55 60	

att aag cag ctg cag cag ttc cag aag gag gac gcc gca gtg acc atc	240
Ile Lys Gln Leu Gln Gln Phe Gln Lys Glu Asp Ala Ala Val Thr Ile	
65 70 75 80	

tat gag atg ctc cag aac atc ttt gct att ttc aga caa gat tca tcg	288
Tyr Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln Asp Ser Ser	
85 90 95	

agc act ggc tgg aat gag act att gtt gag aac ctc ctg gct aat gtc	336
Ser Thr Gly Trp Asn Glu Thr Ile Val Glu Asn Leu Ala Asn Val	
100 105 110	

tat cat cag aga aac cat ctg aag aca gtc ctg gaa gaa aaa ctg gag	384
Tyr His Gln Arg Asn His Leu Lys Thr Val Leu Glu Glu Lys Leu Glu	
115 120 125	

aaa gaa gat ttc acc agg gga aaa cgc atg agc agt ctg cac ctg aaa	432
Lys Glu Asp Phe Thr Arg Gly Lys Arg Met Ser Ser Leu His Leu Lys	
130 135 140	

aga tat tat ggg agg att ctg cat tac ctg aag gcc aag gag gac agt	480
Arg Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys Ala Lys Glu Asp Ser	
145 150 155 160	

cac tgt gcc tgg acc ata gtc aga gtg gaa atc cta agg aac ttt tac	528
His Cys Ala Trp Thr Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr	
165 170 175	

gtc att aac aga ctt aca ggt tac ctc cga aac tga	564
---	-----

US 10,435,695 B2

95**96**

-continued

Val Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn
180 185

<210> SEQ ID NO 58

<211> LENGTH: 187

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 58

Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe Ser
1 5 10 15

Thr Thr Ala Leu Ser Met Ser Tyr Asn Leu Leu Gly Phe Leu Gln Arg
20 25 30

Ser Ser Asn Cys Gln Cys Gln Lys Leu Leu Trp Gln Leu Asn Gly Arg
35 40 45

Leu Glu Tyr Cys Leu Lys Asp Arg Arg Asn Phe Asp Ile Pro Glu Glu
50 55 60

Ile Lys Gln Leu Gln Gln Phe Gln Lys Glu Asp Ala Ala Val Thr Ile
65 70 75 80

Tyr Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln Asp Ser Ser
85 90 95

Ser Thr Gly Trp Asn Glu Thr Ile Val Glu Asn Leu Leu Ala Asn Val
100 105 110

Tyr His Gln Arg Asn His Leu Lys Thr Val Leu Glu Glu Lys Leu Glu
115 120 125

Lys Glu Asp Phe Thr Arg Gly Lys Arg Met Ser Ser Leu His Leu Lys
130 135 140

Arg Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys Ala Lys Glu Asp Ser
145 150 155 160

His Cys Ala Trp Thr Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr
165 170 175

Val Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn
180 185

<210> SEQ ID NO 59

<211> LENGTH: 1056

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(1056)

<223> OTHER INFORMATION: Human GlucON Beta

<400> SEQUENCE: 59

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag 48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu
1 5 10 15

gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc 96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala
20 25 30

agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc 144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
35 40 45

ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc 192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
50 55 60

cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc 240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
65 70 75 80

US 10,435,695 B2

97

98

-continued

aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr 85	90	95	288
tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag ggc atc Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100	105	110	336
gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115	120	125	384
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130	135	140	432
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp 145	150	155	480
ctg ccg caa cgc tgt gcg acc ttt gcc agc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165	170	175	528
gac aag atc aag ggg gcc ggt ggt gac atg agc tac aac ttg ctt gga Asp Lys Ile Lys Gly Ala Gly Gly Asp Met Ser Tyr Asn Leu Leu Gly 180	185	190	576
ttc cta caa aga agc agc aat tgt cag tgt cag aag ctc ctg tgg caa Phe Leu Gln Arg Ser Ser Asn Cys Gln Cys Gln Lys Leu Leu Trp Gln 195	200	205	624
ttg aat ggg agg ctt gaa tac tgc ctc aag gac agg agg aac ttt gac Leu Asn Gly Arg Leu Glu Tyr Cys Leu Lys Asp Arg Arg Asn Phe Asp 210	215	220	672
atc cct gag gag att aag cag ctg cag cag ttc cag aag gag gac gcc Ile Pro Glu Glu Ile Lys Gln Leu Gln Gln Phe Gln Lys Glu Asp Ala 225	230	235	720
gca gtg acc atc tat gag atg ctc cag aac atc ttt gct att ttc aga Ala Val Thr Ile Tyr Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg 245	250	255	768
caa gat tca tcg agc act ggc tgg aat gag act att gtt gag aac ctc Gln Asp Ser Ser Thr Gly Trp Asn Glu Thr Ile Val Glu Asn Leu 260	265	270	816
ctg gct aat gtc tat cat cag aga aac cat ctg aag aca gtc ctg gaa Leu Ala Asn Val Tyr His Gln Arg Asn His Leu Lys Thr Val Leu Glu 275	280	285	864
gaa aaa ctg gag aaa gaa gat ttc acc agg gga aaa cgc atg agc agt Glu Lys Leu Glu Lys Glu Asp Phe Thr Arg Gly Lys Arg Met Ser Ser 290	295	300	912
ctg cac ctg aaa aga tat tat ggg agg att ctg cat tac ctg aag gcc Leu His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys Ala 305	310	315	960
aag gag gac agt cac tgt gcc tgg acc ata gtc aga gtg gaa atc cta Lys Glu Asp Ser His Cys Ala Trp Thr Ile Val Arg Val Glu Ile Leu 325	330	335	1008
agg aac ttt tac gtc att aac aga ctt aca ggt tac ctc cga aac tga Arg Asn Phe Tyr Val Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn 340	345	350	1056

<210> SEQ ID NO 60

<211> LENGTH: 351

<212> TYPE: PRT

<213> ORGANISM: *Homo sapiens*

<400> SEQUENCE: 60

Met	Gly	Val	Lys	Val	Leu	Phe	Ala	Leu	Ile	Cys	Ile	Ala	Val	Ala	Glut
1				5					10						15

US 10,435,695 B2

99**100**

-continued

Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala
 20 25 30
 Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
 35 40 45
 Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
 50 55 60
 Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
 65 70 75 80
 Lys Cys Thr Pro Lys Met Lys Phe Ile Pro Gly Arg Cys His Thr
 85 90 95
 Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile
 100 105 110
 Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu
 115 120 125
 Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys
 130 135 140
 Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
 145 150 155 160
 Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
 165 170 175
 Asp Lys Ile Lys Gly Ala Gly Gly Asp Met Ser Tyr Asn Leu Leu Gly
 180 185 190
 Phe Leu Gln Arg Ser Ser Asn Cys Gln Cys Gln Lys Leu Leu Trp Gln
 195 200 205
 Leu Asn Gly Arg Leu Glu Tyr Cys Leu Lys Asp Arg Arg Asn Phe Asp
 210 215 220
 Ile Pro Glu Glu Ile Lys Gln Leu Gln Phe Gln Lys Glu Asp Ala
 225 230 235 240
 Ala Val Thr Ile Tyr Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg
 245 250 255
 Gln Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val Glu Asn Leu
 260 265 270
 Leu Ala Asn Val Tyr His Gln Arg Asn His Leu Lys Thr Val Leu Glu
 275 280 285
 Glu Lys Leu Glu Lys Glu Asp Phe Thr Arg Gly Lys Arg Met Ser Ser
 290 295 300
 Leu His Leu Lys Arg Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys Ala
 305 310 315 320
 Lys Glu Asp Ser His Cys Ala Trp Thr Ile Val Arg Val Glu Ile Leu
 325 330 335
 Arg Asn Phe Tyr Val Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn
 340 345 350

```

<210> SEQ_ID NO 61
<211> LENGTH: 561
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(561)
<223> OTHER INFORMATION: Bovine Interferon Beta

<400> SEQUENCE: 61
  
```

atg acc tac cgg tgc ctc ctc cag atg gtt ctc ctg ctg tgt ttc tcc
 Met Thr Tyr Arg Cys Leu Leu Gln Met Val Leu Leu Cys Phe Ser
 1 5 10 15

48

US 10,435,695 B2

101

102

-continued

acc aca gct ctt tcc agg agc tac agc ttg ctt cga ttc caa caa cgt	96
Thr Thr Ala Leu Ser Arg Ser Tyr Ser Leu Leu Arg Phe Gln Gln Arg	
20 25 30	
cag agc ctt aaa gag tgt cag aaa ctc ctg ggg cag tta cct tca act	144
Gln Ser Leu Lys Glu Cys Gln Lys Leu Leu Gly Gln Leu Pro Ser Thr	
35 40 45	
cct caa cat tgc ctc gag gcc agg atg gac ttc cag atg cct gag gag	192
Pro Gln His Cys Leu Glu Ala Arg Met Asp Phe Gln Met Pro Glu Glu	
50 55 60	
atg aag caa gaa cag cag ttc cag aag gaa gat gcc ata ttg gtc atg	240
Met Lys Gln Glu Gln Gln Phe Gln Lys Glu Asp Ala Ile Leu Val Met	
65 70 75 80	
tat gag gtg ctc cag cac atc ttc ggc att ctc acc aga gac ttc tcc	288
Tyr Glu Val Leu Gln His Ile Phe Gly Ile Leu Thr Arg Asp Phe Ser	
85 90 95	
agc act ggc tgg tct gag acc atc atc gag gac ctc ctt gag gaa ctc	336
Ser Thr Gly Trp Ser Glu Thr Ile Ile Glu Asp Leu Leu Glu Glu Leu	
100 105 110	
tat ggg cag atg aat cgt ctg cag cca atc cag aag gaa ata atg cag	384
Tyr Gly Gln Met Asn Arg Leu Gln Pro Ile Gln Lys Glu Ile Met Gln	
115 120 125	
aag caa aac acc aca gcg gga gac acg atc gtt ccc cac cta ggg aaa	432
Lys Gln Asn Thr Thr Ala Gly Asp Thr Ile Val Pro His Leu Gly Lys	
130 135 140	
tat tac ttc aac ctc atg cag tac ctg gag tcc aag gag tac gac agg	480
Tyr Tyr Phe Asn Leu Met Gln Tyr Leu Glu Ser Lys Glu Tyr Asp Arg	
145 150 155 160	
tgt gcc tgg aca gtc gtgcaa gtgata ctc acg aac gtt tct ttc	528
Cys Ala Trp Thr Val Val Gln Val Gln Ile Leu Thr Asn Val Ser Phe	
165 170 175	
ctg atg aga cta aca ggt tac gtc cgt gac tga	561
Leu Met Arg Leu Thr Gly Tyr Val Arg Asp	
180 185	
<210> SEQ_ID NO 62	
<211> LENGTH: 186	
<212> TYPE: PRT	
<213> ORGANISM: Bos taurus	
<400> SEQUENCE: 62	
Met Thr Tyr Arg Cys Leu Leu Gln Met Val Leu Leu Leu Cys Phe Ser	
1 5 10 15	
Thr Thr Ala Leu Ser Arg Ser Tyr Ser Leu Leu Arg Phe Gln Gln Arg	
20 25 30	
Gln Ser Leu Lys Glu Cys Gln Lys Leu Leu Gly Gln Leu Pro Ser Thr	
35 40 45	
Pro Gln His Cys Leu Glu Ala Arg Met Asp Phe Gln Met Pro Glu Glu	
50 55 60	
Met Lys Gln Glu Gln Gln Phe Gln Lys Glu Asp Ala Ile Leu Val Met	
65 70 75 80	
Tyr Glu Val Leu Gln His Ile Phe Gly Ile Leu Thr Arg Asp Phe Ser	
85 90 95	
Ser Thr Gly Trp Ser Glu Thr Ile Ile Glu Asp Leu Leu Glu Glu Leu	
100 105 110	
Tyr Gly Gln Met Asn Arg Leu Gln Pro Ile Gln Lys Glu Ile Met Gln	
115 120 125	
Lys Gln Asn Thr Thr Ala Gly Asp Thr Ile Val Pro His Leu Gly Lys	
130 135 140	

US 10,435,695 B2

103

104

-continued

Tyr	Tyr	Phe	Asn	Leu	Met	Gln	Tyr	Leu	Glu	Ser	Lys	Glu	Tyr	Asp	Arg
145							150		155			160			
Cys	Ala	Trp	Thr	Val	Val	Gln	Val	Gln	Ile	Leu	Thr	Asn	Val	Ser	Phe
				165				170			175				
Leu	Met	Arg	Leu	Thr	Gly	Tyr	Val	Arg	Asp						
				180			185								

<210> SEQ_ID NO 63
<211> LENGTH: 1053
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1053)
<223> OTHER INFORMATION: GlucON Beta Bovine

<400> SEQUENCE: 63

atg	gga	gtc	aaa	gtt	ctg	ttt	gcc	ctg	atc	tgc	atc	gct	gtg	gcc	gag	48	
Met	Gly	Val	Lys	Val	Leu	Phe	Ala	Leu	Ile	Cys	Ile	Ala	Val	Ala	Glu		
1							5		10		15						
gcc	aag	ccc	acc	gag	aac	aac	gaa	gac	ttc	aatc	gtg	gcc	gtg	gcc	96		
Ala	Lys	Pro	Thr	Glu	Asn	Asn	Glu	Asp	Phe	Asn	Ile	Val	Ala	Val	Ala		
							20		25		30						
agc	aac	ttc	gcg	acc	acg	gat	ctc	gat	gct	gac	cgc	ggg	aag	ttg	ccc	144	
Ser	Asn	Phe	Ala	Thr	Thr	Asp	Leu	Asp	Ala	Asp	Arg	Gly	Lys	Leu	Pro		
							35		40		45						
ggc	aag	aag	ctg	ccg	ctg	gag	gtg	ctc	aaa	gag	atg	gaa	gcc	aat	gcc	192	
Gly	Lys	Lys	Leu	Pro	Leu	Glu	Val	Leu	Lys	Glu	Met	Glu	Ala	Asn	Ala		
							50		55		60						
cgg	aaa	gct	ggc	tgc	acc	agg	ggc	tgt	ctg	atc	tgc	ctg	tcc	cac	atc	240	
Arg	Lys	Ala	Gly	Cys	Thr	Arg	Gly	Cys	Leu	Ile	Cys	Leu	Ser	His	Ile		
							65		70		75		80				
aag	tgc	acg	ccc	aag	atg	aag	aag	ttc	atc	cca	gga	cgc	tgc	cac	acc	288	
Lys	Cys	Thr	Pro	Lys	Met	Lys	Lys	Phe	Ile	Pro	Gly	Arg	Cys	His	Thr		
							85		90		95						
tac	gaa	ggc	gac	aaa	gag	tcc	gca	cag	ggc	ggc	ata	ggc	gag	gag	atc	336	
Tyr	Glu	Gly	Asp	Lys	Glu	Ser	Ala	Gln	Gly	Gly	Ile	Gly	Glu	Ala	Ile		
							100		105		110						
gtc	gac	att	cct	gag	att	cct	ggg	ttc	aag	gac	ttg	gag	ccc	atg	gag	384	
Val	Asp	Ile	Pro	Glu	Ile	Pro	Gly	Phe	Lys	Asp	Leu	Glu	Pro	Met	Glu		
							115		120		125						
cag	ttc	atc	gca	cag	gtc	gat	ctg	tgt	gtg	gac	tgc	aca	act	ggc	tgc	432	
Gln	Phe	Ile	Ala	Gln	Val	Asp	Leu	Cys	Val	Asp	Cys	Thr	Thr	Gly	Cys		
							130		135		140						
ctc	aaa	ggg	ctt	gcc	aac	gtg	cag	tgt	tct	gac	ctg	ctc	aag	tgg		480	
Leu	Lys	Gly	Leu	Ala	Asn	Val	Gln	Cys	Ser	Asp	Leu	Lys	Lys	Trp			
							145		150		155		160				
ctg	ccg	caa	cgc	tgt	ggc	acc	ttt	gcc	agc	aag	atc	cag	ggc	cag	gtg	528	
Leu	Pro	Gln	Arg	Cys	Ala	Thr	Phe	Ala	Ser	Lys	Ile	Gln	Gly	Gln	Val		
							165		170		175						
gac	aag	atc	aag	ggg	gcc	ggt	ggt	gac	agg	agc	tac	agc	ttg	ctt	cga	576	
Asp	Lys	Ile	Lys	Gly	Ala	Gly	Gly	Asp	Arg	Ser	Tyr	Ser	Leu	Leu	Arg		
							180		185		190						
tcc	caa	caa	cgt	cag	agc	ctt	aaa	gag	tgt	cag	aaa	ctc	ctg	ggg	cag	624	
Phe	Gln	Gln	Arg	Gln	Ser	Leu	Lys	Glu	Cys	Gln	Lys	Leu	Leu	Gly	Gln		
							195		200		205						
tta	cct	tca	act	cct	caa	cat	tgc	ctc	gag	gcc	agg	atg	gac	ttc	cag	672	
Leu	Pro	Ser	Thr	Pro	Gln	His	Cys	Leu	Glu	Ala	Arg	Met	Asp	Phe	Gln		
							210		215		220						
atg	cct	gag	gag	atg	aag	caa	cag	cag	ttc	cag	aag	gaa	gat	gcc	720		
Met	Pro	Glu	Glu	Met	Lys	Gln	Glu	Gln	Gln	Gln	Gly	Gln	Lys	Glu	Asp		

US 10,435,695 B2

105**106**

-continued

225	230	235	240	
ata ttg gtc atg tat gag gtg ctc cag cac atc ttc ggc att ctc acc Ile Leu Val Met Tyr Glu Val Leu Gln His Ile Phe Gly Ile Leu Thr 245 250 255				768
aga gac ttc tcc agc act ggc tgg tct gag acc atc atc gag gac ctc Arg Asp Phe Ser Ser Thr Gly Trp Ser Glu Thr Ile Ile Glu Asp Leu 260 265 270				816
ctt gag gaa ctc tat ggg cag atg aat cgt ctg cag cca atc cag aag Leu Glu Glu Leu Tyr Gly Gln Met Asn Arg Leu Gln Pro Ile Gln Lys 275 280 285				864
gaa ata atg cag aag caa aac acc aca gcg gga gac acg atc gtt ccc Glu Ile Met Gln Lys Gln Asn Thr Thr Ala Gly Asp Thr Ile Val Pro 290 295 300				912
cac cta ggg aaa tat tac ttc aac ctc atg cag tac ctg gag tcc aag His Leu Gly Lys Tyr Tyr Phe Asn Leu Met Gln Tyr Leu Glu Ser Lys 305 310 315 320				960
gag tac gac agg tgt gcc tgg aca gtc gtgcaa gtc gac tcc acg Glu Tyr Asp Arg Cys Ala Trp Thr Val Val Gln Val Gln Ile Leu Thr 325 330 335				1008
aac gtt tct ttc ctg atg aga cta aca ggt tac gtc cgt gac tga Asn Val Ser Phe Leu Met Arg Leu Thr Gly Tyr Val Arg Asp 340 345 350				1053

<210> SEQ ID NO 64

<211> LENGTH: 350

<212> TYPE: PRT

<213> ORGANISM: Bos taurus

<400> SEQUENCE: 64

Met	Gly	Val	Lys	Val	Leu	Phe	Ala	Leu	Ile	Cys	Ile	Ala	Val	Ala	Glu
1				5				10			15				

Ala	Lys	Pro	Thr	Glu	Asn	Asn	Glu	Asp	Phe	Asn	Ile	Val	Ala	Val	Ala
				20			25				30				

Ser	Asn	Phe	Ala	Thr	Thr	Asp	Leu	Asp	Ala	Asp	Arg	Gly	Lys	Leu	Pro
				35		40				45					

Gly	Lys	Lys	Leu	Pro	Leu	Glu	Val	Leu	Lys	Glu	Met	Glu	Ala	Asn	Ala
				50		55		60							

Arg	Lys	Ala	Gly	Cys	Thr	Arg	Gly	Cys	Leu	Ile	Cys	Leu	Ser	His	Ile
65				70			75			80					

Lys	Cys	Thr	Pro	Lys	Met	Lys	Phe	Ile	Pro	Gly	Arg	Cys	His	Thr
				85		90			95					

Tyr	Glu	Gly	Asp	Lys	Glu	Ser	Ala	Gln	Gly	Gly	Ile	Gly	Glu	Ala	Ile
				100		105			110						

Val	Asp	Ile	Pro	Glu	Ile	Pro	Gly	Phe	Lys	Asp	Leu	Glu	Pro	Met	Glu
				115		120			125						

Gln	Phe	Ile	Ala	Gln	Val	Asp	Leu	Cys	Val	Asp	Cys	Thr	Thr	Gly	Cys
				130		135		140							

Leu	Lys	Gly	Leu	Ala	Asn	Val	Gln	Cys	Ser	Asp	Leu	Leu	Lys	Lys	Trp
145					150			155			160				

Leu	Pro	Gln	Arg	Cys	Ala	Thr	Phe	Ala	Ser	Lys	Ile	Gln	Gly	Gln	Val
					165		170		175						

Asp	Lys	Ile	Lys	Gly	Ala	Gly	Gly	Asp	Arg	Ser	Tyr	Ser	Leu	Leu	Arg
				180		185			190						

Phe	Gln	Gln	Arg	Gln	Ser	Leu	Lys	Glu	Cys	Gln	Lys	Leu	Leu	Gly	Gln
				195		200		205							

Leu	Pro	Ser	Thr	Pro	Gln	His	Cys	Leu	Glu	Ala	Arg	Met	Asp	Phe	Gln
				210		215		220							

US 10,435,695 B2

107

-continued

108

Met Pro Glu Glu Met Lys Gln Glu Gln Gln Phe Gln Lys Glu Asp Ala
 225 230 235 240
 Ile Leu Val Met Tyr Glu Val Leu Gln His Ile Phe Gly Ile Leu Thr
 245 250 255
 Arg Asp Phe Ser Ser Thr Gly Trp Ser Glu Thr Ile Ile Glu Asp Leu
 260 265 270
 Leu Glu Glu Leu Tyr Gly Gln Met Asn Arg Leu Gln Pro Ile Gln Lys
 275 280 285
 Glu Ile Met Gln Gln Asn Thr Thr Ala Gly Asp Thr Ile Val Pro
 290 295 300
 His Leu Gly Lys Tyr Tyr Phe Asn Leu Met Gln Tyr Leu Glu Ser Lys
 305 310 315 320
 Glu Tyr Asp Arg Cys Ala Trp Thr Val Val Gln Val Gln Ile Leu Thr
 325 330 335
 Asn Val Ser Phe Leu Met Arg Leu Thr Gly Tyr Val Arg Asp
 340 345 350

<210> SEQ ID NO 65

<211> LENGTH: 561

<212> TYPE: DNA

<213> ORGANISM: Sus scrofa

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(561)

<223> OTHER INFORMATION: Porcine Interferon Beta

<400> SEQUENCE: 65

atg gct aac aag tgc atc ctc caa atc gct ctc ctg atg tgt ttc tcc	48
Met Ala Asn Lys Cys Ile Leu Gln Ile Ala Leu Leu Met Cys Phe Ser	
1 5 10 15	
acc aca gct ctt tcc atg agc tat gat gtg ctt cga tac caa caa agg	96
Thr Thr Ala Leu Ser Met Ser Tyr Asp Val Leu Arg Tyr Gln Gln Arg	
20 25 30	
agc agc aat ttg gca tgt cag aag ctc ctg gga cag ttg cct ggg act	144
Ser Ser Asn Leu Ala Cys Gln Lys Leu Leu Gly Gln Leu Pro Gly Thr	
35 40 45	
cct caa tat tgc ctc gaa gat agg atg aac ttt gag gtc cct gag gag	192
Pro Gln Tyr Cys Leu Glu Asp Arg Met Asn Phe Glu Val Pro Glu Glu	
50 55 60	
att atg caa cca cca caa ttc cag aag gaa gat gca gta ttg att atc	240
Ile Met Gln Pro Pro Gln Phe Gln Lys Glu Asp Ala Val Leu Ile Ile	
65 70 75 80	
cac gag atg ctc cag cag atc ttc ggc att ctc aga aga aat ttc tct	288
His Glu Met Leu Gln Gln Ile Phe Gly Ile Leu Arg Arg Asn Phe Ser	
85 90 95	
agc act ggc tgg aat gaa acc gtc att aag act atc ctt gtg gaa ctt	336
Ser Thr Gly Trp Asn Glu Thr Val Ile Lys Thr Ile Leu Val Glu Leu	
100 105 110	
gat ggg cag atg gat gac ctg gag aca atc ctg gag gaa atc atg gag	384
Asp Gly Gln Met Asp Asp Leu Glu Thr Ile Leu Glu Glu Ile Met Glu	
115 120 125	
gag gaa aat ttc ccc agg gga gac atg acc att ctt cac ctg aag aaa	432
Glu Glu Asn Phe Pro Arg Gly Asp Met Thr Ile Leu His Leu Lys Lys	
130 135 140	
tat tac ttg agc att ctg cag tac ctg aag tcc aag gag tac aga agc	480
Tyr Tyr Leu Ser Ile Leu Gln Tyr Leu Lys Ser Lys Glu Tyr Arg Ser	
145 150 155 160	
tgt gcc tgg aca gtc gtc caa gtg gaa atc ctc agg aac ttt tct ttc	528
Cys Ala Trp Thr Val Val Gln Val Glu Ile Leu Arg Asn Phe Ser Phe	

US 10,435,695 B2

109**110**

-continued

165

170

175

ctt aac aga ctt aca gat tac ctc cg^g aac tga
 Leu Asn Arg Leu Thr Asp Tyr Leu Arg Asn
 180 185

561

<210> SEQ ID NO 66

<211> LENGTH: 186

<212> TYPE: PRT

<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 66

Met Ala Asn Lys Cys Ile Leu Gln Ile Ala Leu Leu Met Cys Phe Ser
 1 5 10 15

Thr Thr Ala Leu Ser Met Ser Tyr Asp Val Leu Arg Tyr Gln Gln Arg
 20 25 30

Ser Ser Asn Leu Ala Cys Gln Lys Leu Leu Gly Gln Leu Pro Gly Thr
 35 40 45

Pro Gln Tyr Cys Leu Glu Asp Arg Met Asn Phe Glu Val Pro Glu Glu
 50 55 60

Ile Met Gln Pro Pro Gln Phe Gln Lys Glu Asp Ala Val Leu Ile Ile
 65 70 75 80

His Glu Met Leu Gln Gln Ile Phe Gly Ile Leu Arg Arg Asn Phe Ser
 85 90 95

Ser Thr Gly Trp Asn Glu Thr Val Ile Lys Thr Ile Leu Val Glu Leu
 100 105 110

Asp Gly Gln Met Asp Asp Leu Glu Thr Ile Leu Glu Glu Ile Met Glu
 115 120 125

Glu Glu Asn Phe Pro Arg Gly Asp Met Thr Ile Leu His Leu Lys Lys
 130 135 140

Tyr Tyr Leu Ser Ile Leu Gln Tyr Leu Lys Ser Lys Glu Tyr Arg Ser
 145 150 155 160

Cys Ala Trp Thr Val Val Gln Val Glu Ile Leu Arg Asn Phe Ser Phe
 165 170 175

Leu Asn Arg Leu Thr Asp Tyr Leu Arg Asn
 180 185

<210> SEQ ID NO 67

<211> LENGTH: 1059

<212> TYPE: DNA

<213> ORGANISM: Sus scrofa

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(1059)

<223> OTHER INFORMATION: GLuCON Beta porcine

<400> SEQUENCE: 67

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag
 Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu
 1 5 10 15

48

gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc
 Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala
 20 25 30

96

agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc
 Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
 35 40 45

144

ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc
 Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
 50 55 60

192

cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc

240

US 10,435,695 B2

111

112

-continued

Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	
aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc	288
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr	
85 90 95	
tac gaa ggc gac aaa gag tcc gca cag ggc ata ggc gag gcg atc	336
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile	
100 105 110	
gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag	384
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115 120 125	
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc	432
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130 135 140	
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg	480
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145 150 155 160	
ctg ccg caa cgc tgt gcg acc ttt gcc agc aag atc cag ggc cag gtg	528
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val	
165 170 175	
gac aag atc aag ggg gcc ggt ggt gac ggg ccc atg agc tat gat gtg	576
Asp Lys Ile Lys Gly Ala Gly Gly Asp Gly Pro Met Ser Tyr Asp Val	
180 185 190	
ctt cga tac caa caa agg agc agc aat ttg gca tgt cag aag ctc ctg	624
Leu Arg Tyr Gln Gln Arg Ser Ser Asn Leu Ala Cys Gln Lys Leu Leu	
195 200 205	
gga cag ttg cct ggg act cct caa tat tgc ctc gaa gat agg atg aac	672
Gly Gln Leu Pro Gly Thr Pro Gln Tyr Cys Leu Glu Asp Arg Met Asn	
210 215 220	
ttt gag gtc cct gag gag att atg caa cca cca caa ttc cag aag gaa	720
Phe Glu Val Pro Glu Glu Ile Met Gln Pro Pro Gln Phe Gln Lys Glu	
225 230 235 240	
gat gca gta ttg att atc cac gag atg ctc cag cag atc ttc ggc att	768
Asp Ala Val Leu Ile Ile His Glu Met Leu Gln Gln Ile Phe Gly Ile	
245 250 255	
ctc aga aga aat ttc tct agc act ggc tgg aat gaa acc gtc att aag	816
Leu Arg Arg Asn Phe Ser Ser Thr Gly Trp Asn Glu Thr Val Ile Lys	
260 265 270	
act atc ctt gtg gaa ctt gat ggg cag atg gat gac ctg gag aca atc	864
Thr Ile Leu Val Glu Leu Asp Gly Gln Met Asp Asp Leu Glu Thr Ile	
275 280 285	
ctg gag gaa atc atg gag gag gaa aat ttc ccc agg gga gac atg acc	912
Leu Glu Glu Ile Met Glu Glu Asn Phe Pro Arg Gly Asp Met Thr	
290 295 300	
att ctt cac ctg aag aaa tat tac ttg agc att ctg cag tac ctg aag	960
Ile Leu His Leu Lys Lys Tyr Tyr Leu Ser Ile Leu Gln Tyr Leu Lys	
305 310 315 320	
tcc aag gag tac aga agc tgt gcc tgg aca gtc gtc caa gtg gaa atc	1008
Ser Lys Glu Tyr Arg Ser Cys Ala Trp Thr Val Val Gln Val Glu Ile	
325 330 335	
ctc agg aac ttt tct ttc ctt aac aga ctt aca gat tac ctc cgg aac	1056
Leu Arg Asn Phe Ser Phe Leu Asn Arg Leu Thr Asp Tyr Leu Arg Asn	
340 345 350	
tga	1059

<210> SEQ ID NO 68

<211> LENGTH: 352

<212> TYPE: PRT

<213> ORGANISM: Sus scrofa

-continued

<400> SEQUENCE: 68

```

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu
1           5           10          15

Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala
20          25          30

Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
35          40          45

Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
50          55          60

Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
65          70          75          80

Lys Cys Thr Pro Lys Met Lys Phe Ile Pro Gly Arg Cys His Thr
85          90          95

Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile
100         105         110

Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu
115         120         125

Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys
130         135         140

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
145         150         155         160

Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
165         170         175

Asp Lys Ile Lys Gly Ala Gly Asp Gly Pro Met Ser Tyr Asp Val
180         185         190

Leu Arg Tyr Gln Gln Arg Ser Ser Asn Leu Ala Cys Gln Lys Leu Leu
195         200         205

Gly Gln Leu Pro Gly Thr Pro Gln Tyr Cys Leu Glu Asp Arg Met Asn
210         215         220

Phe Glu Val Pro Glu Glu Ile Met Gln Pro Pro Gln Phe Gln Lys Glu
225         230         235         240

Asp Ala Val Leu Ile Ile His Glu Met Leu Gln Gln Ile Phe Gly Ile
245         250         255

Leu Arg Arg Asn Phe Ser Ser Thr Gly Trp Asn Glu Thr Val Ile Lys
260         265         270

Thr Ile Leu Val Glu Leu Asp Gly Gln Met Asp Asp Leu Glu Thr Ile
275         280         285

Leu Glu Glu Ile Met Glu Glu Asn Phe Pro Arg Gly Asp Met Thr
290         295         300

Ile Leu His Leu Lys Lys Tyr Tyr Leu Ser Ile Leu Gln Tyr Leu Lys
305         310         315         320

Ser Lys Glu Tyr Arg Ser Cys Ala Trp Thr Val Val Gln Val Glu Ile
325         330         335

Leu Arg Asn Phe Ser Phe Leu Asn Arg Leu Thr Asp Tyr Leu Arg Asn
340         345         350

```

<210> SEQ_ID NO 69

<211> LENGTH: 1062

<212> TYPE: DNA

<213> ORGANISM: Sus scrofa

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(1062)

<223> OTHER INFORMATION: SGLucON Beta porcine

<400> SEQUENCE: 69

-continued

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu 1 5 10 15	48
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala 20 25 30	96
agc aac ttt gcg acc acg gat ctc gat gct gac cga ggg aag ttg ccc Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro 35 40 45	144
ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala 50 55 60	192
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile 65 70 75 80	240
aag tgc acg ccc aag atg aag aag tgg ctc cca gga cgc tgc cac acc Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr 85 90 95	288
tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag ggc atc Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100 105 110	336
gtc gat att cct gag att cct ggg ttc aag gac ttg gag cca atg gag Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115 120 125	384
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130 135 140	432
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp 145 150 155 160	480
ctg ccc caa cgc tgt ggc acc ttt gcc agc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175	528
gac aag atc aag ggg gcc ggt ggt gac ggg ccc ggg atg agc tat gat Asp Lys Ile Lys Gly Ala Gly Gly Asp Gly Pro Gly Met Ser Tyr Asp 180 185 190	576
gtg ctt cga tac caa caa agg agc aat ttg gca tgt cag aag ctc Val Leu Arg Tyr Gln Gln Arg Ser Ser Asn Leu Ala Cys Gln Lys Leu 195 200 205	624
ctg gga cag ttg cct ggg act cct caa tat tgc ctc gaa gat agg atg Leu Gly Gln Leu Pro Gly Thr Pro Gln Tyr Cys Leu Glu Asp Arg Met 210 215 220	672
aac ttt gag gtc cct gag gag att atg caa cca cca caa ttc cag aag Asn Phe Glu Val Pro Glu Glu Ile Met Gln Pro Pro Gln Phe Gln Lys 225 230 235 240	720
gaa gat gca gta ttg att atc cac gag atg ctc cag cag atc ttc ggc Glu Asp Ala Val Leu Ile Ile His Glu Met Leu Gln Gln Ile Phe Gly 245 250 255	768
att ctc aga aga aat ttc tct agc act ggc tgg aat gaa acc gtc att Ile Leu Arg Arg Asn Phe Ser Ser Thr Gly Trp Asn Glu Thr Val Ile 260 265 270	816
aag act atc ctt gtg gaa ctt gat ggg cag atg gat gac ctg gag aca Lys Thr Ile Leu Val Glu Leu Asp Gly Gln Met Asp Asp Leu Glu Thr 275 280 285	864
atc ctg gag gaa atc atg gag gag gaa aat ttc ccc agg gga gac atg Ile Leu Glu Glu Ile Met Glu Glu Glu Asn Phe Pro Arg Gly Asp Met 290 295 300	912
acc att ctt cac ctg aag aaa tat tac ttg agc att ctg cag tac ctg Thr Ile Leu His Leu Lys Tyr Tyr Leu Ser Ile Leu Gln Tyr Leu	960

US 10,435,695 B2

117

-continued

118

305	310	315	320	
aag tcc aag gag tac aga agc tgt gcc tgg aca gtc gtc caa gtg gaa				1008
Lys Ser Lys Glu Tyr Arg Ser Cys Ala Trp Thr Val Val Gln Val Glu				
325	330	335		
atc ctc agg aac ttt tct ttc ctt aac aga ctt aca gat tac ctc cgg				1056
Ile Leu Arg Asn Phe Ser Phe Leu Asn Arg Leu Thr Asp Tyr Leu Arg				
340	345	350		
aac tga				1062
Asn				
<210> SEQ ID NO 70				
<211> LENGTH: 353				
<212> TYPE: PRT				
<213> ORGANISM: Sus scrofa				
<400> SEQUENCE: 70				
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu				
1	5	10	15	
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala				
20	25	30		
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro				
35	40	45		
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala				
50	55	60		
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile				
65	70	75	80	
Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr				
85	90	95		
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Glu Ala Ile				
100	105	110		
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu				
115	120	125		
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys				
130	135	140		
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp				
145	150	155	160	
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val				
165	170	175		
Asp Lys Ile Lys Gly Ala Gly Gly Asp Gly Pro Gly Met Ser Tyr Asp				
180	185	190		
Val Leu Arg Tyr Gln Gln Arg Ser Ser Asn Leu Ala Cys Gln Lys Leu				
195	200	205		
Leu Gly Gln Leu Pro Gly Thr Pro Gln Tyr Cys Leu Glu Asp Arg Met				
210	215	220		
Asn Phe Glu Val Pro Glu Glu Ile Met Gln Pro Pro Gln Phe Gln Lys				
225	230	235	240	
Glu Asp Ala Val Leu Ile Ile His Glu Met Leu Gln Gln Ile Phe Gly				
245	250	255		
Ile Leu Arg Arg Asn Phe Ser Ser Thr Gly Trp Asn Glu Thr Val Ile				
260	265	270		
Lys Thr Ile Leu Val Glu Leu Asp Gly Gln Met Asp Asp Leu Glu Thr				
275	280	285		
Ile Leu Glu Glu Ile Met Glu Glu Asn Phe Pro Arg Gly Asp Met				
290	295	300		
Thr Ile Leu His Leu Lys Tyr Tyr Leu Ser Ile Leu Gln Tyr Leu				

US 10,435,695 B2

119

-continued

120

305	310	315	320
Lys Ser Lys Glu Tyr Arg Ser Cys Ala Trp Thr Val Val Gln Val Glu			
325	330	335	
Ile Leu Arg Asn Phe Ser Phe Leu Asn Arg Leu Thr Asp Tyr Leu Arg			
340	345	350	

Asn

<210> SEQ ID NO 71
<211> LENGTH: 501
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(501)
<223> OTHER INFORMATION: Human Interferon Gamma

<400> SEQUENCE: 71

atg aaa tat aca agt tat atc ttg gct ttt cag ctc tgc atc gtt ttg	48
Met Lys Tyr Thr Ser Tyr Ile Leu Ala Phe Gln Leu Cys Ile Val Leu	
1 5 10 15	
ggt tct ctt ggc tgt tac tgc cag gac cca tat gta aaa gaa gca gaa	96
Gly Ser Leu Gly Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu	
20 25 30	
aac ctt aag aaa tat ttt aat gca ggt cat tca gat gta gcg gat aat	144
Asn Leu Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn	
35 40 45	
gga act ctt ttc tta ggc att ttg aag aat tgg aaa gag gag agt gac	192
Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp	
50 55 60	
aga aaa ata atg cag agc caa att gtc tcc ttt tac ttc aaa ctt ttt	240
Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe	
65 70 75 80	
aaa aac ttt aaa gat gac cag agc atc caa aag agt gtg gag acc atc	288
Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile	
85 90 95	
aag gaa gac atg aat gtc aag ttt ttc aat agc aac aaa aag aaa cga	336
Lys Glu Asp Met Asn Val Lys Phe Asn Ser Asn Lys Lys Arg	
100 105 110	
gat gac ttc gaa aag ctg act aat tat tcg gta act gac ttg aat gtc	384
Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val	
115 120 125	
caa cgc aaa gca ata cat gaa ctc atc caa gtg atg gct gaa ctg tcg	432
Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser	
130 135 140	
cca gca gct aaa aca ggg aag cga aaa agg agt cag atg ctg ttt cga	480
Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Arg	
145 150 155 160	
ggt cga aga gca tcc cag taa	501
Gly Arg Arg Ala Ser Gln	
165	

<210> SEQ ID NO 72
<211> LENGTH: 166
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 72

Met Lys Tyr Thr Ser Tyr Ile Leu Ala Phe Gln Leu Cys Ile Val Leu	
1 5 10 15	
Gly Ser Leu Gly Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu	
20 25 30	

US 10,435,695 B2

121

122

-continued

Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn
 35 40 45
 Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp
 50 55 60
 Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe
 65 70 75 80
 Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile
 85 90 95
 Lys Glu Asp Met Asn Val Lys Phe Asn Ser Asn Lys Lys Lys Arg
 100 105 110
 Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val
 115 120 125
 Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser
 130 135 140
 Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Arg
 145 150 155 160
 Gly Arg Arg Ala Ser Gln
 165

<210> SEQ_ID NO 73
 <211> LENGTH: 987
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(987)
 <223> OTHER INFORMATION: Human GlucON Gamma

<400> SEQUENCE: 73

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag	48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc	96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	
agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc	144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	
ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc	192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc	240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	
aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc	288
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr	
85 90 95	
tac gaa ggc gac aaa gag tcc gca cag ggc ata ggc gag gcg atc	336
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile	
100 105 110	
gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag	384
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115 120 125	
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc	432
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130 135 140	
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg	480
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145 150 155 160	

-continued

ctg ccg caa cgc tgt gcg acc ttt gcc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175	528
gac aag atc aag ggg gcc ggt ggt gac cag gac cca tat gta aaa gaa Asp Lys Ile Lys Gly Ala Gly Asp Gln Asp Pro Tyr Val Lys Glu 180 185 190	576
gca gaa aac ctt aag aaa tat ttt aat gca ggt cat tca gat gta gcg Ala Glu Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala 195 200 205	624
gat aat gga act ctt ttc tta ggc att ttg aag aat tgg aaa gag gag Asp Asn Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu 210 215 220	672
agt gac aga aaa ata atg cag agc caa att gtc tcc ttt tac ttc aaa Ser Asp Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys 225 230 235 240	720
ctt ttt aaa aac ttt aaa gat gac cag agc atc caa aag agt gtg gag Leu Phe Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu 245 250 255	768
acc atc aag gaa gac atg aat gtc aag ttt ttc aat agc aac aaa aag Thr Ile Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys 260 265 270	816
aaa cga gat gac ttc gaa aag ctg act aat tat tcc gta act gac ttg Lys Arg Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu 275 280 285	864
aat gtc caa cgc aaa gca ata cat gaa ctc atc caa gtg atg gct gaa Asn Val Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu 290 295 300	912
ctg tcg cca gca gct aaa aca ggg aag cga aaa agg agt cag atg ctg Leu Ser Pro Ala Ala Lys Thr Gly Lys Arg Ser Gln Met Leu 305 310 315 320	960
ttt cga ggt cga aga gca tcc cag taa Phe Arg Gly Arg Arg Ala Ser Gln 325	987

<210> SEQ ID NO 74
<211> LENGTH: 328
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 74

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu 1 5 10 15
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala 20 25 30
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro 35 40 45
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala 50 55 60
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile 65 70 75 80
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr 85 90 95
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100 105 110
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115 120 125
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130 135 140

US 10,435,695 B2

125

126

-continued

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
 145 150 155 160
 Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
 165 170 175
 Asp Lys Ile Lys Gly Ala Gly Asp Gln Asp Pro Tyr Val Lys Glu
 180 185 190
 Ala Glu Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala
 195 200 205
 Asp Asn Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu
 210 215 220
 Ser Asp Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys
 225 230 235 240
 Leu Phe Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu
 245 250 255
 Thr Ile Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys
 260 265 270
 Lys Arg Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu
 275 280 285
 Asn Val Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu
 290 295 300
 Leu Ser Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu
 305 310 315 320
 Phe Arg Gly Arg Arg Ala Ser Gln
 325

<210> SEQ ID NO 75
 <211> LENGTH: 501
 <212> TYPE: DNA
 <213> ORGANISM: Bos taurus
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(501)
 <223> OTHER INFORMATION: 75)Bovine Interferon Gamma

<400> SEQUENCE: 75

atg aaa tat aca agc tat ttc tta gct tta ctg ctc tgt ggg ctt ttg	48
Met Lys Tyr Thr Ser Tyr Phe Leu Ala Leu Leu Leu Cys Gly Leu Leu	
1 5 10 15	
ggt ttt tct ggt tat ggc cag ggc caa ttt ttt aga gaa ata gaa	96
Gly Phe Ser Gly Ser Tyr Gly Gln Gly Gln Phe Phe Arg Glu Ile Glu	
20 25 30	
aac tta aag gag tat ttt aat gca agt agc cca gat gta gct aag ggt	144
Asn Leu Lys Glu Tyr Phe Asn Ala Ser Ser Pro Asp Val Ala Lys Gly	
35 40 45	
ggg cct ctc ttc tca gaa att ttg aag aat tgg aaa gat gaa agt gac	192
Gly Pro Leu Phe Ser Glu Ile Leu Lys Asn Trp Lys Asp Glu Ser Asp	
50 55 60	
aaa aaa att att cag agc caa att gtc tcc tac ttc aaa ctc ttt	240
Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe	
65 70 75 80	
gaa aac ctc aaa gat aac cag gtc att caa agg agc atg gat atc atc	288
Glu Asn Leu Lys Asp Asn Gln Val Ile Gln Arg Ser Met Asp Ile Ile	
85 90 95	
aag caa gac atg ttt cag aag ttc ttg aat ggc agc tct gag aaa ctg	336
Lys Gln Asp Met Phe Gln Lys Phe Leu Asn Gly Ser Ser Glu Lys Leu	
100 105 110	
gag gac ttc aaa aag ctg att caa att ccg gtg gat gat ctg cag atc	384
Glu Asp Phe Lys Lys Leu Ile Gln Ile Pro Val Asp Asp Leu Gln Ile	

US 10,435,695 B2

127

128

-continued

115	120	125	
cag cgc aaa gcc ata aat gaa ctc atc aaa gtg atg aat gac ctg tca Gln Arg Lys Ala Ile Asn Glu Leu Ile Lys Val Met Asn Asp Leu Ser 130 135 140			432
cca aaa tct aac ctc aga aag cgg aag aga agt cag aat ctc ttt cga Pro Lys Ser Asn Leu Arg Lys Arg Ser Gln Asn Leu Phe Arg 145 150 155 160			480
ggc cgg aga gca tca acg taa Gly Arg Arg Ala Ser Thr 165			501
 <210> SEQ_ID NO 76			
<211> LENGTH: 166			
<212> TYPE: PRT			
<213> ORGANISM: Bos taurus			
<400> SEQUENCE: 76			
Met Lys Tyr Thr Ser Tyr Phe Leu Ala Leu Leu Leu Cys Gly Leu Leu 1 5 10 15			
Gly Phe Ser Gly Ser Tyr Gly Gln Gly Gln Phe Phe Arg Glu Ile Glu 20 25 30			
Asn Leu Lys Glu Tyr Phe Asn Ala Ser Ser Pro Asp Val Ala Lys Gly 35 40 45			
Gly Pro Leu Phe Ser Glu Ile Leu Lys Asn Trp Lys Asp Glu Ser Asp 50 55 60			
Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe 65 70 75 80			
Glu Asn Leu Lys Asp Asn Gln Val Ile Gln Arg Ser Met Asp Ile Ile 85 90 95			
Lys Gln Asp Met Phe Gln Lys Phe Leu Asn Gly Ser Ser Glu Lys Leu 100 105 110			
Glu Asp Phe Lys Lys Leu Ile Gln Ile Pro Val Asp Asp Leu Gln Ile 115 120 125			
Gln Arg Lys Ala Ile Asn Glu Leu Ile Lys Val Met Asn Asp Leu Ser 130 135 140			
Pro Lys Ser Asn Leu Arg Lys Arg Lys Ser Gln Asn Leu Phe Arg 145 150 155 160			
Gly Arg Arg Ala Ser Thr 165			
 <210> SEQ_ID NO 77			
<211> LENGTH: 993			
<212> TYPE: DNA			
<213> ORGANISM: Bos taurus			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (1)..(993)			
<223> OTHER INFORMATION: Bovine GlucON Gamma			
<400> SEQUENCE: 77			
atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu 1 5 10 15			48
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala 20 25 30			96
agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro 35 40 45			144

US 10,435,695 B2

129

130

-continued

ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala 50 55 60	192
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile 65 70 75 80	240
aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr 85 90 95	288
tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag gcg atc Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100 105 110	336
gtt gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115 120 125	384
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130 135 140	432
ctc aaa ggg ctt gcc aac gtc cag tgt tct gac ctg ctc aag aag tgg Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp 145 150 155 160	480
ctg ccg caa cgc tgt ggc acc ttt gcc agc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175	528
gac aag atc aag ggg gcc ggt ggt gac ggg ccc cag ggc caa ttt ttt Asp Lys Ile Lys Gly Ala Gly Asp Gly Pro Gln Gly Gln Phe Phe 180 185 190	576
aga gaa ata gaa aac tta aag gag tat ttt aat gca agt agc cca gat Arg Glu Ile Glu Asn Leu Lys Glu Tyr Phe Asn Ala Ser Ser Pro Asp 195 200 205	624
gta gct aag ggt ggg cct ctc ttc tca gaa att ttg aag aat tgg aaa Val Ala Lys Gly Gly Pro Leu Phe Ser Glu Ile Leu Lys Asn Trp Lys 210 215 220	672
gat gaa agt gac aaa aaa att att cag agc caa att gtc tcc ttc tac Asp Glu Ser Asp Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr 225 230 235 240	720
ttc aaa ctc ttt gaa aac ctc aaa gat aac cag gtc att caa agg agc Phe Lys Leu Phe Glu Asn Leu Lys Asp Asn Gln Val Ile Gln Arg Ser 245 250 255	768
atg gat ata atc aag caa gac atg ttt cag aag ttc ttg aat ggc agc Met Asp Ile Ile Lys Gln Asp Met Phe Gln Lys Phe Leu Asn Gly Ser 260 265 270	816
tct gag aaa ctg gag gac ttc aaa aag ctg att caa att ccg gtg gat Ser Glu Lys Leu Glu Asp Phe Lys Lys Leu Ile Gln Ile Pro Val Asp 275 280 285	864
gat ctc cag atc cag cgc aaa gcc ata aat gaa ctc atc aaa gtg atg Asp Leu Gln Ile Gln Arg Lys Ala Ile Asn Glu Leu Ile Lys Val Met 290 295 300	912
aat gac ctg tca cca aaa tct aac ctc aga aag cgg aag aga agt cag Asn Asp Leu Ser Pro Lys Ser Asn Leu Arg Lys Arg Lys Arg Ser Gln 305 310 315 320	960
aat ctc ttt cga ggc cgg aga gca tca acg taa Asn Leu Phe Arg Gly Arg Arg Ala Ser Thr 325 330	993

<210> SEQ ID NO 78

<211> LENGTH: 330

<212> TYPE: PRT

<213> ORGANISM: Bos taurus

<400> SEQUENCE: 78

-continued

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu
 1 5 10 15
 Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala
 20 25 30
 Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
 35 40 45
 Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
 50 55 60
 Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
 65 70 75 80
 Lys Cys Thr Pro Lys Met Lys Phe Ile Pro Gly Arg Cys His Thr
 85 90 95
 Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile
 100 105 110
 Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu
 115 120 125
 Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys
 130 135 140
 Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
 145 150 155 160
 Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
 165 170 175
 Asp Lys Ile Lys Gly Ala Gly Asp Gly Pro Gln Gly Gln Phe Phe
 180 185 190
 Arg Glu Ile Glu Asn Leu Lys Glu Tyr Phe Asn Ala Ser Ser Pro Asp
 195 200 205
 Val Ala Lys Gly Gly Pro Leu Phe Ser Glu Ile Leu Lys Asn Trp Lys
 210 215 220
 Asp Glu Ser Asp Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr
 225 230 235 240
 Phe Lys Leu Phe Glu Asn Leu Lys Asp Asn Gln Val Ile Gln Arg Ser
 245 250 255
 Met Asp Ile Ile Lys Gln Asp Met Phe Gln Lys Phe Leu Asn Gly Ser
 260 265 270
 Ser Glu Lys Leu Glu Asp Phe Lys Lys Leu Ile Gln Ile Pro Val Asp
 275 280 285
 Asp Leu Gln Ile Gln Arg Lys Ala Ile Asn Glu Leu Ile Lys Val Met
 290 295 300
 Asn Asp Leu Ser Pro Lys Ser Asn Leu Arg Lys Arg Lys Arg Ser Gln
 305 310 315 320
 Asn Leu Phe Arg Gly Arg Arg Ala Ser Thr
 325 330

<210> SEQ ID NO 79
 <211> LENGTH: 501
 <212> TYPE: DNA
 <213> ORGANISM: Sus scrofa
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(501)
 <223> OTHER INFORMATION: Porcine Interferon Gamma

<400> SEQUENCE: 79

atg agt tat aca act tat ttc tta gct ttt cag ctt tgc gtg act ttg
 Met Ser Tyr Thr Tyr Phe Leu Ala Phe Gln Leu Cys Val Thr Leu
 1 5 10 15

-continued

tgt ttt tct ggc tct tac tgc cag gcg ccc ttt ttt aaa gaa ata acg Cys Phe Ser Gly Ser Tyr Cys Gln Ala Pro Phe Phe Lys Glu Ile Thr 20 25 30	96
atc cta aag gac tat ttt aat gca agt acc tca gat gta cct aat ggt Ile Leu Lys Asp Tyr Phe Asn Ala Ser Thr Ser Asp Val Pro Asn Gly 35 40 45	144
gga cct ctt ttc tta gaa att ttg aag aat tgg aaa gag gag agt gac Gly Pro Leu Phe Leu Glu Ile Leu Lys Asn Trp Lys Glu Ser Asp 50 55 60	192
aaa aaa ata att cag agc caa att gtc tcc ttc tac ttc aaa ttc ttt Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Phe Phe 65 70 75 80	240
gaa atc ttc aaa gat aac cag gcc att caa agg agc atg gat gtg atc Glu Ile Phe Lys Asp Asn Gln Ala Ile Gln Arg Ser Met Asp Val Ile 85 90 95	288
aag caa gac atg ttt cag agg ttc cta aat ggt agc tct ggg aaa ctg Lys Gln Asp Met Phe Gln Arg Phe Leu Asn Gly Ser Ser Gly Lys Leu 100 105 110	336
aat gac ttc gaa aag ctg att aaa att ccg gta gat aat ctg cag atc Asn Asp Phe Glu Lys Leu Ile Lys Ile Pro Val Asp Asn Leu Gln Ile 115 120 125	384
cag cgcc aaa gcc atc agt gaa ctc atc aaa gtg atg aat gat ctg tca Gln Arg Lys Ala Ile Ser Glu Leu Ile Lys Val Met Asn Asp Leu Ser 130 135 140	432
cca aga tct aac cta aga aag cgg aag aga agt cag act atg ttc caa Pro Arg Ser Asn Leu Arg Lys Arg Ser Gln Thr Met Phe Gln 145 150 155 160	480
ggc cag aga gca tca aaa taa Gly Gln Arg Ala Ser Lys 165	501

<210> SEQ ID NO 80
<211> LENGTH: 166
<212> TYPE: PRT
<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 80

Met Ser Tyr Thr Thr Tyr Phe Leu Ala Phe Gln Leu Cys Val Thr Leu 1 5 10 15
Cys Phe Ser Gly Ser Tyr Cys Gln Ala Pro Phe Phe Lys Glu Ile Thr 20 25 30
Ile Leu Lys Asp Tyr Phe Asn Ala Ser Thr Ser Asp Val Pro Asn Gly 35 40 45
Gly Pro Leu Phe Leu Glu Ile Leu Lys Asn Trp Lys Glu Ser Asp 50 55 60
Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Phe Phe 65 70 75 80
Glu Ile Phe Lys Asp Asn Gln Ala Ile Gln Arg Ser Met Asp Val Ile 85 90 95
Lys Gln Asp Met Phe Gln Arg Phe Leu Asn Gly Ser Ser Gly Lys Leu 100 105 110
Asn Asp Phe Glu Lys Leu Ile Lys Ile Pro Val Asp Asn Leu Gln Ile 115 120 125
Gln Arg Lys Ala Ile Ser Glu Leu Ile Lys Val Met Asn Asp Leu Ser 130 135 140
Pro Arg Ser Asn Leu Arg Lys Arg Ser Gln Thr Met Phe Gln 145 150 155 160

US 10,435,695 B2

135

136

-continued

Gly Gln Arg Ala Ser Lys
165

```

<210> SEQ ID NO 81
<211> LENGTH: 987
<212> TYPE: DNA
<213> ORGANISM: Sus scrofa
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(987)
<223> OTHER INFORMATION: Porcine GLucON Gamma

<400> SEQUENCE: 81

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag      48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu
1          5           10          15

gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc      96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala
20          25          30

agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc      144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
35          40          45

ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc      192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
50          55          60

cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc      240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
65          70          75          80

aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc      288
Lys Cys Thr Pro Lys Met Lys Phe Ile Pro Gly Arg Cys His Thr
85          90          95

tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag gcg atc      336
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Glu Ala Ile
100         105         110

gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag      384
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu
115         120         125

cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc      432
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys
130         135         140

ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg      480
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
145         150         155         160

ctg ccg caa cgc tgt gcg acc ttt gcc agc aag atc cag ggc cag gtg      528
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
165         170         175

gac aag atc aag ggg gcc ggt ggt gac cag ggc ccc ttt ttt aaa gaa      576
Asp Lys Ile Lys Gly Ala Gly Gly Asp Gln Ala Pro Phe Phe Lys Glu
180         185         190

ata acg atc cta aag gac tat ttt aat gca agt acc tca gat gta cct      624
Ile Thr Ile Leu Lys Asp Tyr Phe Asn Ala Ser Thr Ser Asp Val Pro
195         200         205

aat ggt gga cct ctt ttc tta gaa att ttg aag aat tgg aaa gag gag      672
Asn Gly Gly Pro Leu Phe Leu Glu Ile Leu Lys Asn Trp Lys Glu Glu
210         215         220

agt gac aaa aaa ata att cag agc caa att gtc tcc ttc tac ttc aaa      720
Ser Asp Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Lys
225         230         235         240

ttc ttt gaa atc ttc aaa gat aac cag gcc att caa agg agc atg gat      768
Phe Phe Glu Ile Phe Lys Asp Asn Gln Ala Ile Gln Arg Ser Met Asp
245         250         255

```

US 10,435,695 B2

137

138

-continued

gtg atc aag caa gac atg ttt cag agg ttc cta aat ggt agc tct ggg	816
Val Ile Lys Gln Asp Met Phe Gln Arg Phe Leu Asn Gly Ser Ser Gly	
260	265
	270

aaa ctg aat gac ttc gaa aag ctg att aaa att ccg gta gat aat ctg	864
Lys Leu Asn Asp Phe Glu Lys Leu Ile Lys Ile Pro Val Asp Asn Leu	
275	280
	285

cag atc cag cgc aaa gcc atc agt gaa ctc atc aaa gtg atg aat gat	912
Gln Ile Gln Arg Lys Ala Ile Ser Glu Leu Ile Lys Val Met Asn Asp	
290	295
	300

ctg tca cca aga tct aac cta aga aag cgg aag aga agt cag act atg	960
Leu Ser Pro Arg Ser Asn Leu Arg Lys Arg Ser Gln Thr Met	
305	310
	315
	320

ttc caa ggc cag aga gca tca aaa taa	987
Phe Gln Gly Gln Arg Ala Ser Lys	
325	

<210> SEQ_ID NO 82

<211> LENGTH: 328

<212> TYPE: PRT

<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 82

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1	5
	10
	15

Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20	25
	30

Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35	40
	45

Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50	55
	60

Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65	70
	75
	80

Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr	
85	90
	95

Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile	
100	105
	110

Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115	120
	125

Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130	135
	140

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145	150
	155
	160

Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val	
165	170
	175

Asp Lys Ile Lys Gly Ala Gly Gly Asp Gln Ala Pro Phe Phe Lys Glu	
180	185
	190

Ile Thr Ile Leu Lys Asp Tyr Phe Asn Ala Ser Thr Ser Asp Val Pro	
195	200
	205

Asn Gly Gly Pro Leu Phe Leu Glu Ile Leu Lys Asn Trp Lys Glu Glu	
210	215
	220

Ser Asp Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys	
225	230
	235
	240

Phe Phe Glu Ile Phe Lys Asp Asn Gln Ala Ile Gln Arg Ser Met Asp	
245	250
	255

Val Ile Lys Gln Asp Met Phe Gln Arg Phe Leu Asn Gly Ser Ser Gly	
260	265
	270

US 10,435,695 B2

139

140

-continued

Lys Leu Asn Asp Phe Glu Lys Leu Ile Lys Ile Pro Val Asp Asn Leu
275 280 285

Gln Ile Gln Arg Lys Ala Ile Ser Glu Leu Ile Lys Val Met Asn Asp
290 295 300

Leu Ser Pro Arg Ser Asn Leu Arg Lys Arg Lys Arg Ser Gln Thr Met
305 310 315 320

Phe Gln Gly Gln Arg Ala Ser Lys
325

<210> SEQ ID NO 83

<211> LENGTH: 588

<212> TYPE: DNA

<213> ORGANISM: Bos taurus

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(588)

<223> OTHER INFORMATION: Bovine Interferon Lambda IL29

<400> SEQUENCE: 83

atg gcc ccg ggc tgc acg ctg gtg ctg gtg atg ctg acg acc gtg	48
Met Ala Pro Gly Cys Thr Leu Val Leu Val Leu Met Leu Thr Thr Val	
1 5 10 15	

gcg ctg agc agg aca gga gca gtt cct gtg ccc tct gcc ccc agg gcc	96
Ala Leu Ser Arg Thr Gly Ala Val Pro Val Pro Ser Ala Pro Arg Ala	
20 25 30	

ctc cca cct gcc agg ggc tgc cac gtg gcc cag ttc aag tct ctg tcc	144
Leu Pro Pro Ala Arg Gly Cys His Val Ala Gln Phe Lys Ser Leu Ser	
35 40 45	

cct caa gag ctg cag gcc ttc aag acg gcc agg gat gcc ttt gaa gac	192
Pro Gln Glu Leu Gln Ala Phe Lys Thr Ala Arg Asp Ala Phe Glu Asp	
50 55 60	

tcc ttc ttg cca aag gac tgg gac tgc agc acc cac ctt ttc ccc agg	240
Ser Phe Leu Pro Lys Asp Trp Asp Cys Ser Thr His Leu Phe Pro Arg	
65 70 75 80	

acc cgg gac ctg aag cac ctg cag gtg tgg gag cgc cct gtg gct ctg	288
Thr Arg Asp Leu Lys His Leu Gln Val Trp Glu Arg Pro Val Ala Leu	
85 90 95	

gag gca gag ctg gcc ctg aca ctg acg gtc ctg gag gcc atg gct aac	336
Glu Ala Glu Leu Ala Leu Thr Leu Thr Val Leu Glu Ala Met Ala Asn	
100 105 110	

tca tcc ctg ggc cac agc ctg gag cag ccc ctt ctc acg ctg cag aac	384
Ser Ser Leu Gly His Ser Leu Glu Gln Pro Leu Leu Thr Leu Gln Asn	
115 120 125	

atc cac tcc aag ctc cag gcc tgt gtc cca gct cag ccc aca gca agc	432
Ile His Ser Lys Leu Gln Ala Cys Val Pro Ala Gln Pro Thr Ala Ser	
130 135 140	

tcc agg ccc cgg ggc cgc ctc cac cac tgg ctg cac cgc ctc cag gag	480
Ser Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu	
145 150 155 160	

gcc cgg aag gag tcc cag gac tgc ctc gaa gcc tct gtg atg ttc aac	528
Ala Arg Lys Glu Ser Gln Asp Cys Leu Glu Ala Ser Val Met Phe Asn	
165 170 175	

ctc ctc cgc ctc acc cgg gac ctg aaa tgt gtt gcc agc gga gac	576
Leu Leu Arg Leu Leu Thr Arg Asp Leu Lys Cys Val Ala Ser Gly Asp	
180 185 190	

cag tgt gtc tga	588
Gln Cys Val	
195	

<210> SEQ ID NO 84

<211> LENGTH: 195

US 10,435,695 B2

141**142**

-continued

<212> TYPE: PRT

<213> ORGANISM: Bos taurus

<400> SEQUENCE: 84

Met Ala Pro Gly Cys Thr Leu Val	Leu Val Leu Met	Leu Thr Thr Val
1 5	10	15

Ala Leu Ser Arg Thr Gly Ala Val	Pro Val Pro Ser Ala Pro Arg Ala
20 25	30

Leu Pro Pro Ala Arg Gly Cys His Val	Ala Gln Phe Lys Ser Leu Ser
35 40	45

Pro Gln Glu Leu Gln Ala Phe Lys Thr Ala Arg Asp Ala Phe Glu Asp
50 55 60

Ser Phe Leu Pro Lys Asp Trp Asp Cys Ser Thr His Leu Phe Pro Arg
65 70 75 80

Thr Arg Asp Leu Lys His Leu Gln Val Trp Glu Arg Pro Val Ala Leu
85 90 95

Glu Ala Glu Leu Ala Leu Thr Leu Thr Val Leu Glu Ala Met Ala Asn
100 105 110

Ser Ser Leu Gly His Ser Leu Glu Gln Pro Leu Leu Thr Leu Gln Asn
115 120 125

Ile His Ser Lys Leu Gln Ala Cys Val Pro Ala Gln Pro Thr Ala Ser
130 135 140

Ser Arg Pro Arg Gly Arg Leu His His Trp Leu His Arg Leu Gln Glu
145 150 155 160

Ala Arg Lys Glu Ser Gln Asp Cys Leu Glu Ala Ser Val Met Phe Asn
165 170 175

Leu Leu Arg Leu Leu Thr Arg Asp Leu Lys Cys Val Ala Ser Gly Asp
180 185 190

Gln Cys Val
195

<210> SEQ_ID NO 85

<211> LENGTH: 1092

<212> TYPE: DNA

<213> ORGANISM: Bos taurus

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(1092)

<223> OTHER INFORMATION: Bovine GLuCON Lambda

<400> SEQUENCE: 85

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag	48
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	

gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc	96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	

agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc	144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	

ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc	192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	

cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc	240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	

aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc	288
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr	
85 90 95	

US 10,435,695 B2

143

144

-continued

tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag ggc atc Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100 105 110	336
gtt gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115 120 125	384
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130 135 140	432
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp 145 150 155 160	480
ctg ccg caa cgc tgt gcg acc ttt gcc agc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175	528
gac aag atc aag ggg gcc ggt ggt gac ggg ccc agg aca gga gca gtt Asp Lys Ile Lys Gly Ala Gly Asp Gly Pro Arg Thr Gly Ala Val 180 185 190	576
cct gtg ccc tct gcc ccc agg gca ctc cca cct gcc agg ggc tgc cac Pro Val Pro Ser Ala Pro Arg Ala Leu Pro Pro Ala Arg Gly Cys His 195 200 205	624
gtg gcc cag ttc aag tct ctg tcc cct caa gag ctg caa gcc ttc aag Val Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe Lys 210 215 220	672
acg gcc agg gat gcc ttt gaa gac tcg ttc ttg ccg aag gac tgg gac Thr Ala Arg Asp Ala Phe Glu Asp Ser Phe Leu Pro Lys Asp Trp Asp 225 230 235 240	720
tgt agc acc cac ctt ttc ccc agg aca cga gac ctg aag cac ctg caa Cys Ser Thr His Leu Phe Pro Arg Thr Arg Asp Leu Lys His Leu Gln 245 250 255	768
gtg tgg gag cgc cct gtg gct ctg gag gca gag ctg gcc ctg aca ctg Val Trp Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu 260 265 270	816
acg gtc ctg gag gca atg gct aac tca tcc ctg ggc cac agc ctg gag Thr Val Leu Glu Ala Met Ala Asn Ser Ser Leu Gly His Ser Leu Glu 275 280 285	864
cag ccc ctt ctc acg ctg caa aac atc cac tcc aag cag ctc cag gcc tgg Gln Pro Leu Leu Thr Leu Gln Asn Ile His Ser Lys Leu Gln Ala Cys 290 295 300	912
gtc cca gct cag ccc aca gca agc tcc aga ccc cga ggc cgc ctc cac Val Pro Ala Gln Pro Thr Ala Ser Ser Arg Pro Arg Gly Arg Leu His 305 310 315 320	960
cac tgg ctg cac cgc ctc caa gag gcc cggt aag gag tcc cag gac tgc His Trp Leu His Arg Leu Gln Glu Ala Arg Lys Glu Ser Gln Asp Cys 325 330 335	1008
ctc gaa gcc tct gtg atg ttc aac ctc ctc cgc ctc acc cga gac Leu Glu Ala Ser Val Met Phe Asn Leu Leu Arg Leu Leu Thr Arg Asp 340 345 350	1056
ctg aaa tgt gtt gcc agc gga gac cag tgt gtc tga Leu Lys Cys Val Ala Ser Gly Asp Gln Cys Val 355 360	1092

<210> SEQ ID NO 86

<211> LENGTH: 363

<212> TYPE: PRT

<213> ORGANISM: Bos taurus

<400> SEQUENCE: 86

Met	Gly	Val	Lys	Val	Leu	Phe	Ala	Leu	Ile	Cys	Ile	Ala	Val	Ala	Glu
1				5				10			15				

US 10,435,695 B2

145**146**

-continued

Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala
 20 25 30

Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro
 35 40 45

Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala
 50 55 60

Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile
 65 70 75 80

Lys Cys Thr Pro Lys Met Lys Phe Ile Pro Gly Arg Cys His Thr
 85 90 95

Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile
 100 105 110

Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu
 115 120 125

Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys
 130 135 140

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
 145 150 155 160

Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
 165 170 175

Asp Lys Ile Lys Gly Ala Gly Gly Asp Gly Pro Arg Thr Gly Ala Val
 180 185 190

Pro Val Pro Ser Ala Pro Arg Ala Leu Pro Pro Ala Arg Gly Cys His
 195 200 205

Val Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe Lys
 210 215 220

Thr Ala Arg Asp Ala Phe Glu Asp Ser Phe Leu Pro Lys Asp Trp Asp
 225 230 235 240

Cys Ser Thr His Leu Phe Pro Arg Thr Arg Asp Leu Lys His Leu Gln
 245 250 255

Val Trp Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
 260 265 270

Thr Val Leu Glu Ala Met Ala Asn Ser Ser Leu Gly His Ser Leu Glu
 275 280 285

Gln Pro Leu Leu Thr Leu Gln Asn Ile His Ser Lys Leu Gln Ala Cys
 290 295 300

Val Pro Ala Gln Pro Thr Ala Ser Ser Arg Pro Arg Gly Arg Leu His
 305 310 315 320

His Trp Leu His Arg Leu Gln Glu Ala Arg Lys Glu Ser Gln Asp Cys
 325 330 335

Leu Glu Ala Ser Val Met Phe Asn Leu Leu Arg Leu Leu Thr Arg Asp
 340 345 350

Leu Lys Cys Val Ala Ser Gly Asp Gln Cys Val
 355 360

<210> SEQ ID NO 87
 <211> LENGTH: 603
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(603)
 <223> OTHER INFORMATION: Human Interferon Lambda 1 (IL29)

<400> SEQUENCE: 87

US 10,435,695 B2

147

148

-continued

atg gct gca gct tgg acc gtg gtg ctg gtg act ttg gtg cta ggc ttg Met Ala Ala Ala Trp Thr Val Val Leu Val Thr Leu Val Leu Gly Leu 1 5 10 15	48
gcc gtg gca ggc cct gtc ccc act tcc aag ccc acc aca act ggg aag Ala Val Ala Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys 20 25 30	96
ggc tgc cac att ggc agg ttc aaa tct ctg tca cca cag gag cta gcg Gly Cys His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala 35 40 45	144
agc ttc aag aag gcc agg gac gcc ttg gaa gag tca ctc aag ctg aaa Ser Phe Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys 50 55 60	192
aac tgg agt tgc agc tct cct gtc ttc ccc ggg aat tgg gac ctg agg Asn Trp Ser Cys Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg 65 70 75 80	240
ctt ctc cag gtg agg gag cgc cct gtg gcc ttg gag gct gag ctg gcc Leu Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala 85 90 95	288
ctg acg ctg aag gtc ctg gag gcc gct gtc ggc cca gcc ctg gag gac Leu Thr Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp 100 105 110	336
gtc cta gac cag ccc ctt cac acc ctg cac atc ctc tcc cag ctc Val Leu Asp Gln Pro Leu His Thr Leu His His Ile Leu Ser Gln Leu 115 120 125	384
cag gcc tgt atc cag cct cag ccc aca gca ggg ccc agg ccc cgg ggc Gln Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly 130 135 140	432
cgc ctc cac cac tgg ctg cac cgg ctc cag gag gcc ccc aaa aag gag Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu 145 150 155 160	480
tcc gct ggc tgc ctg gag gca tct gtc acc ttc aac ctc ttc cgc ctc Ser Ala Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu 165 170 175	528
ctc acg cga gac ctc aaa tat gtg gcc gat ggg aac ctg tgt ctg aga Leu Thr Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg 180 185 190	576
acg tca acc cac cct gag tcc acc tga Thr Ser Thr His Pro Glu Ser Thr 195 200	603

<210> SEQ ID NO: 88

<211> LENGTH: 200

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 88

Met Ala Ala Ala Trp Thr Val Val Leu Val Thr Leu Val Leu Gly Leu
1 5 10 15

Ala Val Ala Gly Pro Val Pro Thr Ser Lys Pro Thr Thr Gly Lys
20 25 30

Gly Cys His Ile Gly Arg Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala
35 40 45

Ser Phe Lys Lys Ala Arg Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys
50 55 60

Asn Trp Ser Cys Ser Ser Pro Val Phe Pro Gly Asn Trp Asp Leu Arg
65 70 75 80

Leu Leu Gln Val Arg Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala
85 90 95

Leu Thr Leu Lys Val Leu Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp

US 10,435,695 B2

149**150**

-continued

100	105	110
Val Leu Asp Gln Pro Leu His Thr	Leu His His Ile Leu Ser Gln Leu	
115	120	125
Gln Ala Cys Ile Gln Pro Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly		
130	135	140
Arg Leu His His Trp Leu His Arg Leu Gln Glu Ala Pro Lys Lys Glu		
145	150	155
Ser Ala Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe Arg Leu		
165	170	175
Leu Thr Arg Asp Leu Lys Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg		
180	185	190
Thr Ser Thr His Pro Glu Ser Thr		
195	200	

<210> SEQ_ID NO 89
 <211> LENGTH: 1113
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1113)
 <223> OTHER INFORMATION: Human GlucON Lambda

<400> SEQUENCE: 89

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag	48		
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu			
1	5	10	15
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc	96		
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala			
20	25	30	
agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc	144		
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro			
35	40	45	
ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc	192		
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala			
50	55	60	
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc	240		
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile			
65	70	75	80
aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc	288		
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr			
85	90	95	
tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag gcg atc	336		
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile			
100	105	110	
gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag	384		
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu			
115	120	125	
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc	432		
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys			
130	135	140	
ctc aaa ggg ctt gcc aac gtc gat ctg tgt gtg gac tgc ctc aag aag tgg	480		
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp			
145	150	155	160
ctg ccg caa cgc tgt ggc acc ttt gcc agc aag atc cag ggc cag gtg	528		
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val			
165	170	175	
gac aag atc aag ggg gcc ggt ggt gac ttg gcc gtg gca ggc cct gtc	576		
Asp Lys Ile Lys Gly Ala Gly Gly Asp Leu Ala Val Ala Gly Pro Val			
180	185	190	

US 10,435,695 B2

151

-continued

152

ccc act tcc aag ccc acc aca act ggg aag ggc tgc cac att ggc agg	624
Pro Thr Ser Lys Pro Thr Thr Thr Gly Lys Gly Cys His Ile Gly Arg	
195 200 205	
tcc aaa tct ctg tca cca cag gag cta gcg agc ttc aag aag gcc agg	672
Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg	
210 215 220	
gac gcc ttg gaa gag tca ctc aag ctg aaa aac tgg agt tgc agc tct	720
Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser	
225 230 235 240	
cct gtc ttc ccc ggg aat tgg gac ctg agg ctt ctc cag gtg agg gag	768
Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu	
245 250 255	
cgc cct gtg gcc ttg gag gct gag ctg gcc ctg acg ctg aag gtc ctg	816
Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu	
260 265 270	
gag gcc gct ggc cca gcc ctg gag gac gtc cta gac cag ccc ctt	864
Glu Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu	
275 280 285	
cac acc ctg cac cac atc ctc tcc cag ctc cag gcc tgt atc cag cct	912
His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro	
290 295 300	
cag ccc aca gca ggg ccc agg ccc cgg ggc cgc ctc cac cac tgg ctg	960
Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu	
305 310 315 320	
cac cgg ctc cag gag gcc ccc aaa aag gag tcc gct ggc tgc ctg gag	1008
His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu	
325 330 335	
gca tct gtc acc ttc aac ctc ttc cgc ctc acg cga gac ctc aaa	1056
Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys	
340 345 350	
tat gtg gcc gat ggg aac ctg tgt ctg aga acg tca acc cac cct gag	1104
Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser Thr His Pro Glu	
355 360 365	
tcc acc tga	1113
Ser Thr	
370	
<210> SEQ ID NO 90	
<211> LENGTH: 370	
<212> TYPE: PRT	
<213> ORGANISM: Homo sapiens	
<400> SEQUENCE: 90	
Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr	
85 90 95	
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile	
100 105 110	
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	

US 10,435,695 B2

153**154**

-continued

115	120	125
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys		
130	135	140
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp		
145	150	155
160		
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val		
165	170	175
Asp Lys Ile Lys Gly Ala Gly Gly Asp Leu Ala Val Ala Gly Pro Val		
180	185	190
Pro Thr Ser Lys Pro Thr Thr Thr Gly Lys Gly Cys His Ile Gly Arg		
195	200	205
Phe Lys Ser Leu Ser Pro Gln Glu Leu Ala Ser Phe Lys Lys Ala Arg		
210	215	220
Asp Ala Leu Glu Glu Ser Leu Lys Leu Lys Asn Trp Ser Cys Ser Ser		
225	230	235
240		
Pro Val Phe Pro Gly Asn Trp Asp Leu Arg Leu Leu Gln Val Arg Glu		
245	250	255
Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu Lys Val Leu		
260	265	270
Glu Ala Ala Ala Gly Pro Ala Leu Glu Asp Val Leu Asp Gln Pro Leu		
275	280	285
His Thr Leu His His Ile Leu Ser Gln Leu Gln Ala Cys Ile Gln Pro		
290	295	300
Gln Pro Thr Ala Gly Pro Arg Pro Arg Gly Arg Leu His His Trp Leu		
305	310	315
320		
His Arg Leu Gln Glu Ala Pro Lys Lys Glu Ser Ala Gly Cys Leu Glu		
325	330	335
Ala Ser Val Thr Phe Asn Leu Phe Arg Leu Leu Thr Arg Asp Leu Lys		
340	345	350
Tyr Val Ala Asp Gly Asn Leu Cys Leu Arg Thr Ser Thr His Pro Glu		
355	360	365
Ser Thr		
370		

<210> SEQ ID NO 91
<211> LENGTH: 576
<212> TYPE: DNA
<213> ORGANISM: Sus scrofa
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(576)
<223> OTHER INFORMATION: Porcine Interferon Lambda 1 (IL29

<400> SEQUENCE: 91

atg gct aca gct tgg atc gtg gtg ctg gcg act gtg atg ctg gac ttg	48
Met Ala Thr Ala Trp Ile Val Val Leu Ala Thr Val Met Leu Asp Leu	
1	5
	10
	15
gcc aga gct ggc cct gtc ccc act ttc aag ccc acc aca acc agg aag	96
Ala Arg Ala Gly Pro Val Pro Thr Phe Lys Pro Thr Thr Arg Lys	
20	25
	30
ggc tgc cac atg ggc cag ttc caa tct ctg tca cca cag gag ctg aag	144
Gly Cys His Met Gly Gln Phe Gln Ser Leu Ser Pro Gln Glu Leu Lys	
35	40
	45
ggc ttc aag aaa gcc aag gat gct ttg gaa gag tca ctc tca ctg aag	192
Gly Phe Lys Lys Ala Lys Asp Ala Leu Glu Glu Ser Leu Ser Leu Lys	
50	55
	60
aac tgg agc tgc agc tct ccc ctc ttc ccc agg acc cgg gac ctg agg	240

US 10,435,695 B2

155**156**

-continued

Asn Trp Ser Cys Ser Ser Pro Leu Phe Pro Arg Thr Arg Asp Leu Arg				
65	70	75	80	
cag ctg cag gtg tgg gag cgc ctc gtg gcc tta gag gct gag cta gac		288		
Gln Leu Gln Val Trp Glu Arg Leu Val Ala Leu Glu Ala Glu Leu Asp				
85	90	95		
ttg act ctg aag gtc cta agg gcc gcg gct gac tca tcc ctg ggg gtc		336		
Leu Thr Leu Lys Val Leu Arg Ala Ala Ala Asp Ser Ser Leu Gly Val				
100	105	110		
acc ctg gac cag cca ctt cgc acg ctg cat cac atc cac gtc gaa ctt		384		
Thr Leu Asp Gln Pro Leu Arg Thr Leu His His Ile His Val Glu Leu				
115	120	125		
cag gct tgc atc agg gct cag ccc acg gca gga tcc cgg ctc cag ggc		432		
Gln Ala Cys Ile Arg Ala Gln Pro Thr Ala Gly Ser Arg Leu Gln Gly				
130	135	140		
cgc ctc aac cac tgg ctg cac cgg ctc caa gaa gcc aca aag aaa gag		480		
Arg Leu Asn His Trp Leu His Arg Leu Gln Glu Ala Thr Lys Lys Glu				
145	150	155	160	
tcc caa ggc tgc ctt gag gcc tct gtg aca ttc aac ctc ttc cac ctc		528		
Ser Gln Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe His Leu				
165	170	175		
ctc gta agg gac ctg aga agt gtt acc agt gga gac ttg cac atc tga		576		
Leu Val Arg Asp Leu Arg Ser Val Thr Ser Gly Asp Leu His Ile				
180	185	190		

<210> SEQ ID NO 92

<211> LENGTH: 191

<212> TYPE: PRT

<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 92

Met Ala Thr Ala Trp Ile Val Val Leu Ala Thr Val Met Leu Asp Leu				
1	5	10	15	
Ala Arg Ala Gly Pro Val Pro Thr Phe Lys Pro Thr Thr Arg Lys				
20	25	30		
Gly Cys His Met Gly Gln Phe Gln Ser Leu Ser Pro Gln Glu Leu Lys				
35	40	45		
Gly Phe Lys Lys Ala Lys Asp Ala Leu Glu Glu Ser Leu Ser Leu Lys				
50	55	60		
Asn Trp Ser Cys Ser Ser Pro Leu Phe Pro Arg Thr Arg Asp Leu Arg				
65	70	75	80	
Gln Leu Gln Val Trp Glu Arg Leu Val Ala Leu Glu Ala Glu Leu Asp				
85	90	95		
Leu Thr Leu Lys Val Leu Arg Ala Ala Ala Asp Ser Ser Leu Gly Val				
100	105	110		
Thr Leu Asp Gln Pro Leu Arg Thr Leu His His Ile His Val Glu Leu				
115	120	125		
Gln Ala Cys Ile Arg Ala Gln Pro Thr Ala Gly Ser Arg Leu Gln Gly				
130	135	140		
Arg Leu Asn His Trp Leu His Arg Leu Gln Glu Ala Thr Lys Lys Glu				
145	150	155	160	
Ser Gln Gly Cys Leu Glu Ala Ser Val Thr Phe Asn Leu Phe His Leu				
165	170	175		
Leu Val Arg Asp Leu Arg Ser Val Thr Ser Gly Asp Leu His Ile				
180	185	190		

<210> SEQ ID NO 93

<211> LENGTH: 1083

<212> TYPE: DNA

US 10,435,695 B2

157

158

-continued

<213> ORGANISM: *Sus scrofa*
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1083)
<223> OTHER INFORMATION: Porcine GLuCON Lambda

<400> SEQUENCE: 93

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag	48
Met Gly Val Lys Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc	96
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	
agc aac ttc gcg acc acg gat ctc gat gct gac cgc ggg aag ttg ccc	144
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	
ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc	192
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc	240
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	
aag tgc acg ccc aag atg aag aag ttc atc cca gga cgc tgc cac acc	288
Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr	
85 90 95	
tac gaa ggc gac aaa gag tcc gca cag ggc ggc ata ggc gag ggc atc	336
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Ile Gly Glu Ala Ile	
100 105 110	
gtc gac att cct gag att cct ggg ttc aag gac ttg gag ccc atg gag	384
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115 120 125	
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc	432
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130 135 140	
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg	480
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145 150 155 160	
ctg ccg caa cgc tgt gcg acc ttt gcc agc aag atc cag ggc cag gtg	528
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val	
165 170 175	
gac aag atc aag ggg gcc ggt ggt gac gcc aga gct ggc cct gtc ccc	576
Asp Lys Ile Lys Gly Ala Gly Asp Ala Arg Ala Gly Pro Val Pro	
180 185 190	
act ttc aag ccc acc aca acc agg aag ggc tgc cac atg ggc cag ttc	624
Thr Phe Lys Pro Thr Thr Arg Lys Gly Cys His Met Gly Gln Phe	
195 200 205	
caa tct ctg tca cca cag gag ctg aag ggc ttc aag aaa gcc aag gat	672
Gln Ser Leu Ser Pro Gln Glu Leu Lys Gly Phe Lys Lys Ala Lys Asp	
210 215 220	
gct ttg gaa gag tca ctc tca ctg aag aac tgg agc tgc agc tct ccc	720
Ala Leu Glu Ser Leu Ser Leu Lys Asn Trp Ser Cys Ser Ser Pro	
225 230 235 240	
ctc ttc ccc agg acc cgg gac ctg agg cag ctg cag gtg tgg gag cgc	768
Leu Phe Pro Arg Thr Arg Asp Leu Arg Gln Leu Gln Val Trp Glu Arg	
245 250 255	
ctc gtg gcc tta gag gct gag cta gac ttg act ctg aag gtc cta agg	816
Leu Val Ala Leu Glu Ala Glu Leu Asp Leu Thr Leu Lys Val Leu Arg	
260 265 270	
gcc gcg gct gac tca tcc ctg ggg gtc acc ctg gac cag cca ctt cgc	864
Ala Ala Ala Asp Ser Ser Leu Gly Val Thr Leu Asp Gln Pro Leu Arg	
275 280 285	

US 10,435,695 B2

159

-continued

160

acg ctg cat cac atc cac gtc gaa ctt cag gct tgc atc agg gct cag	912
Thr Leu His His Ile His Val Glu Leu Gln Ala Cys Ile Arg Ala Gln	
290 295 300	

ccc acg gca gga tcc cgg ctc cag ggc cgc ctc aac cac tgg ctg cac	960
Pro Thr Ala Gly Ser Arg Leu Gln Gly Arg Leu Asn His Trp Leu His	
305 310 315 320	

cgg ctc caa gaa gcc aca aag aaa gag tcc caa ggc tgc ctt gag gcc	1008
Arg Leu Gln Glu Ala Thr Lys Lys Glu Ser Gln Gly Cys Leu Glu Ala	
325 330 335	

tct gtg aca ttc aac ctc ttc cac ctc gta agg gac ctg aga agt	1056
Ser Val Thr Phe Asn Leu Phe His Leu Leu Val Arg Asp Leu Arg Ser	
340 345 350	

gtt acc agt gga gac ttg cac atc tga	1083
Val Thr Ser Gly Asp Leu His Ile	
355 360	

<210> SEQ ID NO 94

<211> LENGTH: 360

<212> TYPE: PRT

<213> ORGANISM: Sus scrofa

<400> SEQUENCE: 94

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	

Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	

Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	

Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	

Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	

Lys Cys Thr Pro Lys Met Lys Lys Phe Ile Pro Gly Arg Cys His Thr	
85 90 95	

Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile	
100 105 110	

Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115 120 125	

Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130 135 140	

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145 150 155 160	

Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val	
165 170 175	

Asp Lys Ile Lys Gly Ala Gly Gly Asp Ala Arg Ala Gly Pro Val Pro	
180 185 190	

Thr Phe Lys Pro Thr Thr Arg Lys Gly Cys His Met Gly Gln Phe	
195 200 205	

Gln Ser Leu Ser Pro Gln Glu Leu Lys Gly Phe Lys Lys Ala Lys Asp	
210 215 220	

Ala Leu Glu Glu Ser Leu Ser Leu Lys Asn Trp Ser Cys Ser Ser Pro	
225 230 235 240	

Leu Phe Pro Arg Thr Arg Asp Leu Arg Gln Leu Gln Val Trp Glu Arg	
245 250 255	

Leu Val Ala Leu Glu Ala Glu Leu Asp Leu Thr Leu Lys Val Leu Arg	
260 265 270	

-continued

Ala Ala Ala Asp Ser Ser Leu Gly Val Thr Leu Asp Gln Pro Leu Arg
275 280 285

Thr Leu His His Ile His Val Glu Leu Gln Ala Cys Ile Arg Ala Gln
290 295 300

Pro Thr Ala Gly Ser Arg Leu Gln Gly Arg Leu Asn His Trp Leu His
305 310 315 320

Arg Leu Gln Glu Ala Thr Lys Lys Glu Ser Gln Gly Cys Leu Glu Ala
325 330 335

Ser Val Thr Phe Asn Leu Phe His Leu Leu Val Arg Asp Leu Arg Ser
340 345 350

Val Thr Ser Gly Asp Leu His Ile
355 360

<210> SEQ ID NO 95
<211> LENGTH: 13
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Kozak Sequence
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (7)..(7)
<223> OTHER INFORMATION: R is A or G

<400> SEQUENCE: 95

gccccccrcca tgg 13

<210> SEQ ID NO 96
<211> LENGTH: 5670
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pTarget Empty Vector

<400> SEQUENCE: 96

tcaatattgg	ccattagcca	tattattcat	tggttatata	gcataaatca	atattggcta	60
ttggccattg	catacgttgt	atctatatca	taatatgtac	atttatatgt	gctcatgtcc	120
aatatgaccg	ccatgttggc	attgattatt	gactagttat	taatagtaat	caattacggg	180
gtcattagtt	catagccat	atatggagtt	cecgcttaca	taacttacgg	taaatggccc	240
gcctggctga	ccgccccaaacg	accccccggcc	attgacgtca	ataatgacgt	atgttcccat	300
agtaacgcca	atagggactt	tccattgacg	tcaatgggt	gagtatttac	ggtaaactgc	360
ccacttggca	gtacatcaag	tgtatcatat	gccaagtccg	ccccctatgt	acgtcaatga	420
cggtaaatgg	cccgcctggc	attatgcccc	gtacatgacc	ttacgggact	ttcctacttg	480
gcagtagatc	tacgtttag	tcatcgctat	taccatggtg	atgcgggtt	ggcagtagac	540
caatgggcgt	ggatagcggt	ttgactcagc	gggatttcca	agtctccacc	ccattgacgt	600
caatgggagt	ttgtttggc	acccaaatca	acgggacttt	ccaaaatgtc	gtaacaactg	660
cgatcgcccc	ccccgttgac	gcaaattgggc	ggtaggcgtg	tacggtgaaa	ggtctatata	720
agcagagatc	gttttagtcaa	ccgtcagatc	actagaagat	ttattgcgggt	agtttatcac	780
agttaaattg	ctaacgcagt	cagtgccttc	gacacaacag	tctcgaaactt	aagctgcagt	840
gactcttta	aggttagcctt	gcagaagttg	gtcgtgaggc	actgggcagg	taagtatcaa	900
ggttacaaga	caggtttaag	gagaccaata	gaaactgggc	ttgtcgagac	agagaagact	960
cttgcgttcc	tgataggcac	ctattggct	tactgacatc	cactttgcct	ttctctccac	1020

US 10,435,695 B2

163

164

-continued

agggtgtccac tccccagttca attacagctc ttaaaaattt gatctccatt cgccattcg	1080
gctgcgcaac tgctggaaag gacgatcaga gggggcctct tcgttattac gccagctggc	1140
gaaagggacg tggcaagcaa ggcgattaag ttgagttacg ccaggatttt cccagtacg	1200
acgttgtaaa acgacggca gagaattata atacgactca ctatagggcg aatcggatc	1260
cttgcgttagcc tcgagacgcg tgatatctt cccggggta ccgtcgactg cggccgcga	1320
ttccaagctt gaggattcta tcgtgtcacc taaataactt ggcgtaatca tggtcatatc	1380
tgtttctgt gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca	1440
taaaggtaa agcctgggt gcctaatttgc tgagctaact cacattaatt gcgttgcgc	1500
atgcttcat tttgtgaggg ttaatgcttc gagaagacat gataagatc attgtatgat	1560
ttggacaaac cacaacaaga atgcgtgaa aaaaatgtt tatttgtaa attttgtatg	1620
ctattgtttt atttgtaacc attataagct gcaataacaac agttaacaac aacaattgca	1680
ttcattttat gtttcagggtt cagggggaga tgtggaggt tttttaaagc aagtaaaacc	1740
tctacaaatg tggtaaaatc cgataaggat cgattccgga gcctgaatgg cgaatggacg	1800
cggcctgttag cggcgcatta agcgccggcggt gtgtgggtt tacgcgcacg tgaccgcac	1860
acttgcacg gcccctagcgc ccgcctttt ccgttcttc ctttccttc tcgcccacgtt	1920
cggcggcttt ccccgtaaag ctctaaatcg ggggctccc tttagggttcc gatttatgc	1980
tttacggcac ctcgacccca aaaaacttga tttagggttgc ggttacgtt gttggccatc	2040
gccctgtatg acggtttttgc gccccttgac gttggagtcc acgttctta atatgtggact	2100
cttggccaa acttggaaacaa cactcaaccc tatctcggtc tattttttt atttataagg	2160
gattttggccg atttcggccct attggtaaa aaatgagctg atttaacaaa aatthaacgc	2220
gaattttaaac aaaatattaa cgcttacaat ttgcgcctgt taccttctga ggccggaaaga	2280
accagctgtg gaatgtgtgt cagtttaggt gtggaaagtc cccaggctcc ccagcaggca	2340
gaagtatgc aagcatgcat ctcaatttgcg cagcaaccag gtgtggaaag tccccaggct	2400
ccccagcagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc atatgtccgc	2460
cccttaactcc gcccattcccg ccccttaactc cggccagttc cggccattctt ccggccatcg	2520
gtgtactaat ttttttttat tatgcagagg ccgaggccgc ctcggctct gagctatcc	2580
agaagtagtg aggaggcttt tttggaggcc taggcttttgc caaaaagctt gattttctg	2640
acacaacagt ctcgaactta aggctagatgc caccatgattt gaacaagatg gattgcacgc	2700
aggttctccg gccgttgggg tggagaggctt attcggtat gactggcac aacagacaat	2760
cggctgtctt gatgecgccg tggtccggct gtcagcgcag gggcgeccgg ttcttttgc	2820
caagaccgac ctgtccgggt cctgtatgc actgcaggac gaggcagcgc ggctatcgt	2880
gtgtggccacg acggggcttc cttgcgcagc tggctcgac gttgtactg aagcggaaag	2940
ggactggctt ctattggccg aagtgcgggg gcaggatctc ctgtcatctc accttgcctt	3000
tgccgagaaa gtatccatca tggctgtatgc aatgcgggg ctgcatacgc ttgtatccggc	3060
tacctgcccc ttcgaccacc aagcgaaaca tcgcatacgag cgagcacgtt ctcggatgg	3120
agccggctttt gtgcgtcagg atgatctggc cgaagagcat caggggctcg cgccagccga	3180
actgttcgcc aggctcaagg cgccatgcc ccacggcgag gatctcgctg tgaccatgg	3240
cgtatgeotgc ttgcgaata tcatgggttgc aaatggccgc ttttctggat tcategactg	3300
tggccggctg ggtgtggccgg accgctatca ggacatagcg ttggctaccc gtgatattgc	3360
tgaagagctt ggccggcaat gggctgaccg cttccctgttgc ctttacggta tcgcccgtcc	3420

-continued

cgattcgcag cgcatgcct tctatgcct tcttgacgag ttcttctgag cgggactctg	3480
gggttcgaaa tgaccgacca agcgacgccc aacctgccat cacgatggcc gcaataaaat	3540
atctttatcc tcattacatc tgtgtgttg ttttttgtt gaagatccgc gtatggtgca	3600
ctctcagtag aatctgctct gatgccgcat agttaagcca gccccgacac ccgccaacac	3660
ccgctgacgc gccctgacgg gcttgcgtgc tccggcattc cgcttacaga caagctgtga	3720
ccgtctccgg gagctgcatg tgtcagaggt tttcaccgtc atcaccgaaa cgcgcgagac	3780
gaaaggccct cgtgatacgc ctattttat aggttaatgt catgataata atggtttctt	3840
agacgtcagg tggcactttt cggggaaatg tgcgccgaac ccctatttgt ttatTTCT	3900
aaatacattc aaatatgtat ccgctcatga gacaataacc ctgataaaatg cttcaataat	3960
attgaaaaag gaagagtatg agtattcaac atttccgtgt cgcccttatt ccctttttt	4020
cggcatttttgccttcgtttt tttgctcacc cagaaacgct ggtgaaagta aaagatgctg	4080
aagatcgtt ggggtcacga gtgggttaca tcgaactggta tctcaacagc ggtaagatcc	4140
ttgagagttt tcgccccgaa gaacgttttc caatgatgag cactttaaa gttctgctat	4200
gtggcgcggtt attatccgtt attgacgcgg ggcaagagca actcgggtcgc cgcatacact	4260
attctcagaa tgacttggtt gagtactcac cagtcacaga aaagcatctt acggatggca	4320
tgacagtaag agaattatgc agtgctgcca taaccatgag tgataaacact gcggccaact	4380
tacttctgac aacgatcgga ggaccgaagg agctaaccgc tttttgcac aacatggggg	4440
atcatgtaa tcgccttgcgtggaaac cggagctgaa tgaagccata ccaaaccgacg	4500
agcgtgacac cacgatgcct gtagcaatgg caacaacggt ggcacaacta ttaactggcg	4560
aactacttac tctagttcccgcaacaat taatagactg gatggaggcg gataaagttt	4620
caggaccact tctgegctcg gcccttcgg ctggctgggtt tattgtgtat aaatctggag	4680
ccgggtgagcg tgggtctcgc ggtatcattt cagcaactggg gccagatggt aagccctccc	4740
gtatcgtagt tatctacacg acggggagtc aggcaactat ggtgaacgaa aatagacaga	4800
tcgctgagat aggtgcctca ctgattaagc attggtaact gtcagaccaa gtttactcat	4860
atataacttta gattgattta aaacttcatt ttaattaa aaggatctag gtgaagatcc	4920
tttttataaa tctcatgacc aaaatccctt aacgtgagg ttcgttccac tgagegtcag	4980
accccgtaga aaagatcaaa ggatctttt gagatcctt tttctgcgc gtaatctgct	5040
gcttgcaaac aaaaaaaccac ccgcttaccag cgggtggttt tttgcggat caagacgtac	5100
caactttttt tccgaaggta actggcttca gcagagcgca gataccaaat actgtccctc	5160
tagtgtagcc gtagttaggc caccacttca agaactctgt agcaccgcct acataccctg	5220
ctctgtaat cctgttacca gtggctgcgt ccagtgccga taagtcgtgt cttaccgggt	5280
tggactcaag acgatagtttta ccggataagg cgcagcggtc gggctgaacg ggggggtcgt	5340
gcacacagcc cagcttggag cgaacgacct acaccgaact gagataccca cagcgtgagc	5400
tatgagaaaag cgccacgcctt cccgaaggga gaaaggcgga caggtatccg gtaagcgca	5460
gggtcgaaac aggagagcgc acgaggggac ttccagggggg aaacgcctgg tatctttata	5520
gtcctgtcgg gttcgcac ctctgacttg agcgtcgatt tttgtatgc tcgtcagggg	5580
ggcggagccct atggaaaaac gccagcaacg cggccctttt acggttccctg gcctttgct	5640
ggccttttgc tcacatggct cgacagatct	5670

US 10,435,695 B2

167

168

-continued

```

<211> LENGTH: 6884
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pTarget IFNa-d1D2A-SGluC (-1M)

<400> SEQUENCE: 97

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta      60
ttggccattg catacggtgt atctatatca taatatgtac atttataatg gctcatgtcc     120
aatatgaccg ccatgttggc attgattatt gactagttat taatagtaat caattacggg     180
gtcattagtt catagccat atatggagtt cgcgttaca taacttacgg taaatggccc     240
gcctggctga cggcccaacg accccccccc attgacgtca ataatgacgt atgttccat     300
agtaacgcca atagggactt tccattgacg tcaatgggtg gagtatttc ggtaaactgc     360
ccacttggca gtacatcaag tgtatcatat gccaagtccg cccctatgt acgtcaatga     420
cggtaaatgg cccgcctggc attatgccc gtacatgacc ttacgggact ttcctacttg     480
gcagtagtacatc tacgttattag tcacatcgctat taccatgggtg atgcgggtt ggcagtagtac 540
caatgggcgt ggatagcggt ttgactcagc gggatttcca agtctccacc ccattgacgt     600
caatgggagt ttgtttggc accaaaatca acgggacttt caaaaatgtc gtaacaactg     660
cgatcgcccg ccccggttgc gcaaattggc ggtaggcggtg tacgggtggg ggtctatata    720
agcagagctc gtttagtgaa ccgtcagatc actagaagct ttattgggtt agtttatcac    780
agttaaatttgc ttaacgcgtc cagtgcttct gacacaacag tctcgaacctt aagctgcagt 840
gactctttaa aggtacgcctt gcagaagtt gtcgtgaggc actgggcagg taatgtatcaa   900
ggttacaaga cagggttaag gagaccaata gaaaactgggc ttgtcgagac agagaagact   960
cttgcgttgc tgataggcac ctatggctt tactgacatc cactttgcct ttctctccac 1020
aggtgtccac tcccaagttca attacagctc taaaaatttgc gatctccatt cgccattcag 1080
gctgcgcaac tgctgggaag gacgtcaga gccccctct tcgttattac gccagctggc 1140
gaaaggacg tggcaagcaa ggcgattaag ttgagttacg ccaggattt cccagtcacg 1200
acgttgtaaa acgacggca gagaattata atacgactca ctataggcg aattcggatc 1260
cttgctagcg ccgcaccat ggcggccacc tcagccttc tcacggccct ggtgtactc 1320
agctgcataatc ccatctgctc tctgggtgt gacctgcctc agacccacag cctggctcac 1380
accagagccc tgaggctctt ggcacaaaatg aggagaatct ctcccttctc ctgcctggac 1440
cacagaaggg actttgggtt ccctcatgag gctttgggg gcaaccaggt ccagaaggct 1500
caagccatgg ctctggtgca tgagatgctc cagcagacctt tccagcttt cagcacagag 1560
ggctcggtctg ctgcctggaa tgagacgtc ctgcaccagg tctgcactgg actggatcag 1620
cagctcaggc accttggaaacg ctgtgtcatg caggaggcg ggcgttggagg gaccccccgt 1680
ctggaggagg actccatctt ggctgtgagg aaatacttcc acagactcac cctctatctg 1740
caagagaaga gctacagccc ctgtgcctgg gagatgtca gggcagaagt catgagatcc 1800
ttctcttccct ccagaaacctt gcaagacaga ctcaggaaga aggagctcgac gacgcgtgt 1860
tgccgcgcac ccatgagcca caagcaaaatg atcattgcac cagcaagca gcttctgaat 1920
tttgacactgc tcaagttggc cggagacgtt gagtccacc ctggggccgg agtcaaagtt 1980
ctgtttggcc tggatctgcat cgctgtggcc gaggccaaacg ccaccggagaa caacggac 2040
ttcaacatcg tggccgtggc cagcaacttt ggcaccacgg atctcgatgc tgaccgggg 2100
aagttggcccg gcaagaagct ggcgtggag gtgtcaaaatg agatggaaacg caatggccgg 2160

```

-continued

aaagctggct gcaccagggg ctgtctgatc tgcctgtccc acatcaagtg cacgccccaa	2220
atgaagaagt ggctcccgagg acgctgccac acctacgaag gcgacaaaaga gtccgcacag	2280
ggcgccatag gcgaggcgat cgtcgatatt cctgagattc ctgggttcaa ggacttggag	2340
ccaatggagc agttcatcgc acaggatcgat ctgtgtgtgg actgcacaac tggctgcctc	2400
aaagggcttg ccaacgtgca gtgttcagac ctgctcaaga agtggctgcc gcaacgcgt	2460
gchgaccccttgc cagcaagat ccaggggccag gtggacaaga tcaagggggc cggtggtag	2520
taageggccg cgaattccaa gcttgagtat tctatcgatc cacctaaata acttggcgta	2580
atcatggtca tatctgtttc ctgtgtgaaa ttgttateccg ctcacaattc cacacaacat	2640
acgagccgga agcataaaagt gtaaagcctg ggggcctaa tgagttagct aactcacatt	2700
aattgegttg cgcgatgcctt ccattttgtg agggtaatg ctgcgagaag acatgataag	2760
atacattgtat gagtttggac aaaccacaac aagaatgcag tgaaaaaat gctttat	2820
tgaaatttgt gatgctatttgc ctttatgtt aaccattata agctgcaata aacaagttaa	2880
caacaacaat tgcatttcatt ttatgttca gggtcagggg gagatgtggg aggttttta	2940
aagcaagtaa aacctctaca aatgtggtaa aatccgataa ggatcgatc cggagccctga	3000
atggcgaatg gacggccct gtacggccgc attaagcgcg ggggtgtgg tggtaacgcg	3060
cacgtgacccg ctacacttgc cageggcccta gggccgcctc ctttcgcctt cttcccttcc	3120
tttctegcca cgttccggg ctttcccgat caagctctaa atcgccggct ccctttaggg	3180
ttccgattta gtgcatttacg gcacccgtac cccaaaaaac ttgatttaggg tgatggtca	3240
cgttagtgggc catcgccctg atagacggtt ttccgcctt tgacgttggaa gtccacgttc	3300
tttaatagtg gactttgtt cccaaacttgc acaacactca accctatctc ggtctattct	3360
tttgattt aaggatttt gccgatttcg gcctattggg taaaaatga gctgatttaa	3420
caaaaattha acgcgaattt taacaaaata ttaacgctta caatttcgc tgcgtacatt	3480
ctgaggccga aagaaccagc tggaaatgt gtgtcagttt ggggtgtggaa agtccccagg	3540
ctcccccgcga ggcagaagta tgcaaaagcat gcatctcaat tagtcagcaa ccaggtgtgg	3600
aaagtcggccca ggctcccgag caggcagaag tatgcaaagc atgcatctca attagtcagc	3660
aaccatagtc cccggccctaa ctccggccat cccggccctca actccgccc gttccgcctt	3720
ttctccggccc catggctgac taattttttt tattttatgca gaggccgagg ccgcctcgcc	3780
ctctgagcta ttccagaagt agtggaggagg ctttttggg ggccttaggt tttgcaaaaa	3840
gcttgcatttct tctgacacaa cagtctcgaa cttaaggctt gaggccacat gattgaacaa	3900
gatggattgc acgcagggttc tccggccgtt tgggtggaga ggctattcg ctatgactgg	3960
gcacacaacaga caatcgccgt ctctgtatcc ggcgtgtcc ggctgtcagc gcaggggccgc	4020
ccgggtttttt ttgtcaagac cgacccgtcc ggtgcctgaa atgaactgca ggacgaggca	4080
gcgccggctat cgtggctggc cacgacggggc gttcccttgcg cagctgtgtt ccacgttgc	4140
actgaagccgg gaaggactg gctgttattt ggcgaagtgc cggggcagga tctcctgtca	4200
tctcacccgtt ctccctggca gaaagtatcc atcatggatc atgcaatgcg ggggtgcac	4260
acgcgttgc acgcgttgc cccatttcgac caccaaggca aacatcgatc cgaggcgagca	4320
cgtactcgaa tggaaaggccgg tcttgcgtat caggatgtatc tggacgaaaga gcatcagggg	4380
ctcgccggccag ccgaactgtt cgccaggctc aaggcgcgc tggccgcacgg cgaggatctc	4440
gtcggtaccc atggcgatgc ctgttgcgg aatatcatgg tggaaaatgg ccgttttct	4500

-continued

ggattcatcg actgtggccg gctgggtgtg	4560
acccgtata ttgctgaaga gcttggccgc	4620
aatgggtttt cttttttttt	4680
ttagttttttt tttttttttt	4740
ggccgcata aaatatctt attttcatta	4800
catctgtgtg ttgggtttt gtgtgaagat	
ccgcgttatgg tgcactctca gtacaatctg	4860
ctctgtatcc gcatagttaa gccagccccg	
acacccgcca acacccgctg acgcgcctg	4920
acgggcttg ctgctcccg catccgccta	
cagacaagct gtgaccgtct ccgggagctg	4980
catgtgtcag aggtttcac cgtcatcacc	
gaaacgcgcg agacgaaagg gcctcgtat	5040
acgcctattt ttataggtta atgtcatgat	
aataatgggt tcttagacgt caggtggcac	5100
ttttggggaa aatgtgcgcg gaacccctat	
ttgtttatcc ttctaaatac attcaaatac	5160
gtatccgctc atgagacaat aaccctgata	
aatgcttcaa taatattgaa aaaggaagag	5220
tatgagtattt caacattcc gtgtgcgcct	
tattcccttt tttgcggcat tttgccttcc	5280
tggttttgc caccggaaaa cgctggtgaa	
agtaaaaat gctgaagatc agttgggtgc	5340
acgagtggtt tacatcgaac tggatctcaa	
cagcgtaag atccttgaga gtttgcggcc	5400
cgaagaacgt tttcaatga tgagcacattt	
taaaggttctg ctatgtggcg cggttattatc	5460
ccgttattgac gcccggcaag agcaactcg	
tcgcccgcata cactattctc agaatgactt	5520
ggttgagttac tcaccagtca cagaaagca	
tcttacggat ggcatgacag taagagaatt	5580
atgcagtgtt ggcataacca tgagtgataa	
cactgcggcc aacttacttc tgacaacgt	5640
cgaggaccg aaggagctaa ccgcctttt	
gcacaacatg ggggatcatg taactcgct	5700
tgatcggtgg gaaccggagc tgaatgaagc	
cataccaaac gacgagcgtg acaccacgt	5760
gcctgtatca atggcaacaa cgttgcgc当地	
actattaact ggcgaactac ttactcttagc	5820
ttcccgccaa caattaatag actggatgga	
ggcggataaa gttgcaggac cacttctgcg	5880
ctcgccctt ccggctggct ggtttattgc	
tgataaatct ggagccggtg agcgtgggtc	5940
tcgcggatc attgcagcac tggggccaga	
tggtaagccc tcccgatcg tagttatcta	6000
cacgacgggg agtcaggcaa ctatggatga	
acgaaataga cagatcgctg agataggtgc	6060
ctcaactgattt aactgtcatt aactgtcaga	
ccaagttac tcataatatac ttttagattga	6120
ttttaaaactt catttttaat ttaaaaggat	
ctaggtgaag atccttttg ataatctcat	6180
gacccaaatc ctttaacgtg agtttcgtt	
ccactgagcg ttagaccccg tagaaaagat	6240
caaaggatct tcttgcgc当地	
gegcgtatc tgctgc当地	6300
aaacaaaaaa accaccgata ccagcggtgg	
tttgc当地	6360
ggatcaagag ctaccaactc ttttccgaa	
ggtaactggc ttcagcagag cgccagataacc	6420
aaatactgtc ttcttagtgc agccgtatgtt	
aggccaccac ttcaagaact ctgtagcacc	6480
gectacatac ctgc当地	
taatccgtttt accagtggct gtc当地	6540
gtgtcttacc ggggtggact caagacgata	
gttaccggat aaggcgc当地 ggtc当地	6600
aacggggggg tcgtgc当地	
acccagctt ggagcgaacg acctacacccg	6660
aactgagata	
cctacacgct gagctatgag aaagcgccac	6720
gcttccgaa gggagaaagg cgagcaggtt	
tcccgtaagc ggcagggtcg	6780
gaacaggaga gcgc当地 gagcttccag	
ggggaaacgc	6840
atgctcgatc gggggccgaa gcctatggaa	
aaacgcccac aacgc当地	6884
cctggccctt tgctggccctt ttgctcacaat	
ggctcgacag atct	

-continued

<210> SEQ_ID NO 98
 <211> LENGTH: 6864
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: pTarget SGLuc-d1D2A-IFNa

 <400> SEQUENCE: 98

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta	60
ttggccattg catabgttgt atctatatca taatatgtac atttatattg gtcatgtcc	120
aatatgaccg ccatgttgcg attgattatt gactagttaat taatagtaat caattacggg	180
gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc	240
gectggctga ccccccacg accccccccc attgacgtca ataatgacgt atgttcccat	300
agtaacgcca atagggactt tccattgacg tcaatgggtg gagtattac ggtaaaactgc	360
caacttggca gtacatcaag tgtatcatat gccaagtccg ccccttattt acgtcaatga	420
cggtaaatgg cccgcgttgc attatgcccc gtacatgacc ttacggact ttcctacttg	480
geagtgacatc tacgttattag tcacatgcata taccatgggtg atgcgggttt ggcagtgacac	540
caatggcggt ggatagcggt ttgactcacg gggatttcca agtctccacc ccattgacgt	600
caatggaggt ttgttttggc accaaaatca acgggacttt ccaaataatgtc gtaacaactg	660
cgatcgcccg ccccggttgcg gcaaatgggc ggttaggcgtg tacgggtggaa ggtctatata	720
agcagagctc gtttagtgaa ccgtcagatc actagaagct ttattggcgtt agtttatcac	780
agttaaattt ctaacgcagt cagtgcattt gacacaacag tctcgaaactt aagctgcagt	840
gactcttta aggttagccctt gcagaagttt gtcgtgaggc actggggcagg taagtatcaa	900
ggttacaaga cagggttaag gagaccaata gaaactgggc ttgtcgagac agagaagact	960
cttgcgttcc tcataggcac ctattggct tactgacatc cactttgcct ttctctccac	1020
aggtgtccac tcccaagtca attacagctc ttaaaaattt gatctccatt cgccattcag	1080
gctgcgcaac tgctggaaag gacgatcaga gggggctct tcgctattac gccagctggc	1140
gaaaggggacg tggcaagcaa ggcgattaag ttgagttacg ccaggatttt cccagtcacg	1200
acggtgtaaa acgaegggca gagaattata atacgactca ctatagggcg aatteggatc	1260
cttggcgtgc gccgcacca tggagtcgaa agttctgttt gcccgtatct gcategcgt	1320
ggcccgaggcc aagcccacgg agaacaacga agacttcaac atcgtggccg tggccagcaa	1380
cttcgcgacc acggatctcg atgctgacccg cggaaagttt cccggcaaga agctgccgt	1440
ggaggtgctc aaagagatgg aagccaatgc cccgaaagct ggctgcacca ggggtgtct	1500
gatctgcctg tccccacatca agtgcacgc caagatgaag aagtggctcc caggacgctg	1560
ccacacccatc gaaggcgaca aagagtccgc acagggccggc atagggcagg cgatcgctga	1620
cattcctgag attcctgggt tcaaggactt ggagccatg gacgatgtca tcgcacaggt	1680
cgtatctgtgt gtggactgca caactggctg cctcaaaggc cttgccaacg tgcaagtgttc	1740
tgacctgctc aagaagtggc tgccgcaacg ctgtgcgacc ttgcccagca agatccagg	1800
ccaggtggac aagatcaagg gggccgggtgg tgacgctacg cacaagcaaa agatcatgc	1860
accagcaaag cagcttctga attttgcacct gctcaagttt gccggagacg ttgagttcaa	1920
ccctggaccc gggatggccc caacctcagc cttcctcagc gcccgttgc tactcagctg	1980
caatgcacatc tgctctctgg gctgtgaccc gcctcagacc cacagectgg ctcacaccag	2040

-continued

agccctgagg ctcctggcac aaatgaggag aatctctccc ttctcctgcc tggaccacag	2100
aaggggacttt ggttccccctc atgaggcctt tgggggcaac caggtccaga aggctcaagc	2160
catggctctg gtgcataaga tgctccagea gaccttccag ctcttcagca cagagggttc	2220
ggctgtgtcc tggaaatgaga gcctcctgca ccagttctgc actggactgg atcagcagct	2280
cagggacctg gaagectgtg tcatacgaga ggccggggctg gaagggaccc ccctgcttgg	2340
ggaggactcc atcctggctg tgaggaaata ctccacaga ctcacccctt atctgcaaga	2400
gaagagactac agccctgtg cctggagat cgtaaggcca gaagtcatga gatccttc	2460
ttcctccaga aacctgcaag acagactcg aaaaaaggag tgagcggccg cgaattccaa	2520
gttttagtat tctatcggt cacctaaata acttggcgta atcatggtca tatctgttcc	2580
ctgtgtgaaa ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt	2640
gtaaagcctg gggtgctaa tgagttagct aactcacatt aattgcgttg cgcatgttt	2700
ccatTTTGTG agggtaatg ctccagaag acatgataag atacattgtat gagttggac	2760
aaaccacaac aagaatgcag tgaaaaaaat gctttatTTG tgaaatttgt gatgtattt	2820
ctttatttgt aaccattata agctgcaata aacaagttaa caacaacaat tgcatttattt	2880
ttatgtttca ggttcagggg gagatgtggg aggtttttta aagcaagtaa aacctctaca	2940
aatgtggtaa aatccgataa ggatcgattc cggagcctga atggcgaatg gacgcgcct	3000
gtagcggcgc attaagcgcg cgggggtgtgg tggtaacgcg cacgtgaccgc ctacacttgc	3060
cagcgcctca gcgcgcgtc ctccgcctt ctcccttc ttctcgcca cggtcgccgg	3120
ctttccccgt caagctctaa atcggggctc ccctttaggg ttccgattta gtgcatttacg	3180
gcacctcgac cccaaaaaac ttgatttaggg tgatggttca cgtagtggc catgcgcctg	3240
atagacggtt ttccgcctt tgacggttga gtccacgttc tttaatagtg gactttgtt	3300
ccaaactgga acaacactca accctatctc ggtctattttt tttgattttt aaggatttt	3360
gccgatttcg gcctattggta taaaaaatgaa gctgatttaa caaaaattta acgcgaattt	3420
taacaaaata ttaacgctta caatttcgc tgtgtacctt ctgaggcgga aagaaccagc	3480
tgtggatgt gtgtcgttta ggggtgtggaa agtccccagg ctccccagca ggcagaagta	3540
tgcaaagcat gcatctcaat tagtcagca ccaggtgtgg aaagtccccca ggctccccag	3600
caggcagaag tatgcaaaagc atgcatactca attagtcagc aaccatagtc ccgcgcctaa	3660
ctccgcctat cccgcgccta actccgcctt gttccgcctt ttctccgcctt catggctgac	3720
taattttttt tatttatgca gaggccgagg ccgcctcgcc ctctgagctt ttccagaagt	3780
agtggaggagg cttttttgaa ggccttaggt tttgcaaaaa gcttgatttt tctgacacaa	3840
cagtctcgaa cttaaggctt gagccaccat gattgaacaa gatggatttc acgcagggttc	3900
tccggccgct tgggtggaga ggctattcgg ctatgactgg gcacaacaga caatcggtt	3960
ctctgatgcc ggcgtgttcc ggctgtcgcg gcaggggccgc ccggtttttt ttgtcaagac	4020
cgacctgtcc ggtgcctga atgaactgca ggacgaggca ggcggctat cgtggctgg	4080
cacgacgggc gttccctgcg cagctgtgtc cgcacgttgc actgaaggccg gaagggactg	4140
gctgctatttggc ggcgaagtgc cggggcagga tctcctgtca tctcaccttgc tccctgc	4200
gaaaatgttcc atcatggctg atgcaatgcg gcccgtcat acgcttgc acgcgttgc	4260
cccatcgac caccaagcga aacatcgat cgacgcgacg cgtactcgga tggaaagccgg	4320
tcttgcgtat caggatgtat tggacgaa gcatcagggg ctcgcgcacag ccgaactgtt	4380
cgccaggctc aaggcgcgcgca tgccgcacgg cgaggatctc gtcgtgaccc atggcgatgc	4440

-continued

ctgcttgcgg aatatcatgg tggaaaatgg ccgttttct ggattcatcg actgtggccg	4500
gctgggtgtg gcgaccgct atcaggacat agcggtggct acccgtata ttgctgaaga	4560
gcttggggc gaatgggctg accgtttct cgtgtttac ggtatcgccg ctcccgattc	4620
gcagcgcata gccttctata gccttctta cgagttttc tgagcgggac tctggggttc	4680
gaaatgaccg accaagcgac gcccaacctg ccatcacatg ggccgcaata aaatatctt	4740
atttcatta catctgtgtg ttgggttttt gtgtgaagat ccgcgtatgg tgcactctca	4800
gtacaatctg ctctgtatgcc gcatagttaa gccagcccc acacccgcca acacccgctg	4860
acgcgcctg acgggcttgc ctgctcccg catccgtta cagacaagct gtgaccgtct	4920
ccgggagctg catgtgtcag aggtttcac cgtcatcacc gaaacgcgcg agacgaaagg	4980
gcctcgtat acgccttattt tttaggtta atgtcatgat aataatgggt tcttagacgt	5040
caggtggcac tttcgggga aatgtgcgcg gaacccctat ttgttttattt ttctaaatac	5100
attcaaataat gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa	5160
aaaggaagag tatgagtatt caacatttcg gtgtcgccct tattccctt tttgeggcat	5220
tttgccttcc tggtttgtct cacccagaaa cgctggtgaa agtaaaagat gctgaagatc	5280
agttgggtgc acgagtggt tacatcgaa tggatctcaa cagcgtaag atccttgaga	5340
gttttgcggc cgaagaacgt ttccaaatga tgagcaattt taaagttctg ctatgtggcg	5400
cggtattatc ccgtatttgc gcccggcaag agcaactcgg tcgcccata cactatttctc	5460
agaatgactt gggttagtac tcaccagtca cagaaaagca tcttacggat ggcacatg	5520
taagagaatt atgcagtgtc gccataacca tgagtataa cactgeggcc aacttacttc	5580
tgacaacatg cggaggaccg aaggagctaa ccgcctttt gcacaacatg ggggatcatg	5640
taactcgct tgatcggtgg gaacccggagc tgaatgaagc cataccaaac gacgagcgtg	5700
acaccacatg gcctgttagca atggcaacaa cgttgcgc当地 actattaact ggcaactac	5760
ttactctagc ttccggcaa caattaatag actggatggaa ggccgataaa gttcaggagc	5820
cacttctgcg ctccggccctt ccggctggct ggtttattgc tgataaaatct ggagccggtg	5880
agcgtgggtc tcgcggatc attgcagcac tggggccaga tggtaagccc tcccgatcg	5940
tagttatcta cacgacgggg agtcaggca cttatggatc acgaaaataga cagatcgctg	6000
agataggtgc ctcactgatt aagcatttgtt aactgtcaga ccaagtttac tcatatatac	6060
ttagatgtt tttaaaactt cattttat tttaaaaggat cttaggtgaag atcccttttgc	6120
ataatctcat gacaaaatc ctttaacgtg agtttcgtt ccactgagcg tcagaccccg	6180
tagaaaaatg caaaggatct tcttgagatc cttttttctt ggcgtataatc tgctgcttc	6240
aaacaaaaaa accacccgcta ccacgggtgg ttgtttgcg ggatcaagag ctaccaactc	6300
ttttccgaa ggttaactggc ttcaaggatc cgcagatacc aaatactgtc cttctagtg	6360
agccgtatgtt aggccaccac ttcaagaact ctgttagcacc gcctacatc ctcgtctgc	6420
taatccgtt accagtggtc gctgccagtg gcgtataatgc gtgtcttacc ggggtggact	6480
caagacgata gttacggat aaggcgcgcg ggtcggttgc aacgggggtt tcgtgcacac	6540
agcccgactt ggagcgaacg acctacacccg aactgagata cttacacgtt gagctatgag	6600
aaagcgccac gttcccgaa gggagaaagg cggacaggta tccggtaagc ggcagggtcg	6660
gaacaggaga ggcgcacgagg gagcttccag ggggaaacgc ctggatctt tatgtctcg	6720
tcgggtttcg ccacctctga cttgagcgtc gatgggtgtg atgctcgta gggggccgga	6780

US 10,435,695 B2

179

180

-continued

gcctatggaa	aaacgccagc	aacgcggcct	tttacggtt	cctggccttt	tgctggcct	6840
ttgctcacat	ggctcgacag	atct				6864
 <210> SEQ ID NO 99						
<211> LENGTH: 6106						
<212> TYPE: DNA						
<213> ORGANISM: Artificial Sequence						
<220> FEATURE:						
<223> OTHER INFORMATION: pTarget Histone H3						
 <400> SEQUENCE: 99						
tcaatattgg	ccattagcca	tattattcat	tggtttatata	gcataaaatca	atattggcta	60
ttggccattg	catacgttgt	atctatatca	taatatgtac	atttatatgt	gctcatgtcc	120
aatatgacccg	ccatgttggc	attgattatt	gactagtta	taatagtaat	caattacggg	180
gtcattagtt	catagcccat	atatggagtt	ccgcgttaca	taacttacgg	taaatggccc	240
gcctggctga	ccgccccaa	cccccggcc	attgacgtca	ataatgacgt	atgttcccat	300
agtaacgcca	atagggactt	tccattgacg	tcaatgggtt	gagttttac	ggtaaactgc	360
ccacttggca	gtacatcaag	tgtatcatat	gccaagtccg	ccccctatgt	acgtcaatga	420
cggtaaatgg	cccgccctggc	attatgccc	gtacatgacc	ttacgggact	ttcctacttg	480
gcagtagatc	tacgttattag	tcatcgctat	taccatgggt	atgcggttt	ggcagtagac	540
caatgggcgt	ggatagcggt	ttgactcagc	gggattttca	agtctccacc	ccattgacgt	600
caatgggagt	ttgttttggc	acccaaatca	acgggacttt	ccaaaatgtc	gtaacaactg	660
cgatcgcccg	ccccgttgac	gcaaatggc	ggtaggcgtg	tacgggtgg	ggcttatata	720
agcagagctc	gttttagtgaa	ccgtcagatc	actagaagct	ttattgcgg	agtttatcac	780
agttaaatgg	ctaacgcagt	cagtgttct	gacacaacag	tctcgaacct	aagctgcagt	840
gactcttta	aggttagcctt	gcagaagtt	gtcgtgaggc	actgggcagg	taagtatcaa	900
ggttacaaga	cagggttaag	gagaccaata	gaaactgggc	ttgtcgagac	agagaagact	960
cttgcgttcc	tgataggcac	ctattggct	tactgacatc	cactttgcct	ttctctccac	1020
aggtgtccac	tcccagttca	attacagtc	ttaaaaattg	gatctccatt	cgccattcag	1080
gtgcgcac	tgctgggaag	gacgatcaga	gccccctct	tcgttattac	gccagctgg	1140
gaaaggacg	ttggcaagcaa	ggcgattha	tttagttacg	ccaggattt	cccagtca	1200
acgttgtaaa	acgacggcca	gagaattata	atacgactca	ctatagggcg	aattcgatc	1260
cttgctagcc	tcgagacgcg	tgataaggag	ctcgagccac	catggctcg	acaaagcaga	1320
ctgcccgc	atcgaccgg	ggttaagcac	cgaggaagca	actcgctaca	aaagccgctc	1380
geaagagtc	gccctctact	ggagggtgt	agaaacctca	tcgttacagg	cctggactg	1440
tggcactccg	tgaaattaga	cgttatcaga	agtccactga	acttctgatt	cgcaaactc	1500
ccttccagcg	tctggtgccgg	gaaattgtct	aggacttcaa	aacagatctg	cgcttccaga	1560
gtgcagctat	ttgtgttttgc	caggaggca	gtgaggccta	tctgggtgg	ctttttgaag	1620
acaccaac	gtgtgtatc	catgccaac	gtgtacaat	tatgccaaa	gacatccagc	1680
tagcacgc	catacgttgg	gaacgtgctt	aaggtaacca	atcttcccg	ggggtaacgt	1740
cgactgcggc	cgcgaattcc	aagcttgagt	attctatcg	gtcacctaaa	taacttggcg	1800
taatcatgtt	catactgttt	tctgtgtga	aattgttac	cgctcacaat	tccacacaac	1860
atacgagccg	gaagcataaa	gtgtaaagcc	tggggtgcct	aatgagttag	ctaaactcaca	1920
ttaattgcgt	tgcgcgatgc	ttccatatttg	tgagggttaa	tgcttcgaga	agacatgata	1980

-continued

agatacattg atgagtttg acaaaccaca acaagaatgc agtaaaaaaaaa atgcatttatt	2040
tgtgaaattt gtgatgctat tgctttattt gtaaccatta taagctgcaa taaaacaagtt	2100
aacaacaaca attgcattca ttttatgttt caggttcagg gggagatgtg ggaggtttt	2160
taaagcaagt aaaacctcta caaatgtgtt aaaatccgat aaggatcgat tccggagcct	2220
gaatggcgaa tggacgcgcc ctgtagcgcc gcattaagcg cggcggtgt ggtggttacg	2280
cgcacgtgac cgctacactt gccagcgccc tagcgccccgc tcctttcgat ttcttcctt	2340
ccttttcgc cacgttcgcc ggctttcccc gtcaagctt aaatcggggg ctcccttag	2400
ggttccgatt tagtgcttta cggcacctcg accccaaaaa acttgattag ggtgtatggtt	2460
cacgtatgtt gccatcgccc ttagatagacgg ttttcgeccc tttgacgtt gagtccacgt	2520
tcttaatag tggactcttgc ttccaaactg gaacaacact caaccctatc tcggcttattt	2580
cctttgattt ataagggatt ttgcgcgattt cggccttattt gttaaaaaat gagctgattt	2640
aacaaaaattt taacgcgaat tttaacaaaaa tattaaacgct tacaatttcg cctgtgtacc	2700
ttctgaggcg gaaagaacca gctgttgaat gtgtgtcagt taggggtgtgg aaagtccca	2760
ggctcccccag caggcagaag tatgc当地 atgc当地 attagtcatc aaccagggtgt	2820
ggaaagtccc caggtccccc agcaggcaga agtatgc当地 goatgc当地 caattagtc当地	2880
gcaaccatag tccccccct aactccgccc atccccccccc taactccgccc cagttccgccc	2940
cattctccgc cccatggctg actaattttt ttttattatg cagaggccga ggccgcctcg	3000
gcctctgagc tattccagaa gtatgttggaa ggctttttt gaggccctagg cttttgc当地	3060
aagcttgattt cttctgacac aacagtctcg aacttaaggc tagageccacc atgattgaac	3120
aagatggattt gcacgcaggt tctccggccg cttgggttggaa gaggcttattt ggctatgact	3180
gggcacaaca gacaatcgcc tgctctgtat ccggcgttccgc gcgcaggggc	3240
ggccgggtct ttttgtcaag accgacctgt ccggcgttccgc gaatgaactt caggacgagg	3300
cagcgcggct atcggtggctg gccacgcacgg gcgttccctt cgcagctgtg ctgcacgttgc	3360
tcactgaagc gggaaaggac tggctgtat tggc当地 gccc当地 gatctccctgt	3420
catctcacct tgctctgtcc gagaaagtat ccatcatggc ttagtgc当地 cggcggctgc	3480
atacgttgc当地 tccggcttacc tgcccatcg accaccaagc gaaacatcgatc atcgacgc当地	3540
cacgtactcg gatggaaagcc ggttttgc当地 atcaggatga tctggacgaa gagcatcagg	3600
ggctc当地 agccgaaactg ttc当地 caggc当地 tcaaggccgat catggccgac ggc当地	3660
tcgtcgatc当地 ccatggcgat gc当地 gcttgc当地 cgaatatcat ggtggaaaat ggccgcttt	3720
ctggattcat ctagtgc当地 cggctgggtg tggc当地 accgc当地 atagcgttgc当地	3780
ctaccggatc当地 tattgttgc当地 gagcttggcg gccaatgggc tgaccgcttc ctgc当地	3840
acggatcgatc当地 cgctcccgat tc当地 cagc当地 tccgcttctt tggc当地 gatc当地	3900
tctgagcggg actctggggt tc当地 aatgc当地 cgacccaagc acgccc当地 tgccatc当地	3960
atggccgcaa taaaatatct ttatattcat tacatctgtg tggggggg ttgtgtgaag	4020
atccgctatc当地 ggtgc当地 ctagtacaatc tgctctgtat cggcatatc当地 aagccagccc	4080
cgacacccgc当地 caacacccgc当地 tgacgc当地 tgacggctt gtctgctcc ggc当地	4140
tacagacaag ctgtgc当地 ctccggggc当地 tgcatgtgc当地 agaggtttc accgtcatca	4200
ccgaaacgc当地 cgagacgaaa gggc当地 cgtg atacgc当地 tttataggt taatgtcatg	4260
ataataatgg tttcttagac gtc当地 ggtggc acttttc当地 gaaatgtgc当地 cggaaccct	4320

-continued

atttgttat tttctaaat acattcaa atgttatccgc tcatacgaca ataaccctga	4380
taaatgcttc aataatattg aaaaaggaag agtatgatgatc ttcaacattt ccgtgtcgcc	4440
cttattccct ttttgccgc attttgccctt cctgttttg ctcaaccaga aacgctggtg	4500
aaagtaaaag atgctgaaga tcaatgggt gcacgactgg gttacatcga actggatctc	4560
aacagcgta agatccttga gagtttccgc cccgaagaac gttttccaat gatgacact	4620
tttaaagttc tgctatgtgg cgccgttatta tcccgttattt acgccccca agagcaactc	4680
ggtcgcccga tacactattc tcagaatgac ttgggtttagt actcaccagt cacagaaaag	4740
catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtat	4800
aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgcttt	4860
ttgcacaaca tggggatca tgtaactcgc ctgtatcgat gggAACCGGA gctgaatgaa	4920
gccataccaa acgacgacgc tgacaccacg atgcctgttag caatggcaac aacgttgcgc	4980
aaactattaa ctggcgaact acttactcta gttcccccgg aacaattaat agactggatg	5040
gaggcggata aagttgcagg accacttgcg cgtccggccc ttccggctgg ctggtttatt	5100
gctgataaat ctggagccgg tgagcgtggg tctcgccgttata tcattgcagc actggggcca	5160
gtatggtaaggc cctcccgat cgtatgttac tacacgacgg ggagtcagc aactatggat	5220
gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcatg gtaactgtca	5280
gaccaagttt actcatatat acttttagatt gatTTAAAC ttcatTTTA attTTAAAGG	5340
atcttaggtga agatccttt tgataatctc atgacaaaaa tcccttaacg tgagtttgc	5400
ttccactgag cgtcagaccc cgtagaaaaa atcaaaggat cttcttgaga tcctttttt	5460
ctgcgcgtaa tctgtgttgc gcaaacaaaa aaaccaccgc taccagcggt ggTTTGTG	5520
ccggatcaag agctaccaac tcttttccg aaggtaactg gttcagcag agcgcagata	5580
ccaaataactg tccttctagt gttagccgtat tttagccacc acttcaagaa ctctgttagca	5640
ccgcctacat acctcgctt gctaattcgtt ttaccagtgg ctgtgtccag tggcgataag	5700
tctgtgttta ccgggttggg ctcagacga tagttaccgg ataaggcgca gcggtcgccc	5760
tgaacgggggg gttcgtgcac acagccacgc ttggagcgaa cgacctacac cgaactgaga	5820
tacctacacgc gtgagctatg agaaaaggccc acgcttcccg aaggagaaaa ggcggacagg	5880
tatccggtaa gccccgggtt cggacacgaa gagcgcacga gggagttcc agggggaaac	5940
gcctggtatac ttatagttcc tgtagggttt cgccacctct gacttgagcg tcgatTTTG	6000
tgatgctcgat cagggggggcg gaggctatgg aaaaacgcca gcaacgcggc cttttacgg	6060
ttcctggctt tttgtggcc ttttgtcac atggctcgac agatct	6106

<210> SEQ ID NO 100
 <211> LENGTH: 6696
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: pTarget SGLucON Alpha Porcine

<400> SEQUENCE: 100

tcaatattgg ccattagccca tattattcat tggttatata gcataaatca atattggcta	60
ttggccatttgcatacgatgttgcataatgtatca taatatgtac atttataatttgcgtatgtcc	120
aatatgacccg ccatgttgcc attgatttattt gactgtttat taatgtatcaatccgg	180
gtcattagttt catagccat atatggatgtt ccgcgttaca taacttacgg taaatggccc	240
gcctggctga ccggccaaacg acccccgcccc attgacgtca ataatgacgt atgttcccat	300

-continued

agtaacgcca ataggactt tccattgacg tcaatgggtg gagtattac ggtaaactgc	360
ccacttggca gtacatcaag tgtatcatat gccaagtcgg ccccctattg acgtcaatga	420
cggtaaatgg cccgcctggc attatgccca gtacatgacc ttacgggact ttcctacttg	480
gcagtagatc tacgttattag tcatcgctat taccatgggtg atgcgggttt ggcagtagac	540
caatggcggt ggatagcggt ttgactcacf gggatttcca agtctccacc ccattgacgt	600
caatggaggt ttgtttggc accaaaatca acgggacttt ccaaataatgtc gtaacaactg	660
cgategcggc ccccggttgcac gcaaatgggc ggttaggcgtg tacgggtgggaa ggtctatata	720
agcagagctc gtttagtgaa ccgtcagatc actagaagct ttattgcgggat agtttatcac	780
agttaaattt ctaacgcagt cagtgcattt gacacaacag tctcgaaactt aagctgcagt	840
gactcttta aggttagcctt gcagaagttt gtcgtggggc actggggcagg taagtatcaa	900
ggttacaaga cagggttaag gagaccaata gaaactgggc ttgtcgagac agagaagact	960
cggcggttgc tggataggcac ctattggctt tactgacatc cactttgcct ttctctccac	1020
aggtgtccac tccccaggtaa attacagctc ttaaaaattt gatctccatt cgccattcag	1080
gctgcgcaac tgctgggaag gacgtcaga gccccctct tcgcttattac gccagctggc	1140
gaaaggacg tggcaagcaa ggcgatataa ttgagttacg ccaggattt cccagtcacg	1200
acgttgtaaa acgacggcca gagaattata atacgactca ctatagggcg aattcgctag	1260
cggcgccacc atgggagtca aagttctgtt tgcctgtatc tgcategcgtg tggcgaggc	1320
caagcccacc gagaacaacg aagacttcaa catcggtggc gtggccagca actttgcgac	1380
cacggatctc gatgtgtacc gaggaaagtt gccccggcaag aagctgcgcg tggaggtgct	1440
caaagagatg gaagccaatg cccggaaagc tggctgcacc aggggtgtc tggatctgcct	1500
gtccccacatc aagtgcacgc ccaagatgaa gaagtggctc ccaggacgct gccacaccta	1560
cgaaggcgac aaagagtccg cacaggcggg cataggcgag ggcgcgtcg atattcctga	1620
gattccctggg ttcaggact tggagccat ggagcagttc atcgacacagg tcgatctgt	1680
tgtggactgc acaactggct gcctcaaagg gcttgccaaat gtgcagtgtt ctgacctgct	1740
caagaagatgg ctgcggcaac gctgtgcac ctttgcacg aagatccagg gccaggtggaa	1800
caagatcaag gggccgggtg gtgacgggccc cgggtgtgac ctgcctcaga cccacagcct	1860
ggctcacacc agagccctga ggctccctggc acaaatacgagg agaatctctc ctttctctg	1920
cctggaccac agaaggact ttgggtcccc tcatgaggct ttggggggca accaggtcca	1980
gaaggctcaa gccatggctc tgggtcatga gatgctccag cagaccttcc agctttcag	2040
cacagagggc tcggctgtcg cctggatga gaggctctcg caccagttct gcactggact	2100
ggatcagcag ctcaggacc tggaaaggcctg tgcacatcgac gaggccgggc tggaaaggac	2160
ccccctgctg gaggaggact ccattcctggc tggaggaaat tacttccaca gactcacct	2220
ctatctgcaa gagaagagct acagccccgtg tgcctgggag atcgatcgacg cagaagtcat	2280
gagatccttc tcttccatca gaaacctgca agacagactc aggaagaagg agtgcggc	2340
cgcgaaatcc aagcttgcgtt attctatcgat gtcacctaaa taacttggcg taatcatgt	2400
catatctgtt tcctgtgtga aattgttatac cgctcacaat tccacacaaat atacgagccg	2460
gaagcataaa gtgtaaagcc tgggggtgcct aatgagtgag ctaactcaca ttaattgcgt	2520
tgcgcgatgc ttccatggtaa tgagggttaa tgcttcgaga agacatgata agatacattt	2580
atgagtttgg acaaaccaca acaagaatgc agtgaaaaaa atgctttattt tggaaattt	2640

-continued

gtgatgtat tgcttattt gtaaccatta taagctcaa taaacaagg aacaacaaca	2700
attgcattca ttttatgttt caggttcagg gggagatgtg ggagggttt taaagcaagt	2760
aaaacctcta caaatgtggt aaaatccat aaggatcgat tccggagct gaatggcga	2820
tggacgcgcc ctgtagccgc gcattaageg cggccgggtg ggtggttacg cgcaegtgac	2880
cgtcacactt gccagccccc tagcgccccc tccttccgt ttcttccctt ccttctcgc	2940
cacgttcgcc ggcttccccc gtcaagctct aaatcggggg ctccctttag ggttccgatt	3000
tagtgcctta cggcacctcg accccaaaaa acttgattag ggtgatggg cacgtatgg	3060
gcacatgcgcc tgatagacgg ttttcgcgcc tttgacgttg gagtccacgt tcttaatacg	3120
tggactcttg ttccaaactg gaacaacact caaccctatc tcggctattt ctttgattt	3180
ataagggatt ttggcattt cggcttattt gttaaaaat gagtgcattt aacaaaaatt	3240
taacgcgaat tttaacaaaa tattaacgt tacaattcg cctgtgtacc ttctgaggcg	3300
gaaagaacca gctgtggaat gtgtgtcagt tagggtgtgg aaagtcggca ggctcccgag	3360
caggcagaag tatgcgaagc atgcacatctca attagtcagc aaccagggtgt ggaaagtccc	3420
caggctcccc agcaggcaga agtgcggaaa gcatgcacatc caattatgc gcaaccatag	3480
tcccgcggcc aactccggcc atccggccccc taactccgc cagttccgc catttcgc	3540
cccatggctg actaattttt ttatattatg cagaggccga ggccgcctcg gcctctgagc	3600
tattccagaa gtagtgcggaa ggctttttt gggccttagg cttttgcggaa aagcttgcatt	3660
cttctgacac aacagtctcg aacttaaggc tagagccacc atgattgaac aagatggatt	3720
gcacgcaggc tctccggcccg cttgggtggaa gaggctattc ggctatgact gggcacaaca	3780
gacaatcgcc tgctctgatc ccggcgtgtt ccggctgtca ggcggggc gcccgggtct	3840
ttttgcggaa accgcacctgt ccgggtccctt gaatgcactg caggacgggg cagcgcggct	3900
atcgtggctg gccacgcgg gcgttccctg cgcagctgtg ctcgcacgttg tcactgaagc	3960
gggaaggggc tggctgttat tggcggaaat gcccggggc gatctctgtt catctcacct	4020
tgcctgcgc gagaaggatcat ccatcatggc tgatgcattt cggcggttc atacgcttgc	4080
tccggctacc tgcccatctcg accaccaagg gaaacatgcg atcgagcgg cacgtactcg	4140
gatggaaaggcc ggtttgtcg atcaggatga tctggacgaa gagcatcagg ggctcgcc	4200
agccgaactg ttcgcggcgc tcaaggcgcg catgcccgc ggcggggatc tcgtcgatgc	4260
ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat ggccgtttt ctggattcat	4320
cgactgtggc cggctgggtg tggcgacgg ctatcaggac atagcggttgc ctaccgtga	4380
tattgcgttgc gagaatgggc tgaccgtttc ctgcgtgttt acggatcgatgc	4440
cgctcccgat tcgcggcgc tgccttcta tgccttctt gacgagttt tctggatgggg	4500
actctggggc tcgaaatgcg cgaccaaggc acggccaaacc tgccatcagc atggccgcaa	4560
taaaatatct ttatattatc tacatctgtg tttttttt ttgtgtgaag atccgcgtat	4620
ggtgactct cagtaatac tgcgtctgatc ccgcataatc aagccacccc cgacaccgc	4680
caacacccgc tgacgcgcc tcacggcgtt gtctgcctt ggcataccgc tacagacaag	4740
ctgtgaccgt ctccggggcgc tgcgtgtgtc agaggtttc accgtatca ccgaaacgcg	4800
cgagacgaaa gggcctcgatc atacgcctat tttataggt taatgtcatg ataataatgg	4860
tttcttagac gtcaggatggc acttttcggg gaaatgtgcg cggaaacccctt atttgtttat	4920
ttttctaaat acattcaat atgtatccgc tcatgagaca ataaccctga taaatgcctc	4980
aataatattt aaaaaggaag agtgcggatc ttcaacattt ccgtgtcgcc cttattccct	5040

US 10,435,695 B2

189

190

-continued

ttttgcggc atttgcctt cctgttttg ctacccaga aacgctggg aaagtaaaag	5100
atgcgtgaaga tcagttgggt gcacgagtgg gttacatcgta actggatctc aacagcgta	5160
agatccttga gagtttcgc cccgaagaac gtttccaat gatgagcaact tttaaagttc	5220
tgctatgtgg cgccgtattt tccccgtattt acgccggca agagcaactc ggtcgccca	5280
tacactattt tcagaatgac ttgggtttagt actcaccagt cacagaaaag catttacgg	5340
atggcatgac agtaagagaa ttatgcgtg ctgcataac catgagtgtat aacactgcgg	5400
ccaaacttact tctgacaacg atcggaggac cgaaggagct aaccgtttt ttgcacaaca	5460
tggggatca tgtaactcgc cttgtatcggtt gggAACCGGA gctgaatgaa gccataccaa	5520
acgacgagcg tgacaccacg atgcctgttag caatggcaac aacgttgcgc aaactattaa	5580
ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg gagggggata	5640
aagttgcagg accacttctg cgctcgcccc ttccggctgg ctgggttatt gctgataaat	5700
ctggagccgg tgagcggtgg tctcgccgtt tcattgcgcg actggggcca gatggtaagc	5760
cctccgtat ogtagttatc tacacgacgg ggagtcaggc aactatggat gaacgaaata	5820
gacagatcgc tgagataggt gcctcaactga ttaagcattt gtaactgtca gaccaagttt	5880
actcatatat acttttagatt gatTTAAAC ttcatTTTA attTTAAAGG atcttaggtga	5940
agatccttt tgataatctc atgacaaaaa tcccttaacg tgatTTTCG ttccactgag	6000
cgtcagaccc cgtagaaaaag atcaaaggat cttcttgaga tccTTTTT ctgcgcgtaa	6060
tctgctgctt gcaaaacaaaa aaaccacccgc taccageggg ggtttgttt ccggatcaag	6120
agctaccaac tcttttccg aaggtaactg gcttcagcag agcgcagata ccaaatactg	6180
tccttctagt gttagccgt taggcccacc acttcaagaa ctctgttagca ccgcctacat	6240
acctcgctct gctaattcctg ttaccagtgg ctgctgccag tggcgataag tcgtgtctta	6300
ccgggttggc ctcaagacga tagttacggg ataaggcgca ggggtcgccc tgaacggggg	6360
gttcgtgcac acagcccgac ttggagcgaa cgacctacac cgaactgaga tacctacagc	6420
gtgagctatg agaaaagcgcc acgtttcccg aaggagaaaa ggccggacagg tatccggtaa	6480
ggggcagggt cggAACAGGA gagegcacga gggagttcc agggggaaac gcctggatc	6540
tttatagttc tgccgggtt cgccacctct gacttgagcg tcgatTTTG ttagtgcgt	6600
caggggggcg gaggctatgg aaaaacgcca gcaacgcggc cttttacgg ttccctggcct	6660
tttgcggcc ttttgcgtac atggctcgac agatct	6696

<210> SEQ ID NO 101
 <211> LENGTH: 6693
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: pTarget GLucON Beta Porcine

<400> SEQUENCE: 101

tcaatattgg ccattagccca tattattcat tggttatata gcataaatca atattggcta	60
ttggccatttgcatacggtt atcttatatca taatatgtac atttatattt gctcatgtcc	120
aatatgaccg ccatgttggc attgatttatt gacttagttat taatagtaat caattacggg	180
gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc	240
gcctggctga cggcccaacg accccggccc attgacgtca ataatgacgt atgttcccat	300
agtaacgcca atagggactt tccattgacg tcaatgggtg gagtattac ggtaaactgc	360

US 10,435,695 B2

191

192

-continued

ccacttggca gtacatcaag tgttatcatat gccaagtccg ccccctattg acgtcaatga	420
cggttaaatgg cccgectggc attatgccca gtacatgacc ttacgggact ttcctacttg	480
gcagtagacatc tacgttattag tcatcgctat taccatggtg atgcggttt ggcagtacac	540
caatggcggt ggatagcggt ttgactcagc gggatttcca agtctccacc ccattgacgt	600
caatggaggat ttgttttggc accaaaatca acgggactt caaaaatgtc gtaacaactg	660
cgatecgccg ccccgtgac gcaaatgggc ggttaggegtg tacgggtggg ggtctatata	720
agcagagctc gtttagtgaa ccgtcagatc actagaagct ttattgcccc agtttatcac	780
agttaaattg ctaacgcagt cagtgcttct gacacaacag tctcgaacctt aagctgcagt	840
gactcttta aggtagcctt gcagaagtt gtcgtgaggc actggggcagg taagtatcaa	900
ggttacaaga cagggttaag gagaccaata gaaactgggc ttgtcgagac agagaagact	960
cttgcgttcc tgataggcac ctattggct tactgacatc cactttgcct ttctctccac	1020
aggtgtccac tcccagttca attacagctc ttaaaaattt gatctccatt cgccattcag	1080
gtgtgcgcaac tgctggaaag gacgatcaga gccccctct tcgcttattac gccagctggc	1140
gaaagggacg tggcaagcaa ggcgattaag tttagttagc ccaggattt cccagtcacg	1200
acgttgtaaa acgacggcca gagaattata atacgactca ctatagggcg aattcgctag	1260
cggccacc accgggatca aagttctgtt tgccctgatc tgcattgcgtg tggccaggc	1320
caagcccacc gagaacaacg aagacttcaa catcggtgcc gtggccagca actttgcgac	1380
cacggatctc gatgtgtgacc gaggaaagtt gcccggcaag aagctgccc tggaggtgct	1440
caaagagatg gaagccaaatg cccggaaagc tggctgcacc aggggctgtc tgcattgcct	1500
gtcccacatc aagtgcacgc ccaagatgaa gaagtggctc ccaggacgct gccacaccta	1560
cgaaggcgcac aaagagtccg cacagggcg cataggcag ggcgcgtcg atattcctga	1620
gattcctggg ttcaaggact tggagccaaat ggacgatgtc atgcacagg tcgatctgt	1680
tgtggactgc acaactggct gcctcaaagg gcttgccaaac gtgcagtgtt ctgcacgt	1740
caagaagtgg ctggccaaac gctgtgcgac ctttgcgcg aagatccagg gccaggtgga	1800
caagatcaag gggggccgtg gtgacgggcc cgggatgagc tatgtatgtc ttgcatacca	1860
acaaaggagc agcaatttgg catgtcagaa gtcctggga cagttgcctg ggactccctca	1920
atattgcctc caagatagga tgaactttga ggtccctgag gagattatgc aaccaccaca	1980
attccagaag gaagatgcag tattgattat ccacgagatg ctccagcaga tcttcggcat	2040
tctcagaaga aatttctcta gcactggctg gaatgaaacc gtcattaaaga ctatccttgt	2100
ggaacttgat gggcagatgg atgacctgga gacaatcctg gaggaaatca tggaggagga	2160
aaatttcccc agggggagaca tgaccattct tcacctgaag aaatattact tgacattct	2220
gcagtagctg aagtccaaagg agtacagaag ctgtgcctgg acagtcgtcc aagtggaaat	2280
cctcaggaaac ttttcttcc ttaacagact tacagattac ctccggaaact gageggccgc	2340
gaattccaag cttgagttt ctatcggtc acctaaataa cttggcgtaa tcatggcat	2400
atctgtttcc tttgtgaaat ttgtatccgc tcacaattcc acacaacata cgagccggaa	2460
gcataaaatgt taaagcctgg ggtgcctaat gagtgcgacta actcacaatata attgcgtgtc	2520
gcgcgttcc cattttgtga gggtaatgc ttgcagaaga catgataaga tacattgt	2580
agtttggaca aaccacaaca agaatgcagt gaaaaaaatg ctttatttgc gaaatttgc	2640
atgcatttgc ttatgttgc accattataa gctgcaataa acaagttaa aacaacaatt	2700
gcattcattt tatgtttcag gttcaggggg agatgtggg ggtttttaa agcaagtaaa	2760

-continued

acctctacaa atgtggtaaa atccgataag gatcgattcc ggagcctgaa tggcaatgg	2820
acgcgcctg tagcggcgca ttaagcgcgg cgggtgtggt ggttacgcgc acgtgaccgc	2880
tacacttgcc agcgccttag cgcccgctcc ttccgcttc ttcccttc ttctcgccac	2940
gttcgcggc ttccccgctc aagctctaaa tcgggggctc cctttagggt tccgatttag	3000
tgctttacgg cacctcgacc ccaaaaaact tgatttagggt gatggttcac gtatgggcc	3060
atcgccctga tagacggttt ttcgcctt gacgttggag tccacgttct ttaatagtgg	3120
actcttgttc caaactggaa caaacactcaa ccctatctcg gtctattttt ttgatttata	3180
agggatttg ccgattcgg cctattgggt aaaaaatgag ctgatcta aaaaatttaa	3240
cgcgaatttt aacaaaatat taacgcttac aatttcgect gtgtaccttc tgaggcggaa	3300
agaaccagct gtggaatgtg tgcgtatgg ggtgtggaaa gtccccagc tccccagcag	3360
gcagaagtat gcaagcatg catctcaatt agtcagcaac caggtgtgga aagtccccag	3420
gtccccagc aggcagaagt atgcaaaagca tgcatactcaa ttagtcagca accatagtcc	3480
cgccccctaac tccgcctatc ccgcctctaa ctccgcctag ttccgcctat tctccgcctt	3540
atggctgact aattttttt atttatgcag aggccgaggc cgccctcgcc tctgagctat	3600
tccagaagta gtgaggaggc tttttggag gcttagggt ttgcaaaaag cttgatttt	3660
ctgacacaac agtctcgaac ttaaggctag agccaccatg attgaacaag atggattgca	3720
cgcaggttct ccggccgctt gggggagag gctatccggc tatgactggg cacaacagac	3780
aatcggctgc tctgatgccg ccgtgttccg gctgtcagcg cagggggccc cggttcttt	3840
tgtcaagacc gacctgtccg gtgcctgaa tgaactgcag gacgaggcag cgccgtatc	3900
gtggctggcc acgaaggccg ttcctgcgc agctgtgtcc gacgttgcata ctgaaggccgg	3960
aagggactgg ctgctattgg gctgaagtgcg ggggcaggat ctccctgtcat ctcacctgc	4020
tcctgcctgag aaagtatcca tcatggctga tgcaatgcgg cggctgcata cgcttgcatt	4080
ggctacccgtc ccattcgacc accaagcgaa acatcgcatc gagcggccac gtactcgat	4140
ggaageccgt ctgtcgatc aggtatgtt ggacgaagag catcaggggc tcgcgcagc	4200
cgaactgttc gccaggctca aggccgcgtc gcccgaaggc gaggatctcg tcgtgaccca	4260
tggcgatgcc tgcttgcga atatcatgtt ggaaaatggc cgctttctg gattcatcg	4320
ctgtggccgg ctgggtgtgg cggaccgtatc tcaggacata gctgtggctatccgtat	4380
tgtctgaagag ctggccggcg aatgggctga ccgttgcctt gtcgtttacg gtatcgccgc	4440
tcccgattcg cagcgatcg cttctatcg cttcttgcac gagttttctt gaggccgact	4500
ctggggttcg aaatgaccga ccaagcgacg cccaaacctgc catcacgtatc gcccgaataa	4560
aatatcttta ttttatttac atctgtgtt tggtttttt tgcgtatggc cgcgtatgg	4620
gcactctcg tacaatctcg tctgatgccg catagttaa ccagccccga caccggccaa	4680
cacccgctga cgcgcctga cgggcttgc tgcctccggc atccgcttac agacaagctg	4740
tgaccgtctc cgggagctgc atgtgtcaga ggttttaccg gtcatcacccg aaacgcgcga	4800
gacgaaaggc octcgtgata cgcctatccc tatagggttata tgcgtatgata ataatggttt	4860
cttagacgtc aggtggact tttcgggaa atgtgcgcgg aacccttattt tgtttatttt	4920
tctaaataca ttcaaaatatg tatccgctca tgagacaata accctgataa atgcttcaat	4980
aatattgaaa aaggaagagt atgagttttc aacatttccg tgcgtccctt attccctttt	5040
ttgcggcatt ttgccttcctt gttttgtctt acccagaaac gctggtaaa gtaaaagatg	5100

US 10,435,695 B2

195

196

-continued

ctgaagatca gttgggtgca cgagtgggtt acatcgaaact ggatctcaac agccgtaaga	5160
tccttgagag ttttgcggcc gaagaacgtt ttccaatgtat gagcactttt aaagtctgc	5220
tatgtggcgc ggtattatcc cgtattgacg cccggcaaga gcaactcggt cgccgcatac	5280
actattctca gaatgacttg gttgagtaact caccagtcac agaaaagcat cttacggatg	5340
gcatgacagt aagagaattt tgcaatgtcc ccataaccat gagtgataac actcgccca	5400
acttacttct gacaacgatc ggaggaccga aggagctaac cgctttttg cacaacatgg	5460
gggatcatgt aactcgccct gategttggg aaccggagct gaatgaagcc ataccaaacg	5520
acgagcgtga caccacgatc cctgttagcaa tggcaacaac gttgcgaaa ctattaactg	5580
gcgaactact tactctagct tcceggcaac aattaataga ctggatggag gcggataaag	5640
ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg	5700
gagccgggtga gcgtgggtct cgcggtatca ttgcagcaact gggggccagat ggttaagccct	5760
cccgatcgatcgt agttatctac acgacgggaa gtcaggcaac tatggatgaa cgaaatagac	5820
agatcgctga gatagggtgcc tcactgatca agcattggta actgtcagac caagtttact	5880
catatataact ttagattgtat taaaacttc attttaattt taaaaggatc taggtgaaga	5940
tccttttgcata taatctcatg accaaaatcc cttAACgtga gtttgcgttc cactgagcgt	6000
cagaccccgta agaaaagatc aaaggatctt cttgagatcc ttttttctg cgcgtaatct	6060
gctgcttgcata aacaaaaaaaaa ccaccgtac cagcgggtgt ttgtttccg gatcaagagc	6120
taccaactct tttccgaag gtaactggct tcagcagacgc gcagatcca aatactgtcc	6180
ttcttagtgta gcccgtatgtt ggccaccact tcaagaactc tgtagcacccg cctacatacc	6240
tcgctctgtat aatccgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg	6300
gggttggactc aagacgatag ttaccggata aggccgcacgc gtcgggctga acgggggggtt	6360
cgtgcacaca gcccacgtt gaggcaacga cctacaccga actgagatcacatcgatc	6420
agctatgaga aagccgcacgc ctccccggaa ggagaaaaggc ggacaggtat ccggtaagegc	6480
gcagggtcgg aacaggagag cgcacggagg agcttcagg gggaaacgcc tggtatctt	6540
atagtcctgtt cgggttcgc cacccgtac ttgagcgtcg atttttgtga tgctcgatc	6600
ggggccggag cctatggaaa aacgcccacgc acggccctt ttacgggttc ctggcccttt	6660
gctggcccttt tgctcatacgatc gctcgacaga tct	6693

```
<210> SEQ ID NO 102
<211> LENGTH: 6624
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pTarget GLucON Gamma Bovine
```

<400> SEQUENCE: 102

tcaatattgg ccatttagcca tattattcat tggttatata gcataaatca atatggcta	60
ttggccattg catacggttg atctatatca taatatgtac atttatattt gctcatgtcc	120
aatatgaccc ccatgttggc attgattatt gactagttat taatagtaat caattacggg	180
gtcatttagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc	240
gcctggctga cccggccaaacg acccccccccc attgacgtca ataatgacgt atgttcccat	300
agtaacgcga ataggggactt tccattgacg tcaatgggtg gagttttac ggtaaactgc	360
ccacttggca gtacatcaag tgtatcatat gccaagtcgg ccccttattt acgtcaatga	420
cggtaaatgg cccgcctggc attatggcca gtacatgacc ttacggggactt tcctacttg	480

US 10,435,695 B2

197

198

-continued

gcagtacatc tacgtattag tcatcgctat taccatggtg atgcggttt ggcagtacac	540
caatggcggt ggatagcggt ttgactcagc gggatttcca agtctccacc ccattgacgt	600
caatggagggt tggtttggc accaaaatca acgggactt caaaaatgtc gtaacaactg	660
cgatcgcccg ccccggttgac gcaaattggc ggttagggcgtg tacgggtggga ggtctatata	720
agcagagctc gtttagtgaa ccgtcagatc actagaagct ttattgggt agtttatcac	780
agttaaattg ctaacgcagt cagtgtttct gacacaacag tctcgaactt aagctgcagt	840
gactcttta aggttagcctt gcagaagttt gtcgtgaggc actgggcagg taagtatcaa	900
ggttacaaga cagggttaag gagaccaata gaaaactgggc ttgtcgagac agagaagact	960
cttgcgtttc tgataggcac ctattggtct tactgacatc cactttgcct ttctctccac	1020
aggtgtccac tcccaggtaa attacagctc ttaaaaattt gatctccattt cgccatttcag	1080
gtgcgcacac tgctggaaag gacgatcaga gccccctct tcgcttattac gccagctggc	1140
gaaaggacg tggcaagcaa ggcgatataag ttgagttacg ccaggattt cccagtcacg	1200
acgttgtaaa acgacggcca gagaattata atacgactca ctatagggcg aattcgctag	1260
cggccgcacc atgggagtca aagttctgtt tgcctgtatc tgcatecgctg tggccgaggc	1320
caagcccaacc gagaacaacg aagacttcaa catcggtggc gtggccagca actttgcac	1380
cacggatctc gatgtgtgacc gagggaaat tccccggcaag aagctggcgc tggaggtgct	1440
caaagagatg gaagecaatg cccggaaagc tggctgcacc aggggtgtc tgatctgcct	1500
gtccccacatc aagtgcacgc ccaagatgaa gaagtggctc ccaggacgct gccacaccta	1560
cgaaggcgcac aaagagtcgg cacaggcgg cataggcggag gcgatcgatcg atattcctga	1620
gattcctggg ttcaaggact tggagccat ggagcgttcc atcgacacagg tcgatctgt	1680
tgtggactgc acaactggct gcctcaaagg gcttgcacac gtgcagtgtt ctgacctgct	1740
caagaagtgg ctgcgcacac gctgtgcac ctttgcac gaaatccagg gccaggtgga	1800
caagatcaag gggccgggtg gtgacggggcc ccagggccaa ttttttagag aaatagaaaa	1860
cttaaaggag tatttaatg caagtagccc agatgtagct aagggtgggc ctctcttc	1920
agaaattttg aagaatttggaa aagatgaaag tgacaaaaaa attattcaga gccaaatgt	1980
ctccttctac ttcaaaactct ttgaaaacct caaaagataac caggcatatc aaaggagcat	2040
ggatataatc aagcaagaca tggatcgaaa gttcttgcacat ggcagctctg agaaaactggaa	2100
ggacttcaa aagctgatcc aaattccggt ggatgtctc cagatccagc gcaaagccat	2160
aaatgaactc atcaaagtga tgaatgaccc tgcacccaaa tctaaccctca gaaagcggaa	2220
gagaagtcag aatcttttc gaggccggag agcatcaacg taagcggccg cgaattccaa	2280
gtttgactat tctatcggtt cacctaaata acttggcgta atcatggtca tatctgttc	2340
ctgtgtgaaa ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaaagt	2400
gtaaaggcctg gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgcgatgtt	2460
ccatttgtg agggtaatg ctgcgagaag acatgataag atacattgtat gagttggac	2520
aaaccacaaac aagaatgcag tgaaaaaaat gctttatgg tggaaatttgcgtt gatgtattt	2580
ctttatgtt aaccattata agctgcaata aacaagttaa caacaacaat tgcatttatt	2640
ttatgtttca gggtcgaggag gagatgtggg aggttttttta aagcaagtaa aacctctaca	2700
aatgtggtaa aatccgataa ggatcgatcc cggagcctga atggcgaatg gacgcgcct	2760
gtacggccgc attaagcgcg gccccgtgtgg tggttacgcg cacgtgaccg ctacacttgc	2820

US 10,435,695 B2

199

200

-continued

cagcgcccta	gcgcccgctc	ctttcgctt	cttcccattcc	tttctegcca	cgttcgcgg	2880
ctttccccgt	caagctctaa	atcgaaaaac	cccttttaggg	ttcccgattta	gtgcgttacg	2940
gcacctcgac	cccaaaaaac	ttgatttaggg	tgtatggttca	cgtatgggc	catcgccctg	3000
atagacggtt	tttcgcctt	tgacggttga	gtccacgttc	ttaaatagtg	gactcttgtt	3060
ccaaactgga	acaacactca	accctatctc	ggtctattct	tttgatttat	aagggatttt	3120
gccgatttcg	gcctatttgtt	taaaaaatga	gtcgatttaa	caaaaattta	acgcgaattt	3180
taacaaaata	ttaacgctta	caatttcgccc	tgtgtacctt	ctgaggcgga	aagaaccagc	3240
tgtggatgt	gtgtcagttt	gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	3300
tgcaaagcat	gcatctcaat	tagtcagcaa	ccaggtgtgg	aaagtcggca	ggctcccgag	3360
caggcagaag	tatgcaagc	atgcatctca	attagtcagc	aaccatagtc	ccgccccctaa	3420
ctccgccccat	cccgccccata	actccgccccaa	gttccgccccaa	ttctccgcccc	catggctgac	3480
taattttttt	tatttatgca	gaggccgagg	ccgccteggg	ctctgagcta	ttccagaagt	3540
agtgaggagg	cttttttggaa	ggcctaggct	tttgcaaaaa	gtttgtttttt	tctgacacaa	3600
cagtctcgaa	cttaaggctt	gagccacccat	gattgaacaa	gatggatttc	acgcagggtt	3660
tccggccgct	tgggtggaga	ggctatttcgg	ctatgactgg	gcacaacaga	caatcggtt	3720
ctctgatgcc	gccgtgttcc	ggctgtcagc	gcagggggcgc	ccgggttcttt	ttgtcaagac	3780
cgacctgtcc	ggtgccctga	atgaacttgc	ggacgaggca	gcgcggctat	cgtggctggc	3840
cacgacgggc	gttcctgtcg	cagctgtgt	cgacgttgc	actgaagcgg	gaaggggactg	3900
gctgctatttgc	ggcgaagtgc	cggggcagga	tctcctgtca	tctcaccttgc	ctccctgcccga	3960
gaaaatgtatcc	atcatggctt	atgcaatgcg	gcccgttgc	acgttgc	cggttgcacttgc	4020
cccatcgac	acccaacgcg	aacatcgcat	cgagcgacca	cgtactcgga	tggaaacccgg	4080
tcttgcgtat	caggatgtatc	tggacgaaga	gcatcagggg	ctcgccg	ccgaaactgtt	4140
cgccaggctc	aaggcgcgc	tggccgacgg	cgaggatctc	gtcgacccc	atggcgatgc	4200
ctgcttgcgc	aatatcatgg	tggaaaatgg	ccgttttttgc	ggatttgc	actgtggccg	4260
gttgggtgttgc	ggggaccgc	atcaggacat	agcggttgc	accctgtata	ttgtctgaaga	4320
gttggggcgc	aatggggcttgc	accgtttctc	cgtgttttac	ggtacgcgc	ctcccgatttgc	4380
geagcgcac	gccttctatc	gccttcttgc	cgagtttctc	tgagcggac	tctgggggttgc	4440
gaaaatgaccgc	accaagcgac	gcccacccat	ccatcacat	ggccgcata	aaatatcttgc	4500
attttcatttgc	catctgtgttgc	ttgggttttttgc	gtgtgaatgc	ccgcgtatgg	tgcactctca	4560
gtacaatctgc	ctctgatgttgc	gcatagtttaa	gccagccccgg	acacccgc	acacccgc	4620
acgcgccttgc	acggggcttgc	ctgttccgg	catccgttta	cagacaagct	gtgaccgttgc	4680
ccggggagctg	catgtgttgc	agggttttgc	cgttgc	gaaacgcgc	agacgaaagg	4740
gcctcgtat	acgccttatttgc	ttttaggttgc	atgttgc	atataatgttgc	tcttagacgt	4800
cagggtggcac	ttttcgccgg	aatgtgcgc	gaaacccat	ttgtttat	ttctaaatac	4860
attcaaatat	gtatccgc	atgagacaat	aaccctgtata	aatgttca	taatattgaa	4920
aaaggaagag	tatgagtattt	caacatttgc	gtgtcgccctt	tattccctt	tttgcggcat	4980
tttgccttgc	tgtttttgttgc	cacccagaaa	cgctgggttgc	aaatggat	gctgttgc	5040
atgtgggtgc	acgagtgggt	tacatcgac	tggatctca	cagcggttgc	atccctgaga	5100
gttttcgc	cgaagaacgt	tttccaaatgc	tgagcacttgc	taaagtctgc	ctatgtggcg	5160
cggattatc	ccgttattgc	gcccggcaag	agcaactcg	tcgcccgcata	cactatttgc	5220

US 10,435,695 B2

201

202

-continued

agaatgactt ggttgagtagtc tcaccaggta cagaaaagca tcttacggat ggcacatgac	5280
taagagaatt atgcagtgtc gccataacca tgagtgataa cactgcggcc aacttacttc	5340
tgacaacatcg cgaggaggaccg aaggagctaa ccgcgttttt gcacaacatg gggatcatg	5400
taactcgct tgatcggtgg gaaccggcgc tgaatgaagc cataccaaac gacgagcgtg	5460
acaccacatcg gcctgttagca atggcaacaa cgttgcgcaa actattaact ggcgaactac	5520
ttactcttagc ttcccgccaa caattaatag actggatgga ggccgataaa gttgcaggac	5580
cacttctgcg ctggccctt ccggctgggt ggtttattgc tgataaatct ggagccggtg	5640
agcgtgggtc tcgcgggtatc attgcagcac tggggccaga tggtaagccc tccccgtatcg	5700
tagttatcta cacgacgggg agtcaggcata ctatggatga acgaaataga cagatcgctg	5760
agatagggtgc ctcaactgatt aagcattgggt aactgtcaga ccaagtttac tcataatatac	5820
ttagattga tttaaaactt catttttaat tttaaaaggat ctaggtgaag atccttttg	5880
ataatctcat gacccaaatc ccttaacgtg agtttcgtt ccactgagcgc tcagaccccg	5940
tagaaaaagat caaaggatct tcttgagatc cttttttctt ggcgtataatc tgctgcttg	6000
aaacaaaaaa accaccgcta ccagcgggtgg ttgtttgcg ggtcaagag ctaccaactc	6060
ttttccgaa ggttaactggc ttcaagcagag cgcagatacc aaatactgtc cttctagtgt	6120
agccgttagtt aggccaccac ttcaagaact ctgttagcacc gcttacatc acgtctgc	6180
taatccgtt accagtggtt gctgccagtg gcttataatc gtgtcttacc gggttggact	6240
caagacgata gttaccggat aaggcgcgc ggtcgggctt aacggggggg tcgtgcacac	6300
agcccgctt ggagcgaacg acctacacccg aactgagata cctacagcgt gagctatgag	6360
aaagcgcacac gttcccgaa gggagaaagg cggacaggta tccggtaagc ggcagggtcg	6420
gaacaggaga ggcacacgagg gagttccag gggaaacgc ctggatctt tatagtctg	6480
tccgggttcg ccacctctga ctttagcgtc gatttttgtt atgtctgtca gggggccgga	6540
gcttatggaa aaacgcccac aacgcccctt ttttacgggtt cctggcttt tgctggcctt	6600
ttgctcacat ggctcgacag atct	6624

<210> SEQ ID NO 103

<211> LENGTH: 6723

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: pTarget GLucON Lambda Bovine

<400> SEQUENCE: 103

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta	60
ttggccatttgc catabgtgt atcttatatac taatatgtac attttatatttgc gctcatgtcc	120
aatatgaccg ccatgttggc attgattattt gactgttat taatagtaat caattacggg	180
gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc	240
gcttgggtga ccggccaaacg acccccgccc attgacgtca ataatgacgt atgttcccat	300
agtaacgcca ataggactt tccattgacg tcaatgggtt ggttatttac ggttaactgc	360
ccacttggca gtacatcaag ttttatcatat gccaagttccg cccctatgtt acgtcaatga	420
cggttaatgg cccgcgttgc attatgcccgttacatgacc ttacggact ttcctacttg	480
gcagttacatc tacgttattag tcatcgctat taccatgggtt atgcgggtttt ggcagttacac	540
caatggggcgtt ggatagcgggtt ttgactcacy gggatttcca agtctccacc ccattgacgt	600

-continued

caatgggagt ttgtttggc accaaaatca acgggacttt caaaaatgtc gtaacaactg	660
cgatcgcccg ccccggtgac gcaaatggc ggttaggggtg tacgggtggga ggtctatata	720
agcagagctc gtttagtgaa ccgtcagatc actagaagct ttattgcggt agtttatcac	780
agttaaattg ctaacgcagt cagtgccttct gacacaacag tctcgaacctt aagctgcagt	840
gactctcta aggtgcgtt gcagaagttg gtcgtgaggc actgggcagg taagtatcaa	900
ggttacaaga cagggttaag gagaccaata gaaactgggc ttgtcgagac agagaagact	960
cttgcgttcc tgataggcac ctattggct tactgacatc cactttgcct ttctctccac	1020
aggtgtccac tcccagttca attacagctc ttaaaaattt gatctccatt cgccattcag	1080
gtgtgcacac tgctgggaag gacgatcaga gcgggcctct tcgctattac gccagctggc	1140
gaaagggacg tggcaagcaa ggcgattaag ttgagttacg ccaggattt cccagtcacg	1200
acgttgtaaa acgacggcca gagaattata atacgactca ctatagggcg aattcgctag	1260
cgccgccacc atgggagtca aagttctgtt tgccctgatc tgcategcgtg tggccgaggc	1320
caagccccacc gagaacaacg aagacttcaa catcggtggc gtggccagca actttgcgac	1380
cacggatctc gatgtcgacc gagggaaagtt gcccggcaag aagctgccc tggaggtgct	1440
caaagagatg gaagccaatg cccggaaagc tggctgcacc aggggtgtc tgatctgcct	1500
gtccccacatc aagtgcacgc ccaagatgaa gaagtggctc ccaggacgct gccacaccta	1560
cgaaggcgcac aaagagtccg cacagggcgcataggcag gcgatcgatcg atattcctga	1620
gattcctggg ttcaaggact tggagccaaat ggagcagttc atgcacagg tcgatctgt	1680
tgtggactgc acaactggct gcctcaaagg gcttgccaaac gtgcagtgtt ctgacctgct	1740
caagaagtgg ctgcccacac gctgtgcgcac cttgccagc aagatccagg gccaggtgga	1800
caagatcaag gggggccgtg gtgacgggccc caggacagga gcagttcccg tgccctctgc	1860
ccccaggggcc ctcccacctg ccaggggctg ccacgtggcc cagttcaagt ctctgtcccc	1920
tcaagagctg caggccttca agacggccag ggatgcctt gaagactcgt tcttgccaaa	1980
ggactgggac tgcagcaccc acctttccc caggacccgg gacctgaagc acctgcaggt	2040
gtggggagcgc cctgtggctc tggaggcaga gctggccctg acactgacgg tcctggaggc	2100
catggctaactc tcatccctgg gccacagctt ggagcagccc cttctacgc tgcagaacat	2160
ccactccaag ctccaggccct gtgtcccacgc tcagcccaca gcaagtcacca ggccccgggg	2220
ccgcctccac cactggctgc accgcctcca ggaggcccg aaggagtccc aggactgcct	2280
cgaaggcctct gtgatgttca acctccctcg cctccctacc cgggacactga aatgtgtgc	2340
cagcggagac cagtgtgtct gageggccgc gaattccaag cttgagtatt ctatcgatgc	2400
acctaataataa cttggcgtaa tcatggatcat atctgtttcc ttgtgtaaat tgttatccgc	2460
tcacaattcc acacaacata cgagccggaa gcataaaagtg taaagcctgg ggtgectaat	2520
gagtgagcta actcacatca attcgcttgc gcgatgttcc cattttgtga gggtaatgc	2580
ttcgagaaga catgataaga tacattgtg agtttggaca aaccacaaca agaatgcagt	2640
aaaaaaaaatg ctttatgtt gaaatttgc atgctattgc ttatgttgc accattataa	2700
gctgcaataa acaagttaac aacaacaatt gcattcattt tatgtttcag gttcaggggg	2760
agatgtggga ggtttttaa agcaagttaa acctctacaa atgtggtaaa atccgataag	2820
gatcgattcc ggagcctgaa tggcgaatgg acgcgcctcg tagcggcgc ttaagcgcgg	2880
cggtgtgggt ggttacgcgc acgtgaccgc tacacttgcc agcgccttag cgccgcctcc	2940
tttcgcgttcc ttcccttctt ttctcgccac gttcgccggc tttccccgtc aagctctaaa	3000

-continued

tcgggggctc ccttaggggt tccgatttag tgcttacgg cacctcgacc ccaaaaaact	3060
tgatttagggat gatgggtcac gtatgggc atcgccctga tagacggttt ttgcacctt	3120
gacgttggag tccacgttct ttaatagtgg actcttgttc caaactggaa caacactcaa	3180
ccctatctcg gtctattctt ttgatttata agggattttg ccgatttcgg cctattggtt	3240
aaaaaatgag ctgatthaac aaaaattaa cgcgaaattt aacaaaatat taacgcttac	3300
aatttcgcct gtgtacccctc tgaggcggaa agaaccagct gtggaatgtg tgtcagttag	3360
ggtgtggaaa gtccccaggc tccccagcag gcagaagttat gcaaagcatg catctcaatt	3420
agtcagcaac cagggtgtga aagtccccag gctccccagc aggcagaagt atgcaagca	3480
tgcatactcaa ttagtcagca accatagttcc cgccccatac tccgccccatc ccgccccaa	3540
ctccgcggcag ttccgcggcat tccgcggccc atggctgact aattttttt atttatgcag	3600
aggccgaggc cgcctcgcc tctgagctat tccagaagta gtgaggaggc tttttggag	3660
gcctaggctt ttgaaaaaaat cttgattttt ctgacacaac agtctcgaac ttaaggctag	3720
agccaccatg attgaacaag atggatttgcg cgcaaggcttcc cggccgcgtt ggggtggagag	3780
gttattccgc tatgacttggg cacaacagac aatcggtcgc tctgatgcgc ccgtgttccg	3840
gtgtcagcg caggggcgcg cggttttttt tgcataagacc gacctgtcgc gtgcctgaa	3900
tgaactgcag gacggggcag cgccgcatac gtggctggcc acgacggggcg ttccctgcgc	3960
agctgtgctc gacgttgcac ctgaagcggg aagggaactgg ctgctattgg gcaagtgcc	4020
ggggcaggat ctccgtcat ctcacccctgc tccgtccggaa aagatccatc tcatggctga	4080
tgcaatgcgg cggctgcata cgcttgcata ggcttgcgc ccatcgacc accaagcgaa	4140
acatcgcatc gagcggcgcac gtactcgatc ggaagccggc ctgtcgcgc aggtatct	4200
ggacgaagag catcaggggc tgcggccgcg cgaactgttc ggcaggctca aggccgcgc	4260
cccgacggc gaggatctcg tgcgtaccca tggcgatgcg tgcgtccgcg atatcatgg	4320
ggaaaaatggc cgctttctg gattcatcgat ctgtggccgg ctgggtgtgg cggaccgcta	4380
tcaggacata gcgttggcta cccgtatgtat tgctgaagag ctggggggcg aatgggtcg	4440
ccgcttccctc gtgttttacg gtatcgccgc tcccgattcg cagcgcatacg cttctatcg	4500
ccttcttgcg gagttttctc gageggact ctgggggtcg aaatgaccga ccaagcgacg	4560
cccaacctgc catcagatg gcccataaa aatatctta ttttatttac atctgtgtgt	4620
tgggttttttgc tgcataatgc cgcgtatgtt gcaatctgc tctgatgcgc	4680
catagttaa ccagccccga caccgcacaa caccgcgtga cgcgcctga cgggttgc	4740
tgctccgcgc atccgtttac agacaagctg tgaccgtctc cgggagctgc atgtgtcaga	4800
gtttttaccg gtcatcaccg aaacgcgcga gacgaaaggc ctcgtata cgcctattt	4860
tataggttaa tgcgtatgata ataatggttt ctttagacgtc aggtggact ttccggggaa	4920
atgtgcgcgg aacccttattt tgcatttttctcaatatac ttcaaatatg tatccgtca	4980
tgagacaata accctgataa atgcttcaat aatattgaaa aaggaagagt atgagtattc	5040
aacatttcgg tgcgtccctt atccctttt ttgcggcatt ttgccttctt gttttgttc	5100
acccagaaac gctgggtggaa gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt	5160
acatcgactt ggtatctcaac agcggtaaga tccttgcggat ttttcgcggcc gaagaacgtt	5220
ttccaaatgtat gacactttt aaagttctgc tatgtggcgc ggtattatcc cgtattgcg	5280
ccggggcaaga gcaactcggt cgccgcatac actattctca gaatgacttg ttgagttact	5340

US 10,435,695 B2

207

208

-continued

caccagtac	agaaaagcat	cttacggatg	gcatgacagt	aagagaatta	tgcagtgtc	5400
ccataaccat	gagtgataac	actgcggca	acttacttct	gacaacgatc	ggaggaccga	5460
aggagetaac	cgcttttg	cacaacatgg	gggatcatgt	aactcgcc	tttgcgttgg	5520
aaccggagct	aatgaaagcc	ataccaaacg	acgagcgtga	caccacgatg	cctgttagcaa	5580
tggcaacaac	gttgcgcaaa	cttataactg	gccaactact	tactctagct	tcccgcaac	5640
aattaataga	ctggatggag	gcccggataaa	ttgcaggacc	acttctgcgc	tcggcccttc	5700
cggtggctg	gtttattgtc	gataaatctg	gagccggta	gcgtgggtct	cgccgttatca	5760
ttgcagca	ggggccagat	ggtaagccct	ccccgtatcg	agtttatctac	acgacgggaa	5820
gtcaggcaac	tatggatgaa	cgaaatagac	agatcgtga	gatagggtgc	tcactgttata	5880
agcattggta	actgtcagac	caagtttact	catatatact	ttagattgtat	ttaaaacttc	5940
attttaatt	taaaaggatc	taggtgaaga	tcctttgt	taatctcatg	acccaaatcc	6000
cttaacgtga	gttttcgttc	cactgagcgt	cagaccccg	agaaaaagatc	aaaggatctt	6060
cttgagatcc	ttttttctg	cgcgtaatct	gctgcttgca	acaaaaaaaaa	ccaccgctac	6120
cagcgggtgt	ttgtttgccg	gatcaagagc	taccaactct	ttttccgaag	gtactggct	6180
tcagcagacg	gcagatacca	aatactgtcc	ttctagtgta	gccgttgta	ggccaccact	6240
tcaagaactc	tgttagcaccc	cctacatacc	tcgctctgt	aatcctgtt	ccagtggtc	6300
ctgccagtgg	cgataagtcg	tgtcttaccg	ggttggactc	aagacgatag	ttaccggata	6360
aggcgcagcg	gtcgggctga	acgggggggtt	cgtgcacaca	gcccagctg	gagcgaacga	6420
cctacaccga	actgagatac	ctacagcgtg	agctatgaga	aagcgcacacg	cttcccaag	6480
ggagaaaaggc	ggacaggtat	ccggtaagcg	gcagggtcgg	aacaggagag	cgcacgaggg	6540
agtttccagg	gggaaacgcc	ttgttatctt	atagtccgt	cggtttcgc	cacctctgac	6600
ttgagcgtcg	attttgtga	tgctcgtag	gggggcggag	cctatggaaa	aacgcacgca	6660
acgcggccctt	tttacggttc	ctggccttt	gtgtccctt	tgctcacatg	gctcgacaga	6720
tct						6723

<210> SEQ ID NO 104
 <211> LENGTH: 6201
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: pTarget porcine interferon alpha

<400> SEQUENCE: 104

tcaatattgg	ccattagcca	tattattcat	tggttatata	gcataaatca	atattggcta	60
ttggccattg	catacggtt	atctatatca	taatatgtac	atttatattg	gctcatgtcc	120
aatatgaccg	ccatgttggc	attgattatt	gactagttat	taatagtaat	caattacggg	180
gtcattagtt	catagccat	atatggagtt	ccgcgttaca	taacttacgg	taaatggccc	240
gcctggctga	ccgccccacg	accccccggcc	attgacgtca	ataatgacgt	atgttcccat	300
agtaacgcca	atagggactt	tccattgacg	tcaatgggtt	gagttttac	ggtaaactgc	360
ccacttggca	gtacatcaag	tgtatcatat	gccaaagtccg	ccccctatgt	acgtcaatga	420
cggtaaatgg	cccgccctggc	attatgcccc	gtacatgacc	ttacgggact	ttcctacttg	480
gcagtgacatc	tacgttattag	tcatcgctat	tacatgggt	atgcgggttt	ggcagtgacac	540
caatgggcgt	ggatagcggt	ttgactcag	gggatttcca	agtctccacc	ccattgacgt	600
caatgggagt	ttgtttggc	acccaaatca	acgggacttt	ccaaaatgtc	gtaacaactg	660

US 10,435,695 B2

209

210

-continued

cgatcgcccg ccccggttgcac gcaaattgggc ggttaggcgtg tacgggtggga ggtcttatata	720
agcagagtc gtttagtgaa ccgtcagatc actagaagtc ttattgcgtt agtttatcac	780
agttaaatttgc ttaacgcgtt cagtgcattt gacacaacag tctcgaactt aagctgcgtt	840
gactcttta aggttagcctt gcagaagttt gtcgtgaggc actgggcagg taagtatcaa	900
ggttacaaga cagggttaag gagaccaata gaaaactgggc ttgtcgagac agagaagact	960
cttgcgtttc tgataggcac ctattggctt tactgcatac cactttgcct ttctctccac	1020
aggtgtccac tcccagttaa attacagtc ttaaaaattt gatctccatt cgccattcag	1080
getgcgcaac tgctggaaag gacgtcaga gggggcctct tcgttattac gccagctggc	1140
gaaaggacg tggcaagcaa ggccgtttaag ttgagttacg ccaggatttt cccagtcaacg	1200
acgttgtaaa acgacggca gagaattata atacgactca ctataggcg gatccgttag	1260
cggccgcacc atggccccaa cctcagcctt cctcacggcc ctgggtgtac tcagctgcaa	1320
tgcctatgc tctctggct gtgacctggc tcagaccac agcctggc acaccagagc	1380
cctgaggcgc otggcacaaa tgaggagaat ctctcccttc tctgtctgg accacagaag	1440
ggactttggt tccctcatg aggctttgg gggcaaccag gtccagaagg ctcaaggccat	1500
ggctctgggt catgagatgc tccagcagac ctccagtc ttcagcacag agggctggc	1560
tgctgectgg aatgagagcc tcctgcacca gttctgcact ggactggatc agcagctcag	1620
ggacctggaa gcctgtgtca tgcaggaggc ggggctggaa gggacccccc tgctggagga	1680
ggactccatc ctggctgtga gggaaatactt ccacagactc accctctatc tgcaagagaa	1740
gagctacagc ccctgtgcct gggagatgtt cagggcagaa gtcgttgcgtt cttcttc	1800
ctccagaaac ctgcaagaca gactcaggaa gaaggagtga gggccggcga attccaagct	1860
ttagtatttc atcggttgcac ctaataact tggcgtaatc atggtcatat ctgtttctg	1920
tgtgaaattt ttatccgctc acaattccac acaacatacg agccggaaagc ataaatgtta	1980
aaggctgggg tgcctaattt gtcgttgcgtc gatgtttcca	2040
ttttgtgagg gttatgtttt cgagaagaca tgataagata cattgtatgg tttggacaaa	2100
ccacaacaag aatgcgttgc aaaaaatgtt ttatgttgc aatgttgcgtt gctattgtt	2160
tatgttgc aattataatc tgcaataaac aagttaacaa caacaattgc attcattta	2220
tgtttcaggt tcaggggggat atgtggggagg ttttttaag caagttaaac ctctacaaat	2280
gtggtaaat ccgataagga tgcattccgg agcctgtatc gcaatggac ggcggctgtt	2340
ggggcgcatt aagcgccgcg ggtgtgggtt ttacgcgtac gtgaccgcata cacttgcag	2400
cccccctagcg cccgttcattt tcgtttttt cccttcattt ctgcgttgcgtt tcggcgctt	2460
tccccgttcaaa gcttcaatc gggggctccc tttaggggtt cgatgttgcgtt ctgttacggca	2520
cctcgacccc aaaaaatgtt attagggttgc tgggttgcgtt agtggccat cggccgtata	2580
gacggttttt cggcccttgc cgttggatgc cacgttgcgtt aatgtggac tcttgcgttca	2640
aactggaaaca acactcaacc ctatctcggt ctattttttt gatttataag ggattttgcc	2700
gatttcggcc tattggttaa aaaatgttgcgtt gatttataacaa aaatgttgcgtt cgttgcgtt	2760
caaaatatta acgttttgcataa ttccgttgcgtt gtaccttgcgtt aggcggaaag aaccagctgt	2820
ggaatgtgttgc ttagttgggg tgggttgcgtt cccaggcgtt cccaggcgtt agaagttatgc	2880
aaagcatgca tctcaatttgc tgcgttgcgtt ggtgtggaaa gtcggccgtt tccggccgtt	2940
gcagaagttttt gcaaaatgttgcgtt cgttgcgtt cttttttttt cccgttgcgtt	3000

-continued

cgcccatccc gccccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa	3060
tttttttat ttatgcagag gcccaggccg cctcggcctc tgagcttattc cagaagttagt	3120
gaggaggctt ttttgaggc ctaggctttt gcaaaaagct tgattttct gacacaacag	3180
tctcgaacct aaggctagag ccaccatgtat tgaacaagat ggattgcacg caggttctcc	3240
ggccgcgttgg gtggagagc tattcggtta tgactggcca caacagacaa tcggctgct	3300
tgatgegcgc gtgtccggc tgtagcgcga gggggcgcggc gtttttttg tcaagacgca	3360
cctgtccggc gcccgtaatg aactgcagga cgaggcagcg cggctatcgt ggctggcac	3420
gacggggcgtt ctttcgcag ctgtgcgtca cggtgtcact gaagcgggaa gggactggct	3480
gttattgggc gaagtgcggg ggcaggatct cctgtcatct cacccgtctc ctggcgagaa	3540
agtatccatc atggctgtatg caatgcggcg gctgcatacg ctgtatccgg ctacctgccc	3600
attcgaccac caagcgaaac atcgcatega gcgagcacgt actcggatgg aagccggct	3660
tgtcgatcag gatgtatctgg acgaagagca tcaggggctc ggcgcagccg aactgttgc	3720
caggctcaag gcgcgcatgc ccgcacggcga ggatctcgctc gtgaccatcg gcgcgcctg	3780
cttgcgaat atcatgggtgg aaaatggccg ctttctggta ttcatcgact gtggccggct	3840
gggtgtggcg gaccgcatac aggacatgcg gttggctacc cgtatgtatg ctgaagagct	3900
tggcggcgaa tgggctgacc gcttcctcggt gctttacggt atcgcgcgtc ccgattcgca	3960
gcgcatcgcc ttctatcgcc ttcttgacga gttcttgcgatc gcccggactct ggggttcgaa	4020
atgaccgacc aagcgacgcc caacctgcgc tcacgtggc cgcaataaaaa tatctttatt	4080
ttcattacat ctgtgtgttg gttttttgtg tgaagatccg cgtatggtgc actctcagta	4140
caatctgctc tgatgcgcga tagttaagcc agccccgaca cccgccaaca cccgctgacg	4200
cgcctgcacg ggcttgcgtc ctccggcat ccgcattacag acaagctgtg accgtctccg	4260
ggagctgcat gtgtcagagg ttttgcaccgt catcaccgaa acgcgcgaga cgaaagggcc	4320
tcgtatacgc octatttta taggttaatg tcatgataat aatggttct tagacgtcag	4380
gtggcaactt tcggggaaat gtgcgcggaa cccctatttg tttattttc taaatacatt	4440
caaatatgtt tccgctcatg agacaataac cctgataat gcttcaataa tattgaaaaaa	4500
ggaagagtagt gagtattcaa catttcgtc tcgccttat tcccttttgcggcattt	4560
gccttcctgt ttttgcac ccagaaacgc tggtaaagt aaaagatgct gaagatcagt	4620
tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaaagatc cttgagagtt	4680
ttcgcggccga agaacgtttt ccaatgtatc gcaacttttta agttctgcgatc tggcgcgg	4740
tattatcccgtt tattgacgcgccc gggcaagagc aactcggctcg ccgcatacac tattctcaga	4800
atgacttgggtt tgtagtactca ccagtcacag aaaagcatct tacggatggc atgacagtaa	4860
gagaattatg cagtgcgtcc ataaccatga gtgataacac tgccggcaac ttacttgcgat	4920
caacgatcgagg aggacgaaag gagctaaacgg ctttttgcgatc caacatgggg gatcatgtaa	4980
ctcgccctgatc tgcgtggaa ccggagctga atgaaggccat accaaacgcgac gagcgtgaca	5040
ccacgatgcc tgcgtccatg gcaacaacgt tgccaaact attaactggc gaactactta	5100
ctcttagcttc ccggcaacaa ttaatagact ggatggggc ggataaaagtt gcaggaccac	5160
ttctgcgtc ggcccttcgg gctggctggat ttattgcgtatc taaatctggat gcccggatc	5220
gtgggttcgc cggatcatttgc gcaacgcgtt ggccagatgg taagccctcc cgtatcgatc	5280
ttatctacac gacggggagttt caggcaacta tggatgaacg aaatagacag atcgtcgtatc	5340
taggtgcctc actgatataa cattggtaac tgcgtccatc agtttactca tatataacttt	5400

-continued

agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc cttttgata	5460
atctcatgac caaaatccct taacgtgagt tttcggttcca ctgagcgtaa gaccggtag	5520
aaaagatcaa aggatcttct tgagatcctt ttttctgcg cgtaatctgc tgcttgaaa	5580
caaaaaacc accgctacca gcggtggttt gtttgcggaa tcaagagcta ccaactctt	5640
ttccgaaggta actggcttc agcagagcgc agataccaa tactgtccctt ctatgttagc	5700
cgtagttagg ccaccacttc aagaactctg tagcaccgccc tacataccctc gctctgctaa	5760
tctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg ttggactcaa	5820
gacgatagtt accggataag gcgagcggtt cgggctgaac ggggggttcg tgcacacagc	5880
ccagcttggaa gcgaacgacc tacaccgaac tgagataacct acagcgtgag ctatgagaaa	5940
ggcccacgct tcccgaaaggaa agaaaaggcg acaggtatcc ggtaagcggc agggtcggaa	6000
caggagagcg cacgagggag cttccagggg gaaacgcctg gtatcttat agtcctgtcg	6060
ggtttcgcctt cctctgactt gagcgtcgtat ttttgtatc ctgcgtcaggg gggcggagcc	6120
tatggaaaaa ogccagcaac gcccccttt tacggtttcc ggcctttgc tggcttttg	6180
ctcacatggc tcgacagatc t	6201

<210> SEQ ID NO 105
<211> LENGTH: 6192
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pTarget Porcine Interferon Beta

<400> SEQUENCE: 105	
tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta	60
ttggccattt catacggtt atctatatca taatatgtac atttatattt gctcatgtcc	120
aatatgacccg ccatgttggc attgattatt gactagttat taatagtaat caattacggg	180
gtcatttagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc	240
gcctggctga ccggccaaacg acccccggcc attgacgtca ataatgacgt atgtcccat	300
agtaacgcca ataggactt tccattgacg tcaatgggtt gagtatttac ggtaaactgc	360
ccacttggca gtacatcaag tgtatcatat gccaagtccg cccctatgt acgtcaatga	420
cggtaaatgg cccgectggc attatgcca gtacatgacc ttacggact ttcctacttg	480
gcagttacatc tacgttattag tcacgtctat taccatgggtt atgcgggtt ggcagttacac	540
caatggcggtt ggatagcggt ttgactcagc gggatttcca agtctccacc ccattgacgt	600
caatggagttt ttgtttggc accaaaatca acgggactttt ccaaaatgtc gtaacaactg	660
cgtatcgcccg ccccggttgcac gcaatgggc ggttagggcgtg tacgggtggaa ggtctatata	720
agcagagcgtc gttagtgaa ccgtcagatc actagaagat ttattggcgtt agtttacac	780
agttaaatttgc ttaacgcgtt cagtgttttctt gacacaacag tctcgaactt aagctgcgt	840
gactcttta aggttagccctt gcagaagttt gtcgtgaggc actggggcagg taagtatcaa	900
ggttacaaga caggtttaag gagaccaata gaaactggggc ttgtcgagac agagaagact	960
cttgcgttcc ttagtggcac ctattggctt tactgacatc cactttgcct ttctctcac	1020
agggtgtccac tcccggttca attacagctc ttaaaaattt gatctccatt cgccattcag	1080
gctgcgttccac tgctggaaag gacgatcaga gccccctctc tcgttattac gcccagttgc	1140
gaaaggacg tggcaagcaa ggcgattaag ttgagttacg ccaggattttt cccagtcacg	1200

-continued

acgttgtaaa acgaeggc当地 gagaattata atacgactca ctatagggcg gatccgctag	1260
cgc当地ccacc atggctaaca agtgc当地ct ccaaatecgct ctccctgatgt gtttctccac	1320
cacagctt tccatgagct atgatgtgct tc当地atccaa caaaggagca gcaat当地ggc	1380
atgtc当地aaag ctccctggac agttgc当地gg gactc当地taa tattgectcg aagataggat	1440
gaactttag gtc当地ctgagg agattatgc当地 accaccacaa ttccagaagg aagatgc当地gt	1500
attgattatc cacgagatgc tccagc当地at cttc当地ggatt ctc当地aagaa atttctctag	1560
cactggctgg aatgaaaccg tc当地taaagac tatc当地tggta gaacttgatg ggc当地agatgg	1620
tgaccttggag acaatc当地gg agggaaatcat ggaggaggaa aatttccc当地 ggggagacat	1680
gaccatttctt cacctgaaga aatattactt gacattctg cagtaatc当地a agtccaagga	1740
gtacagaagc tgtgc当地tggc cagtc当地gtccaa agtggaaatc ctc当地ggact tttcttcc	1800
taacagactt acagattacc tccggaactg agc当地ggcccg aatttccaagc tt当地gatattc	1860
tatc当地gtca cctaaataac tt当地ggctaat catggc当地ata tctgatgttcc local gt当地gaaatt	1920
gttataccct cacaatccaa cacaacatac gagccggaag cataaaatgt aaagcccttgg	1980
gtgc当地taatg agt当地gatctaa ctc当地acattaa tt当地gc当地tgc当地tcc attttgc当地g	2040
ggttaatgc当地 tc当地gaaagac atgataagat acattgtatg gtttggacaa accacaacaa	2100
gaatgc当地gtg aaaaaatgc tt当地atgtg aaatttgtatg tgctatgtt cc当地atgtt	2160
ccattataag ctgcaataaa caagttaaaca acaacaatgg cattc当地tcc atgatccagg	2220
ttc当地ggggaa gatgtggag gttt当地aaa gcaagtaaaa cctctacaaa tggatgtt	2280
tccgataagg atc当地attccg gagc当地ctgaa ggc当地aatggc cgc当地ccctgt agc当地ggccat	2340
taagc当地ggc gggatgtggat gttacgc当地ca cgtgaccgat acacttgc当地a ggc当地ccctagc	2400
gccc当地cttct ttc当地gttccct tcccttccct tctc当地gccacg ttc当地ccggct tccccc当地gtca	2460
agctctaaat cggggatctcc ct当地tagggat cc当地atgttccgat gcttacggc acctc当地gaccc	2520
caaaaaatctt gattagggtg atgatgttccatg tagtggccaa tggatgttccat agacggatgtt	2580
tccccc当地tttccgat acgttggatg ccacgttccct taatagtggc ctcttgc当地tcc aaactggaaac	2640
aacactcaac cctatctccg tctatccctt tgatgttccat gggatgttccgat cgatccggc	2700
ctatggatgaaa aaaaatgttccat tgatgttccat aaaaatgttccat gggatgttccat aaaaatgttccat	2760
aacgcttaca atttcccttccat tgatgttccat gggatgttccat gggatgttccat tgatgttccat	2820
gtc当地atgttccat gttatgttccat tccccc当地gttccat cccccc当地gttccat cccccc当地gttccat	2880
atctcaatta gtc当地atgttccat aggttgc当地ggaa agtccccagg ctccccaggca ggc当地agaatgt	2940
tgc当地aaatgttccat gcatctccat tagtgc当地ccaa cc当地atgttccat gccc当地ctact cc当地ccatcc	3000
ccccc当地ctact tccccc当地gttccat cccccc当地gttccat tggatgttccat atttt当地tttccat	3060
tttatgc当地gttccat gccc当地ggggcc gc当地ctggccct ct当地gatgttccat cc当地agatgttccat tgatgttccat	3120
tttttggagg octatgttccat tgatgttccat tt当地atgttccat tgatgttccat tgatgttccat gtc当地atgttccat	3180
taaggctaga gccaccatga tt当地acaaga tggatgttccat gc当地aggatgttccat cggccgcttgc	3240
ggatgttccat ctatccggct atgacttggcc acaacagaca atc当地gttccat ct当地atgttccat gtc当地atgttccat	3300
cgtgatgttccat ctgatgttccat agggatgttccat gttatgttccat gtc当地atgttccat accttgc当地gg	3360
tccccc当地gttccat gaaatgttccat acgttggatg cc当地atgttccat tggatgttccat cggccgcttgc	3420
tc当地atgttccat gtc当地atgttccat acgttggatg cc当地atgttccat tggatgttccat cggccgcttgc	3480
c当地aaatgttccat gggatgttccat tccccc当地gttccat cccccc当地gttccat cccccc当地gttccat aagatgttccat	3540
catggatgttccat gcaatgttccat ggatgttccat gtc当地atgttccat cccccc当地gttccat cccccc当地gttccat	3600

-continued

ccaaaggaaa catcgcatcg agcgagcacg tactcggatg gaagccggtc ttgtcgatca	3660
ggatgatctg gacaaagagc atcaggggct cgcgcacccgaaactgttgc ccaggctcaa	3720
ggcgccatcg cccgacggcg aggatctcg cgtgaccat ggcatgcct gcttgcgaa	3780
tatcatggtg gaaaatggcc gctttctgg attcatcgac tggccggc tgggtgtggc	3840
ggaccgctat caggacatag cggtggctac ccgtgatatt gctgaagagc ttggccgca	3900
atgggctgac cgcttcctcg tgcttacgg tatcgccgt cccgattcgc agcgcatcg	3960
tttctatcgcttcttgcg agttttctcg agcgggactc tgggttgcgaaatgaccgac	4020
caagcgacgc ccaacccgtcc atcacgatgg ccgcataaa atatctttat tttcattaca	4080
tctgtgtgtt gttttttgt gtgaagatcc gctgtatggtg cactctcagt acaatctgct	4140
ctgatgccgc atagttaaac cagccccgac acccgccaaac acccgctgac gcccctgac	4200
gggcttgcgtct gctccggca tccgcttaca gacaagctgt gaccgtctcc gggagctgca	4260
tgtgtcagag gttttcaccg tcatacaccga aacgcgcgag acgaaaggc ctcgtgatac	4320
gcttattttt ataggttaat gtcataataa taatggtttcttagacgtca ggtggcactt	4380
ttcggggaaa tgtgegcgga accccttattt gtttattttt ctaatacatat ctaataatgt	4440
atccgctcat gagacaataa ccctgataaa tgcttcaata atattgaaaa aggaagagta	4500
tgagtattca acatttcgt gtcgcctta ttcctttttt tgccgcattt tgccctctg	4560
tttttgcata cccagaaacg ctggtaaag taaaagatgc tgaagatcag ttgggtgcac	4620
gagtgggtta catcgaaactg gatctcaaca gcggttaagat ctttgagagt tttcgccccg	4680
aagaacgttt tccaatgatg agcactttta aagttctgct atgtggcgcg gtattatccc	4740
gtattgacgc cggccaagag caactcggtc gcccgcataca ctatttcag aatgacttgg	4800
ttgagtactc accagtcaca gaaaagcatac ttacggatgg catgacagta agagaattat	4860
gcagtgtgc cataaccatg agtataaca ctgcggccaa cttacttcgt acaacgatcg	4920
gaggaccgaa ggagctaaccc gctttttgc acaacatggg ggatcatgta actcgccctg	4980
atcggtggaa accggagctg aatgaagcca taccaaagca cgagcgtgac accacgatgc	5040
ctgttagcaat ggcaacaacg ttgcgcacac tattaactgg cgaactactt actctagctt	5100
cccgccaaca attaatagac tggatggagg cggataaagt tgcaggacca cttctgcgt	5160
cggcccttcc ggctggctgg tttattgtcg ataaatctgg agccggtgag cgtgggtctc	5220
gggttatcat tgcagactg gggccagatg gtaagccctc cctgtatcgta gttatctaca	5280
cgacggggag tcaggcaact atggatgaac gaaatagaca gatcgctgag ataggtgcct	5340
cactgattaa gcatttgtaa ctgtcagacc aagtttactc atatatactt tagattgatt	5400
taaaaactca ttttaattt aaaaggatct aggtgaagat cttttgtat aatctcatga	5460
ccaaaatccc ttaacgtgag tttcggtcc actgagcgctc agaccccgta gaaaagatca	5520
aaggatcttc ttgagatcct tttttctgc gctaatctg ctgcttgcaaa aaaaaaaaaac	5580
caccgctacc agcggtggtt tgttgcggg atcaagagct accaactctt tttccgaagg	5640
taactggctt cagcagagcg cagataccaa atactgtctt totagtgtag cctgtatgg	5700
gccaccacctt caagaactct gtgcacccgctacataacctt cgtctgcata atccgttac	5760
cagtggctgc tgccagtgcc gataagtcgt gtcttaccgg gttggactca agacgatagt	5820
tacccgataa ggcgcagcgg tcggctgaa cgggggttc gtgcacacag cccagcttgg	5880
agcgaacgac ctacaccgaa ctgagatacc tacagcgtga gctatgagaa agcgccacgc	5940

US 10,435,695 B2

219**220**

-continued

tccccgaagg	gagaaaggcg	gacaggtatc	cggtaagcgg	cagggtcgga	acaggagac	6000
gcacgagggg	gcttccaggg	ggaaaacgcct	ggtatctta	tagtcctgtc	gggttcgccc	6060
acctctgact	tgagegtcga	tttttgtat	gctcgtcagg	ggggcggagc	ctatggaaaa	6120
acgccagcaa	cgccgcctt	ttacggttcc	tggcctttt	ctggcctttt	gctcacatgg	6180
ctcgacagat	ct					6192

<210> SEQ ID NO 106
<211> LENGTH: 6124
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pTarget Bovine Interferon Gamma

<400> SEQUENCE: 106						
tcaatattgg	ccattagcca	tattattcat	tggttatata	gcataaatca	atattggcta	60
ttggccattg	catacgttgt	atctatatca	taatatgtac	atttatatgt	gctcatgtcc	120
aatatgaccg	ccatgttggc	attgattatt	gactagtat	taatagtaat	caattacggg	180
gtcattagtt	catagccat	atatggagtt	ccgcgttaca	taacttacgg	taaatggccc	240
gcctggctga	ccgccccaaacg	accccccggcc	attgacgtca	ataatgacgt	atgttcccat	300
agtaacgcua	atagggactt	tccattgacg	tcaatgggtg	gagtatttac	ggtaaaactgc	360
ccacttggca	gtacatcaag	tgtatcatat	gccaagtccg	ccccctattt	acgtcaatga	420
cggtaaatgg	cccgcttggc	attatgcccc	gtacatgacc	ttacgggact	ttcctacttg	480
gcagtagatc	tacgttattag	tcatcgctat	taccatggtg	atgcgggttt	ggcagttacac	540
caatggcggt	ggatagcggt	ttgactcacg	gggatttcca	agtctccacc	ccattgacgt	600
caatgggagt	ttgttttggc	acccaaatca	acgggacttt	ccaaaatgtc	gtaacaactg	660
cgatcgcccc	ccccgttgac	gcaaattggc	ggtagggctg	tacgggtggg	ggtctatata	720
acgagagctc	gttttagtgaa	ccgtcagatc	actagaagct	ttattgcgg	agtttatcac	780
agttaaattt	ctaacgcagt	cagtgtttct	gacacaacag	tctcgaactt	aagctgcagt	840
gactcttta	aggttagccct	gcagaagtt	gtcgtgaggc	actggggagg	taatgtatcaa	900
ggttacaaga	cagggttaag	gagaccaata	gaaactgggc	ttgtcgagac	agagaagact	960
cttgcgtttc	tgataggcac	ctattggct	tactgacatc	cactttgcct	ttctctccac	1020
aggtgtccac	tcccagttca	attacagctc	ttaaaaattt	gatctccatt	cgccattcag	1080
gctgcgcaac	tgctggaaag	gacgtcaga	gcgggcctct	tgcgttattac	gccagctggc	1140
gaaaggacg	tggcaagcaa	ggcgattaaag	ttgagttacg	ccaggatttt	cccagtcaacg	1200
acgttgtaaa	acgacggcca	gagaattata	atacgactca	ctataggcgc	gatccgttag	1260
cgccgcacc	atgaaatata	caagcttattt	cttagcttta	ctgctctgt	ggcttttggg	1320
tttttcttgt	tcttatggcc	aggccaaattt	tttttagagaa	atagaaaact	taaaggagta	1380
tttaaatgca	agtagccac	atgtagctaa	gggtgggcct	ctcttctcag	aaattttgaa	1440
gaattggaaa	gatgaaagt	acaaaaaaat	tattcagacg	caaattgtct	ccttctactt	1500
caaactctt	aaaaacctca	aagataacca	ggtcattcaa	aggagcatgg	atataatcaa	1560
gcaagacatg	tttcagaagt	tcttgaatgg	cagctctgag	aaactggagg	acttcaaaaa	1620
gtgttcaaaat	attccgggtgg	atgatctcca	gatccagcgc	aaagccataa	atgaaactcat	1680
caaagtgtat	aatgacctgt	caccaaaatc	taacctcaga	aagcggaaaga	gaagtcagaa	1740
tctctttcga	ggccggagag	catcaacgta	agaattccaa	gctttagtat	tctatcggt	1800

-continued

cacctaata acttggcgta atcatggta tatctgttcc ctgtgtgaaa ttgttatccg	1860
ctcacaaatc cacacaacat acgagccgga agcataaaagt gtaaaggctg ggggcctaa	1920
ttagtgagct aactcacatt aattgcgttg cgcgatgctt ccattttgtg agggtaatg	1980
cttcgagaag acatgataag atacattgtat gagtttggac aaaccacaac aagaatgcag	2040
tgaaaaaaat gctttatTTT tgaatTTTgt gatgttatttgc ctttattttgtt aaccattata	2100
agctgcaata aacaagttaa caacaacaat tgcatTTTtca ttatgttca ggTTTcagggg	2160
gagatgtggg aggtttttta aagcaagtaa aacctctaca aatgtggtaa aatccgataa	2220
ggatcgatTC cggagccCTGA atggcgaATG gacgcgcCTG gtagcggcgc attaAGcgcG	2280
gggggtgtgg tggTTacgcg cacgtgaccg ctacacttgc cagcgcCTTA ggcggccgctc	2340
cttgcgtttt ctccCTTCC tttctcgcca cgttgcggg ctttccccgtt caagctctaa	2400
atcgggggctt ccTTTtaggg ttccgattta gtgttttacg gcacctcgac cccaaaaaac	2460
ttgatttaggg ttaggttca cgttagggc catgcCTCTG atagacggTT ttgcgcCTT	2520
tgacgttggg gtccacgttC tttaatagtG gactcttGTT ccaaactggA acaacactca	2580
accctatctc ggttatttCT tttgatTTT aagggatTTT ggcatttgc gcctatttgg	2640
taaaaaatga gctgatTTAA caaaaatTTA acgcgaATTt taacaaaATA ttaacgctta	2700
caatttgcC tttgttacCTT ctgaggcgga aagaaccAGC tttgttgcgtt gtttgcgttA	2760
gggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaaagcat gcatctcaat	2820
tagtcagcaa ccagggtgtgg aaagtccccca ggctccccAGC caggcagaAGC tatgeaaAGC	2880
atgcatctca attagtCAGC aaccatAGtC cggccccCTAA ctccgcCCTAT CCCGCCCTA	2940
actccgcCCTA gttccgcCCTA ttccgcCCTC catggctgac taatTTTTT tatttAtgca	3000
gaggcccgagg ccgcctcgGC ctctgagta ttccagaAGT agtgaggagg ctttttggA	3060
ggccttaggt tttgtaaaaa gcttgatttC tctgacacaa cagtctcgaa cttaaggctA	3120
gagccaccat gattgaacaa gatggatttC acgcaggTTt tccggccgct tgggtggaga	3180
ggctatttCGG ctatgactgg gcacaacaga caatcggttC ctctgtatgc gccgtgttCC	3240
ggctgtcAGC gcaggGGGCGC ccggTTCTTT ttgtcaagAC egacctgttCC ggtgcCCTGA	3300
atgaactgca ggacgaggca gcgeggctat cgtggctggc cacgaegggc gttccTTGCG	3360
cagctgtgtc acgacgttGTC actgaageGG gaaggactG gctgtatTTt ggcgaagtG	3420
cggggcaggA tctctgtca tctcacCTT ctctgtccGA gaaagtatCC atcatggCTG	3480
atgcaatgcg gcggctgcat acgcttGATC cggctacCTG cccattcGAC caccaAGcGA	3540
aacatcgcat cgagcgagca cgtactcgGA tggaaAGCCG tcttgcgtat caggatgtc	3600
tggacgaaga gcatcaggGGG ctgcgcGCCAG ccgaactGTt cgccaggCtC aaggcgcGCA	3660
tgcCcgcAGG CGAGGATCTC gtcgtgatCC atggcgtatG ctgttgcgcg aatatcatgg	3720
tggaaaaatgg ccgcttttct ggattcatg acgtgtggcG gctgggtgtg gcccggcgt	3780
atcaggacat acgcttggct acccggtata ttgctgaaga gcttggccgc gaatgggctg	3840
accgcttCTC ogtgtttac ggtatcgccg ctcccgatTC gcaagcgcATC gccttctatC	3900
gccttctGA cgagtcttC TGAGCGGGAC tctggggTTc gaaatgacccg accaAGcGAc	3960
gcccAACCTG CCAATCACGAT ggccgcAATA aaatatCTT atTTTcatTA catctgtgtG	4020
ttggTTTTT gtgtgaagat ccgcgtatgg tgcacttCtca gtacaatCTG ctctgtatGCC	4080
gcatagttaa gcaagccccG acacccgcca acacccgctG acgcgcCCTG acgggcttGt	4140

-continued

ctgctccgg catccgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag	4200
aggtttac acgtcatcacc gaaacgcgcg agacgaaagg gcctcgat acgcatttt	4260
ttataggtta atgtcatgat aataatggtt tcttagacgt caggtggcac ttteggga	4320
aatgtgcgcg gaaccttat ttgttttattt ttctaaatac attcaaataat gtatccgctc	4380
atgagacaat aacctgata aatgttcaa taatattgaa aaaggaagag tatgagtatt	4440
caacatttc gtgtcgccct tattccctt tttgcggcat tttgccttcc tgttttgct	4500
cacccagaaa cgctggtaaa agtaaaagat gctgaagatc agttgggtgc acgagtgggt	4560
tacatcgac tggatctcaa cagcggtaag atccttgaga gtttgcgcc cgaagaacgt	4620
tttccaatga tgagcacttt taaagttctg ctatgtggcg cggattatc ccgtattgac	4680
gcgggcaag agcaactcg tcgcccata cactattctc agaatgactt gttgagttac	4740
tcaccagtca cagaaaagca tcttacggat ggcattgacag taagagaatt atgcagtgt	4800
gccataacca tgagtgataa cactgcggcc aacttacttc tgacaacgtt cgaggaccg	4860
aaggagctaa ccgcgtttttt gcacaacatg gggatcatg taactcgct tgatcggttgg	4920
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgt gcctgttagca	4980
atggcaacaa cgttgcgcaaa actattaact ggcaactac ttactctagc ttccggcaaa	5040
caattaatag actggatgga ggcggataaa gttgcaggac cacttctcg ctcggccctt	5100
ccggctggct gttttattgc tgataatct ggagccggtg agcgtgggtc tcgcgttac	5160
atgcagcac tggggccaga tggtaagccc tccgtatcg tagttatcta cacgacgggg	5220
agtcaggcaa ctatggatga acgaaataga cagatcgctg agatagggtgc ctcactgatt	5280
aagcatttgtt aactgtcaga ccaagtttac tcatatatac tttagattga tttaaaactt	5340
cattttat taaaaggat cttagtgaag atccttttttataatctcat gaccaaatac	5400
ccttaacgtg agtttcgtt ccactgagcg tcagaccccg tagaaaagat caaaggatct	5460
tctttagatc cttttttct gcgcgtatc tgctgcttgc aaacaaaaaa accaccgcta	5520
ccagcggtgg tttgttgcc ggtcaagag ctaccaactc ttttccgaa ggtactggc	5580
ttcagcagag cgcagatacc aaatactgtc cttctagtgtt agccgttagtt aggccaccac	5640
ttcaagaact ctgttagcacc gcctacatac ctcgctctgc taatcctgtt accagtggct	5700
gtgtcccgatg ggcataagtc gtgtcttacc gggttggact caagacgata gttaccggat	5760
aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac agccagctt ggagcgaacg	5820
acctacacgg aacttagata cctacagcgt gagctatgag aaagcgcac gcttccgaa	5880
gggagaaaagg cggacaggta tccggtaagc ggcagggtcg gaacaggaga ggcacggagg	5940
gagcttccag gggaaacgc ctggatcttttataatgtctg tccgggttcg ccacctctga	6000
cttgcggcgtc gatTTTGTG atgctcgtaa ggggggggaa gctatggaa aaacgcacgc	6060
aacgcggcctt tttacggtt cctggccctt tgctggcatt ttgctcacat ggctcgacag	6120
atct	6124

<210> SEQ_ID NO 107
 <211> LENGTH: 6210
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: pTarget Bovine Interferon Lambda

<400> SEQUENCE: 107

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta 60

-continued

ttggccattg	catacggtgt	atctatatca	taatatgtac	atttatattg	gctcatgtcc	120
aatatgaccg	ccatgttggc	attgattatt	gactagttat	taatagtaat	caattacggg	180
gtcattagtt	catagcccat	atatggagtt	ccgcgttaca	taacttacgg	taaatggccc	240
gcctggctga	ccgccccaaacg	accccccggcc	attgacgtca	ataatgacgt	atgttcccat	300
agtaacgcca	atagggactt	tccattgacg	tcaatgggtg	gagtatttac	ggtaaaactgc	360
ccacttggca	gtacatcaag	tgtatcatat	gccaagtccg	ccccctattt	acgtcaatga	420
cggtaaatgg	cccgcttggc	attatgccc	gtacatgacc	ttacgggact	ttcctacttg	480
geagtagatc	tacgttattag	tcatcgctat	taccatgggt	atgcgggttt	ggcagtagcac	540
caatgggcgt	ggatagcggt	ttgactcacc	gggatttcca	agtctccacc	ccattgacgt	600
caatgggagt	ttgttttggc	acccaaatca	acgggacttt	ccaaaatgtc	gtaacaactg	660
cgatecgcccc	ccccgttgac	gcaaattggc	ggtagggctg	tacggtggga	ggtctatata	720
agcagagatc	gttttagtgaa	ccgtcagatc	actagaagct	ttattgoggt	agtttatcac	780
agttaaattt	ctaacgcagt	cagtgcctt	gacacaacag	tctcgaaactt	aagctgcagt	840
gactcttta	aggttagcctt	gcagaagttt	gtcgtgaggc	actggggcagg	taatgtatcaa	900
ggttacaaga	cagggttaag	gagaccaata	gaaactggc	ttgtcgagac	agagaagact	960
cggcggttcc	tgataggcac	ctattggct	tactgacatc	cactttgcct	ttctctccac	1020
aggtgtccac	tcccagttca	attacagctc	ttaaaaattt	gatctccatt	cgccattcag	1080
gctgcgaac	tgctgggaag	gacgatcaga	ggggccctct	tgcgttattac	gccagctggc	1140
gaaagggacg	tggcaagcaa	ggcgattaag	ttgagttacg	ccaggatttt	cccagtcacg	1200
acgttgtaaa	acgacggcca	gagaattata	atacgactca	ctatagggcg	gatccggcgc	1260
gcccgcacca	tggccccagg	ctgeacgctg	gtgctggtgc	tgtgtcgac	gaccgtggc	1320
ctgagcagga	caggagcagt	tctgtgcccc	tctgccccca	gggcactccc	acctgcccagg	1380
ggctgcccac	tggcccagg	caagtctctg	tcccctcaag	agctgcaagc	cttcaagacg	1440
gcccaggatg	cctttaaga	ctcggttctg	ccgaaggact	gggactgttag	cacccacctt	1500
ttccccagga	cacgagacct	gaagcacctg	caagtgtggg	agcgccctgt	ggctctggag	1560
gcagagctgg	ccctgacact	gacggtcctg	gaggcaatgg	ctaactcatc	cctggccac	1620
gcctggagc	agcccccttc	cacgctgcaa	aacatccact	ccaagetcca	ggcctgtgtc	1680
ccagctcagc	ccacagcaag	ctccagaccc	cgaggccgc	tccaccactg	gctgcacccg	1740
ctccaaagg	cccgaaagga	gtcccaggac	tgcctcgaag	cctctgtgt	gttcaacctc	1800
ctccgcctcc	tcacccgaga	cctgaaatgt	gttgccagcg	gagaccagtg	tgtctgagaa	1860
ttccaaagctt	gagtttctta	tcgtgtcacc	taataatact	ggcgtaatca	ttggtcatatc	1920
tgtttcttgt	gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaaagca	1980
taaagtgtaa	agcctgggg	gcctaattgag	ttagcttaact	cacattaatt	gcgttgcgcg	2040
atgcttccat	tttgcgggg	ttaatgcctt	gagaagacat	gataagatac	attgtatgagt	2100
ttggacaaac	cacaacaaga	atgcgtgaa	aaaaatgott	tatttgcgg	atttgcgtat	2160
ctattgcttt	atttgcgtacc	attataagct	gcaataaaca	agttaaacaac	aacaattgca	2220
ttcattttat	gtttcagggtt	cagggggaga	tgtggggagtt	tttttaaagc	aagtaaaacc	2280
tctacaaatg	tggtaaaatc	cgataaggat	cgattccgga	gcctgaatgg	cgaatggacg	2340
cgccctgttag	cgccgcattta	agcgccggcg	gtgtgggtgt	tacgcgcacg	tgaccgctac	2400

US 10,435,695 B2

227

228

-continued

acttgcacgc gcccctagcgcc cccgtcccttt cgctttcttc ctttccttcc tcgcccacgtt	2460
cgcgggtttt cccccgtcaag ctctaaatcg ggggctccct tttagggttcc gatttagtgc	2520
tttacggcac ctcgacccca aaaaacttga tttagggtgat ggttcacgta gtggggccatc	2580
gccctgtatag acggtttttc gccccttgcac gttggagtcc acgttcttta atagtggact	2640
cttggttccaa acttggAACAA cactcaaccc tatctcggtc tattcttttgc atttataagg	2700
gattttgcgc atttgcgcctt atttggtaaa aaatgagctg atttaacaaa aatttacgc	2760
gaattttaac aaaatattaa cgcttacaat ttgcgcgttg taccttctga ggccggaaaga	2820
accagctgtg gaatgtgtgt cagtttagggc gtggaaagtc cccaggctcc ccaggcaggca	2880
gaagtatgca aagcatgcat ctcaattagt cagcaaccag gtgtggaaag tccccagggct	2940
ccccagcagg cagaagtatg caaaagcatgc atctcaatta gtcagcaacc atagtccgc	3000
ccctaactcc gccccatcccc cccctaactc cggccagttc cggccattctt ccggccatcg	3060
gtgactaat ttttttattt tatgcagagg ccgaggccgc ctggcctct gagctattcc	3120
agaagtagtg aggaggctt tttggaggcc taggcttttg caaaaagctt gattttctg	3180
acacaacagt ctcgaactta aggctagagc caccatgatt gaacaagatg gattgcacgc	3240
aggttctccg gccgcttggg tggagaggctt attcggtat gactggcac aacagacaat	3300
cggctgtctt gatggccccc tggtccggct gtcagcgcag gggcgccccc ttcttttgt	3360
caagaccgac ctgtccgggt ccctgaatga actgcaggac gaggcagcgc ggctatcg	3420
gtgtggccacg acggccgttc ctgcgcgc tggtgcgcac gttgtactg aagcggaaag	3480
ggactggctg ctattggcg aagtgcggg gcaggatctc ctgtcatctc accttgctcc	3540
tggcgagaaa gtatccatca tggctgatgc aatgcggcg ctgcatacgc ttgatccgc	3600
tacctgcaca ttcgaccacc aagcgaaaca tcgcacgcag cgagcacgtt ctcggatgg	3660
agccggctt gtcgatcagg atgatctgg cgaagagcat caggggctcg cgccagccga	3720
actgttgcgc aggctcaagg cgccatgc cgcggcgag gatctcgatcg tgaccatgg	3780
cgtgcgtgc ttggcgaata tcatggtgaa aatggccgc ttttctggat tcatgcactg	3840
tggccggctg ggtgtggcg accgcgtatca ggacatgcg ttggctaccc gtgatattgc	3900
tgaagagctt ggccggcaat gggctgaccc ctgcgtcgat ctttacggta tcgcccgc	3960
cgattcgcag cgccatgcct tctatcgct tcttgcgcag ttcttgcgcg cgggactctg	4020
gggttcgaaa tgaccgacca agcgacgccc aacctgcctt cacgtggcc gcaataaaat	4080
atcttttattt tcattacatc tttgtgtttttt gatggatccgc gatgggtca	4140
ctctcagttac aatctgtctt gatggcccat agttaagccca gccccgacac ccggccacac	4200
ccgctgcacgc gcccgtacgg gcttgcgtc tccggcgcac cgcttacaga caagctgtga	4260
ccgtctccgg gagctgcgtg tggtcgaggt ttccaccgtc atcaccgaaa cgccggagac	4320
gaaaggccctt cgtgatacgc ctatccat aggttaatgt catgataata atggtttctt	4380
agacgtcagg tggcactttt cggggaaatg tgccggaaac ccctatttgc ttatccat	4440
aaatacatcc aataatgtat ccgcgtcatga gacaataacc ctgataaaatg cttcaataat	4500
attgaaaaag gaagagatgt agtattcaac atttccgtt cggcccttattt cccttttttg	4560
cggcatttttgc ctttcgtttt tttgtcacc cagaaacgc ggtgaaagta aaagatgcgt	4620
aagatcgatgggtgcacga gtgggttaca tcgaaactggat totcaacagc ggtgatcc	4680
ttgagagttt tcgccccgaa gaaatgttttcaatgtatgag cactttaaa gttctgctat	4740
gtggcgccgtt attatccgtt attgacgcggc ggcacggcactc cgcatacact	4800

US 10,435,695 B2

229**230**

-continued

attctcagaa tgacttgggtt gagtaactcac cagtcacaga aaagcatctt acggatggca	4860
tgacagtaag agaattatgc agtgctgcca taaccatgaag tgataaacact gcggccaaact	4920
tacttctgac aacgatcgga ggaccgaagg agctaaccgc tttttgcac aacatgggg	4980
atcatgtAAC tcgccttgat cgTTGGGAAC cggagctgaa tgaAGCCATA ccaaACGACG	5040
agcgtgacac cacgatgcct gtagcaatgg caacaacgtt gCGCAAACtA ttAAActGGCG	5100
aactactac tctAGCTTCC CGGCAACAtA TAATAGACTG gatggaggcg gataAAAGTTG	5160
caggaccact tctgCGCTCG GccCTTCGG CTGGCTGGTT tattgtgtat aaATCTGGAG	5220
ccggTgAgCg Tgggtctcgc ggtatcattG cagcaCTGGG GccAGATGGT aAGCCCTCCC	5280
gtatcgtAGT tatctacacg acggggagtc aggcaactat ggtGAACGA aatAGACAGA	5340
tcgctgAGAT aggtgcctca ctgattaAGC attggtaact gtcAGACCAA GTTtACTCAT	5400
atatacttta gattgattta aaacttcatt ttAAATTAA aaggatctAG gtGAAGATCC	5460
tttttgataa tctcatgacc aaaatccctt aacgtgaggT ttCGTTCCAC tgAGCGTcAG	5520
accccgtAGA aaAGATCAA GGATCTTCTT gagatcTTT ttttctgcGC gtaatctGCT	5580
gcttgcaAAc AAAAaaaACCA CGCtAccAG CGGTGGTTG ttGCGGGA CAAGAGCTAC	5640
caacttttt tccGAAGGTA actggcttca GcAGAGCgCA gataccAAat actgtcCTC	5700
tagtGTagCC GtagttAGGC CaccACTtCA AGAACTCTGT AGCACCGCCT ACATACCTG	5760
ctctGetaat CCTGTTACCA GTGGCTGCTG CCAGTGGCGA TAAGTGTGT CTTACCGGGT	5820
tggactcaAG acgatAGTTA CGGATAAGG CGCAGCGGT GGGTGAACG GGGGTTcGT	5880
gcacacAGCC CAGCTGGAG CGAACGACt ACACCGAAct GAGATAACtA CAGCGTgAGC	5940
tatgagAAAG CGCCACGCTT CCCGAAGGGA GAAAGGGCGGA CAGGTATCCG GtaAGCGGCA	6000
gggtcggAAC aggAGAGCGC acgAGGGAGC ttccAGGGGG AAACGCTTG tatTTtATA	6060
gtcctGTCGG GttGccAc ctctGacttG AGCtGcAtt ttGtGAtGC TCGtAGGGG	6120
ggcggAGCt atggAAAAC GCCAGCAAGC CGGCCTTT AcGGTTcCTG GcCTTTGcT	6180
ggcctttGc tcACATGGCT CGACAGATCT	6210

<210> SEQ ID NO 108

<211> LENGTH: 6314

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: pTarget d1D2A-SGluc (-1M)

<400> SEQUENCE: 108

tcaatattgg ccattAGCCA tattattcat tggttatata gcataAAatCA atattGGCTA	60
ttggccattG cAtAcGTTGT AtcttatAtCA taatAtGtAC atttAtAtTG GctcatGtCC	120
aatatGACCG CcatGTTGGC attGATTATT GactAGTTat TAATAGTAAt CAATTACGGG	180
gtcattAGTT catAGCCAT AtATGGAGTT CGCGTtACA TAACtTACGG TAAATGGCCC	240
gcctGGGTGA CGGCCCACG ACCCCCCCCC ATTGACGTCA ATAATGACGT ATGTTCCCAT	300
agtaACGCCA AtAGGGACTT TCCATTGACG TCAATGGGTG GAGTATTAC GGTAAACTGC	360
ccacttGGCA GtACATCAAG TGTATCATAT GCCAAGTCCG CCCCCTATG ACGTCAATGA	420
cggtAAATGG CCCGCTGGC ATTATGCCA GTACATGACC TTACGGGACT TCCCTACTTG	480
gcAGTACATC tacgttAtAG TCAtCGCTAt TACCATGGTG ATGCGGTTT GGCAGTACAC	540
caatGGGCGT GGATAGCGGT ttGACTCACG GGGATTCCA AGTCTCCACC CCATTGACGT	600

-continued

caatgggagt ttgtttggc accaaaatca acgggactt caaaaatgtc gtaacaactg	660
cgatcgcccg ccccggtgac gcaaatggc ggttaggggtg tacgggtgggaa ggtctatata	720
agcagagctc gttagtgaa ccgtcagatc actagaagct ttattgcggt agtttatcac	780
agttaaattt ctaacgcagt cagtgcttc gacacaacag tctcgaaacctt aagctgcagt	840
gactctcta aggtggcctt gcagaagttt gtcgtgaggc actgggcagg taagtatcaa	900
ggttacaaga cagggttaag gagaccaata gaaactgggctt tggtcgagac agagaagact	960
cttgcgtttc tgataggcac ctattggctt tactgacatc cactttgcct ttctctccac	1020
aggtgtccac tcccagttca attacagctc ttaaaaattt gatctccatt cgccattcag	1080
gtgtgcacac tgctgggaag gacgatcaga gcgggcctct tcgcttattac gccagctggc	1140
gaaaggggacg tggcaagcaa ggcgattaaatg tttagttagc ccaggattt cccagtcacg	1200
acgttgtaaa acgacggcca gagaattata atacgactca ctatagggcg aattcggatc	1260
cttgcgtagcc tcgagctcgaa gacgcgtgat tgccgcgc ccatgagccaa agcaaaag	1320
atcattgcac cagcaaagca gctctgaat tttgacctgc tcaagtggc cggagacgtt	1380
gagtc当地acc ctggggcccg agtcaaagtt ctgtttgccct tgatctgcattt cgctgtggcc	1440
gaggccaaggcc accccggagaa caacgaagac ttcaacatcg tggccgtggc cagcaacttt	1500
gcgaccacgg atctcgatgc tgaccgaggg aagttgcccgg gcaagaagct gcccgtggag	1560
gtgctcaaag agatggaaagc caatgcccgg aaagctggctt gcaccagggg ctgtctgatc	1620
tgcctgtcccc acatcaagtg cacgcccggatgaaatggcgggatggc acgctgcac	1680
acctacgaag gcgacaaaga gtccgcacag ggccgcatacg gcgaggcgat cgctcgatatt	1740
cctgagattc ctgggttcaa ggacttggag ccaatggagc agttcatcgc acaggtcgat	1800
ctgtgtgtgg actgcacaaac tggctgcctt aaagggttgc ccaacgtgca gtgttgcac	1860
ctgctcaaga agtggctgcc gcaacgcgtt ggcacccctt ccagcaagat ccagggccag	1920
gtggacaaga tcaagggggc cggtggtgac taagcggccg cgaattccaa gcttgagtt	1980
tctatcgatgtt cacctaaata acttggcgta atcatggtca tatctgtttc ctgtgtgaaa	2040
ttgttatccg ctcacaattt cacacaacat acgagccgaa agcataaaatgt gtaaaagcctg	2100
gggtgcctaa tgagtggact aactcacatt aattgcgttgc cgcgtatgc ccattttgt	2160
agggttaatg cttcgagaag acatgataag atacattgtt gatgtttggac aaaccacaac	2220
aagaatgcag tgaaaaaaat gctttatgg tggaaattttt gatgtatgtt ctttatgtt	2280
aaccattata agctgcaata aacaagttaa caacaacaat tgcatttattt ttatgtttca	2340
ggttcagggg gagatgtggg aggttttttta aagcaagtaa aacctctaca aatgtggtaa	2400
aatccgataa ggatcgattt cggaggccttga atggcgaatg gacgcgcctt gtgcggcgc	2460
attaagcgcg ggggggtgtgg tggttacgcg cacgtgaccg ctacacttgc cagcgcccta	2520
ggcccgctt ctttcgcttt ctcccttcc ttctcgccca cgttgcgggg ctttcccg	2580
caagctctaa atcgggggtt ccctttaggg ttccgatttgc gatgttttttgc acacccgt	2640
cccaaaaaac ttgatttaggg tggatgttca cgtatgtggc catcgccctt atagacgtt	2700
tttcgcctt tgacgttggaa gtccacgttca ttatatgtt gactcttgcctt ccataactggaa	2760
acaacactca accctatctc ggtctatttctt ttgttattt aagggtttt gccgatttgc	2820
gcctattgtt taaaaatgtt gctgttttttta caaaaattttt aacgcgttta taacaaata	2880
ttaacgccta caatttcgc tttgttaccc ttgttgcggaa aagaaccaggc tttgtggatgt	2940
gtgtcgttta ggggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaagcat	3000

-continued

gcatctcaat tagtcagcaa ccaggtgtgg aaagtccccca ggctccccag caggcagaag	3060
tatgcaaaggc atgcatctca attagtca gacccatagtc ccggccctaa ctccgcccatt	3120
cccgcccccta actccgccccca gtcccgccccca ttctccgccccca catggctgac taatttttt	3180
tattnatgcg gaggccgagg ccgcctcgcc ctctgagctt ttccagaagtt agtgaggagg	3240
cttttttggaa ggccttaggct tttgcaaaaaa gcttgattct tctgacacaa cagtctcgaa	3300
cttaaggcta gaggccaccat gattgaacaa gatggattgc acgcagggttc tccggccgt	3360
tgggtggaga ggctattcgg ctatgactgg gcacaacaga caatcggtg ctctgatgcc	3420
gecggtgttcc ggctgtcagc gcaggggcgc ccgggtttttt ttgtcaagac cgacctgtcc	3480
gggtccccctga atgaactgca ggacgaggca ggcggctat cgtggctggc cacgacggc	3540
gttccttgcg cagctgtgct cgacggttgc actgaagcgg gaagggactg gctgtatttgc	3600
ggcgaagtgc cggggcagga tctctgtca tctcaccttg ctctgtccgaa gaaagtatcc	3660
atcatggctg atgcaatgcg ggcggctgcat acgcttgcatttgc cggctacccgc cccatttgc	3720
caccaagcga aacatcgcat cgagcgagca cgtactcgga tggaagccgg tcttgcgtat	3780
caggatgatc tggacgaaga gcatcagggg ctgcgcggcc ccgaactgtt cgccagggtc	3840
aaggcgcgcga tgccgcacgg cgaggatctc gtctgtgaccatggcgatgc ctgttgcgg	3900
aatatatcatgg tggaaaatgg ccgttttttgc ggattcatcg actgtggccgg gctgggtgt	3960
ggggaccgct atcaggacat agcggtggct acccggtata ttgtgaaga gcttggccgc	4020
gaatgggctg accgttttgc cgtgttttgc ggtatcgcccttgc ctcccgatttgc gcaatcgatc	4080
gccttctatc gccttcttgc ctagtttttc tgagcgggac tctgggggttgc gaaatgaccg	4140
accaagcgcac gcccacccatc ccatcacatggcccaataaaatctt attttcatgg	4200
catctgtgttgc ttggtttttttgc ttgtgaagat ccgcgtatgg tgcactctca gtacaatctg	4260
ctctgtatgc gcatagttaa gccagccccgg acacccgcac acacccgcgtt acgcgccttgc	4320
acggggctgt ctgcgtccgg catccgcatttgc cagacaagctt gtcgttgcgtt ccggggacttgc	4380
catgtgtcag aggttttac cgtcatcacc gaaacgcgcg agacgaaagg gccttgtat	4440
acgcctatattt ttataggttta atgtcatgtt aataatggtt tcttagacgtt caggtggcac	4500
ttttcgggaa aatgtgcgcg gaacccctat ttgttttattt ttctaaatac attcaatata	4560
gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag	4620
tatgagtattt caacatttcc ttgtgcgcctt tattccctttt ttgtgcggcat tttgccttcc	4680
tggttttgcgtt caccatggaaa cgcgttgcgaa agtaaaagat gtcgttgcgtt agtgggtgt	4740
acgagtggtt tacatcgaaac ttgtatcttgc cagcggttgc atcccttgcgaa gttttcgccc	4800
cgaaagaacgtt ttccaaatgtt tggttgcactttt taaagtttgcgtt ctatgtggcg ccgttatttgc	4860
ccgttatttgc gcccggcaag agcaactcggtt tcgcgcata cactatttgc agaatgactt	4920
gggttggatc tcaccatggatc cagaaaagca tcttacggat ggcgttgcgtt taagagaatt	4980
atgcgttgcgtt gccaataccatggatc cactgcggcc aacttacttgc tgacaatcgat	5040
cgaggaggccg aaggagcttcc ccgttttttgc cacaacatggccgtt ttttgcgtt ccgttatttgc	5100
tgtatcggttgc ttgtgcgcgtt taaatgttgcgtt caccatggatc gtcgttgcgtt acaccacgtt	5160
gcctgtatgc atggcaacaa cgttgcgcata actattaactt ggcgttgcgtt ttacttgcgtt	5220
ttcccgccaa caatataatggatc actggatggatc ggcgttgcgtt ttttgcgtt ccgttatttgc	5280
ctcgccctt ccgttgcgtt ggtttatttgc tgataatctt ggcgttgcgtt agcgttgcgtt	5340

-continued

tgcgggtatc attgcagcac tggggccaga tggtaagccc tcccgatcg tagttatcta	5400
cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc	5460
ctcaactgatt aagcattggt aactgtcaga ccaagttac tcataatatac ttttagatga	5520
tttaaaaactt cattttaat ttAAAAGGAT ctaggtgaag atccttttg ataatctcat	5580
gaccAAAATC CCTTAACGTG AGTTTCGTT CCACTGAGCG TCAGACCCG TAGAAAAGAT	5640
caaaggatct tcttgagatc cttttttct ggcgtatc tgctgttgc aaacaaaaaa	5700
accacccgcta ccagcggtgg tttgtttgcc ggatcaagag ctaccaactc ttttccgaa	5760
ggtaactggc ttcagcagag cgccagatacc aaatactgtc cttctagtgt agccgtagtt	5820
aggccaccac ttcaagaact ctgttagcacc gcctacatac ctgcgtctgc taatcctgtt	5880
accagtggct gtcggcagtgc ggcataagtc gtgtcttacc ggggtggact caagacgata	5940
gttaccggat aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac agccagctt	6000
ggagcgaacg acctacaccc aactgagata cctacagcgt gagctatgag aaagcgccac	6060
gtttccccaa gggagaaagg cggacaggtt tccggtaagc ggcagggtcg gaacaggaga	6120
gcccacgggg gagcttccag ggggaaacgc ctggtatctt tatagtcctg tcgggttcg	6180
ccacctctga cttgagcgtc gatTTTGTG atgctcgatc gggggggcga gcctatggaa	6240
aaacGCCAGC AACGCCGCCT TTTACGGTT CCTGGCCTT TGCTGGCCTT TTGCTCACAT	6300
ggctcgacag atct	6314

<210> SEQ_ID NO 109

<211> LENGTH: 6319

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: pTarget SGLuc-d1D2A

<400> SEQUENCE: 109

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta	60
ttggccattg catabgttgt atctatatca taatatgtac atttatattg gctcatgtcc	120
aatatgaccg ccatgttggc attgattatt gactagttat taatagtaat caattacggg	180
gtcattagtt catabccat atatggagtt ccgcgttaca taacttacgg taaatggccc	240
gcctggctga cccgccaacg accccccccc attgacgtca ataatgacgt atgttcccat	300
agtaacgcca atagggactt tccattgacg tcaatgggtg gagtattac ggtaaactgc	360
ccacttggca gtacatcaag tgtatcatat gccaagtccg ccccttattt acgtcaatga	420
cggtaaatgg cccgectggc attatgcca gtacatgacc ttacggact ttcctacttg	480
geagtagacatc tacgttattag tcatcgatc taccatgggtt atgcgggttt ggcagtagac	540
caatgggcgt ggatagcggt ttgactcactg gggatttcca agtctccacc ccattgacgt	600
caatgggagt ttgtttggc accaaaatca acgggacttt ccaaaatgtc gtaacaactg	660
cgatcgcccg ccccggttgc gcaaatggc ggtaggcgta tacggggaa ggtctatata	720
agcagagctc gtttagtgaa ccgtcagatc actagaagctt ttattgcggt agtttatcac	780
agttaaattt ctaacgcagt cagtgcattc gacacaacag tctcgaactt aagctgcagt	840
gactcttta aggtgcctt gcagaagttt gtcgtgaggc actggggcagg taagtatcaa	900
ggttacaaga cagggttaag gagaccaata gaaactgggg ttgtcgagac agagaagact	960
cttgcgtttc tgataggcac ctattggct tactgacatc cactttgcct ttctctccac	1020
aggtgtccac tcccagttca attacagctc ttaaaaattt gatctccatt cgccattcag	1080

-continued

gctgcgcaac tgctggaaag gacgatcaga gcgggcctct tcgttattac gccagctggc	1140
gaaaggacg tggcaagcaa ggcgattaag tttagttacg ccaggatttt cccagtcacg	1200
acgttgtaaa acgacggcca gagaattata atacgactca ctatagggcg aattcggtc	1260
cttgctagcc tcgagacgctg tgatatctt ggccgcggc caccatggga gtcaaagttc	1320
tgttgccct gatctgcattc gctgtggccg aggccaagcc caccgagaac aacgaagact	1380
tcaacatcggtt ggccgtggcc agcaacttcg cgaccacggg tctcgatgtc gaccggggaa	1440
agttgcccgg caagaagctg ccgctggagg tgctcaaaga gatggaaagcc aatggccggaa	1500
aagctggctg caccaggggc tgcgtatctc gctgttccca catcaagtgc acggccaaaga	1560
tgaagaagtg gctccagga cgctgccaca cctacgaagg cgacaaagag tccgcacagg	1620
ggggcatagg cgaggcgatc gtcgcacattc ctgagattcc tgggttcaag gacttggagc	1680
ccatggagca gttcatcgca caggtcgatc tgcgtgtggc ctgcacaact ggctgcctca	1740
aaggggcttcg caacgtgcag tggcttgacc tgctcaagaa gtggctggcg caacgctgtg	1800
cgacctttgc cagcaagatc cagggccagg tggacaagat caagggggcc ggtggtgacg	1860
ctagccacaa gcaaaaagatc attgcaccatc caaagcagct tctgaatttt gacctgctca	1920
agttggccgg agacgttgag tccaaacctg gacccggggc ggccgcgaat tccaaagcttgc	1980
agtattctat cgtgtcacct aaataacttg gctgtatcat ggtcatatct gtttctgtg	2040
tgaattgtt atccgctcac aattccacac aacatacgag ccggaagcat aaagtgtaaa	2100
gcctgggggt cctaattgtt gagtaactc acattaattt cggttgcgcga tgcttccatt	2160
ttgtgagggt taatgtttcg agaagacatg ataagataca ttgtatgtt gggacaacc	2220
acaacaagaa tgcagtggaa aaaatgtttt atttgcgttttttgcgttgc tattgtttta	2280
tttgcgttca accaaatgttca caataaacaa gttacaaca acaattgcatt tcattttatg	2340
tttcagggttcc agggggagat gtgggggtt tttaaagca agtaaaacctt ctacaatgt	2400
ggtaaaatcc gataaggatc gattccggag cctgaatggc gaatggacgc gcccgttagc	2460
ggcgcattaa ggcggccggg tgggtgggtt acgcgcacgt gaccgcatac cttgcacgc	2520
ccctagcgcc cgcttcttc gctttcttc cttccttctc cgccacgttc gccggcttc	2580
cccgtaaggc tctaaatcggtt ggggttccctt taggggtccg atttgcgttgc ttacggcacc	2640
tcgaccccaa aaaacttgcgtt taggggtgcgtt gttcacgttgc tggccatcg ccctgtatgc	2700
cggtttttcg cccttgcgtt ttgggtgcgtt cgttgcgttca tagtggactc ttgttccaaa	2760
ctggaaacaac actcaaccctt atctcggtctt attctttgcgtt tttataaggat ttttgcgttgc	2820
tttcggcccta ttggttaaaa aatgagctga tttaacaaaa atttaacgcg aattttaaaca	2880
aatatattaaac gcttacaattt tcgcctgtgtt accttctgttgc gggaaagaa ccagctgtgg	2940
aatgtgtgtc agtttaggggtt tggaaagtcc ccaggctccc cagcaggcag aagtatgcac	3000
agcatgcattc tcaatttgcgtt agcaccagg tggaaagttt cccaggctc cccaggcaggc	3060
agaagtatgc aaagcatgc tctcaatttgcgtt tcaagcaacca tagtcccccc ccttactccg	3120
cccatccgcg cccttactcc gcccaggcttcc gcccatttcc cggccatgg ctgactaattt	3180
ttttttttttt atgcagaggc cgaggccggcc tcggccctcg agcttattccaa gaagttgtgttgc	3240
ggaggctttt ttggaggccctt aggttttgc aaaaagcttgc attttttgcgtt cacaacatgc	3300
tgcgttccaa ggcttagagcc accatgatttgcgtt aacaagatgg attgcacgcgaa ggttccgg	3360
ccgcgttgggtt ggagaggctt ttcggctatgc actggccaca acagacaatc ggctgtctgc	3420

US 10,435,695 B2

239

240

-continued

atgcggccgt gttccggctg tcagcgcagg ggccgcggg tcttttgtc aagaccgacc	3480
tgtccgggtc cctgaatgaa ctgcaggacg aggcagcgcc gctatcggtt ctggccacgaa	3540
cgggcgttcc ttgcgcagct gtgcgcacg ttgtcaactga agcgggaaagg gactggctgc	3600
tattggcgaa agtgcggggg caggatctcc tgtcatctca ccttgcgttcc gccgagaaag	3660
tatccatcat ggctgatgca atgcggcgcc tgcatacgct tgatccggct acctggccat	3720
tcgaccacca agcgaacat cgccatcgacg gaggacgtac tcggatggaa gcccgttgc	3780
tcgatcgaga tgatctggac gaagagcatc aggggctcgc gccagccaa ctgttcgcca	3840
ggctcaaggc gcgcgtgccc gacggcgagg atctcgctg gacccatggc gatgcgtgc	3900
tgccgaatat catggggaa aatggccgtt ttctggatt catcgactgt ggccggctgg	3960
gtgtggcgaa ccgcgtatcg gacatagcg tggctacccc tgatattgtt gaagagcttgc	4020
gcggcgaatg ggctgaccgc ttctcggtc ttacggat cgccgtccc gatcgacgc	4080
gcacgcctt ctatgcctt cttgacgagt tcttctgacg gggactctgg ggttcgaaat	4140
gaccgaccaa gcgcgcgc acctgccttc acgatggccg caataaaata tctttat	4200
cattacatct gtgtgttgtt ttttgtgtg aagatcccg tattgtgcac tctcagtgaca	4260
atctgtctg atgcgcata gttaaagccag ccccgacacc cgccaaacacc cgctgacgc	4320
ccctgacggg cttgtctgct cccggcatcc gcttacagac aagctgtac cgctccggg	4380
agctgcgtgt gtcagagggtt ttccacgtca tcaccgaaac gcgcgagacg aaagggcctc	4440
gtgatacgcc tattttata ggttaatgtc atgataataa tggttctta gacgtcagg	4500
ggcacttttc gggaaatgt gcgcggaaacc cctattttgtt tattttcta aatacattca	4560
aatatgtatc cgctcatgag acaataaccc tgataaaatgc ttcaataata ttgaaaaagg	4620
aagagtatga gtattcaaca tttccgtcgc gcccattttcc cttttttgc ggcattttgc	4680
cttcctgttt ttgctcaccc agaaacgctg gtgaaagtaa aagatgtac agatcagg	4740
ggtgacacgag tgggttacat cgaactggat ctcaacacgc gtaagatcct tgagat	4800
cgcggcggaaac aacgtttcc aatgtatgc acctttaaag ttctgtatg tggcgcgta	4860
ttatccgtta ttgacgcgg gcaagagca ctcggcgcgc gcatacacta ttctcagaat	4920
gacttggttt agtactcacc agtacacgaa aagcatctta cggatggcat gacagtaaga	4980
gaattatgcgatgtccat aaccatgagt gataacactg cggccaaactt acttctgaca	5040
acgatcggag gaccgaagga gctaaccgc ttttgcaca acatggggga tcatgtact	5100
cgccttgcgtt gttggaaacc ggactgtaaat gaaaggccatac caaacgcgca gcgacacc	5160
acgatgcctg tagcaatggc aacaacgttg cgccaaactat taactggcgactacttact	5220
ctagcttccc ggcaacaatt aatagactgg atggaggcggtt ataaagggttgc aggaccactt	5280
ctgcgtcgccg cccttcggc tggctggttt attgctgata aatctggacg cggtagcgt	5340
gggtctcgccg gtatcattgc agcactgggg ccagatggta agccctcccg tatecgat	5400
atctacacga cggggagtca ggcacactatg gatgaacgaa atagacagat cgctgagata	5460
ggtgccctac tgattaagca ttggtaactg tcagaccaag tttactcata tatacttttag	5520
attgatttaa aacttcattt ttaattttaa aggatctagg tgaagatcct ttttgcataat	5580
ctcatgacca aaatccctta acgtgagtt tcgttccact gagcgtcaga ccccgtagaa	5640
aagatcaaaag gatcttcttg agatcctttt tttctgcgcg taatctgcgtc cttgcacaa	5700
aaaaaaccac cgctaccacgc ggtgggttgc ttgcggatc aagagctacc aactctttt	5760
ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgcgtcc	5820

-continued

```

tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcg tctgctaattc      5880
ctgttaccag tggctgctgc cagtgccat aagtcgtgtc ttaccgggtt ggactcaaga      5940
cgatagttac cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc      6000
agcttggagc gaacgaccta caccgaactg agataacctac agcgtgagct atgagaaaagc      6060
gcacacgttc ccgaaggggag aaaggcggac aggtatccgg taagcggcag ggtcggaaaca      6120
ggagagcgca cgagggagct tccaggggaa aacgcctggg atctttatag tcctgtcggg      6180
tttcgcacc tctgacttga gctgtcgattt ttgtgatgtc cgtcaggggg gcggagccta      6240
tggaaaaaacg ccagcaacgc ggcctttta cggttccctgg cctttgctg gcctttgct      6300
cacatggctc gacagatct      6319

```

```

<210> SEQ ID NO 110
<211> LENGTH: 993
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(993)
<223> OTHER INFORMATION: SGlucON Bovine gamma

<400> SEQUENCE: 110

```

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu 1 5 10 15	48
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala 20 25 30	96
agc aac ttt gcg acc acg gat ctc gat gct gac cga ggg aag ttg ccc Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro 35 40 45	144
ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala 50 55 60	192
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile 65 70 75 80	240
aag tgc acg ccc aag atg aag aag tgg ctc cca gga cgc tgc cac acc Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr 85 90 95	288
tac gaa ggc gac aaa gag tcc qca cag ggc ggc ata ggc gag ggc atc Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile 100 105 110	336
gtc gat att cct gag att cct ggg ttc aag gac ttg gag cca atg gag Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu 115 120 125	384
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys 130 135 140	432
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp 145 150 155 160	480
ctg ccg caa cgc tgt ggc acc ttt gcc agc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175	528
gac aag atc aag ggg gcc ggt ggt gac ggg ccc cag ggc caa ttt ttt Asp Lys Ile Lys Gly Ala Gly Gly Asp Gly Pro Gln Gly Gln Phe Phe 180 185 190	576

US 10,435,695 B2

243

244

-continued

aga gaa ata gaa aac tta aag gag tat ttt aat gca agt agc cca gat	624
Arg Glu Ile Glu Asn Leu Lys Glu Tyr Phe Asn Ala Ser Ser Pro Asp	
195 200 205	
gta gct aag ggt ggg cct ctc ttc tca gaa att ttg aag aat tgg aaa	672
Val Ala Lys Gly Gly Pro Leu Phe Ser Glu Ile Leu Lys Asn Trp Lys	
210 215 220	
gat gaa agt gac aaa aaa att att cag agc caa att gtc tcc ttc tac	720
Asp Glu Ser Asp Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr	
225 230 235 240	
tcc aaa ctc ttt gaa aac ctc aaa gat aac cag gtc att caa agg agc	768
Phe Lys Leu Phe Glu Asn Leu Lys Asp Asn Gln Val Ile Gln Arg Ser	
245 250 255	
atg gat atc atc aag caa gac atg ttt cag aag ttc ttg aat ggc agc	816
Met Asp Ile Ile Lys Gln Asp Met Phe Gln Lys Phe Leu Asn Gly Ser	
260 265 270	
tct gag aaa ctg gag gac ttc aaa aag ctg att caa att ccg gtg gat	864
Ser Glu Lys Leu Glu Asp Phe Lys Lys Leu Ile Gln Ile Pro Val Asp	
275 280 285	
gat ctg cag atc cag cgc aaa gcc ata aat gaa ctc atc aaa gtg atg	912
Asp Leu Gln Ile Gln Arg Lys Ala Ile Asn Glu Leu Ile Lys Val Met	
290 295 300	
aat gac ctg tca cca aaa tct aac ctc aga aag cgg aag aag aga agt cag	960
Asn Asp Leu Ser Pro Lys Ser Asn Leu Arg Lys Arg Lys Arg Ser Gln	
305 310 315 320	
aat ctc ttt cga ggc cgg aga gca tca acg taa	993
Asn Leu Phe Arg Gly Arg Arg Ala Ser Thr	
325 330	

<210> SEQ_ID NO 111

<211> LENGTH: 330

<212> TYPE: PRT

<213> ORGANISM: Bos taurus

<400> SEQUENCE: 111

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	
1 5 10 15	
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	
20 25 30	
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	
35 40 45	
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	
50 55 60	
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	
65 70 75 80	
Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr	
85 90 95	
Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile	
100 105 110	
Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	
115 120 125	
Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	
130 135 140	
Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	
145 150 155 160	
Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val	
165 170 175	
Asp Lys Ile Lys Gly Ala Gly Gly Asp Gly Pro Gln Gly Gln Phe Phe	
180 185 190	

US 10,435,695 B2

245**246**

-continued

Arg Glu Ile Glu Asn Leu Lys Glu Tyr Phe Asn Ala Ser Ser Pro Asp
195 200 205

Val Ala Lys Gly Gly Pro Leu Phe Ser Glu Ile Leu Lys Asn Trp Lys
210 215 220

Asp Glu Ser Asp Lys Lys Ile Ile Gln Ser Gln Ile Val Ser Phe Tyr
225 230 235 240

Phe Lys Leu Phe Glu Asn Leu Lys Asp Asn Gln Val Ile Gln Arg Ser
245 250 255

Met Asp Ile Ile Lys Gln Asp Met Phe Gln Lys Phe Leu Asn Gly Ser
260 265 270

Ser Glu Lys Leu Glu Asp Phe Lys Lys Leu Ile Gln Ile Pro Val Asp
275 280 285

Asp Leu Gln Ile Gln Arg Lys Ala Ile Asn Glu Leu Ile Lys Val Met
290 295 300

Asn Asp Leu Ser Pro Lys Ser Asn Leu Arg Lys Arg Lys Arg Ser Gln
305 310 315 320

Asn Leu Phe Arg Gly Arg Arg Ala Ser Thr
325 330

<210> SEQ_ID NO 112
<211> LENGTH: 1092
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1092)
<223> OTHER INFORMATION: SGluCON Lambda bovine

<400> SEQUENCE: 112

atg gga gtc aaa gtt ctg ttt gcc ctg atc tgc atc gct gtg gcc gag Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu	48
1 5 10 15	
gcc aag ccc acc gag aac aac gaa gac ttc aac atc gtg gcc gtg gcc Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala	96
20 25 30	
agc aac ttt gcg acc acg gat ctc gat gct gac cga ggg aag ttg ccc Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro	144
35 40 45	
ggc aag aag ctg ccg ctg gag gtg ctc aaa gag atg gaa gcc aat gcc Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala	192
50 55 60	
cgg aaa gct ggc tgc acc agg ggc tgt ctg atc tgc ctg tcc cac atc Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile	240
65 70 75 80	
aag tgc acg ccc aag atg aag aag tgg ctc cca gga cgc tgc cac acc Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr	288
85 90 95	
tac gaa ggc gac aaa gag tcc gca cag ggc ata ggc gag gcg atc Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile	336
100 105 110	
gtc gat att cct gag att cct ggg ttc aag gac ttg gag cca atg gag Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu	384
115 120 125	
cag ttc atc gca cag gtc gat ctg tgt gtg gac tgc aca act ggc tgc Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys	432
130 135 140	
ctc aaa ggg ctt gcc aac gtg cag tgt tct gac ctg ctc aag aag tgg Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp	480
145 150 155 160	

US 10,435,695 B2

247

248

-continued

ctg ccg caa cgc tgt gcg acc ttt gcc agc aag atc cag ggc cag gtg Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val 165 170 175	528
gac aag atc aag ggg gcc ggt ggt gac ggg ccc agg aca gga gca gtt Asp Lys Ile Lys Gly Ala Gly Asp Gly Pro Arg Thr Gly Ala Val 180 185 190	576
cct gtg ccc tct gcc ccc agg gcc ctc cca cct gcc agg ggc tgc cac Pro Val Pro Ser Ala Pro Arg Ala Leu Pro Pro Ala Arg Gly Cys His 195 200 205	624
gtg gcc cag ttc aag tct ctg tcc cct caa gag ctg cag gcc ttc aag Val Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe Lys 210 215 220	672
acg gcc agg gat gcc ttt gaa gac tcg ttc cca aag gac tgg gac Thr Ala Arg Asp Ala Phe Glu Asp Ser Phe Leu Pro Lys Asp Trp Asp 225 230 235 240	720
tgc agc acc cac ctt ttc ccc agg acc cgg gac ctg aag cac ctg cag Cys Ser Thr His Leu Phe Pro Arg Thr Arg Asp Leu Lys His Leu Gln 245 250 255	768
gtg tgg gag cgc cct gtg gct ctg gag gca gag ctg gcc ctg aca ctg Val Trp Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu 260 265 270	816
acg gtc ctg gag gcc atg gct aac tca tcc ctg ggc cac agc ctg gag Thr Val Leu Glu Ala Met Ala Asn Ser Ser Leu Gly His Ser Leu Glu 275 280 285	864
cag ccc ctt ctc acg ctg cag aac atc cac tcc aag ctc cag gcc tgt Gln Pro Leu Leu Thr Leu Gln Asn Ile His Ser Lys Leu Gln Ala Cys 290 295 300	912
gtc cca gct cag ccc aca gca agc tcc agg ccc egg ggc cgc ctc cac Val Pro Ala Gln Pro Thr Ala Ser Ser Arg Pro Arg Gly Arg Leu His 305 310 315 320	960
cac tgg ctg cac cgc ctc cag gag gcc cgg aag gag tcc cag gac tgc His Trp Leu His Arg Leu Gln Glu Ala Arg Lys Glu Ser Gln Asp Cys 325 330 335	1008
ctc gaa gcc tct gtg atg ttc aac ctc ctc cgc ctc acc cgg gac Leu Glu Ala Ser Val Met Phe Asn Leu Leu Arg Leu Leu Thr Arg Asp 340 345 350	1056
ctg aaa tgt gtt gcc agc gga gac cag tgt gtc tga Leu Lys Cys Val Ala Ser Gly Asp Gln Cys Val 355 360	1092

<210> SEQ ID NO 113

<211> LENGTH: 363

<212> TYPE: PRT

<213> ORGANISM: Bos taurus

<400> SEQUENCE: 113

Met Gly Val Lys Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu 1 5 10 15
Ala Lys Pro Thr Glu Asn Asn Glu Asp Phe Asn Ile Val Ala Val Ala 20 25 30
Ser Asn Phe Ala Thr Thr Asp Leu Asp Ala Asp Arg Gly Lys Leu Pro 35 40 45
Gly Lys Lys Leu Pro Leu Glu Val Leu Lys Glu Met Glu Ala Asn Ala 50 55 60
Arg Lys Ala Gly Cys Thr Arg Gly Cys Leu Ile Cys Leu Ser His Ile 65 70 75 80
Lys Cys Thr Pro Lys Met Lys Lys Trp Leu Pro Gly Arg Cys His Thr 85 90 95

-continued

Tyr Glu Gly Asp Lys Glu Ser Ala Gln Gly Gly Ile Gly Glu Ala Ile
100 105 110

Val Asp Ile Pro Glu Ile Pro Gly Phe Lys Asp Leu Glu Pro Met Glu
115 120 125

Gln Phe Ile Ala Gln Val Asp Leu Cys Val Asp Cys Thr Thr Gly Cys
130 135 140

Leu Lys Gly Leu Ala Asn Val Gln Cys Ser Asp Leu Leu Lys Lys Trp
145 150 155 160

Leu Pro Gln Arg Cys Ala Thr Phe Ala Ser Lys Ile Gln Gly Gln Val
165 170 175

Asp Lys Ile Lys Gly Ala Gly Asp Gly Pro Arg Thr Gly Ala Val
180 185 190

Pro Val Pro Ser Ala Pro Arg Ala Leu Pro Pro Ala Arg Gly Cys His
195 200 205

Val Ala Gln Phe Lys Ser Leu Ser Pro Gln Glu Leu Gln Ala Phe Lys
210 215 220

Thr Ala Arg Asp Ala Phe Glu Asp Ser Phe Leu Pro Lys Asp Trp Asp
225 230 235 240

Cys Ser Thr His Leu Phe Pro Arg Thr Arg Asp Leu Lys His Leu Gln
245 250 255

Val Trp Glu Arg Pro Val Ala Leu Glu Ala Glu Leu Ala Leu Thr Leu
260 265 270

Thr Val Leu Glu Ala Met Ala Asn Ser Ser Leu Gly His Ser Leu Glu
275 280 285

Gln Pro Leu Leu Thr Leu Gln Asn Ile His Ser Lys Leu Gln Ala Cys
290 295 300

Val Pro Ala Gln Pro Thr Ala Ser Ser Arg Pro Arg Gly Arg Leu His
305 310 315 320

His Trp Leu His Arg Leu Gln Glu Ala Arg Lys Glu Ser Gln Asp Cys
325 330 335

Leu Glu Ala Ser Val Met Phe Asn Leu Leu Arg Leu Leu Thr Arg Asp
340 345 350

Leu Lys Cys Val Ala Ser Gly Asp Gln Cys Val
355 360

The invention claimed is:

1. A polynucleotide that encodes a fusion protein comprising a luciferase, and at least one interferon, wherein the polynucleotide encodes the fusion protein described by SEQ ID NOS: 48, 52, 56, 60, 64, 68, 70, 74, 78, 82, 86, 90, 94, 111, or 113.

2. The polynucleotide of claim 1 that further comprises a polynucleotide encoding at least one translational interrupter sequence.

3. The polynucleotide of claim 1 that further comprises a polynucleotide encoding at least one Aphthovirus translational interrupter sequence.

4. The polynucleotide of claim 1 that further comprises a polynucleotide encoding at least one foot-and-mouth disease virus (FMDV) translational interrupter sequence.

5. The polynucleotide of claim 1 that further comprises a polynucleotide encoding a FMDV 2A or Δ1D2A sequence.

6. The polynucleotide of claim 1 that comprises a polynucleotide sequence described by SEQ ID NOS: 47, 51, 55, 59, 63, 67, 69, 73, 77, 81, 85, 89, 93, 110 or 112.

7. A vector comprising the polynucleotide of claim 1.

8. The vector of claim 7 that further comprises a polynucleotide encoding at least one promoter or other transcrip-

45 tion regulatory element, at least one prokaryotic or eukaryotic translation initiation sequence or other translation regulatory element, at least one translational interrupter sequence, or at least one reporter polynucleotide sequence operatively linked to, or embedded within, the polynucleotide sequence encoding the fusion protein.

50 9. The vector of claim 7 that further comprises a polynucleotide encoding at least one FMDV translational interrupter sequence.

10. The vector of claim 7 that further comprises a polynucleotide encoding a FMDV 2A or Δ1D2A sequence.

55 11. The vector of claim 7 that is a mRNA, DNA plasmid, minicircle vector, a replication deficient adenovirus vector, a vaccinia virus vector, or other viral vector that expresses the fusion protein.

12. The vector of claim 7 that comprises a polynucleotide sequence described by SEQ ID NOS: 47, 51, 55, 59, 63, 67, 69, 73, 77, 81, 85, 89, 93, 110 or 112.

13. A host cell comprising the vector of claim 7, wherein 60 the host cell expresses the fusion protein.

14. The host cell of claim 13 that is an insect cell.

15. The host cell of claim 13 that is mammalian cell.

251

16. The host cell of claim **13** that is a prokaryotic cell.
17. A fusion protein, that is encoded by the polynucleotide of claim **1**.

18. The fusion protein of claim **17**, wherein the polynucleotide further comprises a polynucleotide encoding at least one translational interrupter sequence.

19. The fusion protein of claim **17**, wherein the polynucleotide further comprises a polynucleotide encoding at least one Aphthovirus translational interrupter sequence.

20. The fusion protein of claim **17**, wherein the polynucleotide further comprises a polynucleotide encoding at least one FMDV translational interrupter sequence.

21. The fusion protein of claim **17**, wherein the polynucleotide further comprises a polynucleotide encoding a FMDV 2A or Δ1D2A sequence.

22. A composition comprising the fusion protein of claim **17** and at least one pharmaceutically acceptable carrier, excipient or adjuvant.

23. A method for producing the fusion protein of claim **17** comprising culturing a host cell that expresses the fusion protein in a suitable medium and recovering the fusion protein.

24. A method for quantifying an amount or concentration of an interferon produced in an expression system comprising:

- a. providing the vector according to claim **7**;
- b. transforming the vector into a host cell;
- c. culturing the cells in a medium;
- d. harvesting the medium; and
- e. quantifying the intensity of luminescent output.

25. A method for quantifying an amount or concentration of an interferon produced in an expression system comprising:

- a. providing the vector according to claim **9**;
- b. transforming the vector into a host cell;
- c. culturing the cells in a medium;
- d. harvesting the medium; and
- e. quantifying the intensity of luminescent output.

26. A method for quantifying an amount or concentration of an interferon produced in an expression system comprising:

- a. providing the vector according to claim **10**;
- b. transforming the vector into a host cell;
- c. culturing the cells in a medium;
- d. harvesting the medium; and
- e. quantifying the intensity of luminescent output, thus quantifying an amount or concentration of an interferon in the expression system.

27. A method for quantifying an amount or concentration of an interferon produced in an expression system comprising:

252
a. providing the vector according to claim **11**;
b. transforming the vector into a host cell;
c. culturing the cells in a medium;
d. harvesting the medium; and
e. quantifying the intensity of luminescent output, thus quantifying an amount or concentration of an interferon in the expression system.

28. A method for quantifying an amount or concentration of an interferon in an expression system comprising:

- a. providing the vector according to claim **12**;
- b. transforming the vector into a host cell;
- c. culturing the cells in a medium;
- d. harvesting the medium; and
- e. quantifying the intensity of luminescent output, thus quantifying an amount or concentration of an interferon in the expression system.

29. A method for facilitating secretion of a fusion protein from a host cell comprising:

- a. providing the vector according to claim **7**;
- b. transforming the vector into a host cell;
- c. culturing the cells in a medium; and
- d. recovering the secretable fusion protein from the medium.

30. A method for facilitating secretion of a fusion protein from a host cell comprising:

- a. providing the vector according to claim **12**;
- b. transforming the vector into a host cell;
- c. culturing the cells in a medium; and
- d. Recovering the secretable fusion protein from the medium.

31. A method for measuring an amount of a biotherapeutic peptide in a subject in need thereof comprising:

- a. providing the vector according to claim **12**;
- b. transforming the vector in the subject;
- c. recovering biological material from the subject;
- d. wherein the biological material comprises blood, serum, plasma, or urine.

32. A method for certifying vaccine expression in vivo comprising:

- a. providing the vector according to claim **12**;
- b. transforming the vector into a host organism;
- c. recovering biological material from the host organism;
- d. wherein the biological material comprises blood, serum, plasma, or urine.

33. A pharmaceutical composition comprising the fusion protein of claim **17** and at least one pharmaceutically acceptable carrier, adjuvant, or excipient.

* * * * *